

# CoVPN COVID-19 Vaccine Efficacy Trial Immune Correlates

January 14, 2021

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
<b>Total</b>						
Negative	D29	Anti-Spike IgG	1089	51.4%	51.4%	51.4%
Negative	D29	Anti-Spike IgG	1089	(49.4%, 53.3%)	(49.4%, 53.3%)	(49.4%, 53.3%)
Negative	D29	Anti-RBD IgG	1089	51.4%	51.4%	51.4%
Negative	D29	Anti-RBD IgG	1089	(49.4%, 53.3%)	(49.4%, 53.3%)	(49.4%, 53.3%)
Negative	D29	Pseudo nAb ID50	1089	41.6%	41.6%	35.3%
Negative	D29	Pseudo nAb ID50	1089	(39.8%, 43.3%)	(39.8%, 43.3%)	(32.0%, 38.7%)
Negative	D29	Pseudo nAb ID80	1089	34.7%	34.7%	27.8%
Negative	D29	Pseudo nAb ID80	1089	(31.4%, 38.0%)	(31.4%, 38.0%)	(23.9%, 31.7%)
Negative	D29	Live Virus nAb ID50	1089	41.8%	41.8%	33.8%
Negative	D29	Live Virus nAb ID50	1089	(39.8%, 43.9%)	(39.8%, 43.9%)	(30.9%, 36.7%)
Negative	D29	Live Virus nAb ID80	1089	35.9%	35.9%	28.7%
Negative	D29	Live Virus nAb ID80	1089	(33.8%, 38.0%)	(33.8%, 38.0%)	(25.5%, 31.9%)
Negative	D57	Anti-Spike IgG	1089	51.4%	51.4%	51.4%
Negative	D57	Anti-Spike IgG	1089	(49.4%, 53.3%)	(49.4%, 53.3%)	(49.4%, 53.3%)
Negative	D57	Anti-RBD IgG	1089	51.4%	51.4%	51.4%
Negative	D57	Anti-RBD IgG	1089	(49.4%, 53.3%)	(49.4%, 53.3%)	(49.4%, 53.3%)
Negative	D57	Pseudo nAb ID50	1089	50.2%	50.2%	49.1%
Negative	D57	Pseudo nAb ID50	1089	(48.0%, 52.4%)	(48.0%, 52.4%)	(47.2%, 51.1%)
Negative	D57	Pseudo nAb ID80	1089	48.6%	48.6%	46.1%
Negative	D57	Pseudo nAb ID80	1089	(47.5%, 49.7%)	(47.5%, 49.7%)	(45.4%, 46.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Live Virus nAb ID50	1089	50.0%	50.0%	48.7%
Negative	D57	Live Virus nAb ID50	1089	(48.4%, 51.7%)	(48.4%, 51.7%)	(46.2%, 51.1%)
Negative	D57	Live Virus nAb ID80	1089	48.6%	48.6%	46.0%
Negative	D57	Live Virus nAb ID80	1089	(47.2%, 50.1%)	(47.2%, 50.1%)	(45.6%, 46.4%)
Positive	D29	Anti-Spike IgG	523	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	523	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	523	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	523	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	523	78.7%	78.7%	67.4%
Positive	D29	Pseudo nAb ID50	523	(73.0%, 84.4%)	(73.0%, 84.4%)	(59.2%, 75.7%)
Positive	D29	Pseudo nAb ID80	523	64.7%	64.7%	49.2%
Positive	D29	Pseudo nAb ID80	523	(56.8%, 72.7%)	(56.8%, 72.7%)	(41.1%, 57.3%)
Positive	D29	Live Virus nAb ID50	523	76.8%	76.8%	65.9%
Positive	D29	Live Virus nAb ID50	523	(71.6%, 82.0%)	(71.6%, 82.0%)	(59.7%, 72.2%)
Positive	D29	Live Virus nAb ID80	523	70.1%	70.1%	55.1%
Positive	D29	Live Virus nAb ID80	523	(65.2%, 75.1%)	(65.2%, 75.1%)	(48.8%, 61.5%)
Positive	D57	Anti-Spike IgG	523	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	523	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	523	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	523	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	523	95.5%	95.5%	93.9%
Positive	D57	Pseudo nAb ID50	523	(93.7%, 97.2%)	(93.7%, 97.2%)	(92.3%, 95.5%)
Positive	D57	Pseudo nAb ID80	523	92.3%	92.3%	87.3%
Positive	D57	Pseudo nAb ID80	523	(90.1%, 94.6%)	(90.1%, 94.6%)	(83.8%, 90.7%)
Positive	D57	Live Virus nAb ID50	523	96.6%	96.6%	93.6%
Positive	D57	Live Virus nAb ID50	523	(95.4%, 97.9%)	(95.4%, 97.9%)	(91.8%, 95.5%)
Positive	D57	Live Virus nAb ID80	523	95.8%	95.8%	92.4%
Positive	D57	Live Virus nAb ID80	523	(92.9%, 98.7%)	(92.9%, 98.7%)	(88.7%, 96.0%)
<b>Age &lt; 65</b>						
Negative	D29	Anti-Spike IgG	513	51.9%	51.9%	51.9%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Anti-Spike IgG	513	(50.6%, 53.1%)	(50.6%, 53.1%)	(50.6%, 53.1%)
Negative	D29	Anti-RBD IgG	513	51.9%	51.9%	51.9%
Negative	D29	Anti-RBD IgG	513	(50.6%, 53.1%)	(50.6%, 53.1%)	(50.6%, 53.1%)
Negative	D29	Pseudo nAb ID50	513	40.9%	40.9%	34.0%
Negative	D29	Pseudo nAb ID50	513	(39.7%, 42.1%)	(39.7%, 42.1%)	(32.6%, 35.3%)
Negative	D29	Pseudo nAb ID80	513	33.4%	33.4%	26.3%
Negative	D29	Pseudo nAb ID80	513	(33.2%, 33.6%)	(33.2%, 33.6%)	(26.0%, 26.6%)
Negative	D29	Live Virus nAb ID50	513	41.4%	41.4%	32.6%
Negative	D29	Live Virus nAb ID50	513	(38.8%, 43.9%)	(38.8%, 43.9%)	(30.9%, 34.3%)
Negative	D29	Live Virus nAb ID80	513	35.1%	35.1%	27.4%
Negative	D29	Live Virus nAb ID80	513	(34.7%, 35.4%)	(34.7%, 35.4%)	(26.8%, 28.0%)
Negative	D57	Anti-Spike IgG	513	51.9%	51.9%	51.9%
Negative	D57	Anti-Spike IgG	513	(50.6%, 53.1%)	(50.6%, 53.1%)	(50.6%, 53.1%)
Negative	D57	Anti-RBD IgG	513	51.9%	51.9%	51.9%
Negative	D57	Anti-RBD IgG	513	(50.6%, 53.1%)	(50.6%, 53.1%)	(50.6%, 53.1%)
Negative	D57	Pseudo nAb ID50	513	50.6%	50.6%	49.5%
Negative	D57	Pseudo nAb ID50	513	(48.7%, 52.6%)	(48.7%, 52.6%)	(47.7%, 51.2%)
Negative	D57	Pseudo nAb ID80	513	48.8%	48.8%	46.1%
Negative	D57	Pseudo nAb ID80	513	(48.0%, 49.7%)	(48.0%, 49.7%)	(45.2%, 47.0%)
Negative	D57	Live Virus nAb ID50	513	50.5%	50.5%	49.0%
Negative	D57	Live Virus nAb ID50	513	(49.4%, 51.5%)	(49.4%, 51.5%)	(46.5%, 51.4%)
Negative	D57	Live Virus nAb ID80	513	48.9%	48.9%	46.1%
Negative	D57	Live Virus nAb ID80	513	(47.7%, 50.2%)	(47.7%, 50.2%)	(45.7%, 46.4%)
Positive	D29	Anti-Spike IgG	295	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	295	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	295	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	295	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	295	76.5%	76.5%	64.4%
Positive	D29	Pseudo nAb ID50	295	(75.4%, 77.6%)	(75.4%, 77.6%)	(64.2%, 64.6%)
Positive	D29	Pseudo nAb ID80	295	61.7%	61.7%	46.1%
Positive	D29	Pseudo nAb ID80	295	(60.9%, 62.5%)	(60.9%, 62.5%)	(45.3%, 46.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Live Virus nAb ID50	295	74.8%	74.8%	63.7%
Positive	D29	Live Virus nAb ID50	295	(73.9%, 75.7%)	(73.9%, 75.7%)	(58.6%, 68.8%)
Positive	D29	Live Virus nAb ID80	295	68.2%	68.2%	52.6%
Positive	D29	Live Virus nAb ID80	295	(66.2%, 70.2%)	(66.2%, 70.2%)	(49.6%, 55.7%)
Positive	D57	Anti-Spike IgG	295	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	295	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	295	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	295	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	295	94.8%	94.8%	93.3%
Positive	D57	Pseudo nAb ID50	295	(94.6%, 95.1%)	(94.6%, 95.1%)	(92.7%, 93.8%)
Positive	D57	Pseudo nAb ID80	295	91.5%	91.5%	86.0%
Positive	D57	Pseudo nAb ID80	295	(91.3%, 91.7%)	(91.3%, 91.7%)	(83.4%, 88.5%)
Positive	D57	Live Virus nAb ID50	295	96.3%	96.3%	92.9%
Positive	D57	Live Virus nAb ID50	295	(95.6%, 97.0%)	(95.6%, 97.0%)	(91.7%, 94.2%)
Positive	D57	Live Virus nAb ID80	295	95.5%	95.5%	92.0%
Positive	D57	Live Virus nAb ID80	295	(92.0%, 99.0%)	(92.0%, 99.0%)	(87.6%, 96.4%)
<b>Age &gt;= 65</b>						
Negative	D29	Anti-Spike IgG	576	48.8%	48.8%	48.8%
Negative	D29	Anti-Spike IgG	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
Negative	D29	Anti-RBD IgG	576	48.8%	48.8%	48.8%
Negative	D29	Anti-RBD IgG	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
Negative	D29	Pseudo nAb ID50	576	45.1%	45.1%	42.4%
Negative	D29	Pseudo nAb ID50	576	(45.1%, 45.1%)	(45.1%, 45.1%)	(42.4%, 42.4%)
Negative	D29	Pseudo nAb ID80	576	41.2%	41.2%	35.7%
Negative	D29	Pseudo nAb ID80	576	(41.2%, 41.2%)	(41.2%, 41.2%)	(35.7%, 35.7%)
Negative	D29	Live Virus nAb ID50	576	44.2%	44.2%	39.8%
Negative	D29	Live Virus nAb ID50	576	(44.2%, 44.2%)	(44.2%, 44.2%)	(39.8%, 39.8%)
Negative	D29	Live Virus nAb ID80	576	40.2%	40.2%	35.3%
Negative	D29	Live Virus nAb ID80	576	(40.2%, 40.2%)	(40.2%, 40.2%)	(35.3%, 35.3%)
Negative	D57	Anti-Spike IgG	576	48.8%	48.8%	48.8%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-Spike IgG	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
Negative	D57	Anti-RBD IgG	576	48.8%	48.8%	48.8%
Negative	D57	Anti-RBD IgG	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
Negative	D57	Pseudo nAb ID50	576	48.0%	48.0%	47.4%
Negative	D57	Pseudo nAb ID50	576	(48.0%, 48.0%)	(48.0%, 48.0%)	(47.4%, 47.4%)
Negative	D57	Pseudo nAb ID80	576	47.4%	47.4%	46.2%
Negative	D57	Pseudo nAb ID80	576	(47.4%, 47.4%)	(47.4%, 47.4%)	(46.2%, 46.2%)
Negative	D57	Live Virus nAb ID50	576	47.8%	47.8%	47.1%
Negative	D57	Live Virus nAb ID50	576	(47.8%, 47.8%)	(47.8%, 47.8%)	(47.1%, 47.1%)
Negative	D57	Live Virus nAb ID80	576	47.2%	47.2%	45.6%
Negative	D57	Live Virus nAb ID80	576	(47.2%, 47.2%)	(47.2%, 47.2%)	(45.6%, 45.6%)
Positive	D29	Anti-Spike IgG	228	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	228	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	228	93.2%	93.2%	87.5%
Positive	D29	Pseudo nAb ID50	228	(93.2%, 93.2%)	(93.2%, 93.2%)	(87.5%, 87.5%)
Positive	D29	Pseudo nAb ID80	228	84.5%	84.5%	69.5%
Positive	D29	Pseudo nAb ID80	228	(84.5%, 84.5%)	(84.5%, 84.5%)	(69.5%, 69.5%)
Positive	D29	Live Virus nAb ID50	228	90.0%	90.0%	80.7%
Positive	D29	Live Virus nAb ID50	228	(90.0%, 90.0%)	(90.0%, 90.0%)	(80.7%, 80.7%)
Positive	D29	Live Virus nAb ID80	228	82.9%	82.9%	71.4%
Positive	D29	Live Virus nAb ID80	228	(82.9%, 82.9%)	(82.9%, 82.9%)	(71.4%, 71.4%)
Positive	D57	Anti-Spike IgG	228	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	228	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	228	99.6%	99.6%	97.9%
Positive	D57	Pseudo nAb ID50	228	(99.6%, 99.6%)	(99.6%, 99.6%)	(97.9%, 97.9%)
Positive	D57	Pseudo nAb ID80	228	97.9%	97.9%	95.7%
Positive	D57	Pseudo nAb ID80	228	(97.9%, 97.9%)	(97.9%, 97.9%)	(95.7%, 95.7%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID50	228	98.8%	98.8%	98.4%
Positive	D57	Live Virus nAb ID50	228	(98.8%, 98.8%)	(98.8%, 98.8%)	(98.4%, 98.4%)
Positive	D57	Live Virus nAb ID80	228	97.8%	97.8%	94.8%
Positive	D57	Live Virus nAb ID80	228	(97.8%, 97.8%)	(97.8%, 97.8%)	(94.8%, 94.8%)
<b>At-risk</b>						
Negative	D29	Anti-Spike IgG	568	50.7%	50.7%	50.7%
Negative	D29	Anti-Spike IgG	568	(49.4%, 51.9%)	(49.4%, 51.9%)	(49.4%, 51.9%)
Negative	D29	Anti-RBD IgG	568	50.7%	50.7%	50.7%
Negative	D29	Anti-RBD IgG	568	(49.4%, 51.9%)	(49.4%, 51.9%)	(49.4%, 51.9%)
Negative	D29	Pseudo nAb ID50	568	41.3%	41.3%	35.8%
Negative	D29	Pseudo nAb ID50	568	(36.2%, 46.4%)	(36.2%, 46.4%)	(27.2%, 44.3%)
Negative	D29	Pseudo nAb ID80	568	36.1%	36.1%	29.1%
Negative	D29	Pseudo nAb ID80	568	(29.3%, 42.9%)	(29.3%, 42.9%)	(21.5%, 36.7%)
Negative	D29	Live Virus nAb ID50	568	40.1%	40.1%	33.5%
Negative	D29	Live Virus nAb ID50	568	(34.7%, 45.5%)	(34.7%, 45.5%)	(25.9%, 41.0%)
Negative	D29	Live Virus nAb ID80	568	36.6%	36.6%	29.6%
Negative	D29	Live Virus nAb ID80	568	(31.8%, 41.4%)	(31.8%, 41.4%)	(22.6%, 36.6%)
Negative	D57	Anti-Spike IgG	568	50.7%	50.7%	50.7%
Negative	D57	Anti-Spike IgG	568	(49.4%, 51.9%)	(49.4%, 51.9%)	(49.4%, 51.9%)
Negative	D57	Anti-RBD IgG	568	50.7%	50.7%	50.7%
Negative	D57	Anti-RBD IgG	568	(49.4%, 51.9%)	(49.4%, 51.9%)	(49.4%, 51.9%)
Negative	D57	Pseudo nAb ID50	568	48.7%	48.7%	47.7%
Negative	D57	Pseudo nAb ID50	568	(46.7%, 50.7%)	(46.7%, 50.7%)	(45.9%, 49.4%)
Negative	D57	Pseudo nAb ID80	568	48.2%	48.2%	45.8%
Negative	D57	Pseudo nAb ID80	568	(46.8%, 49.7%)	(46.8%, 49.7%)	(43.5%, 48.1%)
Negative	D57	Live Virus nAb ID50	568	49.4%	49.4%	46.6%
Negative	D57	Live Virus nAb ID50	568	(48.4%, 50.4%)	(48.4%, 50.4%)	(44.1%, 49.2%)
Negative	D57	Live Virus nAb ID80	568	47.8%	47.8%	46.2%
Negative	D57	Live Virus nAb ID80	568	(46.3%, 49.2%)	(46.3%, 49.2%)	(44.7%, 47.7%)
Positive	D29	Anti-Spike IgG	222	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Anti-Spike IgG	222	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	222	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	222	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	222	78.5%	78.5%	68.9%
Positive	D29	Pseudo nAb ID50	222	(68.8%, 88.1%)	(68.8%, 88.1%)	(57.4%, 80.4%)
Positive	D29	Pseudo nAb ID80	222	65.4%	65.4%	49.7%
Positive	D29	Pseudo nAb ID80	222	(52.2%, 78.7%)	(52.2%, 78.7%)	(36.7%, 62.7%)
Positive	D29	Live Virus nAb ID50	222	77.1%	77.1%	61.8%
Positive	D29	Live Virus nAb ID50	222	(67.4%, 86.8%)	(67.4%, 86.8%)	(47.4%, 76.2%)
Positive	D29	Live Virus nAb ID80	222	68.7%	68.7%	53.4%
Positive	D29	Live Virus nAb ID80	222	(59.6%, 77.7%)	(59.6%, 77.7%)	(39.7%, 67.1%)
Positive	D57	Anti-Spike IgG	222	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	222	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	222	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	222	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	222	96.2%	96.2%	93.7%
Positive	D57	Pseudo nAb ID50	222	(93.7%, 98.7%)	(93.7%, 98.7%)	(90.5%, 96.9%)
Positive	D57	Pseudo nAb ID80	222	92.6%	92.6%	85.0%
Positive	D57	Pseudo nAb ID80	222	(88.7%, 96.6%)	(88.7%, 96.6%)	(77.8%, 92.2%)
Positive	D57	Live Virus nAb ID50	222	97.5%	97.5%	92.4%
Positive	D57	Live Virus nAb ID50	222	(96.8%, 98.3%)	(96.8%, 98.3%)	(89.1%, 95.6%)
Positive	D57	Live Virus nAb ID80	222	91.8%	91.8%	87.5%
Positive	D57	Live Virus nAb ID80	222	(88.3%, 95.4%)	(88.3%, 95.4%)	(82.8%, 92.1%)
<b>Not at-risk</b>						
Negative	D29	Anti-Spike IgG	521	51.6%	51.6%	51.6%
Negative	D29	Anti-Spike IgG	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
Negative	D29	Anti-RBD IgG	521	51.6%	51.6%	51.6%
Negative	D29	Anti-RBD IgG	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
Negative	D29	Pseudo nAb ID50	521	41.6%	41.6%	35.2%
Negative	D29	Pseudo nAb ID50	521	(40.7%, 42.6%)	(40.7%, 42.6%)	(33.0%, 37.4%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Pseudo nAb ID80	521	34.2%	34.2%	27.4%
Negative	D29	Pseudo nAb ID80	521	(32.0%, 36.4%)	(32.0%, 36.4%)	(24.4%, 30.3%)
Negative	D29	Live Virus nAb ID50	521	42.4%	42.4%	33.9%
Negative	D29	Live Virus nAb ID50	521	(42.1%, 42.7%)	(42.1%, 42.7%)	(31.9%, 35.8%)
Negative	D29	Live Virus nAb ID80	521	35.7%	35.7%	28.4%
Negative	D29	Live Virus nAb ID80	521	(34.3%, 37.1%)	(34.3%, 37.1%)	(26.1%, 30.7%)
Negative	D57	Anti-Spike IgG	521	51.6%	51.6%	51.6%
Negative	D57	Anti-Spike IgG	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
Negative	D57	Anti-RBD IgG	521	51.6%	51.6%	51.6%
Negative	D57	Anti-RBD IgG	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
Negative	D57	Pseudo nAb ID50	521	50.7%	50.7%	49.6%
Negative	D57	Pseudo nAb ID50	521	(48.8%, 52.6%)	(48.8%, 52.6%)	(48.1%, 51.1%)
Negative	D57	Pseudo nAb ID80	521	48.7%	48.7%	46.2%
Negative	D57	Pseudo nAb ID80	521	(47.4%, 50.0%)	(47.4%, 50.0%)	(45.6%, 46.9%)
Negative	D57	Live Virus nAb ID50	521	50.2%	50.2%	49.3%
Negative	D57	Live Virus nAb ID50	521	(48.4%, 52.1%)	(48.4%, 52.1%)	(47.8%, 50.9%)
Negative	D57	Live Virus nAb ID80	521	48.9%	48.9%	45.9%
Negative	D57	Live Virus nAb ID80	521	(47.6%, 50.3%)	(47.6%, 50.3%)	(45.1%, 46.8%)
Positive	D29	Anti-Spike IgG	301	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	301	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	301	78.8%	78.8%	67.0%
Positive	D29	Pseudo nAb ID50	301	(73.1%, 84.4%)	(73.1%, 84.4%)	(58.9%, 75.2%)
Positive	D29	Pseudo nAb ID80	301	64.5%	64.5%	49.0%
Positive	D29	Pseudo nAb ID80	301	(57.0%, 72.1%)	(57.0%, 72.1%)	(41.1%, 57.0%)
Positive	D29	Live Virus nAb ID50	301	76.7%	76.7%	67.1%
Positive	D29	Live Virus nAb ID50	301	(71.9%, 81.5%)	(71.9%, 81.5%)	(62.5%, 71.8%)
Positive	D29	Live Virus nAb ID80	301	70.5%	70.5%	55.6%
Positive	D29	Live Virus nAb ID80	301	(65.7%, 75.4%)	(65.7%, 75.4%)	(50.1%, 61.2%)
Positive	D57	Anti-Spike IgG	301	100.0%	100.0%	100.0%



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Anti-Spike IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	301	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	301	95.3%	95.3%	93.9%
Positive	D57	Pseudo nAb ID50	301	(93.7%, 96.9%)	(93.7%, 96.9%)	(92.5%, 95.4%)
Positive	D57	Pseudo nAb ID80	301	92.2%	92.2%	87.9%
Positive	D57	Pseudo nAb ID80	301	(90.2%, 94.3%)	(90.2%, 94.3%)	(84.9%, 90.9%)
Positive	D57	Live Virus nAb ID50	301	96.3%	96.3%	94.0%
Positive	D57	Live Virus nAb ID50	301	(95.3%, 97.3%)	(95.3%, 97.3%)	(92.1%, 95.9%)
Positive	D57	Live Virus nAb ID80	301	96.9%	96.9%	93.8%
Positive	D57	Live Virus nAb ID80	301	(96.5%, 97.4%)	(96.5%, 97.4%)	(93.3%, 94.2%)
<b>Age &lt; 65 At-risk</b>						
Negative	D29	Anti-Spike IgG	259	50.1%	50.1%	50.1%
Negative	D29	Anti-Spike IgG	259	(50.1%, 50.1%)	(50.1%, 50.1%)	(50.1%, 50.1%)
Negative	D29	Anti-RBD IgG	259	50.1%	50.1%	50.1%
Negative	D29	Anti-RBD IgG	259	(50.1%, 50.1%)	(50.1%, 50.1%)	(50.1%, 50.1%)
Negative	D29	Pseudo nAb ID50	259	39.1%	39.1%	32.1%
Negative	D29	Pseudo nAb ID50	259	(39.1%, 39.1%)	(39.1%, 39.1%)	(32.1%, 32.1%)
Negative	D29	Pseudo nAb ID80	259	33.2%	33.2%	25.9%
Negative	D29	Pseudo nAb ID80	259	(33.2%, 33.2%)	(33.2%, 33.2%)	(25.9%, 25.9%)
Negative	D29	Live Virus nAb ID50	259	37.8%	37.8%	30.2%
Negative	D29	Live Virus nAb ID50	259	(37.8%, 37.8%)	(37.8%, 37.8%)	(30.2%, 30.2%)
Negative	D29	Live Virus nAb ID80	259	34.6%	34.6%	26.6%
Negative	D29	Live Virus nAb ID80	259	(34.6%, 34.6%)	(34.6%, 34.6%)	(26.6%, 26.6%)
Negative	D57	Anti-Spike IgG	259	50.1%	50.1%	50.1%
Negative	D57	Anti-Spike IgG	259	(50.1%, 50.1%)	(50.1%, 50.1%)	(50.1%, 50.1%)
Negative	D57	Anti-RBD IgG	259	50.1%	50.1%	50.1%
Negative	D57	Anti-RBD IgG	259	(50.1%, 50.1%)	(50.1%, 50.1%)	(50.1%, 50.1%)
Negative	D57	Pseudo nAb ID50	259	47.8%	47.8%	46.9%
Negative	D57	Pseudo nAb ID50	259	(47.8%, 47.8%)	(47.8%, 47.8%)	(46.9%, 46.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Pseudo nAb ID80	259	47.6%	47.6%	44.8%
Negative	D57	Pseudo nAb ID80	259	(47.6%, 47.6%)	(47.6%, 47.6%)	(44.8%, 44.8%)
Negative	D57	Live Virus nAb ID50	259	49.0%	49.0%	45.5%
Negative	D57	Live Virus nAb ID50	259	(49.0%, 49.0%)	(49.0%, 49.0%)	(45.5%, 45.5%)
Negative	D57	Live Virus nAb ID80	259	47.1%	47.1%	45.5%
Negative	D57	Live Virus nAb ID80	259	(47.1%, 47.1%)	(47.1%, 47.1%)	(45.5%, 45.5%)
Positive	D29	Anti-Spike IgG	147	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	147	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	147	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	147	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	147	74.9%	74.9%	64.7%
Positive	D29	Pseudo nAb ID50	147	(74.9%, 74.9%)	(74.9%, 74.9%)	(64.7%, 64.7%)
Positive	D29	Pseudo nAb ID80	147	60.6%	60.6%	45.0%
Positive	D29	Pseudo nAb ID80	147	(60.6%, 60.6%)	(60.6%, 60.6%)	(45.0%, 45.0%)
Positive	D29	Live Virus nAb ID50	147	73.6%	73.6%	56.6%
Positive	D29	Live Virus nAb ID50	147	(73.6%, 73.6%)	(73.6%, 73.6%)	(56.6%, 56.6%)
Positive	D29	Live Virus nAb ID80	147	65.4%	65.4%	48.4%
Positive	D29	Live Virus nAb ID80	147	(65.4%, 65.4%)	(65.4%, 65.4%)	(48.4%, 48.4%)
Positive	D57	Anti-Spike IgG	147	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	147	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	147	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	147	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	147	95.3%	95.3%	92.5%
Positive	D57	Pseudo nAb ID50	147	(95.3%, 95.3%)	(95.3%, 95.3%)	(92.5%, 92.5%)
Positive	D57	Pseudo nAb ID80	147	91.2%	91.2%	82.4%
Positive	D57	Pseudo nAb ID80	147	(91.2%, 91.2%)	(91.2%, 91.2%)	(82.4%, 82.4%)
Positive	D57	Live Virus nAb ID50	147	97.3%	97.3%	91.2%
Positive	D57	Live Virus nAb ID50	147	(97.3%, 97.3%)	(97.3%, 97.3%)	(91.2%, 91.2%)
Positive	D57	Live Virus nAb ID80	147	90.5%	90.5%	85.8%
Positive	D57	Live Virus nAb ID80	147	(90.5%, 90.5%)	(90.5%, 90.5%)	(85.8%, 85.8%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
<b>Age &lt; 65 Not at-risk</b>						
Negative	D29	Anti-Spike IgG	254	52.3%	52.3%	52.3%
Negative	D29	Anti-Spike IgG	254	(52.3%, 52.3%)	(52.3%, 52.3%)	(52.3%, 52.3%)
Negative	D29	Anti-RBD IgG	254	52.3%	52.3%	52.3%
Negative	D29	Anti-RBD IgG	254	(52.3%, 52.3%)	(52.3%, 52.3%)	(52.3%, 52.3%)
Negative	D29	Pseudo nAb ID50	254	41.3%	41.3%	34.5%
Negative	D29	Pseudo nAb ID50	254	(41.3%, 41.3%)	(41.3%, 41.3%)	(34.5%, 34.5%)
Negative	D29	Pseudo nAb ID80	254	33.5%	33.5%	26.4%
Negative	D29	Pseudo nAb ID80	254	(33.5%, 33.5%)	(33.5%, 33.5%)	(26.4%, 26.4%)
Negative	D29	Live Virus nAb ID50	254	42.3%	42.3%	33.2%
Negative	D29	Live Virus nAb ID50	254	(42.3%, 42.3%)	(42.3%, 42.3%)	(33.2%, 33.2%)
Negative	D29	Live Virus nAb ID80	254	35.2%	35.2%	27.6%
Negative	D29	Live Virus nAb ID80	254	(35.2%, 35.2%)	(35.2%, 35.2%)	(27.6%, 27.6%)
Negative	D57	Anti-Spike IgG	254	52.3%	52.3%	52.3%
Negative	D57	Anti-Spike IgG	254	(52.3%, 52.3%)	(52.3%, 52.3%)	(52.3%, 52.3%)
Negative	D57	Anti-RBD IgG	254	52.3%	52.3%	52.3%
Negative	D57	Anti-RBD IgG	254	(52.3%, 52.3%)	(52.3%, 52.3%)	(52.3%, 52.3%)
Negative	D57	Pseudo nAb ID50	254	51.3%	51.3%	50.1%
Negative	D57	Pseudo nAb ID50	254	(51.3%, 51.3%)	(51.3%, 51.3%)	(50.1%, 50.1%)
Negative	D57	Pseudo nAb ID80	254	49.1%	49.1%	46.5%
Negative	D57	Pseudo nAb ID80	254	(49.1%, 49.1%)	(49.1%, 49.1%)	(46.5%, 46.5%)
Negative	D57	Live Virus nAb ID50	254	50.9%	50.9%	49.9%
Negative	D57	Live Virus nAb ID50	254	(50.9%, 50.9%)	(50.9%, 50.9%)	(49.9%, 49.9%)
Negative	D57	Live Virus nAb ID80	254	49.4%	49.4%	46.2%
Negative	D57	Live Virus nAb ID80	254	(49.4%, 49.4%)	(49.4%, 49.4%)	(46.2%, 46.2%)
Positive	D29	Anti-Spike IgG	148	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	148	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	148	76.9%	76.9%	64.3%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Pseudo nAb ID50	148	(76.9%, 76.9%)	(76.9%, 76.9%)	(64.3%, 64.3%)
Positive	D29	Pseudo nAb ID80	148	62.0%	62.0%	46.4%
Positive	D29	Pseudo nAb ID80	148	(62.0%, 62.0%)	(62.0%, 62.0%)	(46.4%, 46.4%)
Positive	D29	Live Virus nAb ID50	148	75.1%	75.1%	65.6%
Positive	D29	Live Virus nAb ID50	148	(75.1%, 75.1%)	(75.1%, 75.1%)	(65.6%, 65.6%)
Positive	D29	Live Virus nAb ID80	148	68.9%	68.9%	53.8%
Positive	D29	Live Virus nAb ID80	148	(68.9%, 68.9%)	(68.9%, 68.9%)	(53.8%, 53.8%)
Positive	D57	Anti-Spike IgG	148	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	148	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	148	94.7%	94.7%	93.5%
Positive	D57	Pseudo nAb ID50	148	(94.7%, 94.7%)	(94.7%, 94.7%)	(93.5%, 93.5%)
Positive	D57	Pseudo nAb ID80	148	91.5%	91.5%	86.9%
Positive	D57	Pseudo nAb ID80	148	(91.5%, 91.5%)	(91.5%, 91.5%)	(86.9%, 86.9%)
Positive	D57	Live Virus nAb ID50	148	96.0%	96.0%	93.4%
Positive	D57	Live Virus nAb ID50	148	(96.0%, 96.0%)	(96.0%, 96.0%)	(93.4%, 93.4%)
Positive	D57	Live Virus nAb ID80	148	96.8%	96.8%	93.6%
Positive	D57	Live Virus nAb ID80	148	(96.8%, 96.8%)	(96.8%, 96.8%)	(93.6%, 93.6%)
<b>Age &gt;= 65 At-risk</b>						
Negative	D29	Anti-Spike IgG	309	51.8%	51.8%	51.8%
Negative	D29	Anti-Spike IgG	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
Negative	D29	Anti-RBD IgG	309	51.8%	51.8%	51.8%
Negative	D29	Anti-RBD IgG	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
Negative	D29	Pseudo nAb ID50	309	46.1%	46.1%	43.7%
Negative	D29	Pseudo nAb ID50	309	(46.1%, 46.1%)	(46.1%, 46.1%)	(43.7%, 43.7%)
Negative	D29	Pseudo nAb ID80	309	42.4%	42.4%	36.1%
Negative	D29	Pseudo nAb ID80	309	(42.4%, 42.4%)	(42.4%, 42.4%)	(36.1%, 36.1%)
Negative	D29	Live Virus nAb ID50	309	45.1%	45.1%	40.5%
Negative	D29	Live Virus nAb ID50	309	(45.1%, 45.1%)	(45.1%, 45.1%)	(40.5%, 40.5%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Live Virus nAb ID80	309	41.1%	41.1%	36.1%
Negative	D29	Live Virus nAb ID80	309	(41.1%, 41.1%)	(41.1%, 41.1%)	(36.1%, 36.1%)
Negative	D57	Anti-Spike IgG	309	51.8%	51.8%	51.8%
Negative	D57	Anti-Spike IgG	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
Negative	D57	Anti-RBD IgG	309	51.8%	51.8%	51.8%
Negative	D57	Anti-RBD IgG	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
Negative	D57	Pseudo nAb ID50	309	50.6%	50.6%	49.3%
Negative	D57	Pseudo nAb ID50	309	(50.6%, 50.6%)	(50.6%, 50.6%)	(49.3%, 49.3%)
Negative	D57	Pseudo nAb ID80	309	49.6%	49.6%	47.9%
Negative	D57	Pseudo nAb ID80	309	(49.6%, 49.6%)	(49.6%, 49.6%)	(47.9%, 47.9%)
Negative	D57	Live Virus nAb ID50	309	50.3%	50.3%	49.0%
Negative	D57	Live Virus nAb ID50	309	(50.3%, 50.3%)	(50.3%, 50.3%)	(49.0%, 49.0%)
Negative	D57	Live Virus nAb ID80	309	49.1%	49.1%	47.6%
Negative	D57	Live Virus nAb ID80	309	(49.1%, 49.1%)	(49.1%, 49.1%)	(47.6%, 47.6%)
Positive	D29	Anti-Spike IgG	75	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	75	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	75	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	75	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	75	93.2%	93.2%	86.5%
Positive	D29	Pseudo nAb ID50	75	(93.2%, 93.2%)	(93.2%, 93.2%)	(86.5%, 86.5%)
Positive	D29	Pseudo nAb ID80	75	85.7%	85.7%	69.5%
Positive	D29	Pseudo nAb ID80	75	(85.7%, 85.7%)	(85.7%, 85.7%)	(69.5%, 69.5%)
Positive	D29	Live Virus nAb ID50	75	91.9%	91.9%	83.8%
Positive	D29	Live Virus nAb ID50	75	(91.9%, 91.9%)	(91.9%, 91.9%)	(83.8%, 83.8%)
Positive	D29	Live Virus nAb ID80	75	82.5%	82.5%	74.4%
Positive	D29	Live Virus nAb ID80	75	(82.5%, 82.5%)	(82.5%, 82.5%)	(74.4%, 74.4%)
Positive	D57	Anti-Spike IgG	75	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	75	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	75	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	75	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	75	100.0%	100.0%	98.6%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Pseudo nAb ID50	75	(100.0%, 100.0%)	(100.0%, 100.0%)	(98.6%, 98.6%)
Positive	D57	Pseudo nAb ID80	75	98.6%	98.6%	95.9%
Positive	D57	Pseudo nAb ID80	75	(98.6%, 98.6%)	(98.6%, 98.6%)	(95.9%, 95.9%)
Positive	D57	Live Virus nAb ID50	75	98.6%	98.6%	97.3%
Positive	D57	Live Virus nAb ID50	75	(98.6%, 98.6%)	(98.6%, 98.6%)	(97.3%, 97.3%)
Positive	D57	Live Virus nAb ID80	75	97.3%	97.3%	94.6%
Positive	D57	Live Virus nAb ID80	75	(97.3%, 97.3%)	(97.3%, 97.3%)	(94.6%, 94.6%)
<b>Age &gt;= 65 Not at-risk</b>						
Negative	D29	Anti-Spike IgG	267	45.7%	45.7%	45.7%
Negative	D29	Anti-Spike IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
Negative	D29	Anti-RBD IgG	267	45.7%	45.7%	45.7%
Negative	D29	Anti-RBD IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
Negative	D29	Pseudo nAb ID50	267	44.1%	44.1%	41.1%
Negative	D29	Pseudo nAb ID50	267	(44.1%, 44.1%)	(44.1%, 44.1%)	(41.1%, 41.1%)
Negative	D29	Pseudo nAb ID80	267	40.1%	40.1%	35.2%
Negative	D29	Pseudo nAb ID80	267	(40.1%, 40.1%)	(40.1%, 40.1%)	(35.2%, 35.2%)
Negative	D29	Live Virus nAb ID50	267	43.3%	43.3%	39.1%
Negative	D29	Live Virus nAb ID50	267	(43.3%, 43.3%)	(43.3%, 43.3%)	(39.1%, 39.1%)
Negative	D29	Live Virus nAb ID80	267	39.4%	39.4%	34.6%
Negative	D29	Live Virus nAb ID80	267	(39.4%, 39.4%)	(39.4%, 39.4%)	(34.6%, 34.6%)
Negative	D57	Anti-Spike IgG	267	45.7%	45.7%	45.7%
Negative	D57	Anti-Spike IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
Negative	D57	Anti-RBD IgG	267	45.7%	45.7%	45.7%
Negative	D57	Anti-RBD IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
Negative	D57	Pseudo nAb ID50	267	45.5%	45.5%	45.5%
Negative	D57	Pseudo nAb ID50	267	(45.5%, 45.5%)	(45.5%, 45.5%)	(45.5%, 45.5%)
Negative	D57	Pseudo nAb ID80	267	45.3%	45.3%	44.5%
Negative	D57	Pseudo nAb ID80	267	(45.3%, 45.3%)	(45.3%, 45.3%)	(44.5%, 44.5%)
Negative	D57	Live Virus nAb ID50	267	45.3%	45.3%	45.1%
Negative	D57	Live Virus nAb ID50	267	(45.3%, 45.3%)	(45.3%, 45.3%)	(45.1%, 45.1%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Live Virus nAb ID80	267	45.3%	45.3%	43.7%
Negative	D57	Live Virus nAb ID80	267	(45.3%, 45.3%)	(45.3%, 45.3%)	(43.7%, 43.7%)
Positive	D29	Anti-Spike IgG	153	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	153	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	153	93.2%	93.2%	87.9%
Positive	D29	Pseudo nAb ID50	153	(93.2%, 93.2%)	(93.2%, 93.2%)	(87.9%, 87.9%)
Positive	D29	Pseudo nAb ID80	153	83.9%	83.9%	69.4%
Positive	D29	Pseudo nAb ID80	153	(83.9%, 83.9%)	(83.9%, 83.9%)	(69.4%, 69.4%)
Positive	D29	Live Virus nAb ID50	153	89.1%	89.1%	79.1%
Positive	D29	Live Virus nAb ID50	153	(89.1%, 89.1%)	(89.1%, 89.1%)	(79.1%, 79.1%)
Positive	D29	Live Virus nAb ID80	153	83.1%	83.1%	69.9%
Positive	D29	Live Virus nAb ID80	153	(83.1%, 83.1%)	(83.1%, 83.1%)	(69.9%, 69.9%)
Positive	D57	Anti-Spike IgG	153	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	153	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	153	99.3%	99.3%	97.6%
Positive	D57	Pseudo nAb ID50	153	(99.3%, 99.3%)	(99.3%, 99.3%)	(97.6%, 97.6%)
Positive	D57	Pseudo nAb ID80	153	97.6%	97.6%	95.6%
Positive	D57	Pseudo nAb ID80	153	(97.6%, 97.6%)	(97.6%, 97.6%)	(95.6%, 95.6%)
Positive	D57	Live Virus nAb ID50	153	98.9%	98.9%	98.9%
Positive	D57	Live Virus nAb ID50	153	(98.9%, 98.9%)	(98.9%, 98.9%)	(98.9%, 98.9%)
Positive	D57	Live Virus nAb ID80	153	98.0%	98.0%	95.0%
Positive	D57	Live Virus nAb ID80	153	(98.0%, 98.0%)	(98.0%, 98.0%)	(95.0%, 95.0%)
<b>Female</b>						
Negative	D29	Anti-Spike IgG	595	52.2%	52.2%	52.2%
Negative	D29	Anti-Spike IgG	595	(47.4%, 57.0%)	(47.4%, 57.0%)	(47.4%, 57.0%)
Negative	D29	Anti-RBD IgG	595	52.2%	52.2%	52.2%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Anti-RBD IgG	595	(47.4%, 57.0%)	(47.4%, 57.0%)	(47.4%, 57.0%)
Negative	D29	Pseudo nAb ID50	595	42.8%	42.8%	36.5%
Negative	D29	Pseudo nAb ID50	595	(39.9%, 45.7%)	(39.9%, 45.7%)	(34.7%, 38.3%)
Negative	D29	Pseudo nAb ID80	595	35.8%	35.8%	28.2%
Negative	D29	Pseudo nAb ID80	595	(34.5%, 37.0%)	(34.5%, 37.0%)	(26.3%, 30.0%)
Negative	D29	Live Virus nAb ID50	595	41.7%	41.7%	33.0%
Negative	D29	Live Virus nAb ID50	595	(39.1%, 44.2%)	(39.1%, 44.2%)	(30.7%, 35.3%)
Negative	D29	Live Virus nAb ID80	595	35.5%	35.5%	28.5%
Negative	D29	Live Virus nAb ID80	595	(34.5%, 36.6%)	(34.5%, 36.6%)	(25.9%, 31.0%)
Negative	D57	Anti-Spike IgG	595	52.2%	52.2%	52.2%
Negative	D57	Anti-Spike IgG	595	(47.4%, 57.0%)	(47.4%, 57.0%)	(47.4%, 57.0%)
Negative	D57	Anti-RBD IgG	595	52.2%	52.2%	52.2%
Negative	D57	Anti-RBD IgG	595	(47.4%, 57.0%)	(47.4%, 57.0%)	(47.4%, 57.0%)
Negative	D57	Pseudo nAb ID50	595	51.2%	51.2%	50.3%
Negative	D57	Pseudo nAb ID50	595	(45.5%, 56.8%)	(45.5%, 56.8%)	(44.9%, 55.8%)
Negative	D57	Pseudo nAb ID80	595	48.5%	48.5%	46.2%
Negative	D57	Pseudo nAb ID80	595	(45.6%, 51.5%)	(45.6%, 51.5%)	(43.5%, 49.0%)
Negative	D57	Live Virus nAb ID50	595	50.3%	50.3%	49.2%
Negative	D57	Live Virus nAb ID50	595	(46.2%, 54.4%)	(46.2%, 54.4%)	(44.3%, 54.1%)
Negative	D57	Live Virus nAb ID80	595	49.1%	49.1%	45.8%
Negative	D57	Live Virus nAb ID80	595	(45.5%, 52.7%)	(45.5%, 52.7%)	(43.6%, 47.9%)
Positive	D29	Anti-Spike IgG	294	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	294	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	294	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	294	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	294	77.6%	77.6%	63.7%
Positive	D29	Pseudo nAb ID50	294	(71.6%, 83.5%)	(71.6%, 83.5%)	(55.8%, 71.6%)
Positive	D29	Pseudo nAb ID80	294	60.4%	60.4%	46.0%
Positive	D29	Pseudo nAb ID80	294	(52.6%, 68.2%)	(52.6%, 68.2%)	(38.9%, 53.0%)
Positive	D29	Live Virus nAb ID50	294	78.6%	78.6%	63.8%
Positive	D29	Live Virus nAb ID50	294	(74.7%, 82.5%)	(74.7%, 82.5%)	(57.0%, 70.7%)



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Live Virus nAb ID80	294	71.3%	71.3%	54.0%
Positive	D29	Live Virus nAb ID80	294	(65.5%, 77.0%)	(65.5%, 77.0%)	(45.5%, 62.5%)
Positive	D57	Anti-Spike IgG	294	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	294	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	294	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	294	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	294	97.3%	97.3%	94.6%
Positive	D57	Pseudo nAb ID50	294	(95.7%, 98.8%)	(95.7%, 98.8%)	(92.1%, 97.2%)
Positive	D57	Pseudo nAb ID80	294	93.0%	93.0%	89.2%
Positive	D57	Pseudo nAb ID80	294	(91.2%, 94.8%)	(91.2%, 94.8%)	(83.5%, 94.8%)
Positive	D57	Live Virus nAb ID50	294	98.5%	98.5%	95.2%
Positive	D57	Live Virus nAb ID50	294	(97.5%, 99.5%)	(97.5%, 99.5%)	(91.0%, 99.4%)
Positive	D57	Live Virus nAb ID80	294	95.3%	95.3%	92.5%
Positive	D57	Live Virus nAb ID80	294	(91.6%, 99.0%)	(91.6%, 99.0%)	(87.3%, 97.7%)
<b>Male</b>						
Negative	D29	Anti-Spike IgG	494	50.4%	50.4%	50.4%
Negative	D29	Anti-Spike IgG	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
Negative	D29	Anti-RBD IgG	494	50.4%	50.4%	50.4%
Negative	D29	Anti-RBD IgG	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
Negative	D29	Pseudo nAb ID50	494	40.1%	40.1%	34.0%
Negative	D29	Pseudo nAb ID50	494	(35.0%, 45.3%)	(35.0%, 45.3%)	(27.9%, 40.1%)
Negative	D29	Pseudo nAb ID80	494	33.5%	33.5%	27.4%
Negative	D29	Pseudo nAb ID80	494	(27.2%, 39.8%)	(27.2%, 39.8%)	(20.7%, 34.2%)
Negative	D29	Live Virus nAb ID50	494	42.0%	42.0%	34.7%
Negative	D29	Live Virus nAb ID50	494	(39.2%, 44.8%)	(39.2%, 44.8%)	(30.6%, 38.8%)
Negative	D29	Live Virus nAb ID80	494	36.3%	36.3%	29.0%
Negative	D29	Live Virus nAb ID80	494	(32.8%, 39.9%)	(32.8%, 39.9%)	(24.6%, 33.3%)
Negative	D57	Anti-Spike IgG	494	50.4%	50.4%	50.4%
Negative	D57	Anti-Spike IgG	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
Negative	D57	Anti-RBD IgG	494	50.4%	50.4%	50.4%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-RBD IgG	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
Negative	D57	Pseudo nAb ID50	494	49.1%	49.1%	47.7%
Negative	D57	Pseudo nAb ID50	494	(47.0%, 51.1%)	(47.0%, 51.1%)	(45.3%, 50.1%)
Negative	D57	Pseudo nAb ID80	494	48.6%	48.6%	46.0%
Negative	D57	Pseudo nAb ID80	494	(46.9%, 50.4%)	(46.9%, 50.4%)	(43.4%, 48.6%)
Negative	D57	Live Virus nAb ID50	494	49.7%	49.7%	48.0%
Negative	D57	Live Virus nAb ID50	494	(47.9%, 51.5%)	(47.9%, 51.5%)	(45.6%, 50.4%)
Negative	D57	Live Virus nAb ID80	494	48.1%	48.1%	46.3%
Negative	D57	Live Virus nAb ID80	494	(46.3%, 50.0%)	(46.3%, 50.0%)	(44.2%, 48.4%)
Positive	D29	Anti-Spike IgG	229	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	229	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	229	80.2%	80.2%	72.4%
Positive	D29	Pseudo nAb ID50	229	(71.7%, 88.6%)	(71.7%, 88.6%)	(63.4%, 81.3%)
Positive	D29	Pseudo nAb ID80	229	70.4%	70.4%	53.4%
Positive	D29	Pseudo nAb ID80	229	(61.8%, 79.0%)	(61.8%, 79.0%)	(41.5%, 65.4%)
Positive	D29	Live Virus nAb ID50	229	74.4%	74.4%	68.7%
Positive	D29	Live Virus nAb ID50	229	(64.7%, 84.2%)	(64.7%, 84.2%)	(62.8%, 74.6%)
Positive	D29	Live Virus nAb ID80	229	68.6%	68.6%	56.6%
Positive	D29	Live Virus nAb ID80	229	(58.6%, 78.7%)	(58.6%, 78.7%)	(47.3%, 65.9%)
Positive	D57	Anti-Spike IgG	229	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	229	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	229	93.1%	93.1%	92.9%
Positive	D57	Pseudo nAb ID50	229	(89.0%, 97.2%)	(89.0%, 97.2%)	(89.3%, 96.5%)
Positive	D57	Pseudo nAb ID80	229	91.4%	91.4%	84.7%
Positive	D57	Pseudo nAb ID80	229	(87.6%, 95.3%)	(87.6%, 95.3%)	(79.0%, 90.5%)
Positive	D57	Live Virus nAb ID50	229	94.2%	94.2%	91.6%
Positive	D57	Live Virus nAb ID50	229	(90.9%, 97.4%)	(90.9%, 97.4%)	(87.3%, 95.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID80	229	96.4%	96.4%	92.2%
Positive	D57	Live Virus nAb ID80	229	(94.6%, 98.3%)	(94.6%, 98.3%)	(90.6%, 93.8%)
<b>Age &lt; 65 Female</b>						
Negative	D29	Anti-Spike IgG	285	53.8%	53.8%	53.8%
Negative	D29	Anti-Spike IgG	285	(51.7%, 55.8%)	(51.7%, 55.8%)	(51.7%, 55.8%)
Negative	D29	Anti-RBD IgG	285	53.8%	53.8%	53.8%
Negative	D29	Anti-RBD IgG	285	(51.7%, 55.8%)	(51.7%, 55.8%)	(51.7%, 55.8%)
Negative	D29	Pseudo nAb ID50	285	43.2%	43.2%	36.0%
Negative	D29	Pseudo nAb ID50	285	(40.3%, 46.1%)	(40.3%, 46.1%)	(33.9%, 38.1%)
Negative	D29	Pseudo nAb ID80	285	35.4%	35.4%	27.4%
Negative	D29	Pseudo nAb ID80	285	(34.0%, 36.7%)	(34.0%, 36.7%)	(26.0%, 28.9%)
Negative	D29	Live Virus nAb ID50	285	41.7%	41.7%	32.2%
Negative	D29	Live Virus nAb ID50	285	(38.7%, 44.8%)	(38.7%, 44.8%)	(29.9%, 34.5%)
Negative	D29	Live Virus nAb ID80	285	35.1%	35.1%	27.4%
Negative	D29	Live Virus nAb ID80	285	(34.3%, 35.9%)	(34.3%, 35.9%)	(26.0%, 28.9%)
Negative	D57	Anti-Spike IgG	285	53.8%	53.8%	53.8%
Negative	D57	Anti-Spike IgG	285	(51.7%, 55.8%)	(51.7%, 55.8%)	(51.7%, 55.8%)
Negative	D57	Anti-RBD IgG	285	53.8%	53.8%	53.8%
Negative	D57	Anti-RBD IgG	285	(51.7%, 55.8%)	(51.7%, 55.8%)	(51.7%, 55.8%)
Negative	D57	Pseudo nAb ID50	285	52.7%	52.7%	51.8%
Negative	D57	Pseudo nAb ID50	285	(49.0%, 56.4%)	(49.0%, 56.4%)	(48.2%, 55.4%)
Negative	D57	Pseudo nAb ID80	285	49.6%	49.6%	47.1%
Negative	D57	Pseudo nAb ID80	285	(48.8%, 50.3%)	(48.8%, 50.3%)	(46.1%, 48.2%)
Negative	D57	Live Virus nAb ID50	285	51.8%	51.8%	50.6%
Negative	D57	Live Virus nAb ID50	285	(50.6%, 52.9%)	(50.6%, 52.9%)	(47.6%, 53.6%)
Negative	D57	Live Virus nAb ID80	285	50.2%	50.2%	46.6%
Negative	D57	Live Virus nAb ID80	285	(48.7%, 51.8%)	(48.7%, 51.8%)	(46.6%, 46.6%)
Positive	D29	Anti-Spike IgG	177	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	177	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	177	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Anti-RBD IgG	177	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	177	75.5%	75.5%	60.7%
Positive	D29	Pseudo nAb ID50	177	(70.6%, 80.5%)	(70.6%, 80.5%)	(59.9%, 61.5%)
Positive	D29	Pseudo nAb ID80	177	57.4%	57.4%	43.4%
Positive	D29	Pseudo nAb ID80	177	(55.0%, 59.8%)	(55.0%, 59.8%)	(38.6%, 48.1%)
Positive	D29	Live Virus nAb ID50	177	77.5%	77.5%	61.7%
Positive	D29	Live Virus nAb ID50	177	(73.5%, 81.5%)	(73.5%, 81.5%)	(55.1%, 68.4%)
Positive	D29	Live Virus nAb ID80	177	70.2%	70.2%	51.6%
Positive	D29	Live Virus nAb ID80	177	(63.5%, 76.8%)	(63.5%, 76.8%)	(42.8%, 60.5%)
Positive	D57	Anti-Spike IgG	177	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	177	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	177	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	177	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	177	96.9%	96.9%	94.2%
Positive	D57	Pseudo nAb ID50	177	(95.2%, 98.6%)	(95.2%, 98.6%)	(91.2%, 97.1%)
Positive	D57	Pseudo nAb ID80	177	92.4%	92.4%	88.2%
Positive	D57	Pseudo nAb ID80	177	(90.9%, 93.9%)	(90.9%, 93.9%)	(81.6%, 94.8%)
Positive	D57	Live Virus nAb ID50	177	98.3%	98.3%	94.5%
Positive	D57	Live Virus nAb ID50	177	(97.1%, 99.4%)	(97.1%, 99.4%)	(89.6%, 99.5%)
Positive	D57	Live Virus nAb ID80	177	94.9%	94.9%	91.9%
Positive	D57	Live Virus nAb ID80	177	(90.6%, 99.2%)	(90.6%, 99.2%)	(85.7%, 98.1%)
<b>Age &lt; 65 Male</b>						
Negative	D29	Anti-Spike IgG	228	49.7%	49.7%	49.7%
Negative	D29	Anti-Spike IgG	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
Negative	D29	Anti-RBD IgG	228	49.7%	49.7%	49.7%
Negative	D29	Anti-RBD IgG	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
Negative	D29	Pseudo nAb ID50	228	38.2%	38.2%	31.6%
Negative	D29	Pseudo nAb ID50	228	(37.7%, 38.7%)	(37.7%, 38.7%)	(30.9%, 32.3%)
Negative	D29	Pseudo nAb ID80	228	31.2%	31.2%	25.0%
Negative	D29	Pseudo nAb ID80	228	(30.2%, 32.1%)	(30.2%, 32.1%)	(24.1%, 25.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Live Virus nAb ID50	228	40.9%	40.9%	33.1%
Negative	D29	Live Virus nAb ID50	228	(38.9%, 42.9%)	(38.9%, 42.9%)	(32.1%, 34.0%)
Negative	D29	Live Virus nAb ID80	228	35.0%	35.0%	27.4%
Negative	D29	Live Virus nAb ID80	228	(34.9%, 35.2%)	(34.9%, 35.2%)	(27.0%, 27.7%)
Negative	D57	Anti-Spike IgG	228	49.7%	49.7%	49.7%
Negative	D57	Anti-Spike IgG	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
Negative	D57	Anti-RBD IgG	228	49.7%	49.7%	49.7%
Negative	D57	Anti-RBD IgG	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
Negative	D57	Pseudo nAb ID50	228	48.2%	48.2%	46.8%
Negative	D57	Pseudo nAb ID50	228	(48.0%, 48.5%)	(48.0%, 48.5%)	(46.8%, 46.8%)
Negative	D57	Pseudo nAb ID80	228	47.9%	47.9%	44.9%
Negative	D57	Pseudo nAb ID80	228	(46.9%, 49.0%)	(46.9%, 49.0%)	(44.1%, 45.8%)
Negative	D57	Live Virus nAb ID50	228	49.0%	49.0%	47.1%
Negative	D57	Live Virus nAb ID50	228	(47.9%, 50.0%)	(47.9%, 50.0%)	(45.2%, 49.0%)
Negative	D57	Live Virus nAb ID80	228	47.4%	47.4%	45.5%
Negative	D57	Live Virus nAb ID80	228	(46.4%, 48.5%)	(46.4%, 48.5%)	(44.6%, 46.3%)
Positive	D29	Anti-Spike IgG	118	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	118	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	118	77.7%	77.7%	69.4%
Positive	D29	Pseudo nAb ID50	118	(73.4%, 82.1%)	(73.4%, 82.1%)	(66.8%, 71.9%)
Positive	D29	Pseudo nAb ID80	118	67.6%	67.6%	49.8%
Positive	D29	Pseudo nAb ID80	118	(65.0%, 70.1%)	(65.0%, 70.1%)	(44.5%, 55.1%)
Positive	D29	Live Virus nAb ID50	118	71.2%	71.2%	66.3%
Positive	D29	Live Virus nAb ID50	118	(68.5%, 73.8%)	(68.5%, 73.8%)	(63.9%, 68.7%)
Positive	D29	Live Virus nAb ID80	118	65.5%	65.5%	54.0%
Positive	D29	Live Virus nAb ID80	118	(61.7%, 69.3%)	(61.7%, 69.3%)	(49.0%, 59.0%)
Positive	D57	Anti-Spike IgG	118	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	118	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Anti-RBD IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	118	92.1%	92.1%	92.1%
Positive	D57	Pseudo nAb ID50	118	(89.5%, 94.6%)	(89.5%, 94.6%)	(89.5%, 94.6%)
Positive	D57	Pseudo nAb ID80	118	90.2%	90.2%	83.0%
Positive	D57	Pseudo nAb ID80	118	(88.8%, 91.6%)	(88.8%, 91.6%)	(80.6%, 85.3%)
Positive	D57	Live Virus nAb ID50	118	93.6%	93.6%	90.7%
Positive	D57	Live Virus nAb ID50	118	(90.8%, 96.3%)	(90.8%, 96.3%)	(87.4%, 94.1%)
Positive	D57	Live Virus nAb ID80	118	96.3%	96.3%	92.1%
Positive	D57	Live Virus nAb ID80	118	(94.0%, 98.6%)	(94.0%, 98.6%)	(90.0%, 94.1%)
<b>Age &gt;= 65 Female</b>						
Negative	D29	Anti-Spike IgG	310	44.7%	44.7%	44.7%
Negative	D29	Anti-Spike IgG	310	(44.7%, 44.7%)	(44.7%, 44.7%)	(44.7%, 44.7%)
Negative	D29	Anti-RBD IgG	310	44.7%	44.7%	44.7%
Negative	D29	Anti-RBD IgG	310	(44.7%, 44.7%)	(44.7%, 44.7%)	(44.7%, 44.7%)
Negative	D29	Pseudo nAb ID50	310	40.9%	40.9%	38.7%
Negative	D29	Pseudo nAb ID50	310	(40.9%, 40.9%)	(40.9%, 40.9%)	(38.7%, 38.7%)
Negative	D29	Pseudo nAb ID80	310	37.6%	37.6%	31.6%
Negative	D29	Pseudo nAb ID80	310	(37.6%, 37.6%)	(37.6%, 37.6%)	(31.6%, 31.6%)
Negative	D29	Live Virus nAb ID50	310	41.3%	41.3%	36.8%
Negative	D29	Live Virus nAb ID50	310	(41.3%, 41.3%)	(41.3%, 41.3%)	(36.8%, 36.8%)
Negative	D29	Live Virus nAb ID80	310	37.6%	37.6%	33.4%
Negative	D29	Live Virus nAb ID80	310	(37.6%, 37.6%)	(37.6%, 37.6%)	(33.4%, 33.4%)
Negative	D57	Anti-Spike IgG	310	44.7%	44.7%	44.7%
Negative	D57	Anti-Spike IgG	310	(44.7%, 44.7%)	(44.7%, 44.7%)	(44.7%, 44.7%)
Negative	D57	Anti-RBD IgG	310	44.7%	44.7%	44.7%
Negative	D57	Anti-RBD IgG	310	(44.7%, 44.7%)	(44.7%, 44.7%)	(44.7%, 44.7%)
Negative	D57	Pseudo nAb ID50	310	43.8%	43.8%	43.3%
Negative	D57	Pseudo nAb ID50	310	(43.8%, 43.8%)	(43.8%, 43.8%)	(43.3%, 43.3%)
Negative	D57	Pseudo nAb ID80	310	43.5%	43.5%	41.9%
Negative	D57	Pseudo nAb ID80	310	(43.5%, 43.5%)	(43.5%, 43.5%)	(41.9%, 41.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Live Virus nAb ID50	310	43.3%	43.3%	42.5%
Negative	D57	Live Virus nAb ID50	310	(43.3%, 43.3%)	(43.3%, 43.3%)	(42.5%, 42.5%)
Negative	D57	Live Virus nAb ID80	310	43.4%	43.4%	41.6%
Negative	D57	Live Virus nAb ID80	310	(43.4%, 43.4%)	(43.4%, 43.4%)	(41.6%, 41.6%)
Positive	D29	Anti-Spike IgG	117	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	117	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	117	92.5%	92.5%	85.6%
Positive	D29	Pseudo nAb ID50	117	(92.5%, 92.5%)	(92.5%, 92.5%)	(85.6%, 85.6%)
Positive	D29	Pseudo nAb ID80	117	82.5%	82.5%	65.2%
Positive	D29	Pseudo nAb ID80	117	(82.5%, 82.5%)	(82.5%, 82.5%)	(65.2%, 65.2%)
Positive	D29	Live Virus nAb ID50	117	87.0%	87.0%	79.3%
Positive	D29	Live Virus nAb ID50	117	(87.0%, 87.0%)	(87.0%, 87.0%)	(79.3%, 79.3%)
Positive	D29	Live Virus nAb ID80	117	79.3%	79.3%	71.4%
Positive	D29	Live Virus nAb ID80	117	(79.3%, 79.3%)	(79.3%, 79.3%)	(71.4%, 71.4%)
Positive	D57	Anti-Spike IgG	117	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	117	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	117	100.0%	100.0%	98.3%
Positive	D57	Pseudo nAb ID50	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(98.3%, 98.3%)
Positive	D57	Pseudo nAb ID80	117	97.4%	97.4%	96.5%
Positive	D57	Pseudo nAb ID80	117	(97.4%, 97.4%)	(97.4%, 97.4%)	(96.5%, 96.5%)
Positive	D57	Live Virus nAb ID50	117	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID50	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID80	117	98.3%	98.3%	96.6%
Positive	D57	Live Virus nAb ID80	117	(98.3%, 98.3%)	(98.3%, 98.3%)	(96.6%, 96.6%)
<b>Age &gt;= 65 Male</b>						
Negative	D29	Anti-Spike IgG	266	54.0%	54.0%	54.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Anti-Spike IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
Negative	D29	Anti-RBD IgG	266	54.0%	54.0%	54.0%
Negative	D29	Anti-RBD IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
Negative	D29	Pseudo nAb ID50	266	50.6%	50.6%	47.2%
Negative	D29	Pseudo nAb ID50	266	(50.6%, 50.6%)	(50.6%, 50.6%)	(47.2%, 47.2%)
Negative	D29	Pseudo nAb ID80	266	46.0%	46.0%	41.0%
Negative	D29	Pseudo nAb ID80	266	(46.0%, 46.0%)	(46.0%, 46.0%)	(41.0%, 41.0%)
Negative	D29	Live Virus nAb ID50	266	48.0%	48.0%	43.6%
Negative	D29	Live Virus nAb ID50	266	(48.0%, 48.0%)	(48.0%, 48.0%)	(43.6%, 43.6%)
Negative	D29	Live Virus nAb ID80	266	43.7%	43.7%	37.8%
Negative	D29	Live Virus nAb ID80	266	(43.7%, 43.7%)	(43.7%, 43.7%)	(37.8%, 37.8%)
Negative	D57	Anti-Spike IgG	266	54.0%	54.0%	54.0%
Negative	D57	Anti-Spike IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
Negative	D57	Anti-RBD IgG	266	54.0%	54.0%	54.0%
Negative	D57	Anti-RBD IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
Negative	D57	Pseudo nAb ID50	266	53.6%	53.6%	52.8%
Negative	D57	Pseudo nAb ID50	266	(53.6%, 53.6%)	(53.6%, 53.6%)	(52.8%, 52.8%)
Negative	D57	Pseudo nAb ID80	266	52.6%	52.6%	51.8%
Negative	D57	Pseudo nAb ID80	266	(52.6%, 52.6%)	(52.6%, 52.6%)	(51.8%, 51.8%)
Negative	D57	Live Virus nAb ID50	266	53.7%	53.7%	53.0%
Negative	D57	Live Virus nAb ID50	266	(53.7%, 53.7%)	(53.7%, 53.7%)	(53.0%, 53.0%)
Negative	D57	Live Virus nAb ID80	266	52.1%	52.1%	50.9%
Negative	D57	Live Virus nAb ID80	266	(52.1%, 52.1%)	(52.1%, 52.1%)	(50.9%, 50.9%)
Positive	D29	Anti-Spike IgG	111	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	111	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	111	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	111	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	111	94.0%	94.0%	89.4%
Positive	D29	Pseudo nAb ID50	111	(94.0%, 94.0%)	(94.0%, 94.0%)	(89.4%, 89.4%)
Positive	D29	Pseudo nAb ID80	111	86.7%	86.7%	74.0%
Positive	D29	Pseudo nAb ID80	111	(86.7%, 86.7%)	(86.7%, 86.7%)	(74.0%, 74.0%)



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Live Virus nAb ID50	111	93.1%	93.1%	82.1%
Positive	D29	Live Virus nAb ID50	111	(93.1%, 93.1%)	(93.1%, 93.1%)	(82.1%, 82.1%)
Positive	D29	Live Virus nAb ID80	111	86.7%	86.7%	71.3%
Positive	D29	Live Virus nAb ID80	111	(86.7%, 86.7%)	(86.7%, 86.7%)	(71.3%, 71.3%)
Positive	D57	Anti-Spike IgG	111	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	111	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	111	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	111	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	111	99.1%	99.1%	97.6%
Positive	D57	Pseudo nAb ID50	111	(99.1%, 99.1%)	(99.1%, 99.1%)	(97.6%, 97.6%)
Positive	D57	Pseudo nAb ID80	111	98.5%	98.5%	94.8%
Positive	D57	Pseudo nAb ID80	111	(98.5%, 98.5%)	(98.5%, 98.5%)	(94.8%, 94.8%)
Positive	D57	Live Virus nAb ID50	111	97.6%	97.6%	96.7%
Positive	D57	Live Virus nAb ID50	111	(97.6%, 97.6%)	(97.6%, 97.6%)	(96.7%, 96.7%)
Positive	D57	Live Virus nAb ID80	111	97.3%	97.3%	93.0%
Positive	D57	Live Virus nAb ID80	111	(97.3%, 97.3%)	(97.3%, 97.3%)	(93.0%, 93.0%)
<b>Hispanic or Latino</b>						
Negative	D29	Anti-Spike IgG	139	48.8%	48.8%	48.8%
Negative	D29	Anti-Spike IgG	139	(42.3%, 55.2%)	(42.3%, 55.2%)	(42.3%, 55.2%)
Negative	D29	Anti-RBD IgG	139	48.8%	48.8%	48.8%
Negative	D29	Anti-RBD IgG	139	(42.3%, 55.2%)	(42.3%, 55.2%)	(42.3%, 55.2%)
Negative	D29	Pseudo nAb ID50	139	40.2%	40.2%	38.4%
Negative	D29	Pseudo nAb ID50	139	(32.9%, 47.4%)	(32.9%, 47.4%)	(31.3%, 45.6%)
Negative	D29	Pseudo nAb ID80	139	38.1%	38.1%	29.2%
Negative	D29	Pseudo nAb ID80	139	(31.7%, 44.6%)	(31.7%, 44.6%)	(21.9%, 36.6%)
Negative	D29	Live Virus nAb ID50	139	43.7%	43.7%	35.1%
Negative	D29	Live Virus nAb ID50	139	(35.6%, 51.8%)	(35.6%, 51.8%)	(25.2%, 44.9%)
Negative	D29	Live Virus nAb ID80	139	39.2%	39.2%	34.3%
Negative	D29	Live Virus nAb ID80	139	(32.5%, 45.9%)	(32.5%, 45.9%)	(29.7%, 38.8%)
Negative	D57	Anti-Spike IgG	139	48.8%	48.8%	48.8%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-Spike IgG	139	(42.3%, 55.2%)	(42.3%, 55.2%)	(42.3%, 55.2%)
Negative	D57	Anti-RBD IgG	139	48.8%	48.8%	48.8%
Negative	D57	Anti-RBD IgG	139	(42.3%, 55.2%)	(42.3%, 55.2%)	(42.3%, 55.2%)
Negative	D57	Pseudo nAb ID50	139	47.0%	47.0%	47.0%
Negative	D57	Pseudo nAb ID50	139	(38.9%, 55.1%)	(38.9%, 55.1%)	(38.9%, 55.1%)
Negative	D57	Pseudo nAb ID80	139	46.8%	46.8%	45.2%
Negative	D57	Pseudo nAb ID80	139	(39.1%, 54.5%)	(39.1%, 54.5%)	(39.8%, 50.6%)
Negative	D57	Live Virus nAb ID50	139	48.1%	48.1%	47.3%
Negative	D57	Live Virus nAb ID50	139	(43.0%, 53.2%)	(43.0%, 53.2%)	(43.0%, 51.7%)
Negative	D57	Live Virus nAb ID80	139	45.7%	45.7%	43.4%
Negative	D57	Live Virus nAb ID80	139	(39.1%, 52.3%)	(39.1%, 52.3%)	(36.0%, 50.7%)
Positive	D29	Anti-Spike IgG	59	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	59	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	59	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	59	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	59	82.4%	82.4%	72.2%
Positive	D29	Pseudo nAb ID50	59	(75.3%, 89.5%)	(75.3%, 89.5%)	(63.8%, 80.7%)
Positive	D29	Pseudo nAb ID80	59	73.7%	73.7%	56.6%
Positive	D29	Pseudo nAb ID80	59	(67.0%, 80.4%)	(67.0%, 80.4%)	(48.9%, 64.4%)
Positive	D29	Live Virus nAb ID50	59	92.6%	92.6%	83.5%
Positive	D29	Live Virus nAb ID50	59	(86.2%, 98.9%)	(86.2%, 98.9%)	(68.2%, 98.8%)
Positive	D29	Live Virus nAb ID80	59	82.5%	82.5%	65.7%
Positive	D29	Live Virus nAb ID80	59	(66.2%, 98.8%)	(66.2%, 98.8%)	(45.3%, 86.1%)
Positive	D57	Anti-Spike IgG	59	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	59	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	59	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	59	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	59	96.4%	96.4%	96.1%
Positive	D57	Pseudo nAb ID50	59	(93.5%, 99.3%)	(93.5%, 99.3%)	(93.7%, 98.4%)
Positive	D57	Pseudo nAb ID80	59	98.7%	98.7%	97.2%
Positive	D57	Pseudo nAb ID80	59	(95.6%, 101.7%)	(95.6%, 101.7%)	(90.8%, 103.5%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID50	59	99.2%	99.2%	97.2%
Positive	D57	Live Virus nAb ID50	59	(97.0%, 101.4%)	(97.0%, 101.4%)	(90.8%, 103.5%)
Positive	D57	Live Virus nAb ID80	59	98.0%	98.0%	93.0%
Positive	D57	Live Virus nAb ID80	59	(92.5%, 103.4%)	(92.5%, 103.4%)	(87.0%, 99.1%)
<b>Not Hispanic or Latino</b>						
Negative	D29	Anti-Spike IgG	837	53.6%	53.6%	53.6%
Negative	D29	Anti-Spike IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
Negative	D29	Anti-RBD IgG	837	53.6%	53.6%	53.6%
Negative	D29	Anti-RBD IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
Negative	D29	Pseudo nAb ID50	837	43.7%	43.7%	36.2%
Negative	D29	Pseudo nAb ID50	837	(40.3%, 47.2%)	(40.3%, 47.2%)	(32.8%, 39.6%)
Negative	D29	Pseudo nAb ID80	837	36.2%	36.2%	29.2%
Negative	D29	Pseudo nAb ID80	837	(33.5%, 39.0%)	(33.5%, 39.0%)	(25.9%, 32.5%)
Negative	D29	Live Virus nAb ID50	837	43.3%	43.3%	34.7%
Negative	D29	Live Virus nAb ID50	837	(38.5%, 48.1%)	(38.5%, 48.1%)	(31.3%, 38.2%)
Negative	D29	Live Virus nAb ID80	837	36.3%	36.3%	28.7%
Negative	D29	Live Virus nAb ID80	837	(34.2%, 38.5%)	(34.2%, 38.5%)	(25.3%, 32.2%)
Negative	D57	Anti-Spike IgG	837	53.6%	53.6%	53.6%
Negative	D57	Anti-Spike IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
Negative	D57	Anti-RBD IgG	837	53.6%	53.6%	53.6%
Negative	D57	Anti-RBD IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
Negative	D57	Pseudo nAb ID50	837	52.3%	52.3%	51.2%
Negative	D57	Pseudo nAb ID50	837	(47.0%, 57.7%)	(47.0%, 57.7%)	(46.0%, 56.3%)
Negative	D57	Pseudo nAb ID80	837	50.6%	50.6%	48.1%
Negative	D57	Pseudo nAb ID80	837	(46.4%, 54.9%)	(46.4%, 54.9%)	(44.4%, 51.8%)
Negative	D57	Live Virus nAb ID50	837	52.1%	52.1%	50.7%
Negative	D57	Live Virus nAb ID50	837	(47.7%, 56.6%)	(47.7%, 56.6%)	(45.3%, 56.1%)
Negative	D57	Live Virus nAb ID80	837	51.0%	51.0%	48.1%
Negative	D57	Live Virus nAb ID80	837	(46.7%, 55.2%)	(46.7%, 55.2%)	(45.1%, 51.1%)
Positive	D29	Anti-Spike IgG	418	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Anti-Spike IgG	418	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	418	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	418	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	418	77.9%	77.9%	65.7%
Positive	D29	Pseudo nAb ID50	418	(71.8%, 84.1%)	(71.8%, 84.1%)	(56.5%, 74.9%)
Positive	D29	Pseudo nAb ID80	418	62.9%	62.9%	48.3%
Positive	D29	Pseudo nAb ID80	418	(54.6%, 71.2%)	(54.6%, 71.2%)	(39.4%, 57.1%)
Positive	D29	Live Virus nAb ID50	418	75.0%	75.0%	63.3%
Positive	D29	Live Virus nAb ID50	418	(69.0%, 81.0%)	(69.0%, 81.0%)	(57.0%, 69.6%)
Positive	D29	Live Virus nAb ID80	418	67.8%	67.8%	53.6%
Positive	D29	Live Virus nAb ID80	418	(61.1%, 74.6%)	(61.1%, 74.6%)	(45.8%, 61.5%)
Positive	D57	Anti-Spike IgG	418	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	418	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	418	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	418	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	418	95.6%	95.6%	93.7%
Positive	D57	Pseudo nAb ID50	418	(94.1%, 97.1%)	(94.1%, 97.1%)	(92.1%, 95.3%)
Positive	D57	Pseudo nAb ID80	418	92.2%	92.2%	86.3%
Positive	D57	Pseudo nAb ID80	418	(89.8%, 94.7%)	(89.8%, 94.7%)	(82.8%, 89.8%)
Positive	D57	Live Virus nAb ID50	418	96.5%	96.5%	93.1%
Positive	D57	Live Virus nAb ID50	418	(95.1%, 97.8%)	(95.1%, 97.8%)	(90.9%, 95.3%)
Positive	D57	Live Virus nAb ID80	418	96.3%	96.3%	93.3%
Positive	D57	Live Virus nAb ID80	418	(93.1%, 99.6%)	(93.1%, 99.6%)	(88.7%, 98.0%)
<b>American Indian or Alaska Native</b>						
Negative	D29	Anti-Spike IgG	29	57.1%	57.1%	57.1%
Negative	D29	Anti-Spike IgG	29	(1.1%, 113.2%)	(1.1%, 113.2%)	(1.1%, 113.2%)
Negative	D29	Anti-RBD IgG	29	57.1%	57.1%	57.1%
Negative	D29	Anti-RBD IgG	29	(1.1%, 113.2%)	(1.1%, 113.2%)	(1.1%, 113.2%)
Negative	D29	Pseudo nAb ID50	29	41.6%	41.6%	33.8%
Negative	D29	Pseudo nAb ID50	29	(2.7%, 80.5%)	(2.7%, 80.5%)	(3.3%, 64.2%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Pseudo nAb ID80	29	32.2%	32.2%	31.4%
Negative	D29	Pseudo nAb ID80	29	(-0.4%, 64.8%)	(-0.4%, 64.8%)	(-2.2%, 65.0%)
Negative	D29	Live Virus nAb ID50	29	53.4%	53.4%	38.5%
Negative	D29	Live Virus nAb ID50	29	(-7.3%, 114.1%)	(-7.3%, 114.1%)	(-4.4%, 81.4%)
Negative	D29	Live Virus nAb ID80	29	44.9%	44.9%	44.9%
Negative	D29	Live Virus nAb ID80	29	(-8.4%, 98.1%)	(-8.4%, 98.1%)	(-8.4%, 98.1%)
Negative	D57	Anti-Spike IgG	29	57.1%	57.1%	57.1%
Negative	D57	Anti-Spike IgG	29	(1.1%, 113.2%)	(1.1%, 113.2%)	(1.1%, 113.2%)
Negative	D57	Anti-RBD IgG	29	57.1%	57.1%	57.1%
Negative	D57	Anti-RBD IgG	29	(1.1%, 113.2%)	(1.1%, 113.2%)	(1.1%, 113.2%)
Negative	D57	Pseudo nAb ID50	29	54.0%	54.0%	53.4%
Negative	D57	Pseudo nAb ID50	29	(-5.8%, 113.9%)	(-5.8%, 113.9%)	(-7.3%, 114.1%)
Negative	D57	Pseudo nAb ID80	29	50.2%	50.2%	49.5%
Negative	D57	Pseudo nAb ID80	29	(3.6%, 96.8%)	(3.6%, 96.8%)	(1.9%, 97.1%)
Negative	D57	Live Virus nAb ID50	29	55.6%	55.6%	53.4%
Negative	D57	Live Virus nAb ID50	29	(-2.3%, 113.4%)	(-2.3%, 113.4%)	(-7.3%, 114.1%)
Negative	D57	Live Virus nAb ID80	29	57.1%	57.1%	50.8%
Negative	D57	Live Virus nAb ID80	29	(1.1%, 113.2%)	(1.1%, 113.2%)	(5.2%, 96.5%)
Positive	D29	Anti-Spike IgG	8	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	8	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	8	83.5%	83.5%	67.0%
Positive	D29	Pseudo nAb ID50	8	(80.4%, 86.5%)	(80.4%, 86.5%)	(60.8%, 73.1%)
Positive	D29	Pseudo nAb ID80	8	67.0%	67.0%	67.0%
Positive	D29	Pseudo nAb ID80	8	(60.8%, 73.1%)	(60.8%, 73.1%)	(60.8%, 73.1%)
Positive	D29	Live Virus nAb ID50	8	100.0%	100.0%	100.0%
Positive	D29	Live Virus nAb ID50	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Live Virus nAb ID80	8	100.0%	100.0%	64.5%
Positive	D29	Live Virus nAb ID80	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(56.3%, 72.8%)
Positive	D57	Anti-Spike IgG	8	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Anti-Spike IgG	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	8	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	8	100.0%	100.0%	100.0%
Positive	D57	Pseudo nAb ID50	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID80	8	100.0%	100.0%	100.0%
Positive	D57	Pseudo nAb ID80	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID50	8	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID50	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID80	8	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID80	8	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
<b>Asian</b>						
Negative	D29	Anti-Spike IgG	73	44.0%	44.0%	44.0%
Negative	D29	Anti-Spike IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
Negative	D29	Anti-RBD IgG	73	44.0%	44.0%	44.0%
Negative	D29	Anti-RBD IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
Negative	D29	Pseudo nAb ID50	73	33.5%	33.5%	21.4%
Negative	D29	Pseudo nAb ID50	73	(31.0%, 36.1%)	(31.0%, 36.1%)	(9.9%, 32.9%)
Negative	D29	Pseudo nAb ID80	73	20.6%	20.6%	15.8%
Negative	D29	Pseudo nAb ID80	73	(10.4%, 30.8%)	(10.4%, 30.8%)	(0.9%, 30.7%)
Negative	D29	Live Virus nAb ID50	73	31.3%	31.3%	27.4%
Negative	D29	Live Virus nAb ID50	73	(28.9%, 33.8%)	(28.9%, 33.8%)	(23.2%, 31.5%)
Negative	D29	Live Virus nAb ID80	73	30.8%	30.8%	24.6%
Negative	D29	Live Virus nAb ID80	73	(28.6%, 33.0%)	(28.6%, 33.0%)	(19.9%, 29.3%)
Negative	D57	Anti-Spike IgG	73	44.0%	44.0%	44.0%
Negative	D57	Anti-Spike IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
Negative	D57	Anti-RBD IgG	73	44.0%	44.0%	44.0%
Negative	D57	Anti-RBD IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
Negative	D57	Pseudo nAb ID50	73	43.8%	43.8%	40.1%
Negative	D57	Pseudo nAb ID50	73	(39.8%, 47.8%)	(39.8%, 47.8%)	(37.4%, 42.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Pseudo nAb ID80	73	40.9%	40.9%	38.4%
Negative	D57	Pseudo nAb ID80	73	(38.5%, 43.4%)	(38.5%, 43.4%)	(35.3%, 41.5%)
Negative	D57	Live Virus nAb ID50	73	39.2%	39.2%	35.6%
Negative	D57	Live Virus nAb ID50	73	(34.8%, 43.6%)	(34.8%, 43.6%)	(32.0%, 39.2%)
Negative	D57	Live Virus nAb ID80	73	40.1%	40.1%	37.9%
Negative	D57	Live Virus nAb ID80	73	(37.4%, 42.9%)	(37.4%, 42.9%)	(36.0%, 39.7%)
Positive	D29	Anti-Spike IgG	33	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	33	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	33	78.9%	78.9%	60.9%
Positive	D29	Pseudo nAb ID50	33	(57.4%, 100.4%)	(57.4%, 100.4%)	(32.4%, 89.4%)
Positive	D29	Pseudo nAb ID80	33	54.9%	54.9%	34.2%
Positive	D29	Pseudo nAb ID80	33	(38.5%, 71.3%)	(38.5%, 71.3%)	(11.4%, 57.1%)
Positive	D29	Live Virus nAb ID50	33	74.1%	74.1%	63.0%
Positive	D29	Live Virus nAb ID50	33	(60.9%, 87.2%)	(60.9%, 87.2%)	(51.8%, 74.2%)
Positive	D29	Live Virus nAb ID80	33	75.1%	75.1%	49.0%
Positive	D29	Live Virus nAb ID80	33	(66.9%, 83.3%)	(66.9%, 83.3%)	(41.9%, 56.2%)
Positive	D57	Anti-Spike IgG	33	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	33	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	33	100.0%	100.0%	93.0%
Positive	D57	Pseudo nAb ID50	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(85.8%, 100.1%)
Positive	D57	Pseudo nAb ID80	33	85.0%	85.0%	83.0%
Positive	D57	Pseudo nAb ID80	33	(72.0%, 97.9%)	(72.0%, 97.9%)	(74.5%, 91.5%)
Positive	D57	Live Virus nAb ID50	33	100.0%	100.0%	98.0%
Positive	D57	Live Virus nAb ID50	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(93.1%, 102.9%)
Positive	D57	Live Virus nAb ID80	33	93.0%	93.0%	93.0%
Positive	D57	Live Virus nAb ID80	33	(85.8%, 100.1%)	(85.8%, 100.1%)	(85.8%, 100.1%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
<b>Black or African American</b>						
Negative	D29	Anti-Spike IgG	242	61.1%	61.1%	61.1%
Negative	D29	Anti-Spike IgG	242	(56.1%, 66.1%)	(56.1%, 66.1%)	(56.1%, 66.1%)
Negative	D29	Anti-RBD IgG	242	61.1%	61.1%	61.1%
Negative	D29	Anti-RBD IgG	242	(56.1%, 66.1%)	(56.1%, 66.1%)	(56.1%, 66.1%)
Negative	D29	Pseudo nAb ID50	242	48.0%	48.0%	40.9%
Negative	D29	Pseudo nAb ID50	242	(45.4%, 50.6%)	(45.4%, 50.6%)	(36.0%, 45.8%)
Negative	D29	Pseudo nAb ID80	242	41.0%	41.0%	29.9%
Negative	D29	Pseudo nAb ID80	242	(35.9%, 46.1%)	(35.9%, 46.1%)	(21.7%, 38.1%)
Negative	D29	Live Virus nAb ID50	242	50.6%	50.6%	37.0%
Negative	D29	Live Virus nAb ID50	242	(45.8%, 55.3%)	(45.8%, 55.3%)	(31.3%, 42.7%)
Negative	D29	Live Virus nAb ID80	242	42.0%	42.0%	33.8%
Negative	D29	Live Virus nAb ID80	242	(39.0%, 44.9%)	(39.0%, 44.9%)	(30.6%, 37.1%)
Negative	D57	Anti-Spike IgG	242	61.1%	61.1%	61.1%
Negative	D57	Anti-Spike IgG	242	(56.1%, 66.1%)	(56.1%, 66.1%)	(56.1%, 66.1%)
Negative	D57	Anti-RBD IgG	242	61.1%	61.1%	61.1%
Negative	D57	Anti-RBD IgG	242	(56.1%, 66.1%)	(56.1%, 66.1%)	(56.1%, 66.1%)
Negative	D57	Pseudo nAb ID50	242	59.4%	59.4%	57.6%
Negative	D57	Pseudo nAb ID50	242	(53.1%, 65.7%)	(53.1%, 65.7%)	(52.2%, 62.9%)
Negative	D57	Pseudo nAb ID80	242	58.2%	58.2%	54.6%
Negative	D57	Pseudo nAb ID80	242	(54.9%, 61.6%)	(54.9%, 61.6%)	(52.5%, 56.7%)
Negative	D57	Live Virus nAb ID50	242	61.0%	61.0%	57.6%
Negative	D57	Live Virus nAb ID50	242	(55.9%, 66.1%)	(55.9%, 66.1%)	(52.2%, 62.9%)
Negative	D57	Live Virus nAb ID80	242	57.0%	57.0%	53.8%
Negative	D57	Live Virus nAb ID80	242	(53.2%, 60.7%)	(53.2%, 60.7%)	(51.0%, 56.7%)
Positive	D29	Anti-Spike IgG	101	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	101	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	101	69.4%	69.4%	66.1%



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Pseudo nAb ID50	101	(56.4%, 82.4%)	(56.4%, 82.4%)	(52.6%, 79.6%)
Positive	D29	Pseudo nAb ID80	101	59.9%	59.9%	52.7%
Positive	D29	Pseudo nAb ID80	101	(42.8%, 77.0%)	(42.8%, 77.0%)	(42.3%, 63.1%)
Positive	D29	Live Virus nAb ID50	101	76.0%	76.0%	66.4%
Positive	D29	Live Virus nAb ID50	101	(68.8%, 83.1%)	(68.8%, 83.1%)	(58.3%, 74.5%)
Positive	D29	Live Virus nAb ID80	101	66.0%	66.0%	60.8%
Positive	D29	Live Virus nAb ID80	101	(58.1%, 73.9%)	(58.1%, 73.9%)	(56.1%, 65.4%)
Positive	D57	Anti-Spike IgG	101	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	101	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	101	94.0%	94.0%	90.9%
Positive	D57	Pseudo nAb ID50	101	(91.3%, 96.7%)	(91.3%, 96.7%)	(86.9%, 95.0%)
Positive	D57	Pseudo nAb ID80	101	90.6%	90.6%	81.6%
Positive	D57	Pseudo nAb ID80	101	(87.4%, 93.9%)	(87.4%, 93.9%)	(75.6%, 87.6%)
Positive	D57	Live Virus nAb ID50	101	97.0%	97.0%	92.6%
Positive	D57	Live Virus nAb ID50	101	(95.6%, 98.3%)	(95.6%, 98.3%)	(89.3%, 95.9%)
Positive	D57	Live Virus nAb ID80	101	95.3%	95.3%	90.3%
Positive	D57	Live Virus nAb ID80	101	(92.5%, 98.2%)	(92.5%, 98.2%)	(87.8%, 92.8%)
<b>Multiracial</b>						
Negative	D29	Anti-Spike IgG	64	37.8%	37.8%	37.8%
Negative	D29	Anti-Spike IgG	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
Negative	D29	Anti-RBD IgG	64	37.8%	37.8%	37.8%
Negative	D29	Anti-RBD IgG	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
Negative	D29	Pseudo nAb ID50	64	28.6%	28.6%	28.0%
Negative	D29	Pseudo nAb ID50	64	(13.5%, 43.8%)	(13.5%, 43.8%)	(13.7%, 42.3%)
Negative	D29	Pseudo nAb ID80	64	29.8%	29.8%	25.5%
Negative	D29	Pseudo nAb ID80	64	(19.5%, 40.1%)	(19.5%, 40.1%)	(16.9%, 34.2%)
Negative	D29	Live Virus nAb ID50	64	35.0%	35.0%	29.7%
Negative	D29	Live Virus nAb ID50	64	(21.6%, 48.4%)	(21.6%, 48.4%)	(18.5%, 40.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Live Virus nAb ID80	64	31.6%	31.6%	22.6%
Negative	D29	Live Virus nAb ID80	64	(18.2%, 45.0%)	(18.2%, 45.0%)	(12.1%, 33.1%)
Negative	D57	Anti-Spike IgG	64	37.8%	37.8%	37.8%
Negative	D57	Anti-Spike IgG	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
Negative	D57	Anti-RBD IgG	64	37.8%	37.8%	37.8%
Negative	D57	Anti-RBD IgG	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
Negative	D57	Pseudo nAb ID50	64	36.9%	36.9%	36.2%
Negative	D57	Pseudo nAb ID50	64	(20.4%, 53.3%)	(20.4%, 53.3%)	(20.9%, 51.6%)
Negative	D57	Pseudo nAb ID80	64	36.9%	36.9%	35.1%
Negative	D57	Pseudo nAb ID80	64	(20.4%, 53.3%)	(20.4%, 53.3%)	(22.1%, 48.1%)
Negative	D57	Live Virus nAb ID50	64	35.5%	35.5%	35.5%
Negative	D57	Live Virus nAb ID50	64	(22.0%, 48.9%)	(22.0%, 48.9%)	(22.0%, 48.9%)
Negative	D57	Live Virus nAb ID80	64	36.6%	36.6%	36.0%
Negative	D57	Live Virus nAb ID80	64	(20.8%, 52.5%)	(20.8%, 52.5%)	(21.3%, 50.7%)
Positive	D29	Anti-Spike IgG	31	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	31	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	31	76.0%	76.0%	73.8%
Positive	D29	Pseudo nAb ID50	31	(68.5%, 83.4%)	(68.5%, 83.4%)	(62.8%, 84.8%)
Positive	D29	Pseudo nAb ID80	31	71.6%	71.6%	68.5%
Positive	D29	Pseudo nAb ID80	31	(55.9%, 87.3%)	(55.9%, 87.3%)	(53.1%, 83.8%)
Positive	D29	Live Virus nAb ID50	31	88.0%	88.0%	84.8%
Positive	D29	Live Virus nAb ID50	31	(87.1%, 88.9%)	(87.1%, 88.9%)	(78.1%, 91.5%)
Positive	D29	Live Virus nAb ID80	31	83.8%	83.8%	70.6%
Positive	D29	Live Virus nAb ID80	31	(78.1%, 89.6%)	(78.1%, 89.6%)	(60.7%, 80.6%)
Positive	D57	Anti-Spike IgG	31	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	31	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	31	100.0%	100.0%	99.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Pseudo nAb ID50	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(96.2%, 101.7%)
Positive	D57	Pseudo nAb ID80	31	92.2%	92.2%	92.2%
Positive	D57	Pseudo nAb ID80	31	(84.4%, 100.1%)	(84.4%, 100.1%)	(84.4%, 100.1%)
Positive	D57	Live Virus nAb ID50	31	100.0%	100.0%	97.8%
Positive	D57	Live Virus nAb ID50	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(92.3%, 103.3%)
Positive	D57	Live Virus nAb ID80	31	100.0%	100.0%	97.8%
Positive	D57	Live Virus nAb ID80	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(92.3%, 103.3%)
<b>Native Hawaiian or Other Pacific Islander</b>						
Negative	D29	Anti-Spike IgG	11	31.4%	31.4%	31.4%
Negative	D29	Anti-Spike IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D29	Anti-RBD IgG	11	31.4%	31.4%	31.4%
Negative	D29	Anti-RBD IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D29	Pseudo nAb ID50	11	31.4%	31.4%	31.4%
Negative	D29	Pseudo nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D29	Pseudo nAb ID80	11	31.4%	31.4%	28.0%
Negative	D29	Pseudo nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(1.4%, 54.7%)
Negative	D29	Live Virus nAb ID50	11	24.6%	24.6%	23.2%
Negative	D29	Live Virus nAb ID50	11	(4.8%, 44.4%)	(4.8%, 44.4%)	(7.5%, 38.8%)
Negative	D29	Live Virus nAb ID80	11	26.6%	26.6%	25.1%
Negative	D29	Live Virus nAb ID80	11	(3.5%, 49.7%)	(3.5%, 49.7%)	(5.3%, 45.0%)
Negative	D57	Anti-Spike IgG	11	31.4%	31.4%	31.4%
Negative	D57	Anti-Spike IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D57	Anti-RBD IgG	11	31.4%	31.4%	31.4%
Negative	D57	Anti-RBD IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D57	Pseudo nAb ID50	11	31.4%	31.4%	31.4%
Negative	D57	Pseudo nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D57	Pseudo nAb ID80	11	31.4%	31.4%	31.4%
Negative	D57	Pseudo nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Negative	D57	Live Virus nAb ID50	11	31.4%	31.4%	31.4%
Negative	D57	Live Virus nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Live Virus nAb ID80	11	31.4%	31.4%	31.4%
Negative	D57	Live Virus nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
Positive	D29	Anti-Spike IgG	7	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	7	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	7	100.0%	100.0%	63.7%
Positive	D29	Pseudo nAb ID50	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(30.2%, 97.2%)
Positive	D29	Pseudo nAb ID80	7	63.7%	63.7%	50.3%
Positive	D29	Pseudo nAb ID80	7	(30.2%, 97.2%)	(30.2%, 97.2%)	(43.0%, 57.6%)
Positive	D29	Live Virus nAb ID50	7	59.4%	59.4%	50.2%
Positive	D29	Live Virus nAb ID50	7	(32.3%, 86.5%)	(32.3%, 86.5%)	(43.0%, 57.4%)
Positive	D29	Live Virus nAb ID80	7	63.7%	63.7%	12.9%
Positive	D29	Live Virus nAb ID80	7	(30.2%, 97.2%)	(30.2%, 97.2%)	(-21.9%, 47.7%)
Positive	D57	Anti-Spike IgG	7	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	7	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	7	63.7%	63.7%	63.7%
Positive	D57	Pseudo nAb ID50	7	(30.2%, 97.2%)	(30.2%, 97.2%)	(30.2%, 97.2%)
Positive	D57	Pseudo nAb ID80	7	100.0%	100.0%	100.0%
Positive	D57	Pseudo nAb ID80	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID50	7	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID50	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID80	7	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID80	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
<b>Not reported and unknown</b>						
Negative	D29	Anti-Spike IgG	115	43.8%	43.8%	43.8%
Negative	D29	Anti-Spike IgG	115	(39.9%, 47.7%)	(39.9%, 47.7%)	(39.9%, 47.7%)
Negative	D29	Anti-RBD IgG	115	43.8%	43.8%	43.8%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Anti-RBD IgG	115	(39.9%, 47.7%)	(39.9%, 47.7%)	(39.9%, 47.7%)
Negative	D29	Pseudo nAb ID50	115	38.5%	38.5%	31.3%
Negative	D29	Pseudo nAb ID50	115	(35.0%, 41.9%)	(35.0%, 41.9%)	(29.3%, 33.3%)
Negative	D29	Pseudo nAb ID80	115	35.6%	35.6%	29.2%
Negative	D29	Pseudo nAb ID80	115	(32.7%, 38.5%)	(32.7%, 38.5%)	(25.8%, 32.5%)
Negative	D29	Live Virus nAb ID50	115	33.6%	33.6%	30.7%
Negative	D29	Live Virus nAb ID50	115	(31.1%, 36.1%)	(31.1%, 36.1%)	(29.3%, 32.0%)
Negative	D29	Live Virus nAb ID80	115	34.6%	34.6%	28.8%
Negative	D29	Live Virus nAb ID80	115	(30.7%, 38.6%)	(30.7%, 38.6%)	(25.6%, 32.0%)
Negative	D57	Anti-Spike IgG	115	43.8%	43.8%	43.8%
Negative	D57	Anti-Spike IgG	115	(39.9%, 47.7%)	(39.9%, 47.7%)	(39.9%, 47.7%)
Negative	D57	Anti-RBD IgG	115	43.8%	43.8%	43.8%
Negative	D57	Anti-RBD IgG	115	(39.9%, 47.7%)	(39.9%, 47.7%)	(39.9%, 47.7%)
Negative	D57	Pseudo nAb ID50	115	42.5%	42.5%	42.3%
Negative	D57	Pseudo nAb ID50	115	(38.6%, 46.3%)	(38.6%, 46.3%)	(38.3%, 46.3%)
Negative	D57	Pseudo nAb ID80	115	43.8%	43.8%	39.7%
Negative	D57	Pseudo nAb ID80	115	(39.8%, 47.7%)	(39.8%, 47.7%)	(36.9%, 42.5%)
Negative	D57	Live Virus nAb ID50	115	43.7%	43.7%	43.0%
Negative	D57	Live Virus nAb ID50	115	(39.5%, 47.8%)	(39.5%, 47.8%)	(39.4%, 46.6%)
Negative	D57	Live Virus nAb ID80	115	43.5%	43.5%	39.1%
Negative	D57	Live Virus nAb ID80	115	(40.0%, 46.9%)	(40.0%, 46.9%)	(35.1%, 43.0%)
Positive	D29	Anti-Spike IgG	57	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	57	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	57	82.3%	82.3%	70.4%
Positive	D29	Pseudo nAb ID50	57	(76.3%, 88.3%)	(76.3%, 88.3%)	(64.0%, 76.7%)
Positive	D29	Pseudo nAb ID80	57	64.2%	64.2%	43.3%
Positive	D29	Pseudo nAb ID80	57	(57.0%, 71.4%)	(57.0%, 71.4%)	(31.7%, 54.9%)
Positive	D29	Live Virus nAb ID50	57	75.4%	75.4%	64.1%
Positive	D29	Live Virus nAb ID50	57	(65.6%, 85.1%)	(65.6%, 85.1%)	(58.0%, 70.2%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Live Virus nAb ID80	57	63.6%	63.6%	57.5%
Positive	D29	Live Virus nAb ID80	57	(51.4%, 75.7%)	(51.4%, 75.7%)	(55.3%, 59.6%)
Positive	D57	Anti-Spike IgG	57	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	57	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	57	94.8%	94.8%	94.3%
Positive	D57	Pseudo nAb ID50	57	(92.7%, 97.0%)	(92.7%, 97.0%)	(93.5%, 95.0%)
Positive	D57	Pseudo nAb ID80	57	90.3%	90.3%	88.6%
Positive	D57	Pseudo nAb ID80	57	(84.6%, 96.0%)	(84.6%, 96.0%)	(85.5%, 91.8%)
Positive	D57	Live Virus nAb ID50	57	98.9%	98.9%	94.3%
Positive	D57	Live Virus nAb ID50	57	(95.9%, 101.8%)	(95.9%, 101.8%)	(91.9%, 96.8%)
Positive	D57	Live Virus nAb ID80	57	94.8%	94.8%	93.7%
Positive	D57	Live Virus nAb ID80	57	(92.7%, 97.0%)	(92.7%, 97.0%)	(90.1%, 97.3%)
<b>Other</b>						
Negative	D29	Anti-Spike IgG	23	91.5%	91.5%	91.5%
Negative	D29	Anti-Spike IgG	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
Negative	D29	Anti-RBD IgG	23	91.5%	91.5%	91.5%
Negative	D29	Anti-RBD IgG	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
Negative	D29	Pseudo nAb ID50	23	80.4%	80.4%	77.6%
Negative	D29	Pseudo nAb ID50	23	(68.2%, 92.5%)	(68.2%, 92.5%)	(65.1%, 90.1%)
Negative	D29	Pseudo nAb ID80	23	75.3%	75.3%	61.5%
Negative	D29	Pseudo nAb ID80	23	(57.2%, 93.4%)	(57.2%, 93.4%)	(51.1%, 71.8%)
Negative	D29	Live Virus nAb ID50	23	77.6%	77.6%	77.6%
Negative	D29	Live Virus nAb ID50	23	(65.1%, 90.1%)	(65.1%, 90.1%)	(65.1%, 90.1%)
Negative	D29	Live Virus nAb ID80	23	76.5%	76.5%	71.5%
Negative	D29	Live Virus nAb ID80	23	(61.2%, 91.8%)	(61.2%, 91.8%)	(47.5%, 95.4%)
Negative	D57	Anti-Spike IgG	23	91.5%	91.5%	91.5%
Negative	D57	Anti-Spike IgG	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
Negative	D57	Anti-RBD IgG	23	91.5%	91.5%	91.5%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-RBD IgG	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
Negative	D57	Pseudo nAb ID50	23	80.4%	80.4%	80.4%
Negative	D57	Pseudo nAb ID50	23	(68.2%, 92.5%)	(68.2%, 92.5%)	(68.2%, 92.5%)
Negative	D57	Pseudo nAb ID80	23	79.2%	79.2%	78.1%
Negative	D57	Pseudo nAb ID80	23	(64.4%, 94.0%)	(64.4%, 94.0%)	(60.6%, 95.6%)
Negative	D57	Live Virus nAb ID50	23	91.5%	91.5%	91.5%
Negative	D57	Live Virus nAb ID50	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
Negative	D57	Live Virus nAb ID80	23	77.6%	77.6%	77.6%
Negative	D57	Live Virus nAb ID80	23	(65.1%, 90.1%)	(65.1%, 90.1%)	(65.1%, 90.1%)
Positive	D29	Anti-Spike IgG	14	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	14	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	14	84.2%	84.2%	59.7%
Positive	D29	Pseudo nAb ID50	14	(76.9%, 91.5%)	(76.9%, 91.5%)	(54.1%, 65.4%)
Positive	D29	Pseudo nAb ID80	14	50.1%	50.1%	29.1%
Positive	D29	Pseudo nAb ID80	14	(32.9%, 67.2%)	(32.9%, 67.2%)	(21.4%, 36.8%)
Positive	D29	Live Virus nAb ID50	14	81.0%	81.0%	79.4%
Positive	D29	Live Virus nAb ID50	14	(63.7%, 98.2%)	(63.7%, 98.2%)	(59.8%, 99.0%)
Positive	D29	Live Virus nAb ID80	14	84.2%	84.2%	58.2%
Positive	D29	Live Virus nAb ID80	14	(76.9%, 91.5%)	(76.9%, 91.5%)	(56.5%, 59.9%)
Positive	D57	Anti-Spike IgG	14	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	14	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	14	100.0%	100.0%	99.0%
Positive	D57	Pseudo nAb ID50	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(96.0%, 102.0%)
Positive	D57	Pseudo nAb ID80	14	81.0%	81.0%	81.0%
Positive	D57	Pseudo nAb ID80	14	(63.7%, 98.2%)	(63.7%, 98.2%)	(63.7%, 98.2%)
Positive	D57	Live Virus nAb ID50	14	99.0%	99.0%	87.5%
Positive	D57	Live Virus nAb ID50	14	(96.0%, 102.0%)	(96.0%, 102.0%)	(84.8%, 90.1%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID80	14	85.2%	85.2%	72.7%
Positive	D57	Live Virus nAb ID80	14	(78.5%, 91.9%)	(78.5%, 91.9%)	(68.3%, 77.1%)
<b>White</b>						
Negative	D29	Anti-Spike IgG	55	51.6%	51.6%	51.6%
Negative	D29	Anti-Spike IgG	55	(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
Negative	D29	Anti-RBD IgG	55	51.6%	51.6%	51.6%
Negative	D29	Anti-RBD IgG	55	(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
Negative	D29	Pseudo nAb ID50	55	40.3%	40.3%	38.8%
Negative	D29	Pseudo nAb ID50	55	(30.2%, 50.5%)	(30.2%, 50.5%)	(31.6%, 46.0%)
Negative	D29	Pseudo nAb ID80	55	29.5%	29.5%	21.4%
Negative	D29	Pseudo nAb ID80	55	(11.0%, 48.0%)	(11.0%, 48.0%)	(9.2%, 33.7%)
Negative	D29	Live Virus nAb ID50	55	39.6%	39.6%	34.3%
Negative	D29	Live Virus nAb ID50	55	(30.3%, 49.0%)	(30.3%, 49.0%)	(25.4%, 43.2%)
Negative	D29	Live Virus nAb ID80	55	41.2%	41.2%	33.6%
Negative	D29	Live Virus nAb ID80	55	(33.5%, 48.9%)	(33.5%, 48.9%)	(25.2%, 42.0%)
Negative	D57	Anti-Spike IgG	55	51.6%	51.6%	51.6%
Negative	D57	Anti-Spike IgG	55	(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
Negative	D57	Anti-RBD IgG	55	51.6%	51.6%	51.6%
Negative	D57	Anti-RBD IgG	55	(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
Negative	D57	Pseudo nAb ID50	55	51.3%	51.3%	51.3%
Negative	D57	Pseudo nAb ID50	55	(45.6%, 57.0%)	(45.6%, 57.0%)	(45.6%, 57.0%)
Negative	D57	Pseudo nAb ID80	55	47.9%	47.9%	44.2%
Negative	D57	Pseudo nAb ID80	55	(40.9%, 54.9%)	(40.9%, 54.9%)	(35.1%, 53.3%)
Negative	D57	Live Virus nAb ID50	55	48.3%	48.3%	47.9%
Negative	D57	Live Virus nAb ID50	55	(41.2%, 55.4%)	(41.2%, 55.4%)	(40.9%, 54.9%)
Negative	D57	Live Virus nAb ID80	55	47.2%	47.2%	46.9%
Negative	D57	Live Virus nAb ID80	55	(40.0%, 54.4%)	(40.0%, 54.4%)	(39.5%, 54.3%)
Positive	D29	Anti-Spike IgG	29	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	29	100.0%	100.0%	100.0%



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Anti-RBD IgG	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	29	86.0%	86.0%	86.0%
Positive	D29	Pseudo nAb ID50	29	(77.4%, 94.5%)	(77.4%, 94.5%)	(77.4%, 94.5%)
Positive	D29	Pseudo nAb ID80	29	75.1%	75.1%	48.8%
Positive	D29	Pseudo nAb ID80	29	(67.8%, 82.3%)	(67.8%, 82.3%)	(37.9%, 59.7%)
Positive	D29	Live Virus nAb ID50	29	76.1%	76.1%	69.8%
Positive	D29	Live Virus nAb ID50	29	(65.9%, 86.3%)	(65.9%, 86.3%)	(63.0%, 76.6%)
Positive	D29	Live Virus nAb ID80	29	82.4%	82.4%	54.6%
Positive	D29	Live Virus nAb ID80	29	(74.7%, 90.0%)	(74.7%, 90.0%)	(40.7%, 68.5%)
Positive	D57	Anti-Spike IgG	29	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	29	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	29	100.0%	100.0%	100.0%
Positive	D57	Pseudo nAb ID50	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID80	29	91.1%	91.1%	91.1%
Positive	D57	Pseudo nAb ID80	29	(81.8%, 100.3%)	(81.8%, 100.3%)	(81.8%, 100.3%)
Positive	D57	Live Virus nAb ID50	29	100.0%	100.0%	100.0%
Positive	D57	Live Virus nAb ID50	29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Live Virus nAb ID80	29	91.1%	91.1%	82.1%
Positive	D57	Live Virus nAb ID80	29	(81.8%, 100.3%)	(81.8%, 100.3%)	(63.6%, 100.6%)
<b>White Non-Hispanic</b>						
Negative	D29	Anti-Spike IgG	437	52.2%	52.2%	52.2%
Negative	D29	Anti-Spike IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D29	Anti-RBD IgG	437	52.2%	52.2%	52.2%
Negative	D29	Anti-RBD IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D29	Pseudo nAb ID50	437	42.9%	42.9%	36.4%
Negative	D29	Pseudo nAb ID50	437	(38.3%, 47.5%)	(38.3%, 47.5%)	(31.7%, 41.2%)
Negative	D29	Pseudo nAb ID80	437	34.7%	34.7%	28.9%
Negative	D29	Pseudo nAb ID80	437	(31.7%, 37.7%)	(31.7%, 37.7%)	(25.2%, 32.7%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Live Virus nAb ID50	437	42.2%	42.2%	34.1%
Negative	D29	Live Virus nAb ID50	437	(38.0%, 46.4%)	(38.0%, 46.4%)	(30.1%, 38.1%)
Negative	D29	Live Virus nAb ID80	437	33.2%	33.2%	25.6%
Negative	D29	Live Virus nAb ID80	437	(29.2%, 37.2%)	(29.2%, 37.2%)	(20.2%, 31.0%)
Negative	D57	Anti-Spike IgG	437	52.2%	52.2%	52.2%
Negative	D57	Anti-Spike IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D57	Anti-RBD IgG	437	52.2%	52.2%	52.2%
Negative	D57	Anti-RBD IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D57	Pseudo nAb ID50	437	51.4%	51.4%	50.5%
Negative	D57	Pseudo nAb ID50	437	(46.4%, 56.3%)	(46.4%, 56.3%)	(46.1%, 54.8%)
Negative	D57	Pseudo nAb ID80	437	48.9%	48.9%	47.2%
Negative	D57	Pseudo nAb ID80	437	(44.6%, 53.2%)	(44.6%, 53.2%)	(42.8%, 51.6%)
Negative	D57	Live Virus nAb ID50	437	50.7%	50.7%	50.1%
Negative	D57	Live Virus nAb ID50	437	(46.8%, 54.6%)	(46.8%, 54.6%)	(44.8%, 55.4%)
Negative	D57	Live Virus nAb ID80	437	49.5%	49.5%	46.9%
Negative	D57	Live Virus nAb ID80	437	(45.5%, 53.6%)	(45.5%, 53.6%)	(43.5%, 50.4%)
Negative	D29	Anti-Spike IgG	437	52.2%	52.2%	52.2%
Negative	D29	Anti-Spike IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D29	Anti-RBD IgG	437	52.2%	52.2%	52.2%
Negative	D29	Anti-RBD IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D29	Pseudo nAb ID50	437	42.9%	42.9%	36.4%
Negative	D29	Pseudo nAb ID50	437	(38.3%, 47.5%)	(38.3%, 47.5%)	(31.7%, 41.2%)
Negative	D29	Pseudo nAb ID80	437	34.7%	34.7%	28.9%
Negative	D29	Pseudo nAb ID80	437	(31.7%, 37.7%)	(31.7%, 37.7%)	(25.2%, 32.7%)
Negative	D29	Live Virus nAb ID50	437	42.2%	42.2%	34.1%
Negative	D29	Live Virus nAb ID50	437	(38.0%, 46.4%)	(38.0%, 46.4%)	(30.1%, 38.1%)
Negative	D29	Live Virus nAb ID80	437	33.2%	33.2%	25.6%
Negative	D29	Live Virus nAb ID80	437	(29.2%, 37.2%)	(29.2%, 37.2%)	(20.2%, 31.0%)
Negative	D57	Anti-Spike IgG	437	52.2%	52.2%	52.2%
Negative	D57	Anti-Spike IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D57	Anti-RBD IgG	437	52.2%	52.2%	52.2%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-RBD IgG	437	(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
Negative	D57	Pseudo nAb ID50	437	51.4%	51.4%	50.5%
Negative	D57	Pseudo nAb ID50	437	(46.4%, 56.3%)	(46.4%, 56.3%)	(46.1%, 54.8%)
Negative	D57	Pseudo nAb ID80	437	48.9%	48.9%	47.2%
Negative	D57	Pseudo nAb ID80	437	(44.6%, 53.2%)	(44.6%, 53.2%)	(42.8%, 51.6%)
Negative	D57	Live Virus nAb ID50	437	50.7%	50.7%	50.1%
Negative	D57	Live Virus nAb ID50	437	(46.8%, 54.6%)	(46.8%, 54.6%)	(44.8%, 55.4%)
Negative	D57	Live Virus nAb ID80	437	49.5%	49.5%	46.9%
Negative	D57	Live Virus nAb ID80	437	(45.5%, 53.6%)	(45.5%, 53.6%)	(43.5%, 50.4%)
Positive	D29	Anti-Spike IgG	230	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	230	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	230	79.3%	79.3%	65.5%
Positive	D29	Pseudo nAb ID50	230	(73.9%, 84.7%)	(73.9%, 84.7%)	(56.8%, 74.2%)
Positive	D29	Pseudo nAb ID80	230	66.4%	66.4%	48.9%
Positive	D29	Pseudo nAb ID80	230	(58.1%, 74.7%)	(58.1%, 74.7%)	(38.8%, 59.1%)
Positive	D29	Live Virus nAb ID50	230	74.5%	74.5%	61.2%
Positive	D29	Live Virus nAb ID50	230	(68.2%, 80.7%)	(68.2%, 80.7%)	(53.1%, 69.2%)
Positive	D29	Live Virus nAb ID80	230	66.2%	66.2%	50.9%
Positive	D29	Live Virus nAb ID80	230	(58.9%, 73.5%)	(58.9%, 73.5%)	(40.7%, 61.0%)
Positive	D57	Anti-Spike IgG	230	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	230	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	230	94.6%	94.6%	93.6%
Positive	D57	Pseudo nAb ID50	230	(92.8%, 96.4%)	(92.8%, 96.4%)	(91.1%, 96.2%)
Positive	D57	Pseudo nAb ID80	230	94.7%	94.7%	88.0%
Positive	D57	Pseudo nAb ID80	230	(91.7%, 97.6%)	(91.7%, 97.6%)	(84.5%, 91.5%)
Positive	D57	Live Virus nAb ID50	230	94.1%	94.1%	91.8%
Positive	D57	Live Virus nAb ID50	230	(90.7%, 97.5%)	(90.7%, 97.5%)	(89.3%, 94.4%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID80	230	97.2%	97.2%	94.1%
Positive	D57	Live Virus nAb ID80	230	(91.0%, 103.5%)	(91.0%, 103.5%)	(84.5%, 103.8%)
Positive	D29	Anti-Spike IgG	230	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	230	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	230	79.3%	79.3%	65.5%
Positive	D29	Pseudo nAb ID50	230	(73.9%, 84.7%)	(73.9%, 84.7%)	(56.8%, 74.2%)
Positive	D29	Pseudo nAb ID80	230	66.4%	66.4%	48.9%
Positive	D29	Pseudo nAb ID80	230	(58.1%, 74.7%)	(58.1%, 74.7%)	(38.8%, 59.1%)
Positive	D29	Live Virus nAb ID50	230	74.5%	74.5%	61.2%
Positive	D29	Live Virus nAb ID50	230	(68.2%, 80.7%)	(68.2%, 80.7%)	(53.1%, 69.2%)
Positive	D29	Live Virus nAb ID80	230	66.2%	66.2%	50.9%
Positive	D29	Live Virus nAb ID80	230	(58.9%, 73.5%)	(58.9%, 73.5%)	(40.7%, 61.0%)
Positive	D57	Anti-Spike IgG	230	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	230	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	230	94.6%	94.6%	93.6%
Positive	D57	Pseudo nAb ID50	230	(92.8%, 96.4%)	(92.8%, 96.4%)	(91.1%, 96.2%)
Positive	D57	Pseudo nAb ID80	230	94.7%	94.7%	88.0%
Positive	D57	Pseudo nAb ID80	230	(91.7%, 97.6%)	(91.7%, 97.6%)	(84.5%, 91.5%)
Positive	D57	Live Virus nAb ID50	230	94.1%	94.1%	91.8%
Positive	D57	Live Virus nAb ID50	230	(90.7%, 97.5%)	(90.7%, 97.5%)	(89.3%, 94.4%)
Positive	D57	Live Virus nAb ID80	230	97.2%	97.2%	94.1%
Positive	D57	Live Virus nAb ID80	230	(91.0%, 103.5%)	(91.0%, 103.5%)	(84.5%, 103.8%)
<b>Communities of Color</b>						
Negative	D29	Anti-Spike IgG	557	51.6%	51.6%	51.6%
Negative	D29	Anti-Spike IgG	557	(49.5%, 53.7%)	(49.5%, 53.7%)	(49.5%, 53.7%)
Negative	D29	Anti-RBD IgG	557	51.6%	51.6%	51.6%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Anti-RBD IgG	557	(49.5%, 53.7%)	(49.5%, 53.7%)	(49.5%, 53.7%)
Negative	D29	Pseudo nAb ID50	557	41.5%	41.5%	34.7%
Negative	D29	Pseudo nAb ID50	557	(40.1%, 42.9%)	(40.1%, 42.9%)	(30.9%, 38.6%)
Negative	D29	Pseudo nAb ID80	557	35.8%	35.8%	28.1%
Negative	D29	Pseudo nAb ID80	557	(33.3%, 38.3%)	(33.3%, 38.3%)	(23.9%, 32.3%)
Negative	D29	Live Virus nAb ID50	557	42.2%	42.2%	34.2%
Negative	D29	Live Virus nAb ID50	557	(40.0%, 44.3%)	(40.0%, 44.3%)	(31.1%, 37.2%)
Negative	D29	Live Virus nAb ID80	557	38.1%	38.1%	31.4%
Negative	D29	Live Virus nAb ID80	557	(37.1%, 39.2%)	(37.1%, 39.2%)	(30.2%, 32.5%)
Negative	D57	Anti-Spike IgG	557	51.6%	51.6%	51.6%
Negative	D57	Anti-Spike IgG	557	(49.5%, 53.7%)	(49.5%, 53.7%)	(49.5%, 53.7%)
Negative	D57	Anti-RBD IgG	557	51.6%	51.6%	51.6%
Negative	D57	Anti-RBD IgG	557	(49.5%, 53.7%)	(49.5%, 53.7%)	(49.5%, 53.7%)
Negative	D57	Pseudo nAb ID50	557	50.0%	50.0%	48.6%
Negative	D57	Pseudo nAb ID50	557	(47.9%, 52.1%)	(47.9%, 52.1%)	(46.7%, 50.6%)
Negative	D57	Pseudo nAb ID80	557	49.2%	49.2%	46.2%
Negative	D57	Pseudo nAb ID80	557	(47.9%, 50.6%)	(47.9%, 50.6%)	(45.6%, 46.8%)
Negative	D57	Live Virus nAb ID50	557	50.5%	50.5%	48.4%
Negative	D57	Live Virus nAb ID50	557	(48.2%, 52.9%)	(48.2%, 52.9%)	(46.0%, 50.8%)
Negative	D57	Live Virus nAb ID80	557	48.8%	48.8%	45.8%
Negative	D57	Live Virus nAb ID80	557	(47.2%, 50.4%)	(47.2%, 50.4%)	(45.4%, 46.3%)
Positive	D29	Anti-Spike IgG	251	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	251	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	251	77.0%	77.0%	66.8%
Positive	D29	Pseudo nAb ID50	251	(69.6%, 84.4%)	(69.6%, 84.4%)	(56.3%, 77.2%)
Positive	D29	Pseudo nAb ID80	251	61.3%	61.3%	49.1%
Positive	D29	Pseudo nAb ID80	251	(50.1%, 72.5%)	(50.1%, 72.5%)	(40.2%, 58.0%)
Positive	D29	Live Virus nAb ID50	251	78.3%	78.3%	70.1%
Positive	D29	Live Virus nAb ID50	251	(74.1%, 82.6%)	(74.1%, 82.6%)	(64.3%, 75.9%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Live Virus nAb ID80	251	72.0%	72.0%	58.4%
Positive	D29	Live Virus nAb ID80	251	(68.2%, 75.8%)	(68.2%, 75.8%)	(54.2%, 62.7%)
Positive	D57	Anti-Spike IgG	251	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	251	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	251	95.6%	95.6%	93.3%
Positive	D57	Pseudo nAb ID50	251	(93.7%, 97.5%)	(93.7%, 97.5%)	(91.0%, 95.5%)
Positive	D57	Pseudo nAb ID80	251	90.1%	90.1%	86.1%
Positive	D57	Pseudo nAb ID80	251	(86.4%, 93.8%)	(86.4%, 93.8%)	(82.6%, 89.6%)
Positive	D57	Live Virus nAb ID50	251	98.5%	98.5%	94.5%
Positive	D57	Live Virus nAb ID50	251	(97.9%, 99.2%)	(97.9%, 99.2%)	(92.2%, 96.8%)
Positive	D57	Live Virus nAb ID80	251	95.1%	95.1%	91.7%
Positive	D57	Live Virus nAb ID80	251	(93.6%, 96.5%)	(93.6%, 96.5%)	(89.7%, 93.8%)
<b>Age &lt; 65 Communities of Color</b>						
Negative	D29	Anti-Spike IgG	259	52.4%	52.4%	52.4%
Negative	D29	Anti-Spike IgG	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
Negative	D29	Anti-RBD IgG	259	52.4%	52.4%	52.4%
Negative	D29	Anti-RBD IgG	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
Negative	D29	Pseudo nAb ID50	259	41.0%	41.0%	33.3%
Negative	D29	Pseudo nAb ID50	259	(40.6%, 41.4%)	(40.6%, 41.4%)	(32.7%, 33.8%)
Negative	D29	Pseudo nAb ID80	259	34.7%	34.7%	26.6%
Negative	D29	Pseudo nAb ID80	259	(34.0%, 35.5%)	(34.0%, 35.5%)	(25.7%, 27.6%)
Negative	D29	Live Virus nAb ID50	259	41.8%	41.8%	32.9%
Negative	D29	Live Virus nAb ID50	259	(39.1%, 44.5%)	(39.1%, 44.5%)	(31.2%, 34.7%)
Negative	D29	Live Virus nAb ID80	259	37.9%	37.9%	30.9%
Negative	D29	Live Virus nAb ID80	259	(36.6%, 39.3%)	(36.6%, 39.3%)	(30.2%, 31.6%)
Negative	D57	Anti-Spike IgG	259	52.4%	52.4%	52.4%
Negative	D57	Anti-Spike IgG	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
Negative	D57	Anti-RBD IgG	259	52.4%	52.4%	52.4%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Anti-RBD IgG	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
Negative	D57	Pseudo nAb ID50	259	50.6%	50.6%	49.0%
Negative	D57	Pseudo nAb ID50	259	(49.2%, 52.0%)	(49.2%, 52.0%)	(47.4%, 50.6%)
Negative	D57	Pseudo nAb ID80	259	49.8%	49.8%	46.4%
Negative	D57	Pseudo nAb ID80	259	(49.4%, 50.2%)	(49.4%, 50.2%)	(45.9%, 46.9%)
Negative	D57	Live Virus nAb ID50	259	51.3%	51.3%	48.8%
Negative	D57	Live Virus nAb ID50	259	(50.7%, 52.0%)	(50.7%, 52.0%)	(46.7%, 51.0%)
Negative	D57	Live Virus nAb ID80	259	49.3%	49.3%	45.9%
Negative	D57	Live Virus nAb ID80	259	(48.5%, 50.2%)	(48.5%, 50.2%)	(45.4%, 46.5%)
Positive	D29	Anti-Spike IgG	148	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	148	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	148	74.7%	74.7%	64.1%
Positive	D29	Pseudo nAb ID50	148	(72.0%, 77.4%)	(72.0%, 77.4%)	(57.7%, 70.5%)
Positive	D29	Pseudo nAb ID80	148	58.2%	58.2%	46.6%
Positive	D29	Pseudo nAb ID80	148	(52.4%, 64.0%)	(52.4%, 64.0%)	(42.1%, 51.0%)
Positive	D29	Live Virus nAb ID50	148	76.8%	76.8%	68.8%
Positive	D29	Live Virus nAb ID50	148	(76.6%, 77.0%)	(76.6%, 77.0%)	(62.2%, 75.4%)
Positive	D29	Live Virus nAb ID80	148	70.6%	70.6%	56.8%
Positive	D29	Live Virus nAb ID80	148	(69.4%, 71.7%)	(69.4%, 71.7%)	(53.9%, 59.7%)
Positive	D57	Anti-Spike IgG	148	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	148	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	148	95.0%	95.0%	92.7%
Positive	D57	Pseudo nAb ID50	148	(94.3%, 95.7%)	(94.3%, 95.7%)	(91.3%, 94.1%)
Positive	D57	Pseudo nAb ID80	148	89.1%	89.1%	84.8%
Positive	D57	Pseudo nAb ID80	148	(87.1%, 91.1%)	(87.1%, 91.1%)	(82.2%, 87.4%)
Positive	D57	Live Virus nAb ID50	148	98.4%	98.4%	93.9%
Positive	D57	Live Virus nAb ID50	148	(97.6%, 99.2%)	(97.6%, 99.2%)	(91.5%, 96.2%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Live Virus nAb ID80	148	94.5%	94.5%	91.0%
Positive	D57	Live Virus nAb ID80	148	(93.6%, 95.5%)	(93.6%, 95.5%)	(90.7%, 91.2%)
<b>Age &lt; 65 White Non-Hispanic</b>						
Negative	D29	Anti-Spike IgG	216	52.7%	52.7%	52.7%
Negative	D29	Anti-Spike IgG	216	(48.1%, 57.2%)	(48.1%, 57.2%)	(48.1%, 57.2%)
Negative	D29	Anti-RBD IgG	216	52.7%	52.7%	52.7%
Negative	D29	Anti-RBD IgG	216	(48.1%, 57.2%)	(48.1%, 57.2%)	(48.1%, 57.2%)
Negative	D29	Pseudo nAb ID50	216	42.3%	42.3%	35.3%
Negative	D29	Pseudo nAb ID50	216	(36.6%, 48.0%)	(36.6%, 48.0%)	(29.7%, 40.9%)
Negative	D29	Pseudo nAb ID80	216	33.6%	33.6%	27.8%
Negative	D29	Pseudo nAb ID80	216	(31.1%, 36.0%)	(31.1%, 36.0%)	(23.8%, 31.7%)
Negative	D29	Live Virus nAb ID50	216	41.9%	41.9%	33.3%
Negative	D29	Live Virus nAb ID50	216	(36.8%, 47.0%)	(36.8%, 47.0%)	(28.4%, 38.1%)
Negative	D29	Live Virus nAb ID80	216	31.6%	31.6%	23.4%
Negative	D29	Live Virus nAb ID80	216	(30.3%, 33.0%)	(30.3%, 33.0%)	(20.4%, 26.4%)
Negative	D57	Anti-Spike IgG	216	52.7%	52.7%	52.7%
Negative	D57	Anti-Spike IgG	216	(48.1%, 57.2%)	(48.1%, 57.2%)	(48.1%, 57.2%)
Negative	D57	Anti-RBD IgG	216	52.7%	52.7%	52.7%
Negative	D57	Anti-RBD IgG	216	(48.1%, 57.2%)	(48.1%, 57.2%)	(48.1%, 57.2%)
Negative	D57	Pseudo nAb ID50	216	51.9%	51.9%	51.0%
Negative	D57	Pseudo nAb ID50	216	(46.7%, 57.0%)	(46.7%, 57.0%)	(46.5%, 55.4%)
Negative	D57	Pseudo nAb ID80	216	49.0%	49.0%	47.2%
Negative	D57	Pseudo nAb ID80	216	(44.1%, 54.0%)	(44.1%, 54.0%)	(42.0%, 52.3%)
Negative	D57	Live Virus nAb ID50	216	51.1%	51.1%	50.5%
Negative	D57	Live Virus nAb ID50	216	(46.9%, 55.2%)	(46.9%, 55.2%)	(44.8%, 56.2%)
Negative	D57	Live Virus nAb ID80	216	49.8%	49.8%	47.1%
Negative	D57	Live Virus nAb ID80	216	(45.4%, 54.2%)	(45.4%, 54.2%)	(43.2%, 51.0%)
Positive	D29	Anti-Spike IgG	128	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	128	100.0%	100.0%	100.0%



Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D29	Anti-RBD IgG	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	128	77.3%	77.3%	62.1%
Positive	D29	Pseudo nAb ID50	128	(73.3%, 81.3%)	(73.3%, 81.3%)	(57.6%, 66.6%)
Positive	D29	Pseudo nAb ID80	128	63.6%	63.6%	45.3%
Positive	D29	Pseudo nAb ID80	128	(55.8%, 71.4%)	(55.8%, 71.4%)	(37.0%, 53.6%)
Positive	D29	Live Virus nAb ID50	128	72.0%	72.0%	58.0%
Positive	D29	Live Virus nAb ID50	128	(69.5%, 74.6%)	(69.5%, 74.6%)	(55.3%, 60.8%)
Positive	D29	Live Virus nAb ID80	128	63.4%	63.4%	47.0%
Positive	D29	Live Virus nAb ID80	128	(62.4%, 64.4%)	(62.4%, 64.4%)	(46.4%, 47.6%)
Positive	D57	Anti-Spike IgG	128	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	128	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	128	93.9%	93.9%	93.0%
Positive	D57	Pseudo nAb ID50	128	(93.8%, 94.1%)	(93.8%, 94.1%)	(90.1%, 95.8%)
Positive	D57	Pseudo nAb ID80	128	94.1%	94.1%	86.8%
Positive	D57	Pseudo nAb ID80	128	(90.5%, 97.7%)	(90.5%, 97.7%)	(83.9%, 89.7%)
Positive	D57	Live Virus nAb ID50	128	93.3%	93.3%	90.9%
Positive	D57	Live Virus nAb ID50	128	(90.8%, 95.8%)	(90.8%, 95.8%)	(90.6%, 91.1%)
Positive	D57	Live Virus nAb ID80	128	97.4%	97.4%	94.6%
Positive	D57	Live Virus nAb ID80	128	(90.4%, 104.4%)	(90.4%, 104.4%)	(84.0%, 105.2%)
<b>Age &gt;= 65 Communities of Color</b>						
Negative	D29	Anti-Spike IgG	298	47.9%	47.9%	47.9%
Negative	D29	Anti-Spike IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
Negative	D29	Anti-RBD IgG	298	47.9%	47.9%	47.9%
Negative	D29	Anti-RBD IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
Negative	D29	Pseudo nAb ID50	298	43.8%	43.8%	41.7%
Negative	D29	Pseudo nAb ID50	298	(43.8%, 43.8%)	(43.8%, 43.8%)	(41.7%, 41.7%)
Negative	D29	Pseudo nAb ID80	298	40.7%	40.7%	35.4%
Negative	D29	Pseudo nAb ID80	298	(40.7%, 40.7%)	(40.7%, 40.7%)	(35.4%, 35.4%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D29	Live Virus nAb ID50	298	44.0%	44.0%	40.1%
Negative	D29	Live Virus nAb ID50	298	(44.0%, 44.0%)	(44.0%, 44.0%)	(40.1%, 40.1%)
Negative	D29	Live Virus nAb ID80	298	39.1%	39.1%	33.7%
Negative	D29	Live Virus nAb ID80	298	(39.1%, 39.1%)	(39.1%, 39.1%)	(33.7%, 33.7%)
Negative	D57	Anti-Spike IgG	298	47.9%	47.9%	47.9%
Negative	D57	Anti-Spike IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
Negative	D57	Anti-RBD IgG	298	47.9%	47.9%	47.9%
Negative	D57	Anti-RBD IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
Negative	D57	Pseudo nAb ID50	298	47.3%	47.3%	46.8%
Negative	D57	Pseudo nAb ID50	298	(47.3%, 47.3%)	(47.3%, 47.3%)	(46.8%, 46.8%)
Negative	D57	Pseudo nAb ID80	298	46.6%	46.6%	45.1%
Negative	D57	Pseudo nAb ID80	298	(46.6%, 46.6%)	(46.6%, 46.6%)	(45.1%, 45.1%)
Negative	D57	Live Virus nAb ID50	298	46.6%	46.6%	46.1%
Negative	D57	Live Virus nAb ID50	298	(46.6%, 46.6%)	(46.6%, 46.6%)	(46.1%, 46.1%)
Negative	D57	Live Virus nAb ID80	298	46.5%	46.5%	45.4%
Negative	D57	Live Virus nAb ID80	298	(46.5%, 46.5%)	(46.5%, 46.5%)	(45.4%, 45.4%)
Positive	D29	Anti-Spike IgG	103	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	103	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	103	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	103	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	103	93.9%	93.9%	86.0%
Positive	D29	Pseudo nAb ID50	103	(93.9%, 93.9%)	(93.9%, 93.9%)	(86.0%, 86.0%)
Positive	D29	Pseudo nAb ID80	103	84.0%	84.0%	67.3%
Positive	D29	Pseudo nAb ID80	103	(84.0%, 84.0%)	(84.0%, 84.0%)	(67.3%, 67.3%)
Positive	D29	Live Virus nAb ID50	103	89.6%	89.6%	79.7%
Positive	D29	Live Virus nAb ID50	103	(89.6%, 89.6%)	(89.6%, 89.6%)	(79.7%, 79.7%)
Positive	D29	Live Virus nAb ID80	103	82.7%	82.7%	69.9%
Positive	D29	Live Virus nAb ID80	103	(82.7%, 82.7%)	(82.7%, 82.7%)	(69.9%, 69.9%)
Positive	D57	Anti-Spike IgG	103	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	103	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	103	100.0%	100.0%	100.0%

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57	Anti-RBD IgG	103	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	103	100.0%	100.0%	97.4%
Positive	D57	Pseudo nAb ID50	103	(100.0%, 100.0%)	(100.0%, 100.0%)	(97.4%, 97.4%)
Positive	D57	Pseudo nAb ID80	103	97.4%	97.4%	95.4%
Positive	D57	Pseudo nAb ID80	103	(97.4%, 97.4%)	(97.4%, 97.4%)	(95.4%, 95.4%)
Positive	D57	Live Virus nAb ID50	103	99.4%	99.4%	99.4%
Positive	D57	Live Virus nAb ID50	103	(99.4%, 99.4%)	(99.4%, 99.4%)	(99.4%, 99.4%)
Positive	D57	Live Virus nAb ID80	103	99.0%	99.0%	97.4%
Positive	D57	Live Virus nAb ID80	103	(99.0%, 99.0%)	(99.0%, 99.0%)	(97.4%, 97.4%)
<b>Age &gt;= 65 White Non-Hispanic</b>						
Negative	D29	Anti-Spike IgG	221	49.3%	49.3%	49.3%
Negative	D29	Anti-Spike IgG	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
Negative	D29	Anti-RBD IgG	221	49.3%	49.3%	49.3%
Negative	D29	Anti-RBD IgG	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
Negative	D29	Pseudo nAb ID50	221	46.4%	46.4%	42.7%
Negative	D29	Pseudo nAb ID50	221	(46.4%, 46.4%)	(46.4%, 46.4%)	(42.7%, 42.7%)
Negative	D29	Pseudo nAb ID80	221	41.1%	41.1%	35.6%
Negative	D29	Pseudo nAb ID80	221	(41.1%, 41.1%)	(41.1%, 41.1%)	(35.6%, 35.6%)
Negative	D29	Live Virus nAb ID50	221	43.7%	43.7%	38.8%
Negative	D29	Live Virus nAb ID50	221	(43.7%, 43.7%)	(43.7%, 43.7%)	(38.8%, 38.8%)
Negative	D29	Live Virus nAb ID80	221	42.4%	42.4%	37.8%
Negative	D29	Live Virus nAb ID80	221	(42.4%, 42.4%)	(42.4%, 42.4%)	(37.8%, 37.8%)
Negative	D57	Anti-Spike IgG	221	49.3%	49.3%	49.3%
Negative	D57	Anti-Spike IgG	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
Negative	D57	Anti-RBD IgG	221	49.3%	49.3%	49.3%
Negative	D57	Anti-RBD IgG	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
Negative	D57	Pseudo nAb ID50	221	48.5%	48.5%	47.6%
Negative	D57	Pseudo nAb ID50	221	(48.5%, 48.5%)	(48.5%, 48.5%)	(47.6%, 47.6%)
Negative	D57	Pseudo nAb ID80	221	48.1%	48.1%	47.3%
Negative	D57	Pseudo nAb ID80	221	(48.1%, 48.1%)	(48.1%, 48.1%)	(47.3%, 47.3%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Negative	D57	Live Virus nAb ID50	221	48.7%	48.7%	47.6%
Negative	D57	Live Virus nAb ID50	221	(48.7%, 48.7%)	(48.7%, 48.7%)	(47.6%, 47.6%)
Negative	D57	Live Virus nAb ID80	221	47.9%	47.9%	46.2%
Negative	D57	Live Virus nAb ID80	221	(47.9%, 47.9%)	(47.9%, 47.9%)	(46.2%, 46.2%)
Positive	D29	Anti-Spike IgG	102	100.0%	100.0%	100.0%
Positive	D29	Anti-Spike IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Anti-RBD IgG	102	100.0%	100.0%	100.0%
Positive	D29	Anti-RBD IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D29	Pseudo nAb ID50	102	92.0%	92.0%	87.2%
Positive	D29	Pseudo nAb ID50	102	(92.0%, 92.0%)	(92.0%, 92.0%)	(87.2%, 87.2%)
Positive	D29	Pseudo nAb ID80	102	84.1%	84.1%	72.3%
Positive	D29	Pseudo nAb ID80	102	(84.1%, 84.1%)	(84.1%, 84.1%)	(72.3%, 72.3%)
Positive	D29	Live Virus nAb ID50	102	90.1%	90.1%	81.3%
Positive	D29	Live Virus nAb ID50	102	(90.1%, 90.1%)	(90.1%, 90.1%)	(81.3%, 81.3%)
Positive	D29	Live Virus nAb ID80	102	84.2%	84.2%	75.4%
Positive	D29	Live Virus nAb ID80	102	(84.2%, 84.2%)	(84.2%, 84.2%)	(75.4%, 75.4%)
Positive	D57	Anti-Spike IgG	102	100.0%	100.0%	100.0%
Positive	D57	Anti-Spike IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Anti-RBD IgG	102	100.0%	100.0%	100.0%
Positive	D57	Anti-RBD IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	D57	Pseudo nAb ID50	102	99.0%	99.0%	98.0%
Positive	D57	Pseudo nAb ID50	102	(99.0%, 99.0%)	(99.0%, 99.0%)	(98.0%, 98.0%)
Positive	D57	Pseudo nAb ID80	102	98.0%	98.0%	96.0%
Positive	D57	Pseudo nAb ID80	102	(98.0%, 98.0%)	(98.0%, 98.0%)	(96.0%, 96.0%)
Positive	D57	Live Virus nAb ID50	102	99.0%	99.0%	98.0%
Positive	D57	Live Virus nAb ID50	102	(99.0%, 99.0%)	(99.0%, 99.0%)	(98.0%, 98.0%)
Positive	D57	Live Virus nAb ID80	102	96.0%	96.0%	91.1%
Positive	D57	Live Virus nAb ID80	102	(96.0%, 96.0%)	(96.0%, 96.0%)	(91.1%, 91.1%)

Table 1: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 1: Responder rates (*continued*)

Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
----------	-------	----------	---	-----------	-------------	-------------

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Total	Total	Negative	D1	Anti-RBD IgG	1089	17	(17, 17)
Total	Total	Negative	D29	Anti-RBD IgG	1089	707	(592, 845)
Total	Total	Negative	D57	Anti-RBD IgG	1089	5101	(4474, 5816)
Total	Total	Negative	D1	Anti-Spike IgG	1089	17	(17, 17)
Total	Total	Negative	D29	Anti-Spike IgG	1089	957	(815, 1125)
Total	Total	Negative	D57	Anti-Spike IgG	1089	7399	(6478, 8451)
Total	Total	Negative	D1	Pseudo nAb ID50	1089	24	(24, 24)
Total	Total	Negative	D29	Pseudo nAb ID50	1089	79	(64, 98)
Total	Total	Negative	D57	Pseudo nAb ID50	1089	327	(273, 393)
Total	Total	Negative	D1	Pseudo nAb ID80	1089	22	(22, 22)
Total	Total	Negative	D29	Pseudo nAb ID80	1089	50	(41, 62)
Total	Total	Negative	D57	Pseudo nAb ID80	1089	217	(180, 262)
Total	Total	Negative	D1	Live Virus nAb ID50	1089	24	(24, 24)
Total	Total	Negative	D29	Live Virus nAb ID50	1089	78	(69, 88)
Total	Total	Negative	D57	Live Virus nAb ID50	1089	291	(256, 329)
Total	Total	Negative	D1	Live Virus nAb ID80	1089	22	(22, 22)
Total	Total	Negative	D29	Live Virus nAb ID80	1089	54	(46, 62)
Total	Total	Negative	D57	Live Virus nAb ID80	1089	203	(175, 235)
Age	Age < 65	Negative	D1	Anti-RBD IgG	513	17	(17, 17)
Age	Age < 65	Negative	D29	Anti-RBD IgG	513	659	(591, 734)
Age	Age < 65	Negative	D57	Anti-RBD IgG	513	4904	(4243, 5668)
Age	Age < 65	Negative	D1	Anti-Spike IgG	513	17	(17, 17)
Age	Age < 65	Negative	D29	Anti-Spike IgG	513	897	(834, 964)
Age	Age < 65	Negative	D57	Anti-Spike IgG	513	7230	(6121, 8541)
Age	Age < 65	Negative	D1	Pseudo nAb ID50	513	24	(24, 24)
Age	Age < 65	Negative	D29	Pseudo nAb ID50	513	73	(73, 74)
Age	Age < 65	Negative	D57	Pseudo nAb ID50	513	304	(280, 330)
Age	Age < 65	Negative	D1	Pseudo nAb ID80	513	22	(22, 22)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age	Age < 65	Negative	D29	Pseudo nAb ID80	513	47	(46, 47)
Age	Age < 65	Negative	D57	Pseudo nAb ID80	513	201	(192, 211)
Age	Age < 65	Negative	D1	Live Virus nAb ID50	513	24	(24, 24)
Age	Age < 65	Negative	D29	Live Virus nAb ID50	513	74	(70, 79)
Age	Age < 65	Negative	D57	Live Virus nAb ID50	513	276	(270, 282)
Age	Age < 65	Negative	D1	Live Virus nAb ID80	513	22	(22, 22)
Age	Age < 65	Negative	D29	Live Virus nAb ID80	513	51	(51, 51)
Age	Age < 65	Negative	D57	Live Virus nAb ID80	513	192	(188, 196)
Age	Age ≥ 65	Negative	D1	Anti-RBD IgG	576	17	(17, 17)
Age	Age ≥ 65	Negative	D29	Anti-RBD IgG	576	1018	(1018, 1018)
Age	Age ≥ 65	Negative	D57	Anti-RBD IgG	576	6241	(6241, 6241)
Age	Age ≥ 65	Negative	D1	Anti-Spike IgG	576	17	(17, 17)
Age	Age ≥ 65	Negative	D29	Anti-Spike IgG	576	1338	(1338, 1338)
Age	Age ≥ 65	Negative	D57	Anti-Spike IgG	576	8330	(8330, 8330)
Age	Age ≥ 65	Negative	D1	Pseudo nAb ID50	576	25	(24, 25)
Age	Age ≥ 65	Negative	D29	Pseudo nAb ID50	576	120	(120, 120)
Age	Age ≥ 65	Negative	D57	Pseudo nAb ID50	576	478	(478, 478)
Age	Age ≥ 65	Negative	D1	Pseudo nAb ID80	576	22	(22, 22)
Age	Age ≥ 65	Negative	D29	Pseudo nAb ID80	576	74	(74, 74)
Age	Age ≥ 65	Negative	D57	Pseudo nAb ID80	576	320	(320, 320)
Age	Age ≥ 65	Negative	D1	Live Virus nAb ID50	576	25	(24, 25)
Age	Age ≥ 65	Negative	D29	Live Virus nAb ID50	576	101	(101, 101)
Age	Age ≥ 65	Negative	D57	Live Virus nAb ID50	576	376	(376, 376)
Age	Age ≥ 65	Negative	D1	Live Virus nAb ID80	576	22	(22, 22)
Age	Age ≥ 65	Negative	D29	Live Virus nAb ID80	576	71	(71, 71)
Age	Age ≥ 65	Negative	D57	Live Virus nAb ID80	576	269	(269, 269)
High Risk	At-risk	Negative	D1	Anti-RBD IgG	568	17	(17, 17)
High Risk	At-risk	Negative	D29	Anti-RBD IgG	568	715	(415, 1232)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
High Risk	At-risk	Negative	D57	Anti-RBD IgG	568	4914	(3039, 7945)
High Risk	At-risk	Negative	D1	Anti-Spike IgG	568	17	(17, 17)
High Risk	At-risk	Negative	D29	Anti-Spike IgG	568	1003	(610, 1650)
High Risk	At-risk	Negative	D57	Anti-Spike IgG	568	6843	(4493, 10421)
High Risk	At-risk	Negative	D1	Pseudo nAb ID50	568	24	(24, 24)
High Risk	At-risk	Negative	D29	Pseudo nAb ID50	568	86	(58, 128)
High Risk	At-risk	Negative	D57	Pseudo nAb ID50	568	325	(211, 500)
High Risk	At-risk	Negative	D1	Pseudo nAb ID80	568	21	(21, 22)
High Risk	At-risk	Negative	D29	Pseudo nAb ID80	568	55	(39, 78)
High Risk	At-risk	Negative	D57	Pseudo nAb ID80	568	225	(149, 341)
High Risk	At-risk	Negative	D1	Live Virus nAb ID50	568	24	(24, 24)
High Risk	At-risk	Negative	D29	Live Virus nAb ID50	568	78	(58, 104)
High Risk	At-risk	Negative	D57	Live Virus nAb ID50	568	302	(229, 398)
High Risk	At-risk	Negative	D1	Live Virus nAb ID80	568	21	(21, 22)
High Risk	At-risk	Negative	D29	Live Virus nAb ID80	568	56	(44, 72)
High Risk	At-risk	Negative	D57	Live Virus nAb ID80	568	224	(167, 302)
High Risk	Not at-risk	Negative	D1	Anti-RBD IgG	521	17	(17, 17)
High Risk	Not at-risk	Negative	D29	Anti-RBD IgG	521	705	(649, 765)
High Risk	Not at-risk	Negative	D57	Anti-RBD IgG	521	5167	(5142, 5192)
High Risk	Not at-risk	Negative	D1	Anti-Spike IgG	521	17	(17, 17)
High Risk	Not at-risk	Negative	D29	Anti-Spike IgG	521	942	(880, 1009)
High Risk	Not at-risk	Negative	D57	Anti-Spike IgG	521	7599	(7327, 7882)
High Risk	Not at-risk	Negative	D1	Pseudo nAb ID50	521	24	(24, 24)
High Risk	Not at-risk	Negative	D29	Pseudo nAb ID50	521	77	(66, 90)
High Risk	Not at-risk	Negative	D57	Pseudo nAb ID50	521	328	(286, 376)
High Risk	Not at-risk	Negative	D1	Pseudo nAb ID80	521	22	(22, 22)
High Risk	Not at-risk	Negative	D29	Pseudo nAb ID80	521	49	(42, 57)
High Risk	Not at-risk	Negative	D57	Pseudo nAb ID80	521	215	(187, 246)
High Risk	Not at-risk	Negative	D1	Live Virus nAb ID50	521	24	(24, 24)



Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
High Risk	Not at-risk	Negative	D29	Live Virus nAb ID50	521	78	(72, 86)
High Risk	Not at-risk	Negative	D57	Live Virus nAb ID50	521	287	(263, 313)
High Risk	Not at-risk	Negative	D1	Live Virus nAb ID80	521	22	(22, 22)
High Risk	Not at-risk	Negative	D29	Live Virus nAb ID80	521	53	(47, 59)
High Risk	Not at-risk	Negative	D57	Live Virus nAb ID80	521	196	(180, 213)
Age, Risk	Age < 65 At-risk	Negative	D1	Anti-RBD IgG	259	17	(17, 17)
Age, Risk	Age < 65 At-risk	Negative	D29	Anti-RBD IgG	259	565	(565, 565)
Age, Risk	Age < 65 At-risk	Negative	D57	Anti-RBD IgG	259	3992	(3992, 3992)
Age, Risk	Age < 65 At-risk	Negative	D1	Anti-Spike IgG	259	17	(17, 17)
Age, Risk	Age < 65 At-risk	Negative	D29	Anti-Spike IgG	259	809	(809, 809)
Age, Risk	Age < 65 At-risk	Negative	D57	Anti-Spike IgG	259	5706	(5706, 5706)
Age, Risk	Age < 65 At-risk	Negative	D1	Pseudo nAb ID50	259	24	(24, 25)
Age, Risk	Age < 65 At-risk	Negative	D29	Pseudo nAb ID50	259	72	(72, 72)
Age, Risk	Age < 65 At-risk	Negative	D57	Pseudo nAb ID50	259	270	(270, 270)
Age, Risk	Age < 65 At-risk	Negative	D1	Pseudo nAb ID80	259	21	(21, 22)
Age, Risk	Age < 65 At-risk	Negative	D29	Pseudo nAb ID80	259	47	(47, 47)
Age, Risk	Age < 65 At-risk	Negative	D57	Pseudo nAb ID80	259	189	(189, 189)
Age, Risk	Age < 65 At-risk	Negative	D1	Live Virus nAb ID50	259	24	(24, 25)
Age, Risk	Age < 65 At-risk	Negative	D29	Live Virus nAb ID50	259	68	(68, 68)
Age, Risk	Age < 65 At-risk	Negative	D57	Live Virus nAb ID50	259	268	(268, 268)
Age, Risk	Age < 65 At-risk	Negative	D1	Live Virus nAb ID80	259	21	(21, 22)
Age, Risk	Age < 65 At-risk	Negative	D29	Live Virus nAb ID80	259	51	(51, 51)
Age, Risk	Age < 65 At-risk	Negative	D57	Live Virus nAb ID80	259	197	(197, 197)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Anti-RBD IgG	254	17	(17, 17)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Anti-RBD IgG	254	686	(686, 686)
Age, Risk	Age < 65 Not at-risk	Negative	D57	Anti-RBD IgG	254	5175	(5175, 5175)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Anti-Spike IgG	254	17	(17, 17)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Anti-Spike IgG	254	921	(921, 921)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk	Age < 65 Not at-risk	Negative	D57	Anti-Spike IgG	254	7692	(7692, 7692)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Pseudo nAb ID50	254	24	(24, 25)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Pseudo nAb ID50	254	73	(73, 73)
Age, Risk	Age < 65 Not at-risk	Negative	D57	Pseudo nAb ID50	254	313	(313, 313)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Pseudo nAb ID80	254	22	(22, 22)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Pseudo nAb ID80	254	47	(47, 47)
Age, Risk	Age < 65 Not at-risk	Negative	D57	Pseudo nAb ID80	254	205	(205, 205)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Live Virus nAb ID50	254	24	(24, 25)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Live Virus nAb ID50	254	76	(76, 76)
Age, Risk	Age < 65 Not at-risk	Negative	D57	Live Virus nAb ID50	254	279	(279, 279)
Age, Risk	Age < 65 Not at-risk	Negative	D1	Live Virus nAb ID80	254	22	(22, 22)
Age, Risk	Age < 65 Not at-risk	Negative	D29	Live Virus nAb ID80	254	51	(51, 51)
Age, Risk	Age < 65 Not at-risk	Negative	D57	Live Virus nAb ID80	254	191	(191, 191)
Age, Risk	Age >= 65 At-risk	Negative	D1	Anti-RBD IgG	309	17	(17, 17)
Age, Risk	Age >= 65 At-risk	Negative	D29	Anti-RBD IgG	309	1183	(1183, 1183)
Age, Risk	Age >= 65 At-risk	Negative	D57	Anti-RBD IgG	309	7667	(7667, 7667)
Age, Risk	Age >= 65 At-risk	Negative	D1	Anti-Spike IgG	309	17	(17, 17)
Age, Risk	Age >= 65 At-risk	Negative	D29	Anti-Spike IgG	309	1590	(1590, 1590)
Age, Risk	Age >= 65 At-risk	Negative	D57	Anti-Spike IgG	309	10101	(10101, 10101)
Age, Risk	Age >= 65 At-risk	Negative	D1	Pseudo nAb ID50	309	24	(24, 24)
Age, Risk	Age >= 65 At-risk	Negative	D29	Pseudo nAb ID50	309	124	(124, 124)
Age, Risk	Age >= 65 At-risk	Negative	D57	Pseudo nAb ID50	309	485	(485, 485)
Age, Risk	Age >= 65 At-risk	Negative	D1	Pseudo nAb ID80	309	22	(22, 22)
Age, Risk	Age >= 65 At-risk	Negative	D29	Pseudo nAb ID80	309	76	(76, 76)
Age, Risk	Age >= 65 At-risk	Negative	D57	Pseudo nAb ID80	309	330	(330, 330)
Age, Risk	Age >= 65 At-risk	Negative	D1	Live Virus nAb ID50	309	24	(24, 24)
Age, Risk	Age >= 65 At-risk	Negative	D29	Live Virus nAb ID50	309	101	(101, 101)
Age, Risk	Age >= 65 At-risk	Negative	D57	Live Virus nAb ID50	309	390	(390, 390)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk	Age >= 65 At-risk	Negative	D1	Live Virus nAb ID80	309	22	(22, 22)
Age, Risk	Age >= 65 At-risk	Negative	D29	Live Virus nAb ID80	309	70	(70, 70)
Age, Risk	Age >= 65 At-risk	Negative	D57	Live Virus nAb ID80	309	295	(295, 295)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Anti-RBD IgG	267	17	(17, 17)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Anti-RBD IgG	267	878	(878, 878)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Anti-RBD IgG	267	5100	(5100, 5100)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Anti-Spike IgG	267	17	(17, 17)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Anti-Spike IgG	267	1130	(1130, 1130)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Anti-Spike IgG	267	6894	(6894, 6894)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Pseudo nAb ID50	267	24	(24, 24)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Pseudo nAb ID50	267	117	(117, 117)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Pseudo nAb ID50	267	472	(472, 472)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Pseudo nAb ID80	267	21	(21, 22)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Pseudo nAb ID80	267	72	(72, 72)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Pseudo nAb ID80	267	310	(310, 310)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Live Virus nAb ID50	267	24	(24, 24)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Live Virus nAb ID50	267	100	(100, 100)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Live Virus nAb ID50	267	362	(362, 362)
Age, Risk	Age >= 65 Not at-risk	Negative	D1	Live Virus nAb ID80	267	21	(21, 22)
Age, Risk	Age >= 65 Not at-risk	Negative	D29	Live Virus nAb ID80	267	72	(72, 72)
Age, Risk	Age >= 65 Not at-risk	Negative	D57	Live Virus nAb ID80	267	245	(245, 245)
Sex	Female	Negative	D1	Anti-RBD IgG	595	17	(17, 17)
Sex	Female	Negative	D29	Anti-RBD IgG	595	739	(634, 861)
Sex	Female	Negative	D57	Anti-RBD IgG	595	5444	(3962, 7481)
Sex	Female	Negative	D1	Anti-Spike IgG	595	17	(17, 17)
Sex	Female	Negative	D29	Anti-Spike IgG	595	1005	(850, 1187)
Sex	Female	Negative	D57	Anti-Spike IgG	595	8165	(5246, 12710)
Sex	Female	Negative	D1	Pseudo nAb ID50	595	24	(24, 24)
Sex	Female	Negative	D29	Pseudo nAb ID50	595	84	(75, 93)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Sex	Female	Negative	D57	Pseudo nAb ID50	595	340	(286, 404)
Sex	Female	Negative	D1	Pseudo nAb ID80	595	22	(22, 22)
Sex	Female	Negative	D29	Pseudo nAb ID80	595	51	(46, 58)
Sex	Female	Negative	D57	Pseudo nAb ID80	595	220	(199, 244)
Sex	Female	Negative	D1	Live Virus nAb ID50	595	24	(24, 24)
Sex	Female	Negative	D29	Live Virus nAb ID50	595	79	(71, 87)
Sex	Female	Negative	D57	Live Virus nAb ID50	595	293	(266, 323)
Sex	Female	Negative	D1	Live Virus nAb ID80	595	22	(22, 22)
Sex	Female	Negative	D29	Live Virus nAb ID80	595	53	(48, 58)
Sex	Female	Negative	D57	Live Virus nAb ID80	595	206	(198, 215)
Sex	Male	Negative	D1	Anti-RBD IgG	494	17	(17, 17)
Sex	Male	Negative	D29	Anti-RBD IgG	494	672	(437, 1032)
Sex	Male	Negative	D57	Anti-RBD IgG	494	4728	(3032, 7374)
Sex	Male	Negative	D1	Anti-Spike IgG	494	17	(17, 17)
Sex	Male	Negative	D29	Anti-Spike IgG	494	905	(580, 1410)
Sex	Male	Negative	D57	Anti-Spike IgG	494	6595	(4205, 10344)
Sex	Male	Negative	D1	Pseudo nAb ID50	494	24	(24, 24)
Sex	Male	Negative	D29	Pseudo nAb ID50	494	75	(53, 105)
Sex	Male	Negative	D57	Pseudo nAb ID50	494	313	(207, 472)
Sex	Male	Negative	D1	Pseudo nAb ID80	494	22	(22, 22)
Sex	Male	Negative	D29	Pseudo nAb ID80	494	49	(37, 66)
Sex	Male	Negative	D57	Pseudo nAb ID80	494	214	(145, 315)
Sex	Male	Negative	D1	Live Virus nAb ID50	494	24	(24, 24)
Sex	Male	Negative	D29	Live Virus nAb ID50	494	78	(64, 95)
Sex	Male	Negative	D57	Live Virus nAb ID50	494	288	(204, 405)
Sex	Male	Negative	D1	Live Virus nAb ID80	494	22	(22, 22)
Sex	Male	Negative	D29	Live Virus nAb ID80	494	54	(44, 67)
Sex	Male	Negative	D57	Live Virus nAb ID80	494	200	(144, 277)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex	Age < 65 Female	Negative	D1	Anti-RBD IgG	285	17	(17, 17)
Age, Sex	Age < 65 Female	Negative	D29	Anti-RBD IgG	285	750	(635, 885)
Age, Sex	Age < 65 Female	Negative	D57	Anti-RBD IgG	285	5901	(4708, 7395)
Age, Sex	Age < 65 Female	Negative	D1	Anti-Spike IgG	285	17	(17, 17)
Age, Sex	Age < 65 Female	Negative	D29	Anti-Spike IgG	285	1028	(870, 1216)
Age, Sex	Age < 65 Female	Negative	D57	Anti-Spike IgG	285	9108	(6590, 12587)
Age, Sex	Age < 65 Female	Negative	D1	Pseudo nAb ID50	285	24	(24, 24)
Age, Sex	Age < 65 Female	Negative	D29	Pseudo nAb ID50	285	80	(75, 85)
Age, Sex	Age < 65 Female	Negative	D57	Pseudo nAb ID50	285	338	(272, 418)
Age, Sex	Age < 65 Female	Negative	D1	Pseudo nAb ID80	285	22	(22, 22)
Age, Sex	Age < 65 Female	Negative	D29	Pseudo nAb ID80	285	49	(48, 51)
Age, Sex	Age < 65 Female	Negative	D57	Pseudo nAb ID80	285	217	(191, 247)
Age, Sex	Age < 65 Female	Negative	D1	Live Virus nAb ID50	285	24	(24, 24)
Age, Sex	Age < 65 Female	Negative	D29	Live Virus nAb ID50	285	77	(68, 87)
Age, Sex	Age < 65 Female	Negative	D57	Live Virus nAb ID50	285	297	(268, 328)
Age, Sex	Age < 65 Female	Negative	D1	Live Virus nAb ID80	285	22	(22, 22)
Age, Sex	Age < 65 Female	Negative	D29	Live Virus nAb ID80	285	51	(49, 53)
Age, Sex	Age < 65 Female	Negative	D57	Live Virus nAb ID80	285	205	(194, 216)
Age, Sex	Age < 65 Male	Negative	D1	Anti-RBD IgG	228	17	(17, 17)
Age, Sex	Age < 65 Male	Negative	D29	Anti-RBD IgG	228	568	(538, 600)
Age, Sex	Age < 65 Male	Negative	D57	Anti-RBD IgG	228	3971	(3696, 4266)
Age, Sex	Age < 65 Male	Negative	D1	Anti-Spike IgG	228	17	(17, 17)
Age, Sex	Age < 65 Male	Negative	D29	Anti-Spike IgG	228	767	(749, 784)
Age, Sex	Age < 65 Male	Negative	D57	Anti-Spike IgG	228	5556	(5491, 5621)
Age, Sex	Age < 65 Male	Negative	D1	Pseudo nAb ID50	228	24	(24, 24)
Age, Sex	Age < 65 Male	Negative	D29	Pseudo nAb ID50	228	66	(63, 69)
Age, Sex	Age < 65 Male	Negative	D57	Pseudo nAb ID50	228	269	(255, 285)
Age, Sex	Age < 65 Male	Negative	D1	Pseudo nAb ID80	228	22	(22, 22)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex	Age < 65 Male	Negative	D29	Pseudo nAb ID80	228	44	(42, 47)
Age, Sex	Age < 65 Male	Negative	D57	Pseudo nAb ID80	228	185	(178, 193)
Age, Sex	Age < 65 Male	Negative	D1	Live Virus nAb ID50	228	24	(24, 24)
Age, Sex	Age < 65 Male	Negative	D29	Live Virus nAb ID50	228	72	(71, 73)
Age, Sex	Age < 65 Male	Negative	D57	Live Virus nAb ID50	228	255	(239, 271)
Age, Sex	Age < 65 Male	Negative	D1	Live Virus nAb ID80	228	22	(22, 22)
Age, Sex	Age < 65 Male	Negative	D29	Live Virus nAb ID80	228	50	(48, 53)
Age, Sex	Age < 65 Male	Negative	D57	Live Virus nAb ID80	228	179	(163, 196)
Age, Sex	Age >= 65 Female	Negative	D1	Anti-RBD IgG	310	17	(17, 17)
Age, Sex	Age >= 65 Female	Negative	D29	Anti-RBD IgG	310	689	(689, 689)
Age, Sex	Age >= 65 Female	Negative	D57	Anti-RBD IgG	310	3697	(3697, 3697)
Age, Sex	Age >= 65 Female	Negative	D1	Anti-Spike IgG	310	17	(17, 17)
Age, Sex	Age >= 65 Female	Negative	D29	Anti-Spike IgG	310	898	(898, 898)
Age, Sex	Age >= 65 Female	Negative	D57	Anti-Spike IgG	310	4832	(4832, 4832)
Age, Sex	Age >= 65 Female	Negative	D1	Pseudo nAb ID50	310	24	(24, 24)
Age, Sex	Age >= 65 Female	Negative	D29	Pseudo nAb ID50	310	103	(103, 103)
Age, Sex	Age >= 65 Female	Negative	D57	Pseudo nAb ID50	310	352	(352, 352)
Age, Sex	Age >= 65 Female	Negative	D1	Pseudo nAb ID80	310	22	(22, 22)
Age, Sex	Age >= 65 Female	Negative	D29	Pseudo nAb ID80	310	65	(65, 65)
Age, Sex	Age >= 65 Female	Negative	D57	Pseudo nAb ID80	310	238	(238, 238)
Age, Sex	Age >= 65 Female	Negative	D1	Live Virus nAb ID50	310	24	(24, 24)
Age, Sex	Age >= 65 Female	Negative	D29	Live Virus nAb ID50	310	89	(89, 89)
Age, Sex	Age >= 65 Female	Negative	D57	Live Virus nAb ID50	310	276	(276, 276)
Age, Sex	Age >= 65 Female	Negative	D1	Live Virus nAb ID80	310	22	(22, 22)
Age, Sex	Age >= 65 Female	Negative	D29	Live Virus nAb ID80	310	64	(64, 64)
Age, Sex	Age >= 65 Female	Negative	D57	Live Virus nAb ID80	310	212	(212, 212)
Age, Sex	Age >= 65 Male	Negative	D1	Anti-RBD IgG	266	17	(17, 17)
Age, Sex	Age >= 65 Male	Negative	D29	Anti-RBD IgG	266	1700	(1700, 1700)
Age, Sex	Age >= 65 Male	Negative	D57	Anti-RBD IgG	266	12429	(12429, 12429)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex	Age >= 65 Male	Negative	D1	Anti-Spike IgG	266	17	(17, 17)
Age, Sex	Age >= 65 Male	Negative	D29	Anti-Spike IgG	266	2262	(2262, 2262)
Age, Sex	Age >= 65 Male	Negative	D57	Anti-Spike IgG	266	17057	(17057, 17057)
Age, Sex	Age >= 65 Male	Negative	D1	Pseudo nAb ID50	266	24	(24, 24)
Age, Sex	Age >= 65 Male	Negative	D29	Pseudo nAb ID50	266	147	(147, 147)
Age, Sex	Age >= 65 Male	Negative	D57	Pseudo nAb ID50	266	714	(714, 714)
Age, Sex	Age >= 65 Male	Negative	D1	Pseudo nAb ID80	266	22	(22, 22)
Age, Sex	Age >= 65 Male	Negative	D29	Pseudo nAb ID80	266	88	(88, 88)
Age, Sex	Age >= 65 Male	Negative	D57	Pseudo nAb ID80	266	471	(471, 471)
Age, Sex	Age >= 65 Male	Negative	D1	Live Virus nAb ID50	266	24	(24, 24)
Age, Sex	Age >= 65 Male	Negative	D29	Live Virus nAb ID50	266	117	(117, 117)
Age, Sex	Age >= 65 Male	Negative	D57	Live Virus nAb ID50	266	563	(563, 563)
Age, Sex	Age >= 65 Male	Negative	D1	Live Virus nAb ID80	266	22	(22, 22)
Age, Sex	Age >= 65 Male	Negative	D29	Live Virus nAb ID80	266	82	(82, 82)
Age, Sex	Age >= 65 Male	Negative	D57	Live Virus nAb ID80	266	368	(368, 368)
Ethnicity	Hispanic or Latino	Negative	D1	Anti-RBD IgG	139	17	(17, 17)
Ethnicity	Hispanic or Latino	Negative	D29	Anti-RBD IgG	139	652	(324, 1310)
Ethnicity	Hispanic or Latino	Negative	D57	Anti-RBD IgG	139	4523	(2007, 10193)
Ethnicity	Hispanic or Latino	Negative	D1	Anti-Spike IgG	139	17	(17, 17)
Ethnicity	Hispanic or Latino	Negative	D29	Anti-Spike IgG	139	797	(342, 1859)
Ethnicity	Hispanic or Latino	Negative	D57	Anti-Spike IgG	139	6381	(2626, 15501)
Ethnicity	Hispanic or Latino	Negative	D1	Pseudo nAb ID50	139	24	(24, 24)
Ethnicity	Hispanic or Latino	Negative	D29	Pseudo nAb ID50	139	85	(61, 119)
Ethnicity	Hispanic or Latino	Negative	D57	Pseudo nAb ID50	139	370	(219, 627)
Ethnicity	Hispanic or Latino	Negative	D1	Pseudo nAb ID80	139	22	(22, 22)
Ethnicity	Hispanic or Latino	Negative	D29	Pseudo nAb ID80	139	53	(39, 73)
Ethnicity	Hispanic or Latino	Negative	D57	Pseudo nAb ID80	139	214	(134, 343)
Ethnicity	Hispanic or Latino	Negative	D1	Live Virus nAb ID50	139	24	(24, 24)
Ethnicity	Hispanic or Latino	Negative	D29	Live Virus nAb ID50	139	91	(70, 119)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Ethnicity	Hispanic or Latino	Negative	D57	Live Virus nAb ID50	139	293	(216, 398)
Ethnicity	Hispanic or Latino	Negative	D1	Live Virus nAb ID80	139	22	(22, 22)
Ethnicity	Hispanic or Latino	Negative	D29	Live Virus nAb ID80	139	68	(56, 82)
Ethnicity	Hispanic or Latino	Negative	D57	Live Virus nAb ID80	139	199	(127, 312)
Ethnicity	Not Hispanic or Latino	Negative	D1	Anti-RBD IgG	837	17	(17, 17)
Ethnicity	Not Hispanic or Latino	Negative	D29	Anti-RBD IgG	837	826	(628, 1085)
Ethnicity	Not Hispanic or Latino	Negative	D57	Anti-RBD IgG	837	6379	(4313, 9435)
Ethnicity	Not Hispanic or Latino	Negative	D1	Anti-Spike IgG	837	17	(17, 17)
Ethnicity	Not Hispanic or Latino	Negative	D29	Anti-Spike IgG	837	1136	(885, 1459)
Ethnicity	Not Hispanic or Latino	Negative	D57	Anti-Spike IgG	837	9406	(5972, 14816)
Ethnicity	Not Hispanic or Latino	Negative	D1	Pseudo nAb ID50	837	24	(24, 24)
Ethnicity	Not Hispanic or Latino	Negative	D29	Pseudo nAb ID50	837	83	(69, 100)
Ethnicity	Not Hispanic or Latino	Negative	D57	Pseudo nAb ID50	837	354	(281, 446)
Ethnicity	Not Hispanic or Latino	Negative	D1	Pseudo nAb ID80	837	22	(22, 22)
Ethnicity	Not Hispanic or Latino	Negative	D29	Pseudo nAb ID80	837	52	(44, 62)
Ethnicity	Not Hispanic or Latino	Negative	D57	Pseudo nAb ID80	837	232	(190, 283)
Ethnicity	Not Hispanic or Latino	Negative	D1	Live Virus nAb ID50	837	24	(24, 24)
Ethnicity	Not Hispanic or Latino	Negative	D29	Live Virus nAb ID50	837	80	(70, 92)
Ethnicity	Not Hispanic or Latino	Negative	D57	Live Virus nAb ID50	837	317	(276, 363)
Ethnicity	Not Hispanic or Latino	Negative	D1	Live Virus nAb ID80	837	22	(22, 22)
Ethnicity	Not Hispanic or Latino	Negative	D29	Live Virus nAb ID80	837	53	(46, 62)
Ethnicity	Not Hispanic or Latino	Negative	D57	Live Virus nAb ID80	837	220	(195, 249)
Race	American Indian or Alaska Native	Negative	D1	Anti-RBD IgG	29	17	(17, 17)
Race	American Indian or Alaska Native	Negative	D29	Anti-RBD IgG	29	1130	(18, 69837)
Race	American Indian or Alaska Native	Negative	D57	Anti-RBD IgG	29	13295	(16, 10926221)
Race	American Indian or Alaska Native	Negative	D1	Anti-Spike IgG	29	17	(17, 17)
Race	American Indian or Alaska Native	Negative	D29	Anti-Spike IgG	29	1395	(24, 82225)
Race	American Indian or Alaska Native	Negative	D57	Anti-Spike IgG	29	14995	(17, 13109763)



Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	American Indian or Alaska Native	Negative	D1	Pseudo nAb ID50	29	24	(24, 24)
Race	American Indian or Alaska Native	Negative	D29	Pseudo nAb ID50	29	70	(31, 160)
Race	American Indian or Alaska Native	Negative	D57	Pseudo nAb ID50	29	399	(25, 6428)
Race	American Indian or Alaska Native	Negative	D1	Pseudo nAb ID80	29	22	(22, 22)
Race	American Indian or Alaska Native	Negative	D29	Pseudo nAb ID80	29	49	(25, 96)
Race	American Indian or Alaska Native	Negative	D57	Pseudo nAb ID80	29	385	(19, 7644)
Race	American Indian or Alaska Native	Negative	D1	Live Virus nAb ID50	29	24	(24, 24)
Race	American Indian or Alaska Native	Negative	D29	Live Virus nAb ID50	29	86	(26, 281)
Race	American Indian or Alaska Native	Negative	D57	Live Virus nAb ID50	29	373	(19, 7464)
Race	American Indian or Alaska Native	Negative	D1	Live Virus nAb ID80	29	22	(22, 22)
Race	American Indian or Alaska Native	Negative	D29	Live Virus nAb ID80	29	66	(20, 213)
Race	American Indian or Alaska Native	Negative	D57	Live Virus nAb ID80	29	288	(22, 3705)
Race	Asian	Negative	D1	Anti-RBD IgG	73	17	(17, 17)
Race	Asian	Negative	D29	Anti-RBD IgG	73	348	(287, 422)
Race	Asian	Negative	D57	Anti-RBD IgG	73	2118	(2006, 2236)
Race	Asian	Negative	D1	Anti-Spike IgG	73	17	(17, 17)
Race	Asian	Negative	D29	Anti-Spike IgG	73	489	(436, 549)
Race	Asian	Negative	D57	Anti-Spike IgG	73	2837	(2472, 3256)
Race	Asian	Negative	D1	Pseudo nAb ID50	73	24	(24, 24)
Race	Asian	Negative	D29	Pseudo nAb ID50	73	53	(34, 82)
Race	Asian	Negative	D57	Pseudo nAb ID50	73	200	(154, 259)
Race	Asian	Negative	D1	Pseudo nAb ID80	73	22	(22, 22)
Race	Asian	Negative	D29	Pseudo nAb ID80	73	36	(23, 56)
Race	Asian	Negative	D57	Pseudo nAb ID80	73	116	(79, 170)
Race	Asian	Negative	D1	Live Virus nAb ID50	73	24	(24, 24)
Race	Asian	Negative	D29	Live Virus nAb ID50	73	63	(51, 77)
Race	Asian	Negative	D57	Live Virus nAb ID50	73	144	(111, 188)
Race	Asian	Negative	D1	Live Virus nAb ID80	73	22	(22, 22)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Asian	Negative	D29	Live Virus nAb ID80	73	46	(38, 56)
Race	Asian	Negative	D57	Live Virus nAb ID80	73	127	(98, 165)
Race	Black or African American	Negative	D1	Anti-RBD IgG	242	17	(17, 17)
Race	Black or African American	Negative	D29	Anti-RBD IgG	242	1320	(975, 1786)
Race	Black or African American	Negative	D57	Anti-RBD IgG	242	13533	(8887, 20609)
Race	Black or African American	Negative	D1	Anti-Spike IgG	242	17	(17, 17)
Race	Black or African American	Negative	D29	Anti-Spike IgG	242	1773	(1274, 2466)
Race	Black or African American	Negative	D57	Anti-Spike IgG	242	22954	(13933, 37815)
Race	Black or African American	Negative	D1	Pseudo nAb ID50	242	24	(24, 24)
Race	Black or African American	Negative	D29	Pseudo nAb ID50	242	97	(71, 132)
Race	Black or African American	Negative	D57	Pseudo nAb ID50	242	511	(394, 662)
Race	Black or African American	Negative	D1	Pseudo nAb ID80	242	22	(22, 22)
Race	Black or African American	Negative	D29	Pseudo nAb ID80	242	57	(41, 78)
Race	Black or African American	Negative	D57	Pseudo nAb ID80	242	332	(248, 445)
Race	Black or African American	Negative	D1	Live Virus nAb ID50	242	24	(24, 24)
Race	Black or African American	Negative	D29	Live Virus nAb ID50	242	96	(80, 115)
Race	Black or African American	Negative	D57	Live Virus nAb ID50	242	446	(361, 550)
Race	Black or African American	Negative	D1	Live Virus nAb ID80	242	22	(22, 22)
Race	Black or African American	Negative	D29	Live Virus nAb ID80	242	62	(51, 75)
Race	Black or African American	Negative	D57	Live Virus nAb ID80	242	270	(194, 377)
Race	Multiracial	Negative	D1	Anti-RBD IgG	64	17	(17, 17)
Race	Multiracial	Negative	D29	Anti-RBD IgG	64	253	(61, 1037)
Race	Multiracial	Negative	D57	Anti-RBD IgG	64	1224	(156, 9637)
Race	Multiracial	Negative	D1	Anti-Spike IgG	64	17	(17, 17)
Race	Multiracial	Negative	D29	Anti-Spike IgG	64	312	(58, 1692)
Race	Multiracial	Negative	D57	Anti-Spike IgG	64	1740	(211, 14352)
Race	Multiracial	Negative	D1	Pseudo nAb ID50	64	24	(24, 24)
Race	Multiracial	Negative	D29	Pseudo nAb ID50	64	63	(42, 93)
Race	Multiracial	Negative	D57	Pseudo nAb ID50	64	184	(68, 496)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Multiracial	Negative	D1	Pseudo nAb ID80	64	22	(22, 22)
Race	Multiracial	Negative	D29	Pseudo nAb ID80	64	45	(34, 59)
Race	Multiracial	Negative	D57	Pseudo nAb ID80	64	138	(69, 277)
Race	Multiracial	Negative	D1	Live Virus nAb ID50	64	24	(24, 24)
Race	Multiracial	Negative	D29	Live Virus nAb ID50	64	71	(52, 97)
Race	Multiracial	Negative	D57	Live Virus nAb ID50	64	152	(75, 307)
Race	Multiracial	Negative	D1	Live Virus nAb ID80	64	22	(22, 22)
Race	Multiracial	Negative	D29	Live Virus nAb ID80	64	47	(34, 65)
Race	Multiracial	Negative	D57	Live Virus nAb ID80	64	113	(52, 245)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Anti-RBD IgG	11	17	(17, 17)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Anti-RBD IgG	11	234	(13, 4147)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Anti-RBD IgG	11	761	(12, 49173)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Anti-Spike IgG	11	17	(17, 17)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Anti-Spike IgG	11	297	(15, 5859)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Anti-Spike IgG	11	1070	(15, 77760)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Pseudo nAb ID50	11	24	(24, 24)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Pseudo nAb ID50	11	86	(41, 182)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Pseudo nAb ID50	11	149	(35, 627)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Pseudo nAb ID80	11	22	(22, 22)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Pseudo nAb ID80	11	55	(23, 128)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Pseudo nAb ID80	11	114	(25, 521)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Live Virus nAb ID50	11	24	(24, 24)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Live Virus nAb ID50	11	65	(46, 91)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Live Virus nAb ID50	11	181	(36, 908)
Race	Native Hawaiian or Other Pacific Islander	Negative	D1	Live Virus nAb ID80	11	22	(22, 22)
Race	Native Hawaiian or Other Pacific Islander	Negative	D29	Live Virus nAb ID80	11	47	(30, 74)
Race	Native Hawaiian or Other Pacific Islander	Negative	D57	Live Virus nAb ID80	11	126	(27, 597)
Race	Not reported and unknown	Negative	D1	Anti-RBD IgG	115	17	(17, 17)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Not reported and unknown	Negative	D29	Anti-RBD IgG	115	487	(418, 567)
Race	Not reported and unknown	Negative	D57	Anti-RBD IgG	115	2740	(1874, 4004)
Race	Not reported and unknown	Negative	D1	Anti-Spike IgG	115	17	(17, 17)
Race	Not reported and unknown	Negative	D29	Anti-Spike IgG	115	624	(506, 771)
Race	Not reported and unknown	Negative	D57	Anti-Spike IgG	115	3245	(2300, 4579)
Race	Not reported and unknown	Negative	D1	Pseudo nAb ID50	115	24	(24, 24)
Race	Not reported and unknown	Negative	D29	Pseudo nAb ID50	115	72	(67, 77)
Race	Not reported and unknown	Negative	D57	Pseudo nAb ID50	115	279	(238, 327)
Race	Not reported and unknown	Negative	D1	Pseudo nAb ID80	115	22	(22, 22)
Race	Not reported and unknown	Negative	D29	Pseudo nAb ID80	115	54	(50, 58)
Race	Not reported and unknown	Negative	D57	Pseudo nAb ID80	115	178	(161, 196)
Race	Not reported and unknown	Negative	D1	Live Virus nAb ID50	115	24	(24, 24)
Race	Not reported and unknown	Negative	D29	Live Virus nAb ID50	115	69	(64, 75)
Race	Not reported and unknown	Negative	D57	Live Virus nAb ID50	115	233	(212, 257)
Race	Not reported and unknown	Negative	D1	Live Virus nAb ID80	115	22	(22, 22)
Race	Not reported and unknown	Negative	D29	Live Virus nAb ID80	115	54	(51, 57)
Race	Not reported and unknown	Negative	D57	Live Virus nAb ID80	115	198	(155, 253)
Race	Other	Negative	D1	Anti-RBD IgG	23	17	(17, 17)
Race	Other	Negative	D29	Anti-RBD IgG	23	11296	(4418, 28880)
Race	Other	Negative	D57	Anti-RBD IgG	23	530546	(62165, 4527910)
Race	Other	Negative	D1	Anti-Spike IgG	23	17	(17, 17)
Race	Other	Negative	D29	Anti-Spike IgG	23	23151	(7384, 72584)
Race	Other	Negative	D57	Anti-Spike IgG	23	768534	(82667, 7144887)
Race	Other	Negative	D1	Pseudo nAb ID50	23	24	(24, 24)
Race	Other	Negative	D29	Pseudo nAb ID50	23	321	(269, 382)
Race	Other	Negative	D57	Pseudo nAb ID50	23	2747	(1336, 5648)
Race	Other	Negative	D1	Pseudo nAb ID80	23	21	(21, 22)
Race	Other	Negative	D29	Pseudo nAb ID80	23	128	(122, 136)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Other	Negative	D57	Pseudo nAb ID80	23	1260	(529, 3004)
Race	Other	Negative	D1	Live Virus nAb ID50	23	24	(24, 24)
Race	Other	Negative	D29	Live Virus nAb ID50	23	363	(168, 784)
Race	Other	Negative	D57	Live Virus nAb ID50	23	2618	(1080, 6346)
Race	Other	Negative	D1	Live Virus nAb ID80	23	21	(21, 22)
Race	Other	Negative	D29	Live Virus nAb ID80	23	131	(97, 176)
Race	Other	Negative	D57	Live Virus nAb ID80	23	1338	(798, 2243)
Race	White	Negative	D1	Anti-RBD IgG	55	17	(17, 17)
Race	White	Negative	D29	Anti-RBD IgG	55	961	(608, 1520)
Race	White	Negative	D57	Anti-RBD IgG	55	5867	(2557, 13459)
Race	White	Negative	D1	Anti-Spike IgG	55	17	(17, 17)
Race	White	Negative	D29	Anti-Spike IgG	55	1156	(637, 2098)
Race	White	Negative	D57	Anti-Spike IgG	55	8408	(4155, 17015)
Race	White	Negative	D1	Pseudo nAb ID50	55	24	(24, 24)
Race	White	Negative	D29	Pseudo nAb ID50	55	72	(45, 115)
Race	White	Negative	D57	Pseudo nAb ID50	55	368	(211, 644)
Race	White	Negative	D1	Pseudo nAb ID80	55	22	(22, 22)
Race	White	Negative	D29	Pseudo nAb ID80	55	44	(26, 73)
Race	White	Negative	D57	Pseudo nAb ID80	55	233	(112, 484)
Race	White	Negative	D1	Live Virus nAb ID50	55	24	(24, 24)
Race	White	Negative	D29	Live Virus nAb ID50	55	69	(48, 98)
Race	White	Negative	D57	Live Virus nAb ID50	55	316	(185, 541)
Race	White	Negative	D1	Live Virus nAb ID80	55	22	(22, 22)
Race	White	Negative	D29	Live Virus nAb ID80	55	56	(41, 77)
Race	White	Negative	D57	Live Virus nAb ID80	55	219	(148, 324)
Race	White Non-Hispanic	Negative	D1	Anti-RBD IgG	437	17	(17, 17)
Race	White Non-Hispanic	Negative	D29	Anti-RBD IgG	437	733	(537, 1000)
Race	White Non-Hispanic	Negative	D57	Anti-RBD IgG	437	5195	(3535, 7635)
Race	White Non-Hispanic	Negative	D1	Anti-Spike IgG	437	17	(17, 17)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	White Non-Hispanic	Negative	D29	Anti-Spike IgG	437	1030	(775, 1367)
Race	White Non-Hispanic	Negative	D57	Anti-Spike IgG	437	7809	(5118, 11916)
Race	White Non-Hispanic	Negative	D1	Pseudo nAb ID50	437	24	(24, 24)
Race	White Non-Hispanic	Negative	D29	Pseudo nAb ID50	437	82	(67, 101)
Race	White Non-Hispanic	Negative	D57	Pseudo nAb ID50	437	318	(246, 410)
Race	White Non-Hispanic	Negative	D1	Pseudo nAb ID80	437	22	(22, 22)
Race	White Non-Hispanic	Negative	D29	Pseudo nAb ID80	437	51	(42, 61)
Race	White Non-Hispanic	Negative	D57	Pseudo nAb ID80	437	214	(165, 279)
Race	White Non-Hispanic	Negative	D1	Live Virus nAb ID50	437	24	(24, 24)
Race	White Non-Hispanic	Negative	D29	Live Virus nAb ID50	437	76	(64, 90)
Race	White Non-Hispanic	Negative	D57	Live Virus nAb ID50	437	301	(259, 349)
Race	White Non-Hispanic	Negative	D1	Live Virus nAb ID80	437	22	(22, 22)
Race	White Non-Hispanic	Negative	D29	Live Virus nAb ID80	437	51	(41, 62)
Race	White Non-Hispanic	Negative	D57	Live Virus nAb ID80	437	204	(168, 248)
Minority	White Non-Hispanic	Negative	D1	Anti-RBD IgG	437	17	(17, 17)
Minority	White Non-Hispanic	Negative	D29	Anti-RBD IgG	437	733	(537, 1000)
Minority	White Non-Hispanic	Negative	D57	Anti-RBD IgG	437	5195	(3535, 7635)
Minority	White Non-Hispanic	Negative	D1	Anti-Spike IgG	437	17	(17, 17)
Minority	White Non-Hispanic	Negative	D29	Anti-Spike IgG	437	1030	(775, 1367)
Minority	White Non-Hispanic	Negative	D57	Anti-Spike IgG	437	7809	(5118, 11916)
Minority	White Non-Hispanic	Negative	D1	Pseudo nAb ID50	437	24	(24, 24)
Minority	White Non-Hispanic	Negative	D29	Pseudo nAb ID50	437	82	(67, 101)
Minority	White Non-Hispanic	Negative	D57	Pseudo nAb ID50	437	318	(246, 410)
Minority	White Non-Hispanic	Negative	D1	Pseudo nAb ID80	437	22	(22, 22)
Minority	White Non-Hispanic	Negative	D29	Pseudo nAb ID80	437	51	(42, 61)
Minority	White Non-Hispanic	Negative	D57	Pseudo nAb ID80	437	214	(165, 279)
Minority	White Non-Hispanic	Negative	D1	Live Virus nAb ID50	437	24	(24, 24)
Minority	White Non-Hispanic	Negative	D29	Live Virus nAb ID50	437	76	(64, 90)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Minority	White Non-Hispanic	Negative	D57	Live Virus nAb ID50	437	301	(259, 349)
Minority	White Non-Hispanic	Negative	D1	Live Virus nAb ID80	437	22	(22, 22)
Minority	White Non-Hispanic	Negative	D29	Live Virus nAb ID80	437	51	(41, 62)
Minority	White Non-Hispanic	Negative	D57	Live Virus nAb ID80	437	204	(168, 248)
Minority	Communities of Color	Negative	D1	Anti-RBD IgG	557	17	(17, 17)
Minority	Communities of Color	Negative	D29	Anti-RBD IgG	557	711	(625, 809)
Minority	Communities of Color	Negative	D57	Anti-RBD IgG	557	5475	(5032, 5957)
Minority	Communities of Color	Negative	D1	Anti-Spike IgG	557	17	(17, 17)
Minority	Communities of Color	Negative	D29	Anti-Spike IgG	557	947	(822, 1091)
Minority	Communities of Color	Negative	D57	Anti-Spike IgG	557	7825	(7061, 8672)
Minority	Communities of Color	Negative	D1	Pseudo nAb ID50	557	24	(24, 24)
Minority	Communities of Color	Negative	D29	Pseudo nAb ID50	557	80	(64, 99)
Minority	Communities of Color	Negative	D57	Pseudo nAb ID50	557	343	(296, 399)
Minority	Communities of Color	Negative	D1	Pseudo nAb ID80	557	22	(22, 22)
Minority	Communities of Color	Negative	D29	Pseudo nAb ID80	557	52	(43, 62)
Minority	Communities of Color	Negative	D57	Pseudo nAb ID80	557	226	(195, 262)
Minority	Communities of Color	Negative	D1	Live Virus nAb ID50	557	24	(24, 24)
Minority	Communities of Color	Negative	D29	Live Virus nAb ID50	557	82	(74, 91)
Minority	Communities of Color	Negative	D57	Live Virus nAb ID50	557	291	(260, 326)
Minority	Communities of Color	Negative	D1	Live Virus nAb ID80	557	22	(22, 22)
Minority	Communities of Color	Negative	D29	Live Virus nAb ID80	557	57	(52, 62)
Minority	Communities of Color	Negative	D57	Live Virus nAb ID80	557	209	(177, 247)
Age, Minority	Age < 65 Communities of Color	Negative	D1	Anti-RBD IgG	259	17	(17, 17)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Anti-RBD IgG	259	674	(647, 703)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Anti-RBD IgG	259	5466	(4930, 6061)
Age, Minority	Age < 65 Communities of Color	Negative	D1	Anti-Spike IgG	259	17	(17, 17)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Anti-Spike IgG	259	896	(888, 904)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Anti-Spike IgG	259	7861	(6981, 8851)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Age < 65 Communities of Color	Negative	D1	Pseudo nAb ID50	259	24	(24, 24)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Pseudo nAb ID50	259	74	(70, 78)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Pseudo nAb ID50	259	323	(299, 349)
Age, Minority	Age < 65 Communities of Color	Negative	D1	Pseudo nAb ID80	259	22	(22, 22)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Pseudo nAb ID80	259	48	(46, 51)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Pseudo nAb ID80	259	213	(211, 215)
Age, Minority	Age < 65 Communities of Color	Negative	D1	Live Virus nAb ID50	259	24	(24, 24)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Live Virus nAb ID50	259	79	(76, 82)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Live Virus nAb ID50	259	278	(264, 292)
Age, Minority	Age < 65 Communities of Color	Negative	D1	Live Virus nAb ID80	259	22	(22, 22)
Age, Minority	Age < 65 Communities of Color	Negative	D29	Live Virus nAb ID80	259	55	(54, 56)
Age, Minority	Age < 65 Communities of Color	Negative	D57	Live Virus nAb ID80	259	199	(181, 219)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Anti-RBD IgG	216	17	(17, 17)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Anti-RBD IgG	216	678	(473, 972)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Anti-RBD IgG	216	4910	(3053, 7895)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Anti-Spike IgG	216	17	(17, 17)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Anti-Spike IgG	216	969	(690, 1362)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Anti-Spike IgG	216	7625	(4559, 12752)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Pseudo nAb ID50	216	24	(24, 24)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Pseudo nAb ID50	216	76	(65, 89)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Pseudo nAb ID50	216	293	(226, 379)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Pseudo nAb ID80	216	22	(22, 22)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Pseudo nAb ID80	216	47	(43, 52)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Pseudo nAb ID80	216	196	(152, 254)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Live Virus nAb ID50	216	24	(24, 24)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Live Virus nAb ID50	216	72	(61, 86)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Live Virus nAb ID50	216	286	(247, 330)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D1	Live Virus nAb ID80	216	22	(22, 22)



Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Age < 65 White Non-Hispanic	Negative	D29	Live Virus nAb ID80	216	47	(43, 51)
Age, Minority	Age < 65 White Non-Hispanic	Negative	D57	Live Virus nAb ID80	216	191	(159, 229)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Anti-RBD IgG	298	17	(17, 17)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Anti-RBD IgG	298	918	(918, 918)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Anti-RBD IgG	298	5519	(5519, 5519)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Anti-Spike IgG	298	17	(17, 17)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Anti-Spike IgG	298	1240	(1240, 1240)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Anti-Spike IgG	298	7656	(7656, 7656)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Pseudo nAb ID50	298	25	(24, 25)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Pseudo nAb ID50	298	115	(115, 115)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Pseudo nAb ID50	298	462	(462, 462)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Pseudo nAb ID80	298	22	(21, 22)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Pseudo nAb ID80	298	72	(72, 72)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Pseudo nAb ID80	298	299	(299, 299)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Live Virus nAb ID50	298	25	(24, 25)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Live Virus nAb ID50	298	101	(101, 101)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Live Virus nAb ID50	298	365	(365, 365)
Age, Minority	Age >= 65 Communities of Color	Negative	D1	Live Virus nAb ID80	298	22	(21, 22)
Age, Minority	Age >= 65 Communities of Color	Negative	D29	Live Virus nAb ID80	298	66	(66, 66)
Age, Minority	Age >= 65 Communities of Color	Negative	D57	Live Virus nAb ID80	298	264	(264, 264)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Anti-RBD IgG	221	17	(17, 17)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Anti-RBD IgG	221	1146	(1146, 1146)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Anti-RBD IgG	221	7189	(7189, 7189)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Anti-Spike IgG	221	17	(17, 17)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Anti-Spike IgG	221	1458	(1458, 1458)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Anti-Spike IgG	221	8956	(8956, 8956)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Pseudo nAb ID50	221	24	(24, 24)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Pseudo nAb ID50	221	129	(129, 129)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Pseudo nAb ID50	221	507	(507, 507)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Pseudo nAb ID80	221	22	(22, 22)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Pseudo nAb ID80	221	78	(78, 78)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Pseudo nAb ID80	221	355	(355, 355)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Live Virus nAb ID50	221	24	(24, 24)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Live Virus nAb ID50	221	102	(102, 102)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Live Virus nAb ID50	221	400	(400, 400)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D1	Live Virus nAb ID80	221	22	(22, 22)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D29	Live Virus nAb ID80	221	81	(81, 81)
Age, Minority	Age >= 65 White Non-Hispanic	Negative	D57	Live Virus nAb ID80	221	300	(300, 300)
Total	Total	Positive	D1	Anti-RBD IgG	523	17	(17, 17)
Total	Total	Positive	D29	Anti-RBD IgG	523	20277	(12080, 34034)
Total	Total	Positive	D57	Anti-RBD IgG	523	1178653	(767915, 1809084)
Total	Total	Positive	D1	Anti-Spike IgG	523	17	(17, 17)
Total	Total	Positive	D29	Anti-Spike IgG	523	38159	(22997, 63318)
Total	Total	Positive	D57	Anti-Spike IgG	523	2047688	(1298529, 3229060)
Total	Total	Positive	D1	Pseudo nAb ID50	523	24	(24, 24)
Total	Total	Positive	D29	Pseudo nAb ID50	523	246	(157, 385)
Total	Total	Positive	D57	Pseudo nAb ID50	523	4252	(2601, 6952)
Total	Total	Positive	D1	Pseudo nAb ID80	523	22	(22, 22)
Total	Total	Positive	D29	Pseudo nAb ID80	523	111	(74, 165)
Total	Total	Positive	D57	Pseudo nAb ID80	523	1635	(975, 2740)
Total	Total	Positive	D1	Live Virus nAb ID50	523	24	(24, 24)
Total	Total	Positive	D29	Live Virus nAb ID50	523	237	(172, 326)
Total	Total	Positive	D57	Live Virus nAb ID50	523	3501	(2411, 5084)
Total	Total	Positive	D1	Live Virus nAb ID80	523	22	(22, 22)
Total	Total	Positive	D29	Live Virus nAb ID80	523	140	(107, 183)
Total	Total	Positive	D57	Live Virus nAb ID80	523	1922	(1374, 2689)
Age	Age < 65	Positive	D1	Anti-RBD IgG	295	17	(17, 17)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age	Age < 65	Positive	D29	Anti-RBD IgG	295	16593	(14964, 18400)
Age	Age < 65	Positive	D57	Anti-RBD IgG	295	997439	(893511, 1113455)
Age	Age < 65	Positive	D1	Anti-Spike IgG	295	17	(17, 17)
Age	Age < 65	Positive	D29	Anti-Spike IgG	295	31296	(26523, 36929)
Age	Age < 65	Positive	D57	Anti-Spike IgG	295	1713071	(1408080, 2084123)
Age	Age < 65	Positive	D1	Pseudo nAb ID50	295	24	(24, 24)
Age	Age < 65	Positive	D29	Pseudo nAb ID50	295	206	(189, 225)
Age	Age < 65	Positive	D57	Pseudo nAb ID50	295	3546	(2453, 5125)
Age	Age < 65	Positive	D1	Pseudo nAb ID80	295	22	(22, 22)
Age	Age < 65	Positive	D29	Pseudo nAb ID80	295	95	(89, 101)
Age	Age < 65	Positive	D57	Pseudo nAb ID80	295	1335	(1119, 1593)
Age	Age < 65	Positive	D1	Live Virus nAb ID50	295	24	(24, 24)
Age	Age < 65	Positive	D29	Live Virus nAb ID50	295	209	(173, 253)
Age	Age < 65	Positive	D57	Live Virus nAb ID50	295	3025	(2599, 3521)
Age	Age < 65	Positive	D1	Live Virus nAb ID80	295	22	(22, 22)
Age	Age < 65	Positive	D29	Live Virus nAb ID80	295	127	(105, 154)
Age	Age < 65	Positive	D57	Live Virus nAb ID80	295	1697	(1325, 2174)
Age	Age >= 65	Positive	D1	Anti-RBD IgG	228	17	(17, 17)
Age	Age >= 65	Positive	D29	Anti-RBD IgG	228	75484	(75484, 75484)
Age	Age >= 65	Positive	D57	Anti-RBD IgG	228	3521571	(3521571, 3521571)
Age	Age >= 65	Positive	D1	Anti-Spike IgG	228	17	(17, 17)
Age	Age >= 65	Positive	D29	Anti-Spike IgG	228	140004	(140004, 140004)
Age	Age >= 65	Positive	D57	Anti-Spike IgG	228	6596632	(6596632, 6596632)
Age	Age >= 65	Positive	D1	Pseudo nAb ID50	228	24	(24, 24)
Age	Age >= 65	Positive	D29	Pseudo nAb ID50	228	769	(769, 769)
Age	Age >= 65	Positive	D57	Pseudo nAb ID50	228	13988	(13988, 13988)
Age	Age >= 65	Positive	D1	Pseudo nAb ID80	228	21	(21, 22)
Age	Age >= 65	Positive	D29	Pseudo nAb ID80	228	304	(304, 304)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age	Age $\geq$ 65	Positive	D57	Pseudo nAb ID80	228	6158	(6158, 6158)
Age	Age $\geq$ 65	Positive	D1	Live Virus nAb ID50	228	24	(24, 24)
Age	Age $\geq$ 65	Positive	D29	Live Virus nAb ID50	228	530	(530, 530)
Age	Age $\geq$ 65	Positive	D57	Live Virus nAb ID50	228	9132	(9132, 9132)
Age	Age $\geq$ 65	Positive	D1	Live Virus nAb ID80	228	21	(21, 22)
Age	Age $\geq$ 65	Positive	D29	Live Virus nAb ID80	228	271	(271, 271)
Age	Age $\geq$ 65	Positive	D57	Live Virus nAb ID80	228	4349	(4349, 4349)
High Risk	At-risk	Positive	D1	Anti-RBD IgG	222	17	(17, 17)
High Risk	At-risk	Positive	D29	Anti-RBD IgG	222	20339	(7825, 52867)
High Risk	At-risk	Positive	D57	Anti-RBD IgG	222	1166347	(497582, 2733955)
High Risk	At-risk	Positive	D1	Anti-Spike IgG	222	17	(17, 17)
High Risk	At-risk	Positive	D29	Anti-Spike IgG	222	35049	(13597, 90344)
High Risk	At-risk	Positive	D57	Anti-Spike IgG	222	1788765	(747425, 4280939)
High Risk	At-risk	Positive	D1	Pseudo nAb ID50	222	24	(24, 24)
High Risk	At-risk	Positive	D29	Pseudo nAb ID50	222	247	(107, 568)
High Risk	At-risk	Positive	D57	Pseudo nAb ID50	222	3059	(1112, 8416)
High Risk	At-risk	Positive	D1	Pseudo nAb ID80	222	21	(21, 22)
High Risk	At-risk	Positive	D29	Pseudo nAb ID80	222	113	(55, 234)
High Risk	At-risk	Positive	D57	Pseudo nAb ID80	222	1558	(518, 4683)
High Risk	At-risk	Positive	D1	Live Virus nAb ID50	222	24	(24, 24)
High Risk	At-risk	Positive	D29	Live Virus nAb ID50	222	204	(105, 398)
High Risk	At-risk	Positive	D57	Live Virus nAb ID50	222	3129	(1591, 6154)
High Risk	At-risk	Positive	D1	Live Virus nAb ID80	222	21	(21, 22)
High Risk	At-risk	Positive	D29	Live Virus nAb ID80	222	119	(68, 208)
High Risk	At-risk	Positive	D57	Live Virus nAb ID80	222	1550	(766, 3135)
High Risk	Not at-risk	Positive	D1	Anti-RBD IgG	301	17	(17, 17)
High Risk	Not at-risk	Positive	D29	Anti-RBD IgG	301	20258	(12485, 32872)
High Risk	Not at-risk	Positive	D57	Anti-RBD IgG	301	1182262	(802359, 1742043)
High Risk	Not at-risk	Positive	D1	Anti-Spike IgG	301	17	(17, 17)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
High Risk	Not at-risk	Positive	D29	Anti-Spike IgG	301	39116	(24087, 63522)
High Risk	Not at-risk	Positive	D57	Anti-Spike IgG	301	2129922	(1378740, 3290374)
High Risk	Not at-risk	Positive	D1	Pseudo nAb ID50	301	25	(24, 25)
High Risk	Not at-risk	Positive	D29	Pseudo nAb ID50	301	245	(161, 373)
High Risk	Not at-risk	Positive	D57	Pseudo nAb ID50	301	4680	(3070, 7133)
High Risk	Not at-risk	Positive	D1	Pseudo nAb ID80	301	22	(22, 22)
High Risk	Not at-risk	Positive	D29	Pseudo nAb ID80	301	110	(76, 160)
High Risk	Not at-risk	Positive	D57	Pseudo nAb ID80	301	1658	(1054, 2606)
High Risk	Not at-risk	Positive	D1	Live Virus nAb ID50	301	25	(24, 25)
High Risk	Not at-risk	Positive	D29	Live Virus nAb ID50	301	247	(186, 328)
High Risk	Not at-risk	Positive	D57	Live Virus nAb ID50	301	3618	(2504, 5226)
High Risk	Not at-risk	Positive	D1	Live Virus nAb ID80	301	22	(22, 22)
High Risk	Not at-risk	Positive	D29	Live Virus nAb ID80	301	147	(117, 185)
High Risk	Not at-risk	Positive	D57	Live Virus nAb ID80	301	2046	(1538, 2722)
Age, Risk	Age < 65 At-risk	Positive	D1	Anti-RBD IgG	147	17	(17, 17)
Age, Risk	Age < 65 At-risk	Positive	D29	Anti-RBD IgG	147	14352	(14352, 14352)
Age, Risk	Age < 65 At-risk	Positive	D57	Anti-RBD IgG	147	854659	(854659, 854659)
Age, Risk	Age < 65 At-risk	Positive	D1	Anti-Spike IgG	147	17	(17, 17)
Age, Risk	Age < 65 At-risk	Positive	D29	Anti-Spike IgG	147	24807	(24807, 24807)
Age, Risk	Age < 65 At-risk	Positive	D57	Anti-Spike IgG	147	1300844	(1300844, 1300844)
Age, Risk	Age < 65 At-risk	Positive	D1	Pseudo nAb ID50	147	25	(24, 25)
Age, Risk	Age < 65 At-risk	Positive	D29	Pseudo nAb ID50	147	182	(182, 182)
Age, Risk	Age < 65 At-risk	Positive	D57	Pseudo nAb ID50	147	2114	(2114, 2114)
Age, Risk	Age < 65 At-risk	Positive	D1	Pseudo nAb ID80	147	22	(22, 22)
Age, Risk	Age < 65 At-risk	Positive	D29	Pseudo nAb ID80	147	87	(87, 87)
Age, Risk	Age < 65 At-risk	Positive	D57	Pseudo nAb ID80	147	1042	(1042, 1042)
Age, Risk	Age < 65 At-risk	Positive	D1	Live Virus nAb ID50	147	25	(24, 25)
Age, Risk	Age < 65 At-risk	Positive	D29	Live Virus nAb ID50	147	160	(160, 160)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk	Age < 65 At-risk	Positive	D57	Live Virus nAb ID50	147	2444	(2444, 2444)
Age, Risk	Age < 65 At-risk	Positive	D1	Live Virus nAb ID80	147	22	(22, 22)
Age, Risk	Age < 65 At-risk	Positive	D29	Live Virus nAb ID80	147	97	(97, 97)
Age, Risk	Age < 65 At-risk	Positive	D57	Live Virus nAb ID80	147	1199	(1199, 1199)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Anti-RBD IgG	148	17	(17, 17)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Anti-RBD IgG	148	17245	(17245, 17245)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Anti-RBD IgG	148	1039202	(1039202, 1039202)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Anti-Spike IgG	148	17	(17, 17)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Anti-Spike IgG	148	33288	(33288, 33288)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Anti-Spike IgG	148	1842965	(1842965, 1842965)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Pseudo nAb ID50	148	24	(24, 24)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Pseudo nAb ID50	148	213	(213, 213)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Pseudo nAb ID50	148	4068	(4068, 4068)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Pseudo nAb ID80	148	22	(22, 22)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Pseudo nAb ID80	148	97	(97, 97)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Pseudo nAb ID80	148	1426	(1426, 1426)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Live Virus nAb ID50	148	24	(24, 24)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Live Virus nAb ID50	148	225	(225, 225)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Live Virus nAb ID50	148	3201	(3201, 3201)
Age, Risk	Age < 65 Not at-risk	Positive	D1	Live Virus nAb ID80	148	22	(22, 22)
Age, Risk	Age < 65 Not at-risk	Positive	D29	Live Virus nAb ID80	148	136	(136, 136)
Age, Risk	Age < 65 Not at-risk	Positive	D57	Live Virus nAb ID80	148	1861	(1861, 1861)
Age, Risk	Age >= 65 At-risk	Positive	D1	Anti-RBD IgG	75	17	(17, 17)
Age, Risk	Age >= 65 At-risk	Positive	D29	Anti-RBD IgG	75	87437	(87437, 87437)
Age, Risk	Age >= 65 At-risk	Positive	D57	Anti-RBD IgG	75	4282114	(4282114, 4282114)
Age, Risk	Age >= 65 At-risk	Positive	D1	Anti-Spike IgG	75	17	(17, 17)
Age, Risk	Age >= 65 At-risk	Positive	D29	Anti-Spike IgG	75	148764	(148764, 148764)
Age, Risk	Age >= 65 At-risk	Positive	D57	Anti-Spike IgG	75	6778884	(6778884, 6778884)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk	Age $\geq$ 65 At-risk	Positive	D1	Pseudo nAb ID50	75	24	(24, 24)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D29	Pseudo nAb ID50	75	882	(882, 882)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D57	Pseudo nAb ID50	75	14343	(14343, 14343)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D1	Pseudo nAb ID80	75	21	(21, 22)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D29	Pseudo nAb ID80	75	344	(344, 344)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D57	Pseudo nAb ID80	75	8363	(8363, 8363)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D1	Live Virus nAb ID50	75	24	(24, 24)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D29	Live Virus nAb ID50	75	565	(565, 565)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D57	Live Virus nAb ID50	75	8788	(8788, 8788)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D1	Live Virus nAb ID80	75	21	(21, 22)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D29	Live Virus nAb ID80	75	280	(280, 280)
Age, Risk	Age $\geq$ 65 At-risk	Positive	D57	Live Virus nAb ID80	75	4543	(4543, 4543)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Anti-RBD IgG	153	17	(17, 17)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Anti-RBD IgG	153	70239	(70239, 70239)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D57	Anti-RBD IgG	153	3199803	(3199803, 3199803)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Anti-Spike IgG	153	17	(17, 17)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Anti-Spike IgG	153	135901	(135901, 135901)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D57	Anti-Spike IgG	153	6509123	(6509123, 6509123)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Pseudo nAb ID50	153	24	(24, 24)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Pseudo nAb ID50	153	719	(719, 719)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D57	Pseudo nAb ID50	153	13817	(13817, 13817)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Pseudo nAb ID80	153	22	(22, 22)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Pseudo nAb ID80	153	287	(287, 287)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D57	Pseudo nAb ID80	153	5301	(5301, 5301)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Live Virus nAb ID50	153	24	(24, 24)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Live Virus nAb ID50	153	513	(513, 513)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D57	Live Virus nAb ID50	153	9305	(9305, 9305)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D1	Live Virus nAb ID80	153	22	(22, 22)
Age, Risk	Age $\geq$ 65 Not at-risk	Positive	D29	Live Virus nAb ID80	153	266	(266, 266)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk	Age >= 65 Not at-risk	Positive	D57	Live Virus nAb ID80	153	4257	(4257, 4257)
Sex	Female	Positive	D1	Anti-RBD IgG	294	17	(17, 17)
Sex	Female	Positive	D29	Anti-RBD IgG	294	18915	(11740, 30474)
Sex	Female	Positive	D57	Anti-RBD IgG	294	1154615	(754361, 1767239)
Sex	Female	Positive	D1	Anti-Spike IgG	294	17	(17, 17)
Sex	Female	Positive	D29	Anti-Spike IgG	294	35842	(22322, 57551)
Sex	Female	Positive	D57	Anti-Spike IgG	294	1815938	(1120167, 2943877)
Sex	Female	Positive	D1	Pseudo nAb ID50	294	24	(24, 24)
Sex	Female	Positive	D29	Pseudo nAb ID50	294	224	(149, 335)
Sex	Female	Positive	D57	Pseudo nAb ID50	294	3874	(2220, 6763)
Sex	Female	Positive	D1	Pseudo nAb ID80	294	22	(22, 22)
Sex	Female	Positive	D29	Pseudo nAb ID80	294	92	(64, 133)
Sex	Female	Positive	D57	Pseudo nAb ID80	294	1753	(1057, 2908)
Sex	Female	Positive	D1	Live Virus nAb ID50	294	24	(24, 24)
Sex	Female	Positive	D29	Live Virus nAb ID50	294	233	(169, 320)
Sex	Female	Positive	D57	Live Virus nAb ID50	294	3444	(2324, 5105)
Sex	Female	Positive	D1	Live Virus nAb ID80	294	22	(22, 22)
Sex	Female	Positive	D29	Live Virus nAb ID80	294	138	(99, 191)
Sex	Female	Positive	D57	Live Virus nAb ID80	294	1983	(1304, 3015)
Sex	Male	Positive	D1	Anti-RBD IgG	229	17	(17, 17)
Sex	Male	Positive	D29	Anti-RBD IgG	229	22208	(11744, 41995)
Sex	Male	Positive	D57	Anti-RBD IgG	229	1210873	(718001, 2042076)
Sex	Male	Positive	D1	Anti-Spike IgG	229	17	(17, 17)
Sex	Male	Positive	D29	Anti-Spike IgG	229	41419	(22799, 75245)
Sex	Male	Positive	D57	Anti-Spike IgG	229	2396263	(1518286, 3781946)
Sex	Male	Positive	D1	Pseudo nAb ID50	229	24	(24, 24)
Sex	Male	Positive	D29	Pseudo nAb ID50	229	277	(163, 471)
Sex	Male	Positive	D57	Pseudo nAb ID50	229	4802	(3111, 7412)
Sex	Male	Positive	D1	Pseudo nAb ID80	229	21	(21, 22)



Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Sex	Male	Positive	D29	Pseudo nAb ID80	229	141	(91, 218)
Sex	Male	Positive	D57	Pseudo nAb ID80	229	1492	(795, 2798)
Sex	Male	Positive	D1	Live Virus nAb ID50	229	24	(24, 24)
Sex	Male	Positive	D29	Live Virus nAb ID50	229	242	(170, 344)
Sex	Male	Positive	D57	Live Virus nAb ID50	229	3577	(2254, 5677)
Sex	Male	Positive	D1	Live Virus nAb ID80	229	21	(21, 22)
Sex	Male	Positive	D29	Live Virus nAb ID80	229	144	(107, 193)
Sex	Male	Positive	D57	Live Virus nAb ID80	229	1845	(1253, 2717)
Age, Sex	Age < 65 Female	Positive	D1	Anti-RBD IgG	177	17	(17, 17)
Age, Sex	Age < 65 Female	Positive	D29	Anti-RBD IgG	177	15775	(12195, 20406)
Age, Sex	Age < 65 Female	Positive	D57	Anti-RBD IgG	177	986223	(745070, 1305429)
Age, Sex	Age < 65 Female	Positive	D1	Anti-Spike IgG	177	17	(17, 17)
Age, Sex	Age < 65 Female	Positive	D29	Anti-Spike IgG	177	29998	(22550, 39905)
Age, Sex	Age < 65 Female	Positive	D57	Anti-Spike IgG	177	1517697	(1108888, 2077220)
Age, Sex	Age < 65 Female	Positive	D1	Pseudo nAb ID50	177	25	(24, 25)
Age, Sex	Age < 65 Female	Positive	D29	Pseudo nAb ID50	177	191	(162, 226)
Age, Sex	Age < 65 Female	Positive	D57	Pseudo nAb ID50	177	3222	(1968, 5273)
Age, Sex	Age < 65 Female	Positive	D1	Pseudo nAb ID80	177	22	(22, 22)
Age, Sex	Age < 65 Female	Positive	D29	Pseudo nAb ID80	177	80	(74, 86)
Age, Sex	Age < 65 Female	Positive	D57	Pseudo nAb ID80	177	1458	(1018, 2088)
Age, Sex	Age < 65 Female	Positive	D1	Live Virus nAb ID50	177	25	(24, 25)
Age, Sex	Age < 65 Female	Positive	D29	Live Virus nAb ID50	177	208	(160, 272)
Age, Sex	Age < 65 Female	Positive	D57	Live Virus nAb ID50	177	3010	(2166, 4183)
Age, Sex	Age < 65 Female	Positive	D1	Live Virus nAb ID80	177	22	(22, 22)
Age, Sex	Age < 65 Female	Positive	D29	Live Virus nAb ID80	177	125	(90, 175)
Age, Sex	Age < 65 Female	Positive	D57	Live Virus nAb ID80	177	1774	(1135, 2772)
Age, Sex	Age < 65 Male	Positive	D1	Anti-RBD IgG	118	17	(17, 17)
Age, Sex	Age < 65 Male	Positive	D29	Anti-RBD IgG	118	17769	(15791, 19995)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex	Age < 65 Male	Positive	D57	Anti-RBD IgG	118	1012831	(895123, 1146016)
Age, Sex	Age < 65 Male	Positive	D1	Anti-Spike IgG	118	17	(17, 17)
Age, Sex	Age < 65 Male	Positive	D29	Anti-Spike IgG	118	33145	(32896, 33396)
Age, Sex	Age < 65 Male	Positive	D57	Anti-Spike IgG	118	2018334	(2006320, 2030419)
Age, Sex	Age < 65 Male	Positive	D1	Pseudo nAb ID50	118	24	(24, 24)
Age, Sex	Age < 65 Male	Positive	D29	Pseudo nAb ID50	118	228	(220, 237)
Age, Sex	Age < 65 Male	Positive	D57	Pseudo nAb ID50	118	4037	(3386, 4813)
Age, Sex	Age < 65 Male	Positive	D1	Pseudo nAb ID80	118	21	(21, 22)
Age, Sex	Age < 65 Male	Positive	D29	Pseudo nAb ID80	118	119	(119, 120)
Age, Sex	Age < 65 Male	Positive	D57	Pseudo nAb ID80	118	1185	(1129, 1245)
Age, Sex	Age < 65 Male	Positive	D1	Live Virus nAb ID50	118	24	(24, 24)
Age, Sex	Age < 65 Male	Positive	D29	Live Virus nAb ID50	118	210	(193, 230)
Age, Sex	Age < 65 Male	Positive	D57	Live Virus nAb ID50	118	3045	(2784, 3330)
Age, Sex	Age < 65 Male	Positive	D1	Live Virus nAb ID80	118	21	(21, 22)
Age, Sex	Age < 65 Male	Positive	D29	Live Virus nAb ID80	118	129	(129, 130)
Age, Sex	Age < 65 Male	Positive	D57	Live Virus nAb ID80	118	1598	(1581, 1614)
Age, Sex	Age >= 65 Female	Positive	D1	Anti-RBD IgG	117	17	(17, 17)
Age, Sex	Age >= 65 Female	Positive	D29	Anti-RBD IgG	117	72010	(72010, 72010)
Age, Sex	Age >= 65 Female	Positive	D57	Anti-RBD IgG	117	3686701	(3686701, 3686701)
Age, Sex	Age >= 65 Female	Positive	D1	Anti-Spike IgG	117	17	(17, 17)
Age, Sex	Age >= 65 Female	Positive	D29	Anti-Spike IgG	117	132964	(132964, 132964)
Age, Sex	Age >= 65 Female	Positive	D57	Anti-Spike IgG	117	6806544	(6806544, 6806544)
Age, Sex	Age >= 65 Female	Positive	D1	Pseudo nAb ID50	117	24	(24, 24)
Age, Sex	Age >= 65 Female	Positive	D29	Pseudo nAb ID50	117	705	(705, 705)
Age, Sex	Age >= 65 Female	Positive	D57	Pseudo nAb ID50	117	15080	(15080, 15080)
Age, Sex	Age >= 65 Female	Positive	D1	Pseudo nAb ID80	117	21	(21, 22)
Age, Sex	Age >= 65 Female	Positive	D29	Pseudo nAb ID80	117	261	(261, 261)
Age, Sex	Age >= 65 Female	Positive	D57	Pseudo nAb ID80	117	6812	(6812, 6812)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex	Age >= 65 Female	Positive	D1	Live Virus nAb ID50	117	24	(24, 24)
Age, Sex	Age >= 65 Female	Positive	D29	Live Virus nAb ID50	117	523	(523, 523)
Age, Sex	Age >= 65 Female	Positive	D57	Live Virus nAb ID50	117	9289	(9289, 9289)
Age, Sex	Age >= 65 Female	Positive	D1	Live Virus nAb ID80	117	21	(21, 22)
Age, Sex	Age >= 65 Female	Positive	D29	Live Virus nAb ID80	117	273	(273, 273)
Age, Sex	Age >= 65 Female	Positive	D57	Live Virus nAb ID80	117	4501	(4501, 4501)
Age, Sex	Age >= 65 Male	Positive	D1	Anti-RBD IgG	111	17	(17, 17)
Age, Sex	Age >= 65 Male	Positive	D29	Anti-RBD IgG	111	79311	(79311, 79311)
Age, Sex	Age >= 65 Male	Positive	D57	Anti-RBD IgG	111	3356195	(3356195, 3356195)
Age, Sex	Age >= 65 Male	Positive	D1	Anti-Spike IgG	111	17	(17, 17)
Age, Sex	Age >= 65 Male	Positive	D29	Anti-Spike IgG	111	147794	(147794, 147794)
Age, Sex	Age >= 65 Male	Positive	D57	Anti-Spike IgG	111	6383261	(6383261, 6383261)
Age, Sex	Age >= 65 Male	Positive	D1	Pseudo nAb ID50	111	24	(24, 24)
Age, Sex	Age >= 65 Male	Positive	D29	Pseudo nAb ID50	111	842	(842, 842)
Age, Sex	Age >= 65 Male	Positive	D57	Pseudo nAb ID50	111	12927	(12927, 12927)
Age, Sex	Age >= 65 Male	Positive	D1	Pseudo nAb ID80	111	21	(21, 22)
Age, Sex	Age >= 65 Male	Positive	D29	Pseudo nAb ID80	111	357	(357, 357)
Age, Sex	Age >= 65 Male	Positive	D57	Pseudo nAb ID80	111	5539	(5539, 5539)
Age, Sex	Age >= 65 Male	Positive	D1	Live Virus nAb ID50	111	24	(24, 24)
Age, Sex	Age >= 65 Male	Positive	D29	Live Virus nAb ID50	111	536	(536, 536)
Age, Sex	Age >= 65 Male	Positive	D57	Live Virus nAb ID50	111	8970	(8970, 8970)
Age, Sex	Age >= 65 Male	Positive	D1	Live Virus nAb ID80	111	21	(21, 22)
Age, Sex	Age >= 65 Male	Positive	D29	Live Virus nAb ID80	111	268	(268, 268)
Age, Sex	Age >= 65 Male	Positive	D57	Live Virus nAb ID80	111	4195	(4195, 4195)
Ethnicity	Hispanic or Latino	Positive	D1	Anti-RBD IgG	59	17	(17, 17)
Ethnicity	Hispanic or Latino	Positive	D29	Anti-RBD IgG	59	23396	(15585, 35122)
Ethnicity	Hispanic or Latino	Positive	D57	Anti-RBD IgG	59	2242537	(1228777, 4092663)
Ethnicity	Hispanic or Latino	Positive	D1	Anti-Spike IgG	59	17	(17, 17)
Ethnicity	Hispanic or Latino	Positive	D29	Anti-Spike IgG	59	54043	(35496, 82281)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Ethnicity	Hispanic or Latino	Positive	D57	Anti-Spike IgG	59	2865592	(1842286, 4457299)
Ethnicity	Hispanic or Latino	Positive	D1	Pseudo nAb ID50	59	24	(24, 24)
Ethnicity	Hispanic or Latino	Positive	D29	Pseudo nAb ID50	59	336	(226, 501)
Ethnicity	Hispanic or Latino	Positive	D57	Pseudo nAb ID50	59	8848	(3798, 20613)
Ethnicity	Hispanic or Latino	Positive	D1	Pseudo nAb ID80	59	22	(22, 22)
Ethnicity	Hispanic or Latino	Positive	D29	Pseudo nAb ID80	59	138	(96, 198)
Ethnicity	Hispanic or Latino	Positive	D57	Pseudo nAb ID80	59	2181	(1240, 3838)
Ethnicity	Hispanic or Latino	Positive	D1	Live Virus nAb ID50	59	24	(24, 24)
Ethnicity	Hispanic or Latino	Positive	D29	Live Virus nAb ID50	59	449	(255, 790)
Ethnicity	Hispanic or Latino	Positive	D57	Live Virus nAb ID50	59	4088	(2356, 7094)
Ethnicity	Hispanic or Latino	Positive	D1	Live Virus nAb ID80	59	22	(22, 22)
Ethnicity	Hispanic or Latino	Positive	D29	Live Virus nAb ID80	59	203	(111, 372)
Ethnicity	Hispanic or Latino	Positive	D57	Live Virus nAb ID80	59	2813	(1154, 6855)
Ethnicity	Not Hispanic or Latino	Positive	D1	Anti-RBD IgG	418	17	(17, 17)
Ethnicity	Not Hispanic or Latino	Positive	D29	Anti-RBD IgG	418	19917	(11928, 33260)
Ethnicity	Not Hispanic or Latino	Positive	D57	Anti-RBD IgG	418	1079713	(675920, 1724729)
Ethnicity	Not Hispanic or Latino	Positive	D1	Anti-Spike IgG	418	17	(17, 17)
Ethnicity	Not Hispanic or Latino	Positive	D29	Anti-Spike IgG	418	36030	(21191, 61260)
Ethnicity	Not Hispanic or Latino	Positive	D57	Anti-Spike IgG	418	1984198	(1254429, 3138514)
Ethnicity	Not Hispanic or Latino	Positive	D1	Pseudo nAb ID50	418	24	(24, 24)
Ethnicity	Not Hispanic or Latino	Positive	D29	Pseudo nAb ID50	418	234	(148, 371)
Ethnicity	Not Hispanic or Latino	Positive	D57	Pseudo nAb ID50	418	3814	(2402, 6055)
Ethnicity	Not Hispanic or Latino	Positive	D1	Pseudo nAb ID80	418	21	(21, 22)
Ethnicity	Not Hispanic or Latino	Positive	D29	Pseudo nAb ID80	418	108	(72, 162)
Ethnicity	Not Hispanic or Latino	Positive	D57	Pseudo nAb ID80	418	1618	(993, 2638)
Ethnicity	Not Hispanic or Latino	Positive	D1	Live Virus nAb ID50	418	24	(24, 24)
Ethnicity	Not Hispanic or Latino	Positive	D29	Live Virus nAb ID50	418	218	(156, 306)
Ethnicity	Not Hispanic or Latino	Positive	D57	Live Virus nAb ID50	418	3528	(2497, 4984)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Ethnicity	Not Hispanic or Latino	Positive	D1	Live Virus nAb ID80	418	21	(21, 22)
Ethnicity	Not Hispanic or Latino	Positive	D29	Live Virus nAb ID80	418	134	(104, 173)
Ethnicity	Not Hispanic or Latino	Positive	D57	Live Virus nAb ID80	418	1856	(1352, 2548)
Race	American Indian or Alaska Native	Positive	D1	Anti-RBD IgG	8	17	(17, 17)
Race	American Indian or Alaska Native	Positive	D29	Anti-RBD IgG	8	42921	(32224, 57171)
Race	American Indian or Alaska Native	Positive	D57	Anti-RBD IgG	8	1804180	(1602365, 2031413)
Race	American Indian or Alaska Native	Positive	D1	Anti-Spike IgG	8	17	(17, 17)
Race	American Indian or Alaska Native	Positive	D29	Anti-Spike IgG	8	69682	(62813, 77301)
Race	American Indian or Alaska Native	Positive	D57	Anti-Spike IgG	8	3023902	(2733955, 3344599)
Race	American Indian or Alaska Native	Positive	D1	Pseudo nAb ID50	8	25	(24, 25)
Race	American Indian or Alaska Native	Positive	D29	Pseudo nAb ID50	8	415	(381, 453)
Race	American Indian or Alaska Native	Positive	D57	Pseudo nAb ID50	8	9013	(7415, 10955)
Race	American Indian or Alaska Native	Positive	D1	Pseudo nAb ID80	8	22	(22, 22)
Race	American Indian or Alaska Native	Positive	D29	Pseudo nAb ID80	8	179	(164, 196)
Race	American Indian or Alaska Native	Positive	D57	Pseudo nAb ID80	8	4836	(3858, 6061)
Race	American Indian or Alaska Native	Positive	D1	Live Virus nAb ID50	8	25	(24, 25)
Race	American Indian or Alaska Native	Positive	D29	Live Virus nAb ID50	8	634	(575, 700)
Race	American Indian or Alaska Native	Positive	D57	Live Virus nAb ID50	8	11946	(9631, 14819)
Race	American Indian or Alaska Native	Positive	D1	Live Virus nAb ID80	8	22	(22, 22)
Race	American Indian or Alaska Native	Positive	D29	Live Virus nAb ID80	8	267	(220, 324)
Race	American Indian or Alaska Native	Positive	D57	Live Virus nAb ID80	8	2899	(2636, 3189)
Race	Asian	Positive	D1	Anti-RBD IgG	33	17	(17, 17)
Race	Asian	Positive	D29	Anti-RBD IgG	33	23630	(10983, 50843)
Race	Asian	Positive	D57	Anti-RBD IgG	33	1770159	(941781, 3327168)
Race	Asian	Positive	D1	Anti-Spike IgG	33	17	(17, 17)
Race	Asian	Positive	D29	Anti-Spike IgG	33	39067	(16080, 94915)
Race	Asian	Positive	D57	Anti-Spike IgG	33	1809471	(813982, 4022433)
Race	Asian	Positive	D1	Pseudo nAb ID50	33	24	(24, 24)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Asian	Positive	D29	Pseudo nAb ID50	33	198	(54, 723)
Race	Asian	Positive	D57	Pseudo nAb ID50	33	4233	(1432, 12513)
Race	Asian	Positive	D1	Pseudo nAb ID80	33	22	(22, 22)
Race	Asian	Positive	D29	Pseudo nAb ID80	33	94	(34, 257)
Race	Asian	Positive	D57	Pseudo nAb ID80	33	1372	(449, 4193)
Race	Asian	Positive	D1	Live Virus nAb ID50	33	24	(24, 24)
Race	Asian	Positive	D29	Live Virus nAb ID50	33	216	(80, 580)
Race	Asian	Positive	D57	Live Virus nAb ID50	33	5227	(2286, 11950)
Race	Asian	Positive	D1	Live Virus nAb ID80	33	22	(22, 22)
Race	Asian	Positive	D29	Live Virus nAb ID80	33	109	(64, 187)
Race	Asian	Positive	D57	Live Virus nAb ID80	33	1650	(569, 4782)
Race	Black or African American	Positive	D1	Anti-RBD IgG	101	17	(17, 17)
Race	Black or African American	Positive	D29	Anti-RBD IgG	101	17389	(10782, 28047)
Race	Black or African American	Positive	D57	Anti-RBD IgG	101	1065956	(741989, 1531373)
Race	Black or African American	Positive	D1	Anti-Spike IgG	101	17	(17, 17)
Race	Black or African American	Positive	D29	Anti-Spike IgG	101	33099	(22202, 49346)
Race	Black or African American	Positive	D57	Anti-Spike IgG	101	1706573	(1017248, 2863009)
Race	Black or African American	Positive	D1	Pseudo nAb ID50	101	25	(24, 25)
Race	Black or African American	Positive	D29	Pseudo nAb ID50	101	217	(147, 321)
Race	Black or African American	Positive	D57	Pseudo nAb ID50	101	3084	(1956, 4862)
Race	Black or African American	Positive	D1	Pseudo nAb ID80	101	22	(22, 22)
Race	Black or African American	Positive	D29	Pseudo nAb ID80	101	110	(87, 139)
Race	Black or African American	Positive	D57	Pseudo nAb ID80	101	1383	(830, 2303)
Race	Black or African American	Positive	D1	Live Virus nAb ID50	101	25	(24, 25)
Race	Black or African American	Positive	D29	Live Virus nAb ID50	101	236	(168, 333)
Race	Black or African American	Positive	D57	Live Virus nAb ID50	101	3228	(2039, 5110)
Race	Black or African American	Positive	D1	Live Virus nAb ID80	101	22	(22, 22)
Race	Black or African American	Positive	D29	Live Virus nAb ID80	101	141	(114, 174)
Race	Black or African American	Positive	D57	Live Virus nAb ID80	101	1530	(1001, 2340)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Multiracial	Positive	D1	Anti-RBD IgG	31	17	(17, 17)
Race	Multiracial	Positive	D29	Anti-RBD IgG	31	25202	(13055, 48654)
Race	Multiracial	Positive	D57	Anti-RBD IgG	31	1911840	(1162573, 3144002)
Race	Multiracial	Positive	D1	Anti-Spike IgG	31	17	(17, 17)
Race	Multiracial	Positive	D29	Anti-Spike IgG	31	61671	(31660, 120130)
Race	Multiracial	Positive	D57	Anti-Spike IgG	31	3629072	(1701152, 7741908)
Race	Multiracial	Positive	D1	Pseudo nAb ID50	31	24	(24, 24)
Race	Multiracial	Positive	D29	Pseudo nAb ID50	31	372	(198, 700)
Race	Multiracial	Positive	D57	Pseudo nAb ID50	31	8820	(2796, 27821)
Race	Multiracial	Positive	D1	Pseudo nAb ID80	31	22	(22, 22)
Race	Multiracial	Positive	D29	Pseudo nAb ID80	31	176	(101, 306)
Race	Multiracial	Positive	D57	Pseudo nAb ID80	31	2413	(1212, 4804)
Race	Multiracial	Positive	D1	Live Virus nAb ID50	31	24	(24, 24)
Race	Multiracial	Positive	D29	Live Virus nAb ID50	31	606	(377, 972)
Race	Multiracial	Positive	D57	Live Virus nAb ID50	31	4141	(2040, 8406)
Race	Multiracial	Positive	D1	Live Virus nAb ID80	31	22	(22, 22)
Race	Multiracial	Positive	D29	Live Virus nAb ID80	31	199	(158, 250)
Race	Multiracial	Positive	D57	Live Virus nAb ID80	31	4773	(1678, 13579)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Anti-RBD IgG	7	17	(17, 17)
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Anti-RBD IgG	7	9761	(2303, 41365)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Anti-RBD IgG	7	964639	(389361, 2389888)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Anti-Spike IgG	7	17	(17, 17)
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Anti-Spike IgG	7	28121	(13016, 60757)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Anti-Spike IgG	7	2214732	(1317196, 3723848)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Pseudo nAb ID50	7	24	(24, 24)
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Pseudo nAb ID50	7	157	(70, 354)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Pseudo nAb ID50	7	1482	(183, 11965)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Pseudo nAb ID80	7	22	(22, 22)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Pseudo nAb ID80	7	89	(35, 230)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Pseudo nAb ID80	7	418	(131, 1336)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Live Virus nAb ID50	7	24	(24, 24)
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Live Virus nAb ID50	7	88	(36, 212)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Live Virus nAb ID50	7	1357	(630, 2924)
Race	Native Hawaiian or Other Pacific Islander	Positive	D1	Live Virus nAb ID80	7	22	(22, 22)
Race	Native Hawaiian or Other Pacific Islander	Positive	D29	Live Virus nAb ID80	7	64	(23, 179)
Race	Native Hawaiian or Other Pacific Islander	Positive	D57	Live Virus nAb ID80	7	495	(84, 2917)
Race	Not reported and unknown	Positive	D1	Anti-RBD IgG	57	17	(17, 17)
Race	Not reported and unknown	Positive	D29	Anti-RBD IgG	57	21397	(11856, 38615)
Race	Not reported and unknown	Positive	D57	Anti-RBD IgG	57	1348247	(933001, 1948305)
Race	Not reported and unknown	Positive	D1	Anti-Spike IgG	57	17	(17, 17)
Race	Not reported and unknown	Positive	D29	Anti-Spike IgG	57	41513	(24786, 69526)
Race	Not reported and unknown	Positive	D57	Anti-Spike IgG	57	2354129	(1547568, 3581053)
Race	Not reported and unknown	Positive	D1	Pseudo nAb ID50	57	24	(24, 24)
Race	Not reported and unknown	Positive	D29	Pseudo nAb ID50	57	215	(136, 342)
Race	Not reported and unknown	Positive	D57	Pseudo nAb ID50	57	4595	(2635, 8012)
Race	Not reported and unknown	Positive	D1	Pseudo nAb ID80	57	21	(21, 22)
Race	Not reported and unknown	Positive	D29	Pseudo nAb ID80	57	89	(54, 147)
Race	Not reported and unknown	Positive	D57	Pseudo nAb ID80	57	2027	(1537, 2674)
Race	Not reported and unknown	Positive	D1	Live Virus nAb ID50	57	24	(24, 24)
Race	Not reported and unknown	Positive	D29	Live Virus nAb ID50	57	237	(180, 312)
Race	Not reported and unknown	Positive	D57	Live Virus nAb ID50	57	4368	(3172, 6017)
Race	Not reported and unknown	Positive	D1	Live Virus nAb ID80	57	21	(21, 22)
Race	Not reported and unknown	Positive	D29	Live Virus nAb ID80	57	153	(130, 180)
Race	Not reported and unknown	Positive	D57	Live Virus nAb ID80	57	2688	(2255, 3203)
Race	Other	Positive	D1	Anti-RBD IgG	14	17	(17, 17)
Race	Other	Positive	D29	Anti-RBD IgG	14	13558	(9536, 19276)



Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	Other	Positive	D57	Anti-RBD IgG	14	1006396	(779593, 1299182)
Race	Other	Positive	D1	Anti-Spike IgG	14	17	(17, 17)
Race	Other	Positive	D29	Anti-Spike IgG	14	31016	(22150, 43432)
Race	Other	Positive	D57	Anti-Spike IgG	14	1424369	(1010643, 2007461)
Race	Other	Positive	D1	Pseudo nAb ID50	14	24	(24, 24)
Race	Other	Positive	D29	Pseudo nAb ID50	14	153	(106, 222)
Race	Other	Positive	D57	Pseudo nAb ID50	14	3470	(1891, 6365)
Race	Other	Positive	D1	Pseudo nAb ID80	14	21	(21, 22)
Race	Other	Positive	D29	Pseudo nAb ID80	14	48	(27, 86)
Race	Other	Positive	D57	Pseudo nAb ID80	14	569	(246, 1316)
Race	Other	Positive	D1	Live Virus nAb ID50	14	24	(24, 24)
Race	Other	Positive	D29	Live Virus nAb ID50	14	230	(150, 352)
Race	Other	Positive	D57	Live Virus nAb ID50	14	1278	(733, 2230)
Race	Other	Positive	D1	Live Virus nAb ID80	14	21	(21, 22)
Race	Other	Positive	D29	Live Virus nAb ID80	14	137	(109, 171)
Race	Other	Positive	D57	Live Virus nAb ID80	14	420	(204, 864)
Race	White	Positive	D1	Anti-RBD IgG	29	17	(17, 17)
Race	White	Positive	D29	Anti-RBD IgG	29	20304	(8359, 49323)
Race	White	Positive	D57	Anti-RBD IgG	29	1113942	(438949, 2826900)
Race	White	Positive	D1	Anti-Spike IgG	29	17	(17, 17)
Race	White	Positive	D29	Anti-Spike IgG	29	37164	(21777, 63424)
Race	White	Positive	D57	Anti-Spike IgG	29	1671870	(866997, 3223941)
Race	White	Positive	D1	Pseudo nAb ID50	29	24	(24, 24)
Race	White	Positive	D29	Pseudo nAb ID50	29	263	(133, 519)
Race	White	Positive	D57	Pseudo nAb ID50	29	6423	(3676, 11221)
Race	White	Positive	D1	Pseudo nAb ID80	29	21	(21, 22)
Race	White	Positive	D29	Pseudo nAb ID80	29	102	(56, 186)
Race	White	Positive	D57	Pseudo nAb ID80	29	1267	(461, 3478)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race	White	Positive	D1	Live Virus nAb ID50	29	24	(24, 24)
Race	White	Positive	D29	Live Virus nAb ID50	29	222	(139, 353)
Race	White	Positive	D57	Live Virus nAb ID50	29	3159	(1737, 5745)
Race	White	Positive	D1	Live Virus nAb ID80	29	21	(21, 22)
Race	White	Positive	D29	Live Virus nAb ID80	29	137	(79, 237)
Race	White	Positive	D57	Live Virus nAb ID80	29	1575	(593, 4184)
Race	White Non-Hispanic	Positive	D1	Anti-RBD IgG	230	17	(17, 17)
Race	White Non-Hispanic	Positive	D29	Anti-RBD IgG	230	20597	(12022, 35291)
Race	White Non-Hispanic	Positive	D57	Anti-RBD IgG	230	1024342	(621932, 1687126)
Race	White Non-Hispanic	Positive	D1	Anti-Spike IgG	230	17	(17, 17)
Race	White Non-Hispanic	Positive	D29	Anti-Spike IgG	230	36564	(20217, 66129)
Race	White Non-Hispanic	Positive	D57	Anti-Spike IgG	230	2062687	(1265341, 3362474)
Race	White Non-Hispanic	Positive	D1	Pseudo nAb ID50	230	24	(24, 24)
Race	White Non-Hispanic	Positive	D29	Pseudo nAb ID50	230	261	(165, 413)
Race	White Non-Hispanic	Positive	D57	Pseudo nAb ID50	230	4036	(2257, 7218)
Race	White Non-Hispanic	Positive	D1	Pseudo nAb ID80	230	22	(22, 22)
Race	White Non-Hispanic	Positive	D29	Pseudo nAb ID80	230	118	(78, 179)
Race	White Non-Hispanic	Positive	D57	Pseudo nAb ID80	230	1784	(1025, 3106)
Race	White Non-Hispanic	Positive	D1	Live Virus nAb ID50	230	24	(24, 24)
Race	White Non-Hispanic	Positive	D29	Live Virus nAb ID50	230	210	(141, 314)
Race	White Non-Hispanic	Positive	D57	Live Virus nAb ID50	230	3291	(2274, 4762)
Race	White Non-Hispanic	Positive	D1	Live Virus nAb ID80	230	22	(22, 22)
Race	White Non-Hispanic	Positive	D29	Live Virus nAb ID80	230	131	(92, 188)
Race	White Non-Hispanic	Positive	D57	Live Virus nAb ID80	230	2150	(1405, 3289)
Minority	White Non-Hispanic	Positive	D1	Anti-RBD IgG	230	17	(17, 17)
Minority	White Non-Hispanic	Positive	D29	Anti-RBD IgG	230	20597	(12022, 35291)
Minority	White Non-Hispanic	Positive	D57	Anti-RBD IgG	230	1024342	(621932, 1687126)
Minority	White Non-Hispanic	Positive	D1	Anti-Spike IgG	230	17	(17, 17)
Minority	White Non-Hispanic	Positive	D29	Anti-Spike IgG	230	36564	(20217, 66129)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Minority	White Non-Hispanic	Positive	D57	Anti-Spike IgG	230	2062687	(1265341, 3362474)
Minority	White Non-Hispanic	Positive	D1	Pseudo nAb ID50	230	24	(24, 24)
Minority	White Non-Hispanic	Positive	D29	Pseudo nAb ID50	230	261	(165, 413)
Minority	White Non-Hispanic	Positive	D57	Pseudo nAb ID50	230	4036	(2257, 7218)
Minority	White Non-Hispanic	Positive	D1	Pseudo nAb ID80	230	22	(22, 22)
Minority	White Non-Hispanic	Positive	D29	Pseudo nAb ID80	230	118	(78, 179)
Minority	White Non-Hispanic	Positive	D57	Pseudo nAb ID80	230	1784	(1025, 3106)
Minority	White Non-Hispanic	Positive	D1	Live Virus nAb ID50	230	24	(24, 24)
Minority	White Non-Hispanic	Positive	D29	Live Virus nAb ID50	230	210	(141, 314)
Minority	White Non-Hispanic	Positive	D57	Live Virus nAb ID50	230	3291	(2274, 4762)
Minority	White Non-Hispanic	Positive	D1	Live Virus nAb ID80	230	22	(22, 22)
Minority	White Non-Hispanic	Positive	D29	Live Virus nAb ID80	230	131	(92, 188)
Minority	White Non-Hispanic	Positive	D57	Live Virus nAb ID80	230	2150	(1405, 3289)
Minority	Communities of Color	Positive	D1	Anti-RBD IgG	251	17	(17, 17)
Minority	Communities of Color	Positive	D29	Anti-RBD IgG	251	20121	(12379, 32704)
Minority	Communities of Color	Positive	D57	Anti-RBD IgG	251	1310542	(931458, 1843906)
Minority	Communities of Color	Positive	D1	Anti-Spike IgG	251	17	(17, 17)
Minority	Communities of Color	Positive	D29	Anti-Spike IgG	251	39503	(25451, 61315)
Minority	Communities of Color	Positive	D57	Anti-Spike IgG	251	2067190	(1370989, 3116926)
Minority	Communities of Color	Positive	D1	Pseudo nAb ID50	251	24	(24, 24)
Minority	Communities of Color	Positive	D29	Pseudo nAb ID50	251	229	(142, 367)
Minority	Communities of Color	Positive	D57	Pseudo nAb ID50	251	4166	(2761, 6286)
Minority	Communities of Color	Positive	D1	Pseudo nAb ID80	251	21	(21, 22)
Minority	Communities of Color	Positive	D29	Pseudo nAb ID80	251	104	(68, 160)
Minority	Communities of Color	Positive	D57	Pseudo nAb ID80	251	1560	(991, 2457)
Minority	Communities of Color	Positive	D1	Live Virus nAb ID50	251	24	(24, 24)
Minority	Communities of Color	Positive	D29	Live Virus nAb ID50	251	268	(211, 340)
Minority	Communities of Color	Positive	D57	Live Virus nAb ID50	251	3711	(2549, 5402)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Minority	Communities of Color	Positive	D1	Live Virus nAb ID80	251	21	(21, 22)
Minority	Communities of Color	Positive	D29	Live Virus nAb ID80	251	147	(124, 174)
Minority	Communities of Color	Positive	D57	Live Virus nAb ID80	251	1816	(1418, 2326)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Anti-RBD IgG	148	17	(17, 17)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Anti-RBD IgG	148	16832	(16794, 16869)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Anti-RBD IgG	148	1148387	(1011777, 1303441)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Anti-Spike IgG	148	17	(17, 17)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Anti-Spike IgG	148	33412	(30921, 36103)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Anti-Spike IgG	148	1765431	(1596082, 1952749)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Pseudo nAb ID50	148	24	(24, 24)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Pseudo nAb ID50	148	195	(177, 214)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Pseudo nAb ID50	148	3557	(2882, 4390)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Pseudo nAb ID80	148	21	(21, 22)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Pseudo nAb ID80	148	90	(82, 100)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Pseudo nAb ID80	148	1309	(1089, 1574)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Live Virus nAb ID50	148	24	(24, 24)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Live Virus nAb ID50	148	245	(217, 276)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Live Virus nAb ID50	148	3210	(2860, 3602)
Age, Minority	Age < 65 Communities of Color	Positive	D1	Live Virus nAb ID80	148	21	(21, 22)
Age, Minority	Age < 65 Communities of Color	Positive	D29	Live Virus nAb ID80	148	137	(124, 152)
Age, Minority	Age < 65 Communities of Color	Positive	D57	Live Virus nAb ID80	148	1652	(1445, 1888)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Anti-RBD IgG	128	17	(17, 17)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Anti-RBD IgG	128	16693	(12510, 22275)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Anti-RBD IgG	128	842504	(732240, 969373)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Anti-Spike IgG	128	17	(17, 17)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Anti-Spike IgG	128	28984	(21712, 38692)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Anti-Spike IgG	128	1711797	(1237969, 2366982)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Pseudo nAb ID50	128	25	(24, 25)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Pseudo nAb ID50	128	219	(162, 297)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Pseudo nAb ID50	128	3287	(1991, 5424)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Pseudo nAb ID80	128	22	(22, 22)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Pseudo nAb ID80	128	100	(78, 130)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Pseudo nAb ID80	128	1435	(1130, 1822)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Live Virus nAb ID50	128	25	(24, 25)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Live Virus nAb ID50	128	180	(141, 231)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Live Virus nAb ID50	128	2846	(2392, 3387)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D1	Live Virus nAb ID80	128	22	(22, 22)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D29	Live Virus nAb ID80	128	115	(90, 147)
Age, Minority	Age < 65 White Non-Hispanic	Positive	D57	Live Virus nAb ID80	128	1873	(1236, 2837)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Anti-RBD IgG	103	17	(17, 17)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Anti-RBD IgG	103	73816	(73816, 73816)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Anti-RBD IgG	103	3429481	(3429481, 3429481)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Anti-Spike IgG	103	17	(17, 17)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Anti-Spike IgG	103	133776	(133776, 133776)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Anti-Spike IgG	103	6523569	(6523569, 6523569)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Pseudo nAb ID50	103	24	(24, 24)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Pseudo nAb ID50	103	742	(742, 742)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Pseudo nAb ID50	103	13171	(13171, 13171)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Pseudo nAb ID80	103	21	(21, 22)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Pseudo nAb ID80	103	298	(298, 298)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Pseudo nAb ID80	103	5608	(5608, 5608)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Live Virus nAb ID50	103	24	(24, 24)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Live Virus nAb ID50	103	522	(522, 522)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Live Virus nAb ID50	103	10671	(10671, 10671)
Age, Minority	Age >= 65 Communities of Color	Positive	D1	Live Virus nAb ID80	103	21	(21, 22)
Age, Minority	Age >= 65 Communities of Color	Positive	D29	Live Virus nAb ID80	103	235	(235, 235)
Age, Minority	Age >= 65 Communities of Color	Positive	D57	Live Virus nAb ID80	103	3622	(3622, 3622)

Table 2: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

subgroup	Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Anti-RBD IgG	102	17	(17, 17)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Anti-RBD IgG	102	78748	(78748, 78748)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Anti-RBD IgG	102	3564826	(3564826, 3564826)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Anti-Spike IgG	102	17	(17, 17)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Anti-Spike IgG	102	161036	(161036, 161036)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Anti-Spike IgG	102	6779392	(6779392, 6779392)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Pseudo nAb ID50	102	24	(24, 24)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Pseudo nAb ID50	102	795	(795, 795)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Pseudo nAb ID50	102	14967	(14967, 14967)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Pseudo nAb ID80	102	21	(21, 22)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Pseudo nAb ID80	102	328	(328, 328)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Pseudo nAb ID80	102	7169	(7169, 7169)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Live Virus nAb ID50	102	24	(24, 24)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Live Virus nAb ID50	102	563	(563, 563)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Live Virus nAb ID50	102	8306	(8306, 8306)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D1	Live Virus nAb ID80	102	21	(21, 22)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D29	Live Virus nAb ID80	102	311	(311, 311)
Age, Minority	Age >= 65 White Non-Hispanic	Positive	D57	Live Virus nAb ID80	102	5191	(5191, 5191)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Total	D57 vs. Baseline	1975.38	(1500.31, 2600.89)
Negative	Anti-RBD IgG	Total	D57 vs. Baseline	1251.28	(1001.98, 1562.62)
Negative	Pseudo nAb ID50	Total	D57 vs. Baseline	59.22	(44.94, 78.02)
Negative	Live Virus nAb ID50	Total	D57 vs. Baseline	61.89	(50.01, 76.59)
Negative	Pseudo nAb ID80	Total	D57 vs. Baseline	44.79	(33.18, 60.47)
Negative	Live Virus nAb ID80	Total	D57 vs. Baseline	46.84	(39.25, 55.90)
Negative	Anti-Spike IgG	Total	D29 vs. Baseline	267.32	(211.32, 338.17)
Negative	Anti-RBD IgG	Total	D29 vs. Baseline	164.37	(126.35, 213.83)
Negative	Pseudo nAb ID50	Total	D29 vs. Baseline	14.34	(10.81, 19.04)
Negative	Live Virus nAb ID50	Total	D29 vs. Baseline	15.43	(12.85, 18.52)
Negative	Pseudo nAb ID80	Total	D29 vs. Baseline	9.68	(7.31, 12.83)
Negative	Live Virus nAb ID80	Total	D29 vs. Baseline	11.95	(9.96, 14.34)
Negative	Anti-Spike IgG	Total	D57 vs. D29	7.39	(6.34, 8.61)
Negative	Anti-RBD IgG	Total	D57 vs. D29	7.61	(6.75, 8.59)
Negative	Pseudo nAb ID50	Total	D57 vs. D29	4.13	(3.82, 4.46)
Negative	Live Virus nAb ID50	Total	D57 vs. D29	4.01	(3.69, 4.36)
Negative	Pseudo nAb ID80	Total	D57 vs. D29	4.63	(4.31, 4.97)
Negative	Live Virus nAb ID80	Total	D57 vs. D29	3.92	(3.84, 4.00)
Negative	Anti-Spike IgG	Age < 65	D57 vs. Baseline	1848.62	(1328.14, 2573.05)
Negative	Anti-RBD IgG	Age < 65	D57 vs. Baseline	1168.86	(917.56, 1488.97)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Age < 65	D57 vs. Baseline	52.97	(45.73, 61.35)
Negative	Live Virus nAb ID50	Age < 65	D57 vs. Baseline	56.76	(52.59, 61.25)
Negative	Pseudo nAb ID80	Age < 65	D57 vs. Baseline	39.73	(32.97, 47.87)
Negative	Live Virus nAb ID80	Age < 65	D57 vs. Baseline	43.62	(39.58, 48.06)
Negative	Anti-Spike IgG	Age < 65	D29 vs. Baseline	244.33	(203.15, 293.87)
Negative	Anti-RBD IgG	Age < 65	D29 vs. Baseline	148.15	(123.95, 177.08)
Negative	Pseudo nAb ID50	Age < 65	D29 vs. Baseline	12.89	(10.22, 16.27)
Negative	Live Virus nAb ID50	Age < 65	D29 vs. Baseline	14.39	(12.44, 16.64)
Negative	Pseudo nAb ID80	Age < 65	D29 vs. Baseline	8.72	(6.85, 11.12)
Negative	Live Virus nAb ID80	Age < 65	D29 vs. Baseline	11.12	(9.85, 12.56)
Negative	Anti-Spike IgG	Age < 65	D57 vs. D29	7.57	(6.54, 8.76)
Negative	Anti-RBD IgG	Age < 65	D57 vs. D29	7.89	(7.40, 8.41)
Negative	Pseudo nAb ID50	Age < 65	D57 vs. D29	4.11	(3.77, 4.48)
Negative	Live Virus nAb ID50	Age < 65	D57 vs. D29	3.94	(3.68, 4.23)
Negative	Pseudo nAb ID80	Age < 65	D57 vs. D29	4.55	(4.31, 4.82)
Negative	Live Virus nAb ID80	Age < 65	D57 vs. D29	3.92	(3.83, 4.02)
Negative	Anti-Spike IgG	Age ≥ 65	D57 vs. Baseline	2774.43	(2774.43, 2774.43)
Negative	Anti-RBD IgG	Age ≥ 65	D57 vs. Baseline	1773.88	(1773.88, 1773.88)
Negative	Pseudo nAb ID50	Age ≥ 65	D57 vs. Baseline	104.80	(104.80, 104.80)
Negative	Live Virus nAb ID50	Age ≥ 65	D57 vs. Baseline	96.43	(96.43, 96.43)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Age $\geq$ 65	D57 vs. Baseline	82.75	(82.75, 82.75)
Negative	Live Virus nAb ID80	Age $\geq$ 65	D57 vs. Baseline	67.49	(67.49, 67.49)
Negative	Anti-Spike IgG	Age $\geq$ 65	D29 vs. Baseline	423.67	(423.67, 423.67)
Negative	Anti-RBD IgG	Age $\geq$ 65	D29 vs. Baseline	279.78	(279.78, 279.78)
Negative	Pseudo nAb ID50	Age $\geq$ 65	D29 vs. Baseline	24.77	(24.77, 24.77)
Negative	Live Virus nAb ID50	Age $\geq$ 65	D29 vs. Baseline	22.05	(22.05, 22.05)
Negative	Pseudo nAb ID80	Age $\geq$ 65	D29 vs. Baseline	16.52	(16.52, 16.52)
Negative	Live Virus nAb ID80	Age $\geq$ 65	D29 vs. Baseline	17.29	(17.29, 17.29)
Negative	Anti-Spike IgG	Age $\geq$ 65	D57 vs. D29	6.55	(6.55, 6.55)
Negative	Anti-RBD IgG	Age $\geq$ 65	D57 vs. D29	6.34	(6.34, 6.34)
Negative	Pseudo nAb ID50	Age $\geq$ 65	D57 vs. D29	4.23	(4.23, 4.23)
Negative	Live Virus nAb ID50	Age $\geq$ 65	D57 vs. D29	4.37	(4.37, 4.37)
Negative	Pseudo nAb ID80	Age $\geq$ 65	D57 vs. D29	5.01	(5.01, 5.01)
Negative	Live Virus nAb ID80	Age $\geq$ 65	D57 vs. D29	3.90	(3.90, 3.90)
Negative	Anti-Spike IgG	At-risk	D57 vs. Baseline	1610.75	(746.59, 3475.16)
Negative	Anti-RBD IgG	At-risk	D57 vs. Baseline	1102.56	(569.20, 2135.70)
Negative	Pseudo nAb ID50	At-risk	D57 vs. Baseline	58.34	(28.77, 118.30)
Negative	Live Virus nAb ID50	At-risk	D57 vs. Baseline	62.35	(39.03, 99.60)
Negative	Pseudo nAb ID80	At-risk	D57 vs. Baseline	42.02	(19.99, 88.31)
Negative	Live Virus nAb ID80	At-risk	D57 vs. Baseline	47.30	(28.49, 78.55)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	At-risk	D29 vs. Baseline	255.84	(125.31, 522.34)
Negative	Anti-RBD IgG	At-risk	D29 vs. Baseline	161.35	(73.65, 353.51)
Negative	Pseudo nAb ID50	At-risk	D29 vs. Baseline	13.07	(5.89, 28.98)
Negative	Live Virus nAb ID50	At-risk	D29 vs. Baseline	14.51	(8.82, 23.87)
Negative	Pseudo nAb ID80	At-risk	D29 vs. Baseline	8.48	(4.08, 17.64)
Negative	Live Virus nAb ID80	At-risk	D29 vs. Baseline	11.36	(7.25, 17.79)
Negative	Anti-Spike IgG	At-risk	D57 vs. D29	6.30	(5.96, 6.65)
Negative	Anti-RBD IgG	At-risk	D57 vs. D29	6.83	(6.04, 7.73)
Negative	Pseudo nAb ID50	At-risk	D57 vs. D29	4.47	(4.08, 4.88)
Negative	Live Virus nAb ID50	At-risk	D57 vs. D29	4.30	(4.17, 4.43)
Negative	Pseudo nAb ID80	At-risk	D57 vs. D29	4.95	(4.90, 5.01)
Negative	Live Virus nAb ID80	At-risk	D57 vs. D29	4.16	(3.93, 4.41)
Negative	Anti-Spike IgG	Not at-risk	D57 vs. Baseline	2117.76	(2035.91, 2202.91)
Negative	Anti-RBD IgG	Not at-risk	D57 vs. Baseline	1306.46	(1224.89, 1393.46)
Negative	Pseudo nAb ID50	Not at-risk	D57 vs. Baseline	59.52	(49.37, 71.75)
Negative	Live Virus nAb ID50	Not at-risk	D57 vs. Baseline	61.73	(52.17, 73.05)
Negative	Pseudo nAb ID80	Not at-risk	D57 vs. Baseline	45.78	(36.79, 56.96)
Negative	Live Virus nAb ID80	Not at-risk	D57 vs. Baseline	46.68	(42.40, 51.40)
Negative	Anti-Spike IgG	Not at-risk	D29 vs. Baseline	271.36	(243.19, 302.79)
Negative	Anti-RBD IgG	Not at-risk	D29 vs. Baseline	165.41	(144.88, 188.85)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Not at-risk	D29 vs. Baseline	14.81	(12.66, 17.33)
Negative	Live Virus nAb ID50	Not at-risk	D29 vs. Baseline	15.75	(14.11, 17.60)
Negative	Pseudo nAb ID80	Not at-risk	D29 vs. Baseline	10.13	(8.47, 12.12)
Negative	Live Virus nAb ID80	Not at-risk	D29 vs. Baseline	12.16	(10.64, 13.90)
Negative	Anti-Spike IgG	Not at-risk	D57 vs. D29	7.80	(7.28, 8.37)
Negative	Anti-RBD IgG	Not at-risk	D57 vs. D29	7.90	(7.38, 8.45)
Negative	Pseudo nAb ID50	Not at-risk	D57 vs. D29	4.02	(3.90, 4.14)
Negative	Live Virus nAb ID50	Not at-risk	D57 vs. D29	3.92	(3.70, 4.15)
Negative	Pseudo nAb ID80	Not at-risk	D57 vs. D29	4.52	(4.35, 4.70)
Negative	Live Virus nAb ID80	Not at-risk	D57 vs. D29	3.84	(3.70, 3.98)
Negative	Anti-Spike IgG	Age < 65 At-risk	D57 vs. Baseline	1155.45	(1155.45, 1155.45)
Negative	Anti-RBD IgG	Age < 65 At-risk	D57 vs. Baseline	828.61	(828.61, 828.61)
Negative	Pseudo nAb ID50	Age < 65 At-risk	D57 vs. Baseline	42.99	(42.99, 42.99)
Negative	Live Virus nAb ID50	Age < 65 At-risk	D57 vs. Baseline	50.93	(50.93, 50.93)
Negative	Pseudo nAb ID80	Age < 65 At-risk	D57 vs. Baseline	30.48	(30.48, 30.48)
Negative	Live Virus nAb ID80	Age < 65 At-risk	D57 vs. Baseline	38.00	(38.00, 38.00)
Negative	Anti-Spike IgG	Age < 65 At-risk	D29 vs. Baseline	187.95	(187.95, 187.95)
Negative	Anti-RBD IgG	Age < 65 At-risk	D29 vs. Baseline	114.98	(114.98, 114.98)
Negative	Pseudo nAb ID50	Age < 65 At-risk	D29 vs. Baseline	9.26	(9.26, 9.26)
Negative	Live Virus nAb ID50	Age < 65 At-risk	D29 vs. Baseline	11.70	(11.70, 11.70)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Age < 65 At-risk	D29 vs. Baseline	6.18	(6.18, 6.18)
Negative	Live Virus nAb ID80	Age < 65 At-risk	D29 vs. Baseline	9.36	(9.36, 9.36)
Negative	Anti-Spike IgG	Age < 65 At-risk	D57 vs. D29	6.15	(6.15, 6.15)
Negative	Anti-RBD IgG	Age < 65 At-risk	D57 vs. D29	7.21	(7.21, 7.21)
Negative	Pseudo nAb ID50	Age < 65 At-risk	D57 vs. D29	4.64	(4.64, 4.64)
Negative	Live Virus nAb ID50	Age < 65 At-risk	D57 vs. D29	4.35	(4.35, 4.35)
Negative	Pseudo nAb ID80	Age < 65 At-risk	D57 vs. D29	4.93	(4.93, 4.93)
Negative	Live Virus nAb ID80	Age < 65 At-risk	D57 vs. D29	4.06	(4.06, 4.06)
Negative	Anti-Spike IgG	Age < 65 Not at-risk	D57 vs. Baseline	2090.30	(2090.30, 2090.30)
Negative	Anti-RBD IgG	Age < 65 Not at-risk	D57 vs. Baseline	1278.86	(1278.86, 1278.86)
Negative	Pseudo nAb ID50	Age < 65 Not at-risk	D57 vs. Baseline	55.94	(55.94, 55.94)
Negative	Live Virus nAb ID50	Age < 65 Not at-risk	D57 vs. Baseline	58.38	(58.38, 58.38)
Negative	Pseudo nAb ID80	Age < 65 Not at-risk	D57 vs. Baseline	42.58	(42.58, 42.58)
Negative	Live Virus nAb ID80	Age < 65 Not at-risk	D57 vs. Baseline	45.22	(45.22, 45.22)
Negative	Anti-Spike IgG	Age < 65 Not at-risk	D29 vs. Baseline	261.68	(261.68, 261.68)
Negative	Anti-RBD IgG	Age < 65 Not at-risk	D29 vs. Baseline	158.30	(158.30, 158.30)
Negative	Pseudo nAb ID50	Age < 65 Not at-risk	D29 vs. Baseline	14.06	(14.06, 14.06)
Negative	Live Virus nAb ID50	Age < 65 Not at-risk	D29 vs. Baseline	15.19	(15.19, 15.19)
Negative	Pseudo nAb ID80	Age < 65 Not at-risk	D29 vs. Baseline	9.54	(9.54, 9.54)
Negative	Live Virus nAb ID80	Age < 65 Not at-risk	D29 vs. Baseline	11.63	(11.63, 11.63)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Age < 65 Not at-risk	D57 vs. D29	7.99	(7.99, 7.99)
Negative	Anti-RBD IgG	Age < 65 Not at-risk	D57 vs. D29	8.08	(8.08, 8.08)
Negative	Pseudo nAb ID50	Age < 65 Not at-risk	D57 vs. D29	3.98	(3.98, 3.98)
Negative	Live Virus nAb ID50	Age < 65 Not at-risk	D57 vs. D29	3.84	(3.84, 3.84)
Negative	Pseudo nAb ID80	Age < 65 Not at-risk	D57 vs. D29	4.46	(4.46, 4.46)
Negative	Live Virus nAb ID80	Age < 65 Not at-risk	D57 vs. D29	3.89	(3.89, 3.89)
Negative	Anti-Spike IgG	Age ≥ 65 At-risk	D57 vs. Baseline	3282.47	(3282.47, 3282.47)
Negative	Anti-RBD IgG	Age ≥ 65 At-risk	D57 vs. Baseline	2033.48	(2033.48, 2033.48)
Negative	Pseudo nAb ID50	Age ≥ 65 At-risk	D57 vs. Baseline	112.26	(112.26, 112.26)
Negative	Live Virus nAb ID50	Age ≥ 65 At-risk	D57 vs. Baseline	96.20	(96.20, 96.20)
Negative	Pseudo nAb ID80	Age ≥ 65 At-risk	D57 vs. Baseline	83.57	(83.57, 83.57)
Negative	Live Virus nAb ID80	Age ≥ 65 At-risk	D57 vs. Baseline	75.65	(75.65, 75.65)
Negative	Anti-Spike IgG	Age ≥ 65 At-risk	D29 vs. Baseline	495.40	(495.40, 495.40)
Negative	Anti-RBD IgG	Age ≥ 65 At-risk	D29 vs. Baseline	333.53	(333.53, 333.53)
Negative	Pseudo nAb ID50	Age ≥ 65 At-risk	D29 vs. Baseline	27.32	(27.32, 27.32)
Negative	Live Virus nAb ID50	Age ≥ 65 At-risk	D29 vs. Baseline	23.00	(23.00, 23.00)
Negative	Pseudo nAb ID80	Age ≥ 65 At-risk	D29 vs. Baseline	16.71	(16.71, 16.71)
Negative	Live Virus nAb ID80	Age ≥ 65 At-risk	D29 vs. Baseline	17.21	(17.21, 17.21)
Negative	Anti-Spike IgG	Age ≥ 65 At-risk	D57 vs. D29	6.63	(6.63, 6.63)
Negative	Anti-RBD IgG	Age ≥ 65 At-risk	D57 vs. D29	6.10	(6.10, 6.10)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Age $\geq$ 65 At-risk	D57 vs. D29	4.11	(4.11, 4.11)
Negative	Live Virus nAb ID50	Age $\geq$ 65 At-risk	D57 vs. D29	4.18	(4.18, 4.18)
Negative	Pseudo nAb ID80	Age $\geq$ 65 At-risk	D57 vs. D29	5.00	(5.00, 5.00)
Negative	Live Virus nAb ID80	Age $\geq$ 65 At-risk	D57 vs. D29	4.40	(4.40, 4.40)
Negative	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	2352.30	(2352.30, 2352.30)
Negative	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	1551.32	(1551.32, 1551.32)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	97.95	(97.95, 97.95)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	96.67	(96.67, 96.67)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	81.94	(81.94, 81.94)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	60.34	(60.34, 60.34)
Negative	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	363.38	(363.38, 363.38)
Negative	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	235.45	(235.45, 235.45)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	22.51	(22.51, 22.51)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	21.15	(21.15, 21.15)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	16.33	(16.33, 16.33)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	17.36	(17.36, 17.36)
Negative	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D57 vs. D29	6.47	(6.47, 6.47)
Negative	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D57 vs. D29	6.59	(6.59, 6.59)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. D29	4.35	(4.35, 4.35)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. D29	4.57	(4.57, 4.57)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. D29	5.02	(5.02, 5.02)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. D29	3.48	(3.48, 3.48)
Negative	Anti-Spike IgG	Female	D57 vs. Baseline	2160.21	(1297.56, 3596.38)
Negative	Anti-RBD IgG	Female	D57 vs. Baseline	1472.59	(892.18, 2430.60)
Negative	Pseudo nAb ID50	Female	D57 vs. Baseline	66.47	(53.90, 81.96)
Negative	Live Virus nAb ID50	Female	D57 vs. Baseline	66.62	(55.32, 80.24)
Negative	Pseudo nAb ID80	Female	D57 vs. Baseline	49.05	(40.06, 60.05)
Negative	Live Virus nAb ID80	Female	D57 vs. Baseline	51.22	(40.26, 65.17)
Negative	Anti-Spike IgG	Female	D29 vs. Baseline	263.99	(218.52, 318.91)
Negative	Anti-RBD IgG	Female	D29 vs. Baseline	193.39	(152.79, 244.79)
Negative	Pseudo nAb ID50	Female	D29 vs. Baseline	16.67	(13.43, 20.69)
Negative	Live Virus nAb ID50	Female	D29 vs. Baseline	16.35	(12.66, 21.10)
Negative	Pseudo nAb ID80	Female	D29 vs. Baseline	11.49	(8.53, 15.49)
Negative	Live Virus nAb ID80	Female	D29 vs. Baseline	12.57	(10.71, 14.76)
Negative	Anti-Spike IgG	Female	D57 vs. D29	8.18	(5.82, 11.50)
Negative	Anti-RBD IgG	Female	D57 vs. D29	7.61	(5.61, 10.33)
Negative	Pseudo nAb ID50	Female	D57 vs. D29	3.99	(3.82, 4.16)
Negative	Live Virus nAb ID50	Female	D57 vs. D29	4.08	(3.80, 4.37)
Negative	Pseudo nAb ID80	Female	D57 vs. D29	4.27	(3.86, 4.72)
Negative	Live Virus nAb ID80	Female	D57 vs. D29	4.07	(3.66, 4.53)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Male	D57 vs. Baseline	1779.47	(1021.82, 3098.89)
Negative	Anti-RBD IgG	Male	D57 vs. Baseline	1034.58	(543.38, 1969.80)
Negative	Pseudo nAb ID50	Male	D57 vs. Baseline	51.74	(27.67, 96.77)
Negative	Live Virus nAb ID50	Male	D57 vs. Baseline	56.78	(34.79, 92.69)
Negative	Pseudo nAb ID80	Male	D57 vs. Baseline	40.28	(22.50, 72.12)
Negative	Live Virus nAb ID80	Male	D57 vs. Baseline	42.20	(26.49, 67.21)
Negative	Anti-Spike IgG	Male	D29 vs. Baseline	271.27	(168.20, 437.51)
Negative	Anti-RBD IgG	Male	D29 vs. Baseline	135.94	(77.38, 238.81)
Negative	Pseudo nAb ID50	Male	D29 vs. Baseline	12.04	(7.10, 20.40)
Negative	Live Virus nAb ID50	Male	D29 vs. Baseline	14.42	(9.89, 21.04)
Negative	Pseudo nAb ID80	Male	D29 vs. Baseline	7.93	(4.77, 13.17)
Negative	Live Virus nAb ID80	Male	D29 vs. Baseline	11.26	(7.95, 15.96)
Negative	Anti-Spike IgG	Male	D57 vs. D29	6.56	(6.07, 7.09)
Negative	Anti-RBD IgG	Male	D57 vs. D29	7.61	(6.93, 8.36)
Negative	Pseudo nAb ID50	Male	D57 vs. D29	4.30	(3.59, 5.14)
Negative	Live Virus nAb ID50	Male	D57 vs. D29	3.94	(3.51, 4.42)
Negative	Pseudo nAb ID80	Male	D57 vs. D29	5.08	(4.71, 5.48)
Negative	Live Virus nAb ID80	Male	D57 vs. D29	3.75	(3.21, 4.37)
Negative	Anti-Spike IgG	Age < 65 Female	D57 vs. Baseline	2319.91	(1391.42, 3867.98)
Negative	Anti-RBD IgG	Age < 65 Female	D57 vs. Baseline	1615.59	(1027.55, 2540.15)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Age < 65 Female	D57 vs. Baseline	66.87	(52.25, 85.58)
Negative	Live Virus nAb ID50	Age < 65 Female	D57 vs. Baseline	66.11	(52.48, 83.28)
Negative	Pseudo nAb ID80	Age < 65 Female	D57 vs. Baseline	48.04	(37.18, 62.09)
Negative	Live Virus nAb ID80	Age < 65 Female	D57 vs. Baseline	51.86	(39.32, 68.40)
Negative	Anti-Spike IgG	Age < 65 Female	D29 vs. Baseline	263.54	(209.41, 331.66)
Negative	Anti-RBD IgG	Age < 65 Female	D29 vs. Baseline	193.91	(146.24, 257.10)
Negative	Pseudo nAb ID50	Age < 65 Female	D29 vs. Baseline	16.48	(12.59, 21.59)
Negative	Live Virus nAb ID50	Age < 65 Female	D29 vs. Baseline	16.22	(11.84, 22.22)
Negative	Pseudo nAb ID80	Age < 65 Female	D29 vs. Baseline	11.32	(7.80, 16.43)
Negative	Live Virus nAb ID80	Age < 65 Female	D29 vs. Baseline	12.39	(10.11, 15.17)
Negative	Anti-Spike IgG	Age < 65 Female	D57 vs. D29	8.80	(6.64, 11.66)
Negative	Anti-RBD IgG	Age < 65 Female	D57 vs. D29	8.33	(7.03, 9.88)
Negative	Pseudo nAb ID50	Age < 65 Female	D57 vs. D29	4.06	(3.96, 4.15)
Negative	Live Virus nAb ID50	Age < 65 Female	D57 vs. D29	4.08	(3.75, 4.43)
Negative	Pseudo nAb ID80	Age < 65 Female	D57 vs. D29	4.24	(3.78, 4.76)
Negative	Live Virus nAb ID80	Age < 65 Female	D57 vs. D29	4.19	(3.89, 4.51)
Negative	Anti-Spike IgG	Age < 65 Male	D57 vs. Baseline	1426.63	(1229.84, 1654.91)
Negative	Anti-RBD IgG	Age < 65 Male	D57 vs. Baseline	807.91	(779.48, 837.38)
Negative	Pseudo nAb ID50	Age < 65 Male	D57 vs. Baseline	40.60	(38.34, 43.00)
Negative	Live Virus nAb ID50	Age < 65 Male	D57 vs. Baseline	47.68	(43.83, 51.88)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Age < 65 Male	D57 vs. Baseline	31.98	(28.19, 36.29)
Negative	Live Virus nAb ID80	Age < 65 Male	D57 vs. Baseline	35.80	(32.72, 39.17)
Negative	Anti-Spike IgG	Age < 65 Male	D29 vs. Baseline	224.13	(194.68, 258.02)
Negative	Anti-RBD IgG	Age < 65 Male	D29 vs. Baseline	108.98	(99.78, 119.03)
Negative	Pseudo nAb ID50	Age < 65 Male	D29 vs. Baseline	9.74	(7.85, 12.09)
Negative	Live Virus nAb ID50	Age < 65 Male	D29 vs. Baseline	12.55	(12.12, 13.01)
Negative	Pseudo nAb ID80	Age < 65 Male	D29 vs. Baseline	6.48	(5.74, 7.31)
Negative	Live Virus nAb ID80	Age < 65 Male	D29 vs. Baseline	9.84	(9.45, 10.23)
Negative	Anti-Spike IgG	Age < 65 Male	D57 vs. D29	6.37	(6.32, 6.41)
Negative	Anti-RBD IgG	Age < 65 Male	D57 vs. D29	7.41	(7.04, 7.81)
Negative	Pseudo nAb ID50	Age < 65 Male	D57 vs. D29	4.17	(3.56, 4.89)
Negative	Live Virus nAb ID50	Age < 65 Male	D57 vs. D29	3.80	(3.62, 3.99)
Negative	Pseudo nAb ID80	Age < 65 Male	D57 vs. D29	4.94	(4.91, 4.96)
Negative	Live Virus nAb ID80	Age < 65 Male	D57 vs. D29	3.64	(3.20, 4.14)
Negative	Anti-Spike IgG	Age >= 65 Female	D57 vs. Baseline	1533.52	(1533.52, 1533.52)
Negative	Anti-RBD IgG	Age >= 65 Female	D57 vs. Baseline	943.46	(943.46, 943.46)
Negative	Pseudo nAb ID50	Age >= 65 Female	D57 vs. Baseline	64.56	(64.56, 64.56)
Negative	Live Virus nAb ID50	Age >= 65 Female	D57 vs. Baseline	69.13	(69.13, 69.13)
Negative	Pseudo nAb ID80	Age >= 65 Female	D57 vs. Baseline	54.16	(54.16, 54.16)
Negative	Live Virus nAb ID80	Age >= 65 Female	D57 vs. Baseline	48.27	(48.27, 48.27)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Age $\geq$ 65 Female	D29 vs. Baseline	266.15	(266.15, 266.15)
Negative	Anti-RBD IgG	Age $\geq$ 65 Female	D29 vs. Baseline	190.96	(190.96, 190.96)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Female	D29 vs. Baseline	17.57	(17.57, 17.57)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Female	D29 vs. Baseline	16.98	(16.98, 16.98)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Female	D29 vs. Baseline	12.34	(12.34, 12.34)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Female	D29 vs. Baseline	13.53	(13.53, 13.53)
Negative	Anti-Spike IgG	Age $\geq$ 65 Female	D57 vs. D29	5.76	(5.76, 5.76)
Negative	Anti-RBD IgG	Age $\geq$ 65 Female	D57 vs. D29	4.94	(4.94, 4.94)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Female	D57 vs. D29	3.67	(3.67, 3.67)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Female	D57 vs. D29	4.07	(4.07, 4.07)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Female	D57 vs. D29	4.39	(4.39, 4.39)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Female	D57 vs. D29	3.57	(3.57, 3.57)
Negative	Anti-Spike IgG	Age $\geq$ 65 Male	D57 vs. Baseline	6052.49	(6052.49, 6052.49)
Negative	Anti-RBD IgG	Age $\geq$ 65 Male	D57 vs. Baseline	4070.75	(4070.75, 4070.75)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Male	D57 vs. Baseline	198.21	(198.21, 198.21)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Male	D57 vs. Baseline	149.42	(149.42, 149.42)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Male	D57 vs. Baseline	144.52	(144.52, 144.52)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Male	D57 vs. Baseline	104.90	(104.90, 104.90)
Negative	Anti-Spike IgG	Age $\geq$ 65 Male	D29 vs. Baseline	781.02	(781.02, 781.02)
Negative	Anti-RBD IgG	Age $\geq$ 65 Male	D29 vs. Baseline	462.43	(462.43, 462.43)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Age $\geq$ 65 Male	D29 vs. Baseline	38.92	(38.92, 38.92)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Male	D29 vs. Baseline	31.10	(31.10, 31.10)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Male	D29 vs. Baseline	24.23	(24.23, 24.23)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Male	D29 vs. Baseline	23.87	(23.87, 23.87)
Negative	Anti-Spike IgG	Age $\geq$ 65 Male	D57 vs. D29	7.75	(7.75, 7.75)
Negative	Anti-RBD IgG	Age $\geq$ 65 Male	D57 vs. D29	8.80	(8.80, 8.80)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Male	D57 vs. D29	5.09	(5.09, 5.09)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Male	D57 vs. D29	4.80	(4.80, 4.80)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Male	D57 vs. D29	5.96	(5.96, 5.96)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Male	D57 vs. D29	4.40	(4.40, 4.40)
Negative	Anti-Spike IgG	Hispanic or Latino	D57 vs. Baseline	1149.37	(218.43, 6048.01)
Negative	Anti-RBD IgG	Hispanic or Latino	D57 vs. Baseline	1020.95	(362.03, 2879.10)
Negative	Pseudo nAb ID50	Hispanic or Latino	D57 vs. Baseline	58.60	(24.66, 139.26)
Negative	Live Virus nAb ID50	Hispanic or Latino	D57 vs. Baseline	42.22	(17.09, 104.27)
Negative	Pseudo nAb ID80	Hispanic or Latino	D57 vs. Baseline	35.06	(14.58, 84.32)
Negative	Live Virus nAb ID80	Hispanic or Latino	D57 vs. Baseline	38.05	(16.92, 85.60)
Negative	Anti-Spike IgG	Hispanic or Latino	D29 vs. Baseline	145.17	(30.89, 682.18)
Negative	Anti-RBD IgG	Hispanic or Latino	D29 vs. Baseline	119.78	(54.57, 262.92)
Negative	Pseudo nAb ID50	Hispanic or Latino	D29 vs. Baseline	13.80	(7.62, 25.02)
Negative	Live Virus nAb ID50	Hispanic or Latino	D29 vs. Baseline	14.70	(7.40, 29.19)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Hispanic or Latino	D29 vs. Baseline	7.11	(3.12, 16.17)
Negative	Live Virus nAb ID80	Hispanic or Latino	D29 vs. Baseline	13.25	(8.45, 20.76)
Negative	Anti-Spike IgG	Hispanic or Latino	D57 vs. D29	7.92	(6.67, 9.39)
Negative	Anti-RBD IgG	Hispanic or Latino	D57 vs. D29	8.52	(6.58, 11.04)
Negative	Pseudo nAb ID50	Hispanic or Latino	D57 vs. D29	4.25	(2.86, 6.29)
Negative	Live Virus nAb ID50	Hispanic or Latino	D57 vs. D29	2.87	(2.30, 3.59)
Negative	Pseudo nAb ID80	Hispanic or Latino	D57 vs. D29	4.93	(4.65, 5.24)
Negative	Live Virus nAb ID80	Hispanic or Latino	D57 vs. D29	2.87	(1.85, 4.45)
Negative	Anti-Spike IgG	Not Hispanic or Latino	D57 vs. Baseline	2955.05	(1399.48, 6239.70)
Negative	Anti-RBD IgG	Not Hispanic or Latino	D57 vs. Baseline	1617.33	(1030.83, 2537.53)
Negative	Pseudo nAb ID50	Not Hispanic or Latino	D57 vs. Baseline	68.93	(48.11, 98.78)
Negative	Live Virus nAb ID50	Not Hispanic or Latino	D57 vs. Baseline	74.53	(59.38, 93.54)
Negative	Pseudo nAb ID80	Not Hispanic or Latino	D57 vs. Baseline	49.44	(35.06, 69.71)
Negative	Live Virus nAb ID80	Not Hispanic or Latino	D57 vs. Baseline	53.74	(42.82, 67.46)
Negative	Anti-Spike IgG	Not Hispanic or Latino	D29 vs. Baseline	364.70	(223.57, 594.94)
Negative	Anti-RBD IgG	Not Hispanic or Latino	D29 vs. Baseline	202.91	(144.15, 285.64)
Negative	Pseudo nAb ID50	Not Hispanic or Latino	D29 vs. Baseline	16.10	(11.39, 22.75)
Negative	Live Virus nAb ID50	Not Hispanic or Latino	D29 vs. Baseline	16.55	(13.38, 20.47)
Negative	Pseudo nAb ID80	Not Hispanic or Latino	D29 vs. Baseline	10.64	(7.61, 14.89)
Negative	Live Virus nAb ID80	Not Hispanic or Latino	D29 vs. Baseline	12.23	(9.83, 15.23)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Not Hispanic or Latino	D57 vs. D29	8.10	(6.14, 10.70)
Negative	Anti-RBD IgG	Not Hispanic or Latino	D57 vs. D29	7.97	(6.69, 9.50)
Negative	Pseudo nAb ID50	Not Hispanic or Latino	D57 vs. D29	4.28	(4.22, 4.34)
Negative	Live Virus nAb ID50	Not Hispanic or Latino	D57 vs. D29	4.50	(4.43, 4.58)
Negative	Pseudo nAb ID80	Not Hispanic or Latino	D57 vs. D29	4.64	(4.50, 4.80)
Negative	Live Virus nAb ID80	Not Hispanic or Latino	D57 vs. D29	4.39	(3.99, 4.84)
Negative	Anti-Spike IgG	American Indian or Alaska Native	D57 vs. Baseline	5142.84	(2.45, 10815120.25)
Negative	Anti-RBD IgG	American Indian or Alaska Native	D57 vs. Baseline	4398.66	(1.45, 13372734.93)
Negative	Pseudo nAb ID50	American Indian or Alaska Native	D57 vs. Baseline	66.03	(0.84, 5195.38)
Negative	Live Virus nAb ID50	American Indian or Alaska Native	D57 vs. Baseline	135.15	(1.18, 15455.23)
Negative	Pseudo nAb ID80	American Indian or Alaska Native	D57 vs. Baseline	68.45	(1.86, 2512.96)
Negative	Live Virus nAb ID80	American Indian or Alaska Native	D57 vs. Baseline	91.29	(1.49, 5599.74)
Negative	Anti-Spike IgG	American Indian or Alaska Native	D29 vs. Baseline	530.22	(4.16, 67554.52)
Negative	Anti-RBD IgG	American Indian or Alaska Native	D29 vs. Baseline	392.93	(1.84, 83727.06)
Negative	Pseudo nAb ID50	American Indian or Alaska Native	D29 vs. Baseline	16.54	(2.28, 119.80)
Negative	Live Virus nAb ID50	American Indian or Alaska Native	D29 vs. Baseline	35.65	(2.35, 541.24)
Negative	Pseudo nAb ID80	American Indian or Alaska Native	D29 vs. Baseline	9.27	(2.04, 42.23)
Negative	Live Virus nAb ID80	American Indian or Alaska Native	D29 vs. Baseline	26.46	(2.21, 316.92)
Negative	Anti-Spike IgG	American Indian or Alaska Native	D57 vs. D29	9.70	(0.57, 165.65)
Negative	Anti-RBD IgG	American Indian or Alaska Native	D57 vs. D29	11.19	(0.77, 161.97)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	American Indian or Alaska Native	D57 vs. D29	3.99	(0.37, 43.52)
Negative	Live Virus nAb ID50	American Indian or Alaska Native	D57 vs. D29	3.79	(0.48, 29.84)
Negative	Pseudo nAb ID80	American Indian or Alaska Native	D57 vs. D29	7.38	(0.89, 61.03)
Negative	Live Virus nAb ID80	American Indian or Alaska Native	D57 vs. D29	3.45	(0.67, 17.67)
Negative	Anti-Spike IgG	Asian	D57 vs. Baseline	542.14	(494.50, 594.37)
Negative	Anti-RBD IgG	Asian	D57 vs. Baseline	500.61	(428.99, 584.19)
Negative	Pseudo nAb ID50	Asian	D57 vs. Baseline	30.88	(22.41, 42.56)
Negative	Live Virus nAb ID50	Asian	D57 vs. Baseline	22.91	(19.33, 27.16)
Negative	Pseudo nAb ID80	Asian	D57 vs. Baseline	20.55	(14.28, 29.56)
Negative	Live Virus nAb ID80	Asian	D57 vs. Baseline	29.58	(23.40, 37.38)
Negative	Anti-Spike IgG	Asian	D29 vs. Baseline	139.62	(108.18, 180.20)
Negative	Anti-RBD IgG	Asian	D29 vs. Baseline	90.79	(84.01, 98.12)
Negative	Pseudo nAb ID50	Asian	D29 vs. Baseline	7.38	(5.29, 10.30)
Negative	Live Virus nAb ID50	Asian	D29 vs. Baseline	9.68	(7.03, 13.31)
Negative	Pseudo nAb ID80	Asian	D29 vs. Baseline	5.98	(4.28, 8.35)
Negative	Live Virus nAb ID80	Asian	D29 vs. Baseline	7.67	(5.86, 10.04)
Negative	Anti-Spike IgG	Asian	D57 vs. D29	3.88	(3.14, 4.80)
Negative	Anti-RBD IgG	Asian	D57 vs. D29	5.51	(4.96, 6.13)
Negative	Pseudo nAb ID50	Asian	D57 vs. D29	4.18	(3.24, 5.40)
Negative	Live Virus nAb ID50	Asian	D57 vs. D29	2.37	(1.99, 2.81)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Asian	D57 vs. D29	3.44	(2.37, 4.99)
Negative	Live Virus nAb ID80	Asian	D57 vs. D29	3.86	(3.57, 4.16)
Negative	Anti-Spike IgG	Black or African American	D57 vs. Baseline	7322.73	(3657.47, 14661.05)
Negative	Anti-RBD IgG	Black or African American	D57 vs. Baseline	3453.45	(2342.17, 5091.98)
Negative	Pseudo nAb ID50	Black or African American	D57 vs. Baseline	122.29	(80.11, 186.69)
Negative	Live Virus nAb ID50	Black or African American	D57 vs. Baseline	105.70	(77.87, 143.46)
Negative	Pseudo nAb ID80	Black or African American	D57 vs. Baseline	88.92	(60.10, 131.54)
Negative	Live Virus nAb ID80	Black or African American	D57 vs. Baseline	70.76	(53.61, 93.40)
Negative	Anti-Spike IgG	Black or African American	D29 vs. Baseline	657.05	(384.13, 1123.87)
Negative	Anti-RBD IgG	Black or African American	D29 vs. Baseline	321.48	(211.62, 488.37)
Negative	Pseudo nAb ID50	Black or African American	D29 vs. Baseline	22.55	(15.80, 32.19)
Negative	Live Virus nAb ID50	Black or African American	D29 vs. Baseline	22.64	(16.57, 30.94)
Negative	Pseudo nAb ID80	Black or African American	D29 vs. Baseline	12.33	(8.67, 17.53)
Negative	Live Virus nAb ID80	Black or African American	D29 vs. Baseline	15.63	(12.27, 19.92)
Negative	Anti-Spike IgG	Black or African American	D57 vs. D29	11.14	(8.92, 13.92)
Negative	Anti-RBD IgG	Black or African American	D57 vs. D29	10.74	(9.97, 11.57)
Negative	Pseudo nAb ID50	Black or African American	D57 vs. D29	5.42	(5.04, 5.83)
Negative	Live Virus nAb ID50	Black or African American	D57 vs. D29	4.67	(3.56, 6.12)
Negative	Pseudo nAb ID80	Black or African American	D57 vs. D29	7.21	(6.54, 7.95)
Negative	Live Virus nAb ID80	Black or African American	D57 vs. D29	4.53	(3.69, 5.56)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Multiracial	D57 vs. Baseline	240.75	(11.38, 5091.36)
Negative	Anti-RBD IgG	Multiracial	D57 vs. Baseline	234.79	(18.40, 2995.19)
Negative	Pseudo nAb ID50	Multiracial	D57 vs. Baseline	24.67	(4.30, 141.60)
Negative	Live Virus nAb ID50	Multiracial	D57 vs. Baseline	10.69	(2.11, 54.07)
Negative	Pseudo nAb ID80	Multiracial	D57 vs. Baseline	20.22	(5.77, 70.87)
Negative	Live Virus nAb ID80	Multiracial	D57 vs. Baseline	13.48	(3.43, 53.02)
Negative	Anti-Spike IgG	Multiracial	D29 vs. Baseline	51.30	(4.89, 537.68)
Negative	Anti-RBD IgG	Multiracial	D29 vs. Baseline	24.30	(2.72, 217.06)
Negative	Pseudo nAb ID50	Multiracial	D29 vs. Baseline	7.87	(2.87, 21.63)
Negative	Live Virus nAb ID50	Multiracial	D29 vs. Baseline	10.02	(4.20, 23.93)
Negative	Pseudo nAb ID80	Multiracial	D29 vs. Baseline	5.45	(2.27, 13.08)
Negative	Live Virus nAb ID80	Multiracial	D29 vs. Baseline	9.99	(5.65, 17.67)
Negative	Anti-Spike IgG	Multiracial	D57 vs. D29	4.69	(2.30, 9.58)
Negative	Anti-RBD IgG	Multiracial	D57 vs. D29	9.66	(6.72, 13.90)
Negative	Pseudo nAb ID50	Multiracial	D57 vs. D29	3.13	(1.49, 6.57)
Negative	Live Virus nAb ID50	Multiracial	D57 vs. D29	1.07	(0.49, 2.32)
Negative	Pseudo nAb ID80	Multiracial	D57 vs. D29	3.71	(2.54, 5.42)
Negative	Live Virus nAb ID80	Multiracial	D57 vs. D29	1.35	(0.59, 3.08)
Negative	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	657.87	(6.03, 71815.85)
Negative	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	85.57	(0.23, 32151.90)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	8.78	(0.44, 174.52)
Negative	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	31.28	(2.22, 441.24)
Negative	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	13.73	(0.95, 198.48)
Negative	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	21.77	(1.65, 287.94)
Negative	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	138.69	(4.62, 4165.43)
Negative	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	62.86	(0.99, 3978.30)
Negative	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	13.92	(2.28, 85.05)
Negative	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	10.87	(3.06, 38.59)
Negative	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	10.93	(1.87, 63.83)
Negative	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	11.43	(3.55, 36.82)
Negative	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D57 vs. D29	4.74	(1.30, 17.24)
Negative	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D57 vs. D29	1.36	(0.23, 8.09)
Negative	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. D29	0.63	(0.19, 2.08)
Negative	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. D29	2.88	(0.72, 11.44)
Negative	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. D29	1.26	(0.50, 3.18)
Negative	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. D29	1.90	(0.46, 7.83)
Negative	Anti-Spike IgG	Not reported and unknown	D57 vs. Baseline	898.80	(666.66, 1211.78)
Negative	Anti-RBD IgG	Not reported and unknown	D57 vs. Baseline	418.47	(255.82, 684.51)
Negative	Pseudo nAb ID50	Not reported and unknown	D57 vs. Baseline	44.02	(29.03, 66.73)
Negative	Live Virus nAb ID50	Not reported and unknown	D57 vs. Baseline	36.98	(24.97, 54.78)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Not reported and unknown	D57 vs. Baseline	27.55	(19.82, 38.28)
Negative	Live Virus nAb ID80	Not reported and unknown	D57 vs. Baseline	41.53	(30.26, 57.01)
Negative	Anti-Spike IgG	Not reported and unknown	D29 vs. Baseline	148.04	(124.26, 176.37)
Negative	Anti-RBD IgG	Not reported and unknown	D29 vs. Baseline	66.02	(37.25, 117.01)
Negative	Pseudo nAb ID50	Not reported and unknown	D29 vs. Baseline	12.01	(10.11, 14.26)
Negative	Live Virus nAb ID50	Not reported and unknown	D29 vs. Baseline	10.79	(9.57, 12.17)
Negative	Pseudo nAb ID80	Not reported and unknown	D29 vs. Baseline	8.67	(6.91, 10.88)
Negative	Live Virus nAb ID80	Not reported and unknown	D29 vs. Baseline	10.30	(8.93, 11.89)
Negative	Anti-Spike IgG	Not reported and unknown	D57 vs. D29	6.07	(4.74, 7.78)
Negative	Anti-RBD IgG	Not reported and unknown	D57 vs. D29	6.34	(4.94, 8.14)
Negative	Pseudo nAb ID50	Not reported and unknown	D57 vs. D29	3.66	(2.65, 5.06)
Negative	Live Virus nAb ID50	Not reported and unknown	D57 vs. D29	3.43	(2.57, 4.56)
Negative	Pseudo nAb ID80	Not reported and unknown	D57 vs. D29	3.18	(2.65, 3.82)
Negative	Live Virus nAb ID80	Not reported and unknown	D57 vs. D29	4.03	(3.37, 4.82)
Negative	Anti-Spike IgG	Other	D57 vs. Baseline	354735.73	(37240.06, 3379087.78)
Negative	Anti-RBD IgG	Other	D57 vs. Baseline	262653.16	(15807.86, 4364075.78)
Negative	Pseudo nAb ID50	Other	D57 vs. Baseline	1609.92	(271.31, 9553.13)
Negative	Live Virus nAb ID50	Other	D57 vs. Baseline	951.29	(507.51, 1783.12)
Negative	Pseudo nAb ID80	Other	D57 vs. Baseline	1072.56	(160.30, 7176.54)
Negative	Live Virus nAb ID80	Other	D57 vs. Baseline	701.25	(325.09, 1512.66)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Other	D29 vs. Baseline	9991.61	(2639.48, 37822.72)
Negative	Anti-RBD IgG	Other	D29 vs. Baseline	5525.63	(1101.46, 27720.22)
Negative	Pseudo nAb ID50	Other	D29 vs. Baseline	184.62	(52.91, 644.22)
Negative	Live Virus nAb ID50	Other	D29 vs. Baseline	110.26	(54.39, 223.55)
Negative	Pseudo nAb ID80	Other	D29 vs. Baseline	86.50	(41.20, 181.60)
Negative	Live Virus nAb ID80	Other	D29 vs. Baseline	55.52	(31.38, 98.24)
Negative	Anti-Spike IgG	Other	D57 vs. D29	35.50	(14.11, 89.35)
Negative	Anti-RBD IgG	Other	D57 vs. D29	47.53	(14.09, 160.31)
Negative	Pseudo nAb ID50	Other	D57 vs. D29	8.72	(5.11, 14.89)
Negative	Live Virus nAb ID50	Other	D57 vs. D29	8.63	(7.17, 10.38)
Negative	Pseudo nAb ID80	Other	D57 vs. D29	12.40	(3.89, 39.52)
Negative	Live Virus nAb ID80	Other	D57 vs. D29	12.63	(10.35, 15.41)
Negative	Anti-Spike IgG	White	D57 vs. Baseline	2706.36	(1252.22, 5849.13)
Negative	Anti-RBD IgG	White	D57 vs. Baseline	2335.33	(987.03, 5525.44)
Negative	Pseudo nAb ID50	White	D57 vs. Baseline	72.44	(32.87, 159.66)
Negative	Live Virus nAb ID50	White	D57 vs. Baseline	96.38	(61.31, 151.53)
Negative	Pseudo nAb ID80	White	D57 vs. Baseline	85.99	(53.01, 139.47)
Negative	Live Virus nAb ID80	White	D57 vs. Baseline	74.85	(45.94, 121.95)
Negative	Anti-Spike IgG	White	D29 vs. Baseline	273.50	(101.43, 737.47)
Negative	Anti-RBD IgG	White	D29 vs. Baseline	379.41	(216.77, 664.06)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	White	D29 vs. Baseline	11.64	(4.23, 32.05)
Negative	Live Virus nAb ID50	White	D29 vs. Baseline	19.60	(16.56, 23.20)
Negative	Pseudo nAb ID80	White	D29 vs. Baseline	11.74	(6.36, 21.66)
Negative	Live Virus nAb ID80	White	D29 vs. Baseline	15.86	(10.49, 23.96)
Negative	Anti-Spike IgG	White	D57 vs. D29	9.90	(7.35, 13.32)
Negative	Anti-RBD IgG	White	D57 vs. D29	6.16	(4.55, 8.33)
Negative	Pseudo nAb ID50	White	D57 vs. D29	6.23	(3.44, 11.26)
Negative	Live Virus nAb ID50	White	D57 vs. D29	4.92	(3.46, 6.99)
Negative	Pseudo nAb ID80	White	D57 vs. D29	7.32	(4.64, 11.57)
Negative	Live Virus nAb ID80	White	D57 vs. D29	4.72	(3.85, 5.79)
Negative	Anti-Spike IgG	White Non-Hispanic	D57 vs. Baseline	2216.21	(1101.03, 4460.92)
Negative	Anti-RBD IgG	White Non-Hispanic	D57 vs. Baseline	1440.93	(709.69, 2925.61)
Negative	Pseudo nAb ID50	White Non-Hispanic	D57 vs. Baseline	57.22	(36.62, 89.39)
Negative	Live Virus nAb ID50	White Non-Hispanic	D57 vs. Baseline	76.39	(57.87, 100.84)
Negative	Pseudo nAb ID80	White Non-Hispanic	D57 vs. Baseline	43.43	(27.31, 69.05)
Negative	Live Virus nAb ID80	White Non-Hispanic	D57 vs. Baseline	47.82	(36.40, 62.80)
Negative	Anti-Spike IgG	White Non-Hispanic	D29 vs. Baseline	296.59	(182.23, 482.72)
Negative	Anti-RBD IgG	White Non-Hispanic	D29 vs. Baseline	199.50	(117.59, 338.48)
Negative	Pseudo nAb ID50	White Non-Hispanic	D29 vs. Baseline	14.67	(9.59, 22.44)
Negative	Live Virus nAb ID50	White Non-Hispanic	D29 vs. Baseline	15.18	(11.50, 20.04)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	White Non-Hispanic	D29 vs. Baseline	10.20	(6.78, 15.34)
Negative	Live Virus nAb ID80	White Non-Hispanic	D29 vs. Baseline	11.22	(8.53, 14.75)
Negative	Anti-Spike IgG	White Non-Hispanic	D57 vs. D29	7.47	(5.85, 9.54)
Negative	Anti-RBD IgG	White Non-Hispanic	D57 vs. D29	7.22	(5.83, 8.95)
Negative	Pseudo nAb ID50	White Non-Hispanic	D57 vs. D29	3.90	(3.78, 4.03)
Negative	Live Virus nAb ID50	White Non-Hispanic	D57 vs. D29	5.03	(4.69, 5.40)
Negative	Pseudo nAb ID80	White Non-Hispanic	D57 vs. D29	4.26	(3.95, 4.59)
Negative	Live Virus nAb ID80	White Non-Hispanic	D57 vs. D29	4.26	(3.63, 5.00)
Negative	Anti-Spike IgG	White Non-Hispanic	D57 vs. Baseline	2216.21	(1101.03, 4460.92)
Negative	Anti-RBD IgG	White Non-Hispanic	D57 vs. Baseline	1440.93	(709.69, 2925.61)
Negative	Pseudo nAb ID50	White Non-Hispanic	D57 vs. Baseline	57.22	(36.62, 89.39)
Negative	Live Virus nAb ID50	White Non-Hispanic	D57 vs. Baseline	76.39	(57.87, 100.84)
Negative	Pseudo nAb ID80	White Non-Hispanic	D57 vs. Baseline	43.43	(27.31, 69.05)
Negative	Live Virus nAb ID80	White Non-Hispanic	D57 vs. Baseline	47.82	(36.40, 62.80)
Negative	Anti-Spike IgG	White Non-Hispanic	D29 vs. Baseline	296.59	(182.23, 482.72)
Negative	Anti-RBD IgG	White Non-Hispanic	D29 vs. Baseline	199.50	(117.59, 338.48)
Negative	Pseudo nAb ID50	White Non-Hispanic	D29 vs. Baseline	14.67	(9.59, 22.44)
Negative	Live Virus nAb ID50	White Non-Hispanic	D29 vs. Baseline	15.18	(11.50, 20.04)
Negative	Pseudo nAb ID80	White Non-Hispanic	D29 vs. Baseline	10.20	(6.78, 15.34)
Negative	Live Virus nAb ID80	White Non-Hispanic	D29 vs. Baseline	11.22	(8.53, 14.75)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	White Non-Hispanic	D57 vs. D29	7.47	(5.85, 9.54)
Negative	Anti-RBD IgG	White Non-Hispanic	D57 vs. D29	7.22	(5.83, 8.95)
Negative	Pseudo nAb ID50	White Non-Hispanic	D57 vs. D29	3.90	(3.78, 4.03)
Negative	Live Virus nAb ID50	White Non-Hispanic	D57 vs. D29	5.03	(4.69, 5.40)
Negative	Pseudo nAb ID80	White Non-Hispanic	D57 vs. D29	4.26	(3.95, 4.59)
Negative	Live Virus nAb ID80	White Non-Hispanic	D57 vs. D29	4.26	(3.63, 5.00)
Negative	Anti-Spike IgG	Communities of Color	D57 vs. Baseline	2084.36	(1721.51, 2523.68)
Negative	Anti-RBD IgG	Communities of Color	D57 vs. Baseline	1194.71	(995.41, 1433.93)
Negative	Pseudo nAb ID50	Communities of Color	D57 vs. Baseline	63.48	(51.77, 77.84)
Negative	Live Virus nAb ID50	Communities of Color	D57 vs. Baseline	52.26	(41.78, 65.37)
Negative	Pseudo nAb ID80	Communities of Color	D57 vs. Baseline	46.12	(35.78, 59.47)
Negative	Live Virus nAb ID80	Communities of Color	D57 vs. Baseline	47.20	(41.10, 54.21)
Negative	Anti-Spike IgG	Communities of Color	D29 vs. Baseline	277.62	(231.85, 332.42)
Negative	Anti-RBD IgG	Communities of Color	D29 vs. Baseline	140.86	(100.71, 197.01)
Negative	Pseudo nAb ID50	Communities of Color	D29 vs. Baseline	15.03	(12.78, 17.69)
Negative	Live Virus nAb ID50	Communities of Color	D29 vs. Baseline	16.00	(14.38, 17.80)
Negative	Pseudo nAb ID80	Communities of Color	D29 vs. Baseline	9.61	(7.82, 11.82)
Negative	Live Virus nAb ID80	Communities of Color	D29 vs. Baseline	12.80	(10.97, 14.94)
Negative	Anti-Spike IgG	Communities of Color	D57 vs. D29	7.51	(6.52, 8.65)
Negative	Anti-RBD IgG	Communities of Color	D57 vs. D29	8.48	(7.28, 9.89)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Communities of Color	D57 vs. D29	4.22	(3.71, 4.80)
Negative	Live Virus nAb ID50	Communities of Color	D57 vs. D29	3.27	(2.69, 3.97)
Negative	Pseudo nAb ID80	Communities of Color	D57 vs. D29	4.80	(4.39, 5.25)
Negative	Live Virus nAb ID80	Communities of Color	D57 vs. D29	3.69	(3.26, 4.17)
Negative	Anti-Spike IgG	Age < 65 Communities of Color	D57 vs. Baseline	1999.47	(1576.60, 2535.75)
Negative	Anti-RBD IgG	Age < 65 Communities of Color	D57 vs. Baseline	1117.09	(1084.49, 1150.66)
Negative	Pseudo nAb ID50	Age < 65 Communities of Color	D57 vs. Baseline	58.46	(56.30, 60.71)
Negative	Live Virus nAb ID50	Age < 65 Communities of Color	D57 vs. Baseline	47.81	(46.82, 48.83)
Negative	Pseudo nAb ID80	Age < 65 Communities of Color	D57 vs. Baseline	41.68	(40.41, 42.98)
Negative	Live Virus nAb ID80	Age < 65 Communities of Color	D57 vs. Baseline	44.71	(40.32, 49.57)
Negative	Anti-Spike IgG	Age < 65 Communities of Color	D29 vs. Baseline	258.36	(228.46, 292.17)
Negative	Anti-RBD IgG	Age < 65 Communities of Color	D29 vs. Baseline	124.30	(119.07, 129.75)
Negative	Pseudo nAb ID50	Age < 65 Communities of Color	D29 vs. Baseline	14.18	(12.17, 16.51)
Negative	Live Virus nAb ID50	Age < 65 Communities of Color	D29 vs. Baseline	15.51	(13.72, 17.54)
Negative	Pseudo nAb ID80	Age < 65 Communities of Color	D29 vs. Baseline	8.83	(7.92, 9.86)
Negative	Live Virus nAb ID80	Age < 65 Communities of Color	D29 vs. Baseline	12.48	(10.25, 15.19)
Negative	Anti-Spike IgG	Age < 65 Communities of Color	D57 vs. D29	7.74	(6.90, 8.68)
Negative	Anti-RBD IgG	Age < 65 Communities of Color	D57 vs. D29	8.99	(8.87, 9.11)
Negative	Pseudo nAb ID50	Age < 65 Communities of Color	D57 vs. D29	4.12	(3.68, 4.63)
Negative	Live Virus nAb ID50	Age < 65 Communities of Color	D57 vs. D29	3.08	(2.78, 3.41)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID80	Age < 65 Communities of Color	D57 vs. D29	4.72	(4.36, 5.10)
Negative	Live Virus nAb ID80	Age < 65 Communities of Color	D57 vs. D29	3.58	(3.26, 3.93)
Negative	Anti-Spike IgG	Age < 65 White Non-Hispanic	D57 vs. Baseline	2158.00	(928.42, 5016.01)
Negative	Anti-RBD IgG	Age < 65 White Non-Hispanic	D57 vs. Baseline	1396.38	(592.76, 3289.47)
Negative	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D57 vs. Baseline	50.93	(30.61, 84.73)
Negative	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D57 vs. Baseline	71.74	(51.61, 99.71)
Negative	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D57 vs. Baseline	38.49	(22.66, 65.38)
Negative	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D57 vs. Baseline	44.58	(32.60, 60.95)
Negative	Anti-Spike IgG	Age < 65 White Non-Hispanic	D29 vs. Baseline	279.91	(153.31, 511.03)
Negative	Anti-RBD IgG	Age < 65 White Non-Hispanic	D29 vs. Baseline	187.27	(97.43, 359.93)
Negative	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D29 vs. Baseline	13.04	(8.13, 20.92)
Negative	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D29 vs. Baseline	13.96	(10.39, 18.74)
Negative	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D29 vs. Baseline	9.31	(5.73, 15.12)
Negative	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D29 vs. Baseline	10.10	(8.35, 12.21)
Negative	Anti-Spike IgG	Age < 65 White Non-Hispanic	D57 vs. D29	7.71	(6.06, 9.82)
Negative	Anti-RBD IgG	Age < 65 White Non-Hispanic	D57 vs. D29	7.46	(6.08, 9.14)
Negative	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D57 vs. D29	3.91	(3.77, 4.05)
Negative	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D57 vs. D29	5.14	(4.97, 5.32)
Negative	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D57 vs. D29	4.13	(3.95, 4.32)
Negative	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D57 vs. D29	4.41	(3.90, 4.99)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Anti-Spike IgG	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	2549.40	(2549.40, 2549.40)
Negative	Anti-RBD IgG	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	1654.18	(1654.18, 1654.18)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	94.55	(94.55, 94.55)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	80.36	(80.36, 80.36)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	75.37	(75.37, 75.37)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	61.42	(61.42, 61.42)
Negative	Anti-Spike IgG	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	393.27	(393.27, 393.27)
Negative	Anti-RBD IgG	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	258.18	(258.18, 258.18)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	19.99	(19.99, 19.99)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	18.58	(18.58, 18.58)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	14.47	(14.47, 14.47)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	14.49	(14.49, 14.49)
Negative	Anti-Spike IgG	Age $\geq$ 65 Communities of Color	D57 vs. D29	6.48	(6.48, 6.48)
Negative	Anti-RBD IgG	Age $\geq$ 65 Communities of Color	D57 vs. D29	6.41	(6.41, 6.41)
Negative	Pseudo nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. D29	4.73	(4.73, 4.73)
Negative	Live Virus nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. D29	4.33	(4.33, 4.33)
Negative	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. D29	5.21	(5.21, 5.21)
Negative	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. D29	4.24	(4.24, 4.24)
Negative	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	2581.95	(2581.95, 2581.95)
Negative	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	1725.43	(1725.43, 1725.43)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Negative	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	111.63	(111.63, 111.63)
Negative	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	109.59	(109.59, 109.59)
Negative	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	86.76	(86.76, 86.76)
Negative	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	71.48	(71.48, 71.48)
Negative	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	413.49	(413.49, 413.49)
Negative	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	286.85	(286.85, 286.85)
Negative	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	28.86	(28.86, 28.86)
Negative	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	24.55	(24.55, 24.55)
Negative	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	17.22	(17.22, 17.22)
Negative	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	20.51	(20.51, 20.51)
Negative	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	6.24	(6.24, 6.24)
Negative	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	6.02	(6.02, 6.02)
Negative	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	3.87	(3.87, 3.87)
Negative	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	4.46	(4.46, 4.46)
Negative	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	5.04	(5.04, 5.04)
Negative	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	3.48	(3.48, 3.48)
Positive	Anti-Spike IgG	Total	D57 vs. Baseline	2495597.86	(1395967.64, 4461427.68)
Positive	Anti-RBD IgG	Total	D57 vs. Baseline	1289604.60	(770765.88, 2157698.03)
Positive	Pseudo nAb ID50	Total	D57 vs. Baseline	4396.88	(2638.73, 7326.44)
Positive	Live Virus nAb ID50	Total	D57 vs. Baseline	3601.66	(2495.30, 5198.57)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Total	D57 vs. Baseline	1610.72	(934.67, 2775.76)
Positive	Live Virus nAb ID80	Total	D57 vs. Baseline	1834.44	(1283.12, 2622.66)
Positive	Anti-Spike IgG	Total	D29 vs. Baseline	39909.50	(24196.71, 65825.81)
Positive	Anti-RBD IgG	Total	D29 vs. Baseline	20080.73	(11960.52, 33713.89)
Positive	Pseudo nAb ID50	Total	D29 vs. Baseline	220.40	(133.77, 363.13)
Positive	Live Virus nAb ID50	Total	D29 vs. Baseline	217.30	(155.23, 304.21)
Positive	Pseudo nAb ID80	Total	D29 vs. Baseline	92.34	(57.35, 148.68)
Positive	Live Virus nAb ID80	Total	D29 vs. Baseline	112.02	(80.54, 155.81)
Positive	Anti-Spike IgG	Total	D57 vs. D29	62.53	(57.33, 68.21)
Positive	Anti-RBD IgG	Total	D57 vs. D29	64.22	(63.16, 65.30)
Positive	Pseudo nAb ID50	Total	D57 vs. D29	19.95	(15.52, 25.64)
Positive	Live Virus nAb ID50	Total	D57 vs. D29	16.57	(15.65, 17.55)
Positive	Pseudo nAb ID80	Total	D57 vs. D29	17.44	(16.28, 18.69)
Positive	Live Virus nAb ID80	Total	D57 vs. D29	16.38	(15.53, 17.27)
Positive	Anti-Spike IgG	Age < 65	D57 vs. Baseline	1989987.95	(1711960.14, 2313168.35)
Positive	Anti-RBD IgG	Age < 65	D57 vs. Baseline	1059131.73	(993306.23, 1129319.43)
Positive	Pseudo nAb ID50	Age < 65	D57 vs. Baseline	3668.87	(2387.79, 5637.26)
Positive	Live Virus nAb ID50	Age < 65	D57 vs. Baseline	3124.12	(2893.21, 3373.46)
Positive	Pseudo nAb ID80	Age < 65	D57 vs. Baseline	1301.89	(1101.45, 1538.81)
Positive	Live Virus nAb ID80	Age < 65	D57 vs. Baseline	1594.60	(1383.26, 1838.23)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age < 65	D29 vs. Baseline	32892.47	(29957.04, 36115.54)
Positive	Anti-RBD IgG	Age < 65	D29 vs. Baseline	16495.05	(15772.89, 17250.29)
Positive	Pseudo nAb ID50	Age < 65	D29 vs. Baseline	181.28	(154.83, 212.24)
Positive	Live Virus nAb ID50	Age < 65	D29 vs. Baseline	190.46	(168.07, 215.83)
Positive	Pseudo nAb ID80	Age < 65	D29 vs. Baseline	76.67	(67.22, 87.46)
Positive	Live Virus nAb ID80	Age < 65	D29 vs. Baseline	98.52	(90.94, 106.74)
Positive	Anti-Spike IgG	Age < 65	D57 vs. D29	60.50	(57.15, 64.05)
Positive	Anti-RBD IgG	Age < 65	D57 vs. D29	64.21	(62.98, 65.47)
Positive	Pseudo nAb ID50	Age < 65	D57 vs. D29	20.24	(15.42, 26.56)
Positive	Live Virus nAb ID50	Age < 65	D57 vs. D29	16.40	(15.63, 17.21)
Positive	Pseudo nAb ID80	Age < 65	D57 vs. D29	16.98	(16.39, 17.59)
Positive	Live Virus nAb ID80	Age < 65	D57 vs. D29	16.19	(15.21, 17.22)
Positive	Anti-Spike IgG	Age ≥ 65	D57 vs. Baseline	11011423.72	(11011423.72, 11011423.72)
Positive	Anti-RBD IgG	Age ≥ 65	D57 vs. Baseline	4689064.67	(4689064.67, 4689064.67)
Positive	Pseudo nAb ID50	Age ≥ 65	D57 vs. Baseline	14406.96	(14406.96, 14406.96)
Positive	Live Virus nAb ID50	Age ≥ 65	D57 vs. Baseline	9152.49	(9152.49, 9152.49)
Positive	Pseudo nAb ID80	Age ≥ 65	D57 vs. Baseline	6503.45	(6503.45, 6503.45)
Positive	Live Virus nAb ID80	Age ≥ 65	D57 vs. Baseline	4597.18	(4597.18, 4597.18)
Positive	Anti-Spike IgG	Age ≥ 65	D29 vs. Baseline	141806.14	(141806.14, 141806.14)
Positive	Anti-RBD IgG	Age ≥ 65	D29 vs. Baseline	72925.44	(72925.44, 72925.44)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Age $\geq 65$	D29 vs. Baseline	793.55	(793.55, 793.55)
Positive	Live Virus nAb ID50	Age $\geq 65$	D29 vs. Baseline	515.90	(515.90, 515.90)
Positive	Pseudo nAb ID80	Age $\geq 65$	D29 vs. Baseline	312.43	(312.43, 312.43)
Positive	Live Virus nAb ID80	Age $\geq 65$	D29 vs. Baseline	259.93	(259.93, 259.93)
Positive	Anti-Spike IgG	Age $\geq 65$	D57 vs. D29	77.65	(77.65, 77.65)
Positive	Anti-RBD IgG	Age $\geq 65$	D57 vs. D29	64.30	(64.30, 64.30)
Positive	Pseudo nAb ID50	Age $\geq 65$	D57 vs. D29	18.16	(18.16, 18.16)
Positive	Live Virus nAb ID50	Age $\geq 65$	D57 vs. D29	17.74	(17.74, 17.74)
Positive	Pseudo nAb ID80	Age $\geq 65$	D57 vs. D29	20.82	(20.82, 20.82)
Positive	Live Virus nAb ID80	Age $\geq 65$	D57 vs. D29	17.69	(17.69, 17.69)
Positive	Anti-Spike IgG	At-risk	D57 vs. Baseline	2303219.98	(864956.04, 6133054.21)
Positive	Anti-RBD IgG	At-risk	D57 vs. Baseline	1381499.13	(521177.35, 3661977.73)
Positive	Pseudo nAb ID50	At-risk	D57 vs. Baseline	2887.30	(1066.57, 7816.20)
Positive	Live Virus nAb ID50	At-risk	D57 vs. Baseline	3488.15	(1919.42, 6338.99)
Positive	Pseudo nAb ID80	At-risk	D57 vs. Baseline	1543.09	(509.15, 4676.65)
Positive	Live Virus nAb ID80	At-risk	D57 vs. Baseline	1676.37	(845.94, 3321.98)
Positive	Anti-Spike IgG	At-risk	D29 vs. Baseline	38420.02	(17521.19, 84246.43)
Positive	Anti-RBD IgG	At-risk	D29 vs. Baseline	21955.96	(8442.83, 57097.46)
Positive	Pseudo nAb ID50	At-risk	D29 vs. Baseline	202.99	(81.18, 507.59)
Positive	Live Virus nAb ID50	At-risk	D29 vs. Baseline	201.37	(106.84, 379.52)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	At-risk	D29 vs. Baseline	87.87	(36.45, 211.83)
Positive	Live Virus nAb ID80	At-risk	D29 vs. Baseline	109.60	(60.14, 199.76)
Positive	Anti-Spike IgG	At-risk	D57 vs. D29	59.95	(49.37, 72.80)
Positive	Anti-RBD IgG	At-risk	D57 vs. D29	62.92	(61.73, 64.14)
Positive	Pseudo nAb ID50	At-risk	D57 vs. D29	14.22	(13.14, 15.40)
Positive	Live Virus nAb ID50	At-risk	D57 vs. D29	17.32	(16.70, 17.96)
Positive	Pseudo nAb ID80	At-risk	D57 vs. D29	17.56	(13.97, 22.08)
Positive	Live Virus nAb ID80	At-risk	D57 vs. D29	15.29	(14.07, 16.63)
Positive	Anti-Spike IgG	Not at-risk	D57 vs. Baseline	2554593.26	(1427388.68, 4571947.95)
Positive	Anti-RBD IgG	Not at-risk	D57 vs. Baseline	1264007.71	(798278.11, 2001452.20)
Positive	Pseudo nAb ID50	Not at-risk	D57 vs. Baseline	4969.85	(3229.86, 7647.21)
Positive	Live Virus nAb ID50	Not at-risk	D57 vs. Baseline	3635.42	(2512.34, 5260.53)
Positive	Pseudo nAb ID80	Not at-risk	D57 vs. Baseline	1630.97	(999.20, 2662.21)
Positive	Live Virus nAb ID80	Not at-risk	D57 vs. Baseline	1883.23	(1339.48, 2647.70)
Positive	Anti-Spike IgG	Not at-risk	D29 vs. Baseline	40354.08	(24239.10, 67182.84)
Positive	Anti-RBD IgG	Not at-risk	D29 vs. Baseline	19565.30	(12315.95, 31081.73)
Positive	Pseudo nAb ID50	Not at-risk	D29 vs. Baseline	225.74	(139.33, 365.75)
Positive	Live Virus nAb ID50	Not at-risk	D29 vs. Baseline	222.18	(160.87, 306.85)
Positive	Pseudo nAb ID80	Not at-risk	D29 vs. Baseline	93.68	(59.46, 147.60)
Positive	Live Virus nAb ID80	Not at-risk	D29 vs. Baseline	112.73	(82.26, 154.50)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Not at-risk	D57 vs. D29	63.30	(58.89, 68.05)
Positive	Anti-RBD IgG	Not at-risk	D57 vs. D29	64.60	(64.39, 64.82)
Positive	Pseudo nAb ID50	Not at-risk	D57 vs. D29	22.02	(20.91, 23.18)
Positive	Live Virus nAb ID50	Not at-risk	D57 vs. D29	16.36	(15.62, 17.14)
Positive	Pseudo nAb ID80	Not at-risk	D57 vs. D29	17.41	(16.81, 18.04)
Positive	Live Virus nAb ID80	Not at-risk	D57 vs. D29	16.71	(16.28, 17.14)
Positive	Anti-Spike IgG	Age < 65 At-risk	D57 vs. Baseline	1610970.64	(1610970.64, 1610970.64)
Positive	Anti-RBD IgG	Age < 65 At-risk	D57 vs. Baseline	967885.90	(967885.90, 967885.90)
Positive	Pseudo nAb ID50	Age < 65 At-risk	D57 vs. Baseline	2007.38	(2007.38, 2007.38)
Positive	Live Virus nAb ID50	Age < 65 At-risk	D57 vs. Baseline	2804.83	(2804.83, 2804.83)
Positive	Pseudo nAb ID80	Age < 65 At-risk	D57 vs. Baseline	1029.51	(1029.51, 1029.51)
Positive	Live Virus nAb ID80	Age < 65 At-risk	D57 vs. Baseline	1306.03	(1306.03, 1306.03)
Positive	Anti-Spike IgG	Age < 65 At-risk	D29 vs. Baseline	28846.71	(28846.71, 28846.71)
Positive	Anti-RBD IgG	Age < 65 At-risk	D29 vs. Baseline	15490.16	(15490.16, 15490.16)
Positive	Pseudo nAb ID50	Age < 65 At-risk	D29 vs. Baseline	145.27	(145.27, 145.27)
Positive	Live Virus nAb ID50	Age < 65 At-risk	D29 vs. Baseline	159.78	(159.78, 159.78)
Positive	Pseudo nAb ID80	Age < 65 At-risk	D29 vs. Baseline	63.73	(63.73, 63.73)
Positive	Live Virus nAb ID80	Age < 65 At-risk	D29 vs. Baseline	88.04	(88.04, 88.04)
Positive	Anti-Spike IgG	Age < 65 At-risk	D57 vs. D29	55.85	(55.85, 55.85)
Positive	Anti-RBD IgG	Age < 65 At-risk	D57 vs. D29	62.48	(62.48, 62.48)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Age < 65 At-risk	D57 vs. D29	13.82	(13.82, 13.82)
Positive	Live Virus nAb ID50	Age < 65 At-risk	D57 vs. D29	17.55	(17.55, 17.55)
Positive	Pseudo nAb ID80	Age < 65 At-risk	D57 vs. D29	16.15	(16.15, 16.15)
Positive	Live Virus nAb ID80	Age < 65 At-risk	D57 vs. D29	14.83	(14.83, 14.83)
Positive	Anti-Spike IgG	Age < 65 Not at-risk	D57 vs. Baseline	2104817.23	(2104817.23, 2104817.23)
Positive	Anti-RBD IgG	Age < 65 Not at-risk	D57 vs. Baseline	1084771.52	(1084771.52, 1084771.52)
Positive	Pseudo nAb ID50	Age < 65 Not at-risk	D57 vs. Baseline	4305.96	(4305.96, 4305.96)
Positive	Live Virus nAb ID50	Age < 65 Not at-risk	D57 vs. Baseline	3214.84	(3214.84, 3214.84)
Positive	Pseudo nAb ID80	Age < 65 Not at-risk	D57 vs. Baseline	1385.62	(1385.62, 1385.62)
Positive	Live Virus nAb ID80	Age < 65 Not at-risk	D57 vs. Baseline	1681.40	(1681.40, 1681.40)
Positive	Anti-Spike IgG	Age < 65 Not at-risk	D29 vs. Baseline	34058.90	(34058.90, 34058.90)
Positive	Anti-RBD IgG	Age < 65 Not at-risk	D29 vs. Baseline	16772.65	(16772.65, 16772.65)
Positive	Pseudo nAb ID50	Age < 65 Not at-risk	D29 vs. Baseline	192.25	(192.25, 192.25)
Positive	Live Virus nAb ID50	Age < 65 Not at-risk	D29 vs. Baseline	199.55	(199.55, 199.55)
Positive	Pseudo nAb ID80	Age < 65 Not at-risk	D29 vs. Baseline	80.53	(80.53, 80.53)
Positive	Live Virus nAb ID80	Age < 65 Not at-risk	D29 vs. Baseline	101.51	(101.51, 101.51)
Positive	Anti-Spike IgG	Age < 65 Not at-risk	D57 vs. D29	61.80	(61.80, 61.80)
Positive	Anti-RBD IgG	Age < 65 Not at-risk	D57 vs. D29	64.68	(64.68, 64.68)
Positive	Pseudo nAb ID50	Age < 65 Not at-risk	D57 vs. D29	22.40	(22.40, 22.40)
Positive	Live Virus nAb ID50	Age < 65 Not at-risk	D57 vs. D29	16.11	(16.11, 16.11)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Age < 65 Not at-risk	D57 vs. D29	17.21	(17.21, 17.21)
Positive	Live Virus nAb ID80	Age < 65 Not at-risk	D57 vs. D29	16.56	(16.56, 16.56)
Positive	Anti-Spike IgG	Age ≥ 65 At-risk	D57 vs. Baseline	10273356.42	(10273356.42, 10273356.42)
Positive	Anti-RBD IgG	Age ≥ 65 At-risk	D57 vs. Baseline	6119420.47	(6119420.47, 6119420.47)
Positive	Pseudo nAb ID50	Age ≥ 65 At-risk	D57 vs. Baseline	13206.98	(13206.98, 13206.98)
Positive	Live Virus nAb ID50	Age ≥ 65 At-risk	D57 vs. Baseline	8682.88	(8682.88, 8682.88)
Positive	Pseudo nAb ID80	Age ≥ 65 At-risk	D57 vs. Baseline	8386.36	(8386.36, 8386.36)
Positive	Live Virus nAb ID80	Age ≥ 65 At-risk	D57 vs. Baseline	4762.64	(4762.64, 4762.64)
Positive	Anti-Spike IgG	Age ≥ 65 At-risk	D29 vs. Baseline	127397.12	(127397.12, 127397.12)
Positive	Anti-RBD IgG	Age ≥ 65 At-risk	D29 vs. Baseline	94458.09	(94458.09, 94458.09)
Positive	Pseudo nAb ID50	Age ≥ 65 At-risk	D29 vs. Baseline	822.57	(822.57, 822.57)
Positive	Live Virus nAb ID50	Age ≥ 65 At-risk	D29 vs. Baseline	529.92	(529.92, 529.92)
Positive	Pseudo nAb ID80	Age ≥ 65 At-risk	D29 vs. Baseline	336.72	(336.72, 336.72)
Positive	Live Virus nAb ID80	Age ≥ 65 At-risk	D29 vs. Baseline	274.04	(274.04, 274.04)
Positive	Anti-Spike IgG	Age ≥ 65 At-risk	D57 vs. D29	80.64	(80.64, 80.64)
Positive	Anti-RBD IgG	Age ≥ 65 At-risk	D57 vs. D29	64.78	(64.78, 64.78)
Positive	Pseudo nAb ID50	Age ≥ 65 At-risk	D57 vs. D29	16.06	(16.06, 16.06)
Positive	Live Virus nAb ID50	Age ≥ 65 At-risk	D57 vs. D29	16.39	(16.39, 16.39)
Positive	Pseudo nAb ID80	Age ≥ 65 At-risk	D57 vs. D29	24.91	(24.91, 24.91)
Positive	Live Virus nAb ID80	Age ≥ 65 At-risk	D57 vs. D29	17.38	(17.38, 17.38)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	11392217.18	(11392217.18, 11392217.18)
Positive	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	4115554.74	(4115554.74, 4115554.74)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	15034.18	(15034.18, 15034.18)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	9391.79	(9391.79, 9391.79)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	5741.58	(5741.58, 5741.58)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. Baseline	4518.21	(4518.21, 4518.21)
Positive	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	149450.79	(149450.79, 149450.79)
Positive	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	64242.23	(64242.23, 64242.23)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	779.71	(779.71, 779.71)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	509.17	(509.17, 509.17)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	301.17	(301.17, 301.17)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D29 vs. Baseline	253.29	(253.29, 253.29)
Positive	Anti-Spike IgG	Age $\geq$ 65 Not at-risk	D57 vs. D29	76.23	(76.23, 76.23)
Positive	Anti-RBD IgG	Age $\geq$ 65 Not at-risk	D57 vs. D29	64.06	(64.06, 64.06)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. D29	19.28	(19.28, 19.28)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Not at-risk	D57 vs. D29	18.45	(18.45, 18.45)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. D29	19.06	(19.06, 19.06)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Not at-risk	D57 vs. D29	17.84	(17.84, 17.84)
Positive	Anti-Spike IgG	Female	D57 vs. Baseline	1994970.66	(1097001.56, 3627987.48)
Positive	Anti-RBD IgG	Female	D57 vs. Baseline	1253140.08	(776373.40, 2022686.61)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Female	D57 vs. Baseline	3773.58	(2052.81, 6936.77)
Positive	Live Virus nAb ID50	Female	D57 vs. Baseline	3459.99	(2435.89, 4914.63)
Positive	Pseudo nAb ID80	Female	D57 vs. Baseline	1738.71	(1001.28, 3019.24)
Positive	Live Virus nAb ID80	Female	D57 vs. Baseline	1805.85	(1280.78, 2546.18)
Positive	Anti-Spike IgG	Female	D29 vs. Baseline	35467.09	(22360.82, 56255.30)
Positive	Anti-RBD IgG	Female	D29 vs. Baseline	19295.59	(12101.34, 30766.82)
Positive	Pseudo nAb ID50	Female	D29 vs. Baseline	191.84	(115.02, 319.97)
Positive	Live Virus nAb ID50	Female	D29 vs. Baseline	214.94	(156.51, 295.18)
Positive	Pseudo nAb ID80	Female	D29 vs. Baseline	78.32	(49.01, 125.16)
Positive	Live Virus nAb ID80	Female	D29 vs. Baseline	110.71	(81.23, 150.87)
Positive	Anti-Spike IgG	Female	D57 vs. D29	56.25	(48.90, 64.70)
Positive	Anti-RBD IgG	Female	D57 vs. D29	64.94	(64.11, 65.79)
Positive	Pseudo nAb ID50	Female	D57 vs. D29	19.67	(15.94, 24.27)
Positive	Live Virus nAb ID50	Female	D57 vs. D29	16.10	(15.24, 17.00)
Positive	Pseudo nAb ID80	Female	D57 vs. D29	22.20	(20.16, 24.45)
Positive	Live Virus nAb ID80	Female	D57 vs. D29	16.31	(15.76, 16.88)
Positive	Anti-Spike IgG	Male	D57 vs. Baseline	3345335.86	(1923534.33, 5818077.60)
Positive	Anti-RBD IgG	Male	D57 vs. Baseline	1338937.23	(714968.92, 2507455.74)
Positive	Pseudo nAb ID50	Male	D57 vs. Baseline	5370.77	(3726.55, 7740.46)
Positive	Live Virus nAb ID50	Male	D57 vs. Baseline	3795.89	(2434.24, 5919.23)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Male	D57 vs. Baseline	1457.34	(782.12, 2715.49)
Positive	Live Virus nAb ID80	Male	D57 vs. Baseline	1872.55	(1223.50, 2865.91)
Positive	Anti-Spike IgG	Male	D29 vs. Baseline	46575.02	(26195.49, 82809.39)
Positive	Anti-RBD IgG	Male	D29 vs. Baseline	21156.78	(10976.62, 40778.45)
Positive	Pseudo nAb ID50	Male	D29 vs. Baseline	264.28	(156.76, 445.57)
Positive	Live Virus nAb ID50	Male	D29 vs. Baseline	220.44	(146.42, 331.88)
Positive	Pseudo nAb ID80	Male	D29 vs. Baseline	114.55	(67.70, 193.81)
Positive	Live Virus nAb ID80	Male	D29 vs. Baseline	113.76	(73.13, 176.96)
Positive	Anti-Spike IgG	Male	D57 vs. D29	71.83	(67.14, 76.84)
Positive	Anti-RBD IgG	Male	D57 vs. D29	63.29	(61.08, 65.58)
Positive	Pseudo nAb ID50	Male	D57 vs. D29	20.32	(14.74, 28.01)
Positive	Live Virus nAb ID50	Male	D57 vs. D29	17.22	(15.90, 18.65)
Positive	Pseudo nAb ID80	Male	D57 vs. D29	12.72	(11.54, 14.03)
Positive	Live Virus nAb ID80	Male	D57 vs. D29	16.46	(15.00, 18.06)
Positive	Anti-Spike IgG	Age < 65 Female	D57 vs. Baseline	1583448.00	(1295485.53, 1935419.20)
Positive	Anti-RBD IgG	Age < 65 Female	D57 vs. Baseline	1042591.97	(833613.82, 1303958.74)
Positive	Pseudo nAb ID50	Age < 65 Female	D57 vs. Baseline	3075.67	(1816.10, 5208.84)
Positive	Live Virus nAb ID50	Age < 65 Female	D57 vs. Baseline	3029.47	(2481.31, 3698.73)
Positive	Pseudo nAb ID80	Age < 65 Female	D57 vs. Baseline	1415.31	(997.16, 2008.79)
Positive	Live Virus nAb ID80	Age < 65 Female	D57 vs. Baseline	1593.64	(1248.15, 2034.78)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age < 65 Female	D29 vs. Baseline	29682.88	(24679.85, 35700.12)
Positive	Anti-RBD IgG	Age < 65 Female	D29 vs. Baseline	16126.41	(13029.66, 19959.17)
Positive	Pseudo nAb ID50	Age < 65 Female	D29 vs. Baseline	157.95	(119.30, 209.12)
Positive	Live Virus nAb ID50	Age < 65 Female	D29 vs. Baseline	191.40	(153.41, 238.80)
Positive	Pseudo nAb ID80	Age < 65 Female	D29 vs. Baseline	65.51	(51.00, 84.14)
Positive	Live Virus nAb ID80	Age < 65 Female	D29 vs. Baseline	98.95	(79.18, 123.66)
Positive	Anti-Spike IgG	Age < 65 Female	D57 vs. D29	53.35	(52.49, 54.21)
Positive	Anti-RBD IgG	Age < 65 Female	D57 vs. D29	64.65	(63.98, 65.33)
Positive	Pseudo nAb ID50	Age < 65 Female	D57 vs. D29	19.47	(15.22, 24.91)
Positive	Live Virus nAb ID50	Age < 65 Female	D57 vs. D29	15.83	(15.49, 16.17)
Positive	Pseudo nAb ID80	Age < 65 Female	D57 vs. D29	21.61	(19.55, 23.87)
Positive	Live Virus nAb ID80	Age < 65 Female	D57 vs. D29	16.11	(15.76, 16.45)
Positive	Anti-Spike IgG	Age < 65 Male	D57 vs. Baseline	2711753.41	(2645531.26, 2779633.21)
Positive	Anti-RBD IgG	Age < 65 Male	D57 vs. Baseline	1081948.91	(925814.05, 1264415.28)
Positive	Pseudo nAb ID50	Age < 65 Male	D57 vs. Baseline	4658.57	(3616.64, 6000.67)
Positive	Live Virus nAb ID50	Age < 65 Male	D57 vs. Baseline	3257.02	(2955.03, 3589.88)
Positive	Pseudo nAb ID80	Age < 65 Male	D57 vs. Baseline	1162.66	(1095.48, 1233.96)
Positive	Live Virus nAb ID80	Age < 65 Male	D57 vs. Baseline	1595.89	(1590.07, 1601.74)
Positive	Anti-Spike IgG	Age < 65 Male	D29 vs. Baseline	37799.04	(35746.27, 39969.71)
Positive	Anti-RBD IgG	Age < 65 Male	D29 vs. Baseline	17007.74	(14077.73, 20547.58)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Age < 65 Male	D29 vs. Baseline	218.46	(209.13, 228.20)
Positive	Live Virus nAb ID50	Age < 65 Male	D29 vs. Baseline	189.19	(188.45, 189.94)
Positive	Pseudo nAb ID80	Age < 65 Male	D29 vs. Baseline	94.88	(88.57, 101.65)
Positive	Live Virus nAb ID80	Age < 65 Male	D29 vs. Baseline	97.95	(87.55, 109.57)
Positive	Anti-Spike IgG	Age < 65 Male	D57 vs. D29	71.74	(66.19, 77.76)
Positive	Anti-RBD IgG	Age < 65 Male	D57 vs. D29	63.62	(61.54, 65.76)
Positive	Pseudo nAb ID50	Age < 65 Male	D57 vs. D29	21.32	(15.85, 28.69)
Positive	Live Virus nAb ID50	Age < 65 Male	D57 vs. D29	17.22	(15.68, 18.90)
Positive	Pseudo nAb ID80	Age < 65 Male	D57 vs. D29	12.25	(12.14, 12.37)
Positive	Live Virus nAb ID80	Age < 65 Male	D57 vs. D29	16.29	(14.51, 18.29)
Positive	Anti-Spike IgG	Age >= 65 Female	D57 vs. Baseline	10935892.55	(10935892.55, 10935892.55)
Positive	Anti-RBD IgG	Age >= 65 Female	D57 vs. Baseline	4856556.60	(4856556.60, 4856556.60)
Positive	Pseudo nAb ID50	Age >= 65 Female	D57 vs. Baseline	17015.11	(17015.11, 17015.11)
Positive	Live Virus nAb ID50	Age >= 65 Female	D57 vs. Baseline	9206.05	(9206.05, 9206.05)
Positive	Pseudo nAb ID80	Age >= 65 Female	D57 vs. Baseline	7914.98	(7914.98, 7914.98)
Positive	Live Virus nAb ID80	Age >= 65 Female	D57 vs. Baseline	4534.39	(4534.39, 4534.39)
Positive	Anti-Spike IgG	Age >= 65 Female	D29 vs. Baseline	131600.83	(131600.83, 131600.83)
Positive	Anti-RBD IgG	Age >= 65 Female	D29 vs. Baseline	72329.70	(72329.70, 72329.70)
Positive	Pseudo nAb ID50	Age >= 65 Female	D29 vs. Baseline	803.02	(803.02, 803.02)
Positive	Live Virus nAb ID50	Age >= 65 Female	D29 vs. Baseline	505.06	(505.06, 505.06)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Age $\geq$ 65 Female	D29 vs. Baseline	291.81	(291.81, 291.81)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Female	D29 vs. Baseline	253.07	(253.07, 253.07)
Positive	Anti-Spike IgG	Age $\geq$ 65 Female	D57 vs. D29	83.10	(83.10, 83.10)
Positive	Anti-RBD IgG	Age $\geq$ 65 Female	D57 vs. D29	67.14	(67.14, 67.14)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Female	D57 vs. D29	21.19	(21.19, 21.19)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Female	D57 vs. D29	18.23	(18.23, 18.23)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Female	D57 vs. D29	27.12	(27.12, 27.12)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Female	D57 vs. D29	17.92	(17.92, 17.92)
Positive	Anti-Spike IgG	Age $\geq$ 65 Male	D57 vs. Baseline	11091265.29	(11091265.29, 11091265.29)
Positive	Anti-RBD IgG	Age $\geq$ 65 Male	D57 vs. Baseline	4519468.91	(4519468.91, 4519468.91)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Male	D57 vs. Baseline	12098.27	(12098.27, 12098.27)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Male	D57 vs. Baseline	9096.61	(9096.61, 9096.61)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Male	D57 vs. Baseline	5291.80	(5291.80, 5291.80)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Male	D57 vs. Baseline	4664.01	(4664.01, 4664.01)
Positive	Anti-Spike IgG	Age $\geq$ 65 Male	D29 vs. Baseline	153370.39	(153370.39, 153370.39)
Positive	Anti-RBD IgG	Age $\geq$ 65 Male	D29 vs. Baseline	73556.02	(73556.02, 73556.02)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Male	D29 vs. Baseline	783.73	(783.73, 783.73)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Male	D29 vs. Baseline	527.54	(527.54, 527.54)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Male	D29 vs. Baseline	335.63	(335.63, 335.63)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Male	D29 vs. Baseline	267.33	(267.33, 267.33)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age $\geq$ 65 Male	D57 vs. D29	72.32	(72.32, 72.32)
Positive	Anti-RBD IgG	Age $\geq$ 65 Male	D57 vs. D29	61.44	(61.44, 61.44)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Male	D57 vs. D29	15.44	(15.44, 15.44)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Male	D57 vs. D29	17.24	(17.24, 17.24)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Male	D57 vs. D29	15.77	(15.77, 15.77)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Male	D57 vs. D29	17.45	(17.45, 17.45)
Positive	Anti-Spike IgG	Hispanic or Latino	D57 vs. Baseline	2547676.63	(1406116.89, 4616014.66)
Positive	Anti-RBD IgG	Hispanic or Latino	D57 vs. Baseline	1845741.14	(970777.55, 3509311.02)
Positive	Pseudo nAb ID50	Hispanic or Latino	D57 vs. Baseline	9123.62	(4307.94, 19322.53)
Positive	Live Virus nAb ID50	Hispanic or Latino	D57 vs. Baseline	3376.42	(2163.71, 5268.82)
Positive	Pseudo nAb ID80	Hispanic or Latino	D57 vs. Baseline	1884.69	(1054.61, 3368.12)
Positive	Live Virus nAb ID80	Hispanic or Latino	D57 vs. Baseline	2057.18	(1180.53, 3584.82)
Positive	Anti-Spike IgG	Hispanic or Latino	D29 vs. Baseline	44700.05	(28091.46, 71128.18)
Positive	Anti-RBD IgG	Hispanic or Latino	D29 vs. Baseline	17901.73	(12241.17, 26179.85)
Positive	Pseudo nAb ID50	Hispanic or Latino	D29 vs. Baseline	332.22	(234.54, 470.58)
Positive	Live Virus nAb ID50	Hispanic or Latino	D29 vs. Baseline	364.89	(257.17, 517.75)
Positive	Pseudo nAb ID80	Hispanic or Latino	D29 vs. Baseline	112.02	(74.61, 168.19)
Positive	Live Virus nAb ID80	Hispanic or Latino	D29 vs. Baseline	149.06	(106.27, 209.08)
Positive	Anti-Spike IgG	Hispanic or Latino	D57 vs. D29	56.99	(49.95, 65.04)
Positive	Anti-RBD IgG	Hispanic or Latino	D57 vs. D29	103.10	(63.52, 167.36)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Hispanic or Latino	D57 vs. D29	27.46	(16.16, 46.67)
Positive	Live Virus nAb ID50	Hispanic or Latino	D57 vs. D29	9.25	(6.74, 12.71)
Positive	Pseudo nAb ID80	Hispanic or Latino	D57 vs. D29	16.82	(13.19, 21.45)
Positive	Live Virus nAb ID80	Hispanic or Latino	D57 vs. D29	13.80	(11.03, 17.27)
Positive	Anti-Spike IgG	Not Hispanic or Latino	D57 vs. Baseline	2511471.28	(1434979.87, 4395523.69)
Positive	Anti-RBD IgG	Not Hispanic or Latino	D57 vs. Baseline	1231405.90	(714036.97, 2123644.23)
Positive	Pseudo nAb ID50	Not Hispanic or Latino	D57 vs. Baseline	3918.25	(2424.27, 6332.91)
Positive	Live Virus nAb ID50	Not Hispanic or Latino	D57 vs. Baseline	3695.93	(2645.45, 5163.54)
Positive	Pseudo nAb ID80	Not Hispanic or Latino	D57 vs. Baseline	1600.71	(952.96, 2688.75)
Positive	Live Virus nAb ID80	Not Hispanic or Latino	D57 vs. Baseline	1841.14	(1310.27, 2587.11)
Positive	Anti-Spike IgG	Not Hispanic or Latino	D29 vs. Baseline	38503.98	(23003.94, 64447.92)
Positive	Anti-RBD IgG	Not Hispanic or Latino	D29 vs. Baseline	20457.12	(12204.91, 34288.97)
Positive	Pseudo nAb ID50	Not Hispanic or Latino	D29 vs. Baseline	207.41	(124.61, 345.22)
Positive	Live Virus nAb ID50	Not Hispanic or Latino	D29 vs. Baseline	201.26	(139.83, 289.69)
Positive	Pseudo nAb ID80	Not Hispanic or Latino	D29 vs. Baseline	89.45	(55.46, 144.27)
Positive	Live Virus nAb ID80	Not Hispanic or Latino	D29 vs. Baseline	107.58	(77.66, 149.03)
Positive	Anti-Spike IgG	Not Hispanic or Latino	D57 vs. D29	65.23	(60.41, 70.43)
Positive	Anti-RBD IgG	Not Hispanic or Latino	D57 vs. D29	60.19	(57.01, 63.55)
Positive	Pseudo nAb ID50	Not Hispanic or Latino	D57 vs. D29	18.89	(15.64, 22.82)
Positive	Live Virus nAb ID50	Not Hispanic or Latino	D57 vs. D29	18.36	(17.72, 19.03)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Not Hispanic or Latino	D57 vs. D29	17.90	(17.15, 18.68)
Positive	Live Virus nAb ID80	Not Hispanic or Latino	D57 vs. D29	17.11	(16.21, 18.07)
Positive	Anti-Spike IgG	American Indian or Alaska Native	D57 vs. Baseline	1817565.52	(1283780.82, 2573293.19)
Positive	Anti-RBD IgG	American Indian or Alaska Native	D57 vs. Baseline	1551508.54	(1458861.57, 1650039.18)
Positive	Pseudo nAb ID50	American Indian or Alaska Native	D57 vs. Baseline	9428.83	(7920.94, 11223.78)
Positive	Live Virus nAb ID50	American Indian or Alaska Native	D57 vs. Baseline	4918.05	(3728.77, 6486.65)
Positive	Pseudo nAb ID80	American Indian or Alaska Native	D57 vs. Baseline	7081.47	(6072.59, 8257.95)
Positive	Live Virus nAb ID80	American Indian or Alaska Native	D57 vs. Baseline	1881.88	(1329.98, 2662.80)
Positive	Anti-Spike IgG	American Indian or Alaska Native	D29 vs. Baseline	39762.94	(27722.99, 57031.78)
Positive	Anti-RBD IgG	American Indian or Alaska Native	D29 vs. Baseline	35237.55	(28430.28, 43674.75)
Positive	Pseudo nAb ID50	American Indian or Alaska Native	D29 vs. Baseline	473.15	(422.21, 530.24)
Positive	Live Virus nAb ID50	American Indian or Alaska Native	D29 vs. Baseline	261.09	(209.30, 325.70)
Positive	Pseudo nAb ID80	American Indian or Alaska Native	D29 vs. Baseline	230.24	(219.79, 241.19)
Positive	Live Virus nAb ID80	American Indian or Alaska Native	D29 vs. Baseline	173.40	(160.16, 187.73)
Positive	Anti-Spike IgG	American Indian or Alaska Native	D57 vs. D29	45.71	(45.10, 46.33)
Positive	Anti-RBD IgG	American Indian or Alaska Native	D57 vs. D29	44.03	(36.19, 53.57)
Positive	Pseudo nAb ID50	American Indian or Alaska Native	D57 vs. D29	19.93	(15.93, 24.93)
Positive	Live Virus nAb ID50	American Indian or Alaska Native	D57 vs. D29	18.84	(15.04, 23.59)
Positive	Pseudo nAb ID80	American Indian or Alaska Native	D57 vs. D29	30.76	(27.48, 34.42)
Positive	Live Virus nAb ID80	American Indian or Alaska Native	D57 vs. D29	10.85	(8.17, 14.42)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Asian	D57 vs. Baseline	2357816.68	(1004834.79, 5532550.75)
Positive	Anti-RBD IgG	Asian	D57 vs. Baseline	2348445.30	(1039145.95, 5307430.91)
Positive	Pseudo nAb ID50	Asian	D57 vs. Baseline	2920.61	(924.25, 9229.07)
Positive	Live Virus nAb ID50	Asian	D57 vs. Baseline	6161.61	(3207.26, 11837.32)
Positive	Pseudo nAb ID80	Asian	D57 vs. Baseline	774.36	(158.52, 3782.62)
Positive	Live Virus nAb ID80	Asian	D57 vs. Baseline	2030.39	(632.54, 6517.38)
Positive	Anti-Spike IgG	Asian	D29 vs. Baseline	44620.28	(22011.74, 90450.34)
Positive	Anti-RBD IgG	Asian	D29 vs. Baseline	27559.22	(13534.57, 56116.34)
Positive	Pseudo nAb ID50	Asian	D29 vs. Baseline	115.15	(25.20, 526.18)
Positive	Live Virus nAb ID50	Asian	D29 vs. Baseline	239.92	(113.79, 505.86)
Positive	Pseudo nAb ID80	Asian	D29 vs. Baseline	52.18	(11.76, 231.62)
Positive	Live Virus nAb ID80	Asian	D29 vs. Baseline	121.39	(74.31, 198.31)
Positive	Anti-Spike IgG	Asian	D57 vs. D29	52.84	(43.27, 64.54)
Positive	Anti-RBD IgG	Asian	D57 vs. D29	85.21	(76.05, 95.48)
Positive	Pseudo nAb ID50	Asian	D57 vs. D29	25.36	(16.97, 37.90)
Positive	Live Virus nAb ID50	Asian	D57 vs. D29	25.68	(20.67, 31.91)
Positive	Pseudo nAb ID80	Asian	D57 vs. D29	14.84	(13.48, 16.34)
Positive	Live Virus nAb ID80	Asian	D57 vs. D29	16.73	(8.51, 32.86)
Positive	Anti-Spike IgG	Black or African American	D57 vs. Baseline	2151392.53	(1282694.42, 3608411.90)
Positive	Anti-RBD IgG	Black or African American	D57 vs. Baseline	1258054.53	(858480.59, 1843607.44)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Black or African American	D57 vs. Baseline	3007.79	(2005.16, 4511.78)
Positive	Live Virus nAb ID50	Black or African American	D57 vs. Baseline	3044.34	(2144.00, 4322.78)
Positive	Pseudo nAb ID80	Black or African American	D57 vs. Baseline	1245.79	(743.28, 2088.02)
Positive	Live Virus nAb ID80	Black or African American	D57 vs. Baseline	1368.67	(1042.92, 1796.18)
Positive	Anti-Spike IgG	Black or African American	D29 vs. Baseline	35833.01	(25300.17, 50750.83)
Positive	Anti-RBD IgG	Black or African American	D29 vs. Baseline	18518.30	(12073.58, 28403.14)
Positive	Pseudo nAb ID50	Black or African American	D29 vs. Baseline	173.08	(107.03, 279.90)
Positive	Live Virus nAb ID50	Black or African American	D29 vs. Baseline	199.89	(156.06, 256.02)
Positive	Pseudo nAb ID80	Black or African American	D29 vs. Baseline	74.16	(43.29, 127.03)
Positive	Live Virus nAb ID80	Black or African American	D29 vs. Baseline	104.76	(86.43, 126.98)
Positive	Anti-Spike IgG	Black or African American	D57 vs. D29	60.04	(49.12, 73.39)
Positive	Anti-RBD IgG	Black or African American	D57 vs. D29	67.94	(59.51, 77.55)
Positive	Pseudo nAb ID50	Black or African American	D57 vs. D29	17.38	(12.15, 24.86)
Positive	Live Virus nAb ID50	Black or African American	D57 vs. D29	15.23	(13.54, 17.13)
Positive	Pseudo nAb ID80	Black or African American	D57 vs. D29	16.80	(9.57, 29.49)
Positive	Live Virus nAb ID80	Black or African American	D57 vs. D29	13.07	(10.59, 16.13)
Positive	Anti-Spike IgG	Multiracial	D57 vs. Baseline	3301044.90	(1576729.50, 6911075.99)
Positive	Anti-RBD IgG	Multiracial	D57 vs. Baseline	1088967.59	(573106.50, 2069162.39)
Positive	Pseudo nAb ID50	Multiracial	D57 vs. Baseline	8512.90	(2619.74, 27662.80)
Positive	Live Virus nAb ID50	Multiracial	D57 vs. Baseline	2720.43	(1296.32, 5709.00)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Multiracial	D57 vs. Baseline	1611.45	(677.57, 3832.50)
Positive	Live Virus nAb ID80	Multiracial	D57 vs. Baseline	2543.95	(1214.84, 5327.19)
Positive	Anti-Spike IgG	Multiracial	D29 vs. Baseline	51552.48	(26634.20, 99783.69)
Positive	Anti-RBD IgG	Multiracial	D29 vs. Baseline	13896.76	(6318.90, 30562.25)
Positive	Pseudo nAb ID50	Multiracial	D29 vs. Baseline	347.82	(174.72, 692.43)
Positive	Live Virus nAb ID50	Multiracial	D29 vs. Baseline	416.71	(294.73, 589.19)
Positive	Pseudo nAb ID80	Multiracial	D29 vs. Baseline	135.40	(69.81, 262.61)
Positive	Live Virus nAb ID80	Multiracial	D29 vs. Baseline	113.89	(79.13, 163.94)
Positive	Anti-Spike IgG	Multiracial	D57 vs. D29	64.03	(52.36, 78.31)
Positive	Anti-RBD IgG	Multiracial	D57 vs. D29	78.36	(67.70, 90.70)
Positive	Pseudo nAb ID50	Multiracial	D57 vs. D29	24.47	(9.03, 66.35)
Positive	Live Virus nAb ID50	Multiracial	D57 vs. D29	6.53	(3.75, 11.38)
Positive	Pseudo nAb ID80	Multiracial	D57 vs. D29	11.90	(7.51, 18.85)
Positive	Live Virus nAb ID80	Multiracial	D57 vs. D29	22.34	(9.13, 54.62)
Positive	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	2221189.32	(745917.26, 6614248.33)
Positive	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	1018984.77	(315444.51, 3291640.63)
Positive	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	783.75	(165.27, 3716.68)
Positive	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	1850.92	(862.16, 3973.66)
Positive	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	225.30	(91.92, 552.21)
Positive	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. Baseline	566.73	(196.99, 1630.44)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	27058.25	(10242.87, 71478.88)
Positive	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	8902.73	(3126.01, 25354.55)
Positive	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	71.45	(38.84, 131.43)
Positive	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	113.78	(65.57, 197.42)
Positive	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	45.82	(21.23, 98.87)
Positive	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D29 vs. Baseline	39.66	(14.24, 110.50)
Positive	Anti-Spike IgG	Native Hawaiian or Other Pacific Islander	D57 vs. D29	82.09	(54.06, 124.65)
Positive	Anti-RBD IgG	Native Hawaiian or Other Pacific Islander	D57 vs. D29	114.46	(62.35, 210.12)
Positive	Pseudo nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. D29	10.97	(3.31, 36.34)
Positive	Live Virus nAb ID50	Native Hawaiian or Other Pacific Islander	D57 vs. D29	16.27	(10.33, 25.63)
Positive	Pseudo nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. D29	4.92	(3.87, 6.24)
Positive	Live Virus nAb ID80	Native Hawaiian or Other Pacific Islander	D57 vs. D29	14.29	(9.06, 22.54)
Positive	Anti-Spike IgG	Not reported and unknown	D57 vs. Baseline	3199218.96	(1714305.45, 5970349.08)
Positive	Anti-RBD IgG	Not reported and unknown	D57 vs. Baseline	1637735.79	(1036186.91, 2588508.42)
Positive	Pseudo nAb ID50	Not reported and unknown	D57 vs. Baseline	5031.17	(3197.21, 7917.10)
Positive	Live Virus nAb ID50	Not reported and unknown	D57 vs. Baseline	5182.98	(3919.19, 6854.29)
Positive	Pseudo nAb ID80	Not reported and unknown	D57 vs. Baseline	2181.14	(1777.54, 2676.39)
Positive	Live Virus nAb ID80	Not reported and unknown	D57 vs. Baseline	3107.90	(2493.77, 3873.26)
Positive	Anti-Spike IgG	Not reported and unknown	D29 vs. Baseline	48749.55	(26749.73, 88842.73)
Positive	Anti-RBD IgG	Not reported and unknown	D29 vs. Baseline	23701.00	(13018.25, 43150.00)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Not reported and unknown	D29 vs. Baseline	180.05	(99.26, 326.62)
Positive	Live Virus nAb ID50	Not reported and unknown	D29 vs. Baseline	239.23	(179.33, 319.12)
Positive	Pseudo nAb ID80	Not reported and unknown	D29 vs. Baseline	74.36	(43.47, 127.20)
Positive	Live Virus nAb ID80	Not reported and unknown	D29 vs. Baseline	139.60	(109.50, 177.99)
Positive	Anti-Spike IgG	Not reported and unknown	D57 vs. D29	65.63	(57.88, 74.40)
Positive	Anti-RBD IgG	Not reported and unknown	D57 vs. D29	69.10	(54.76, 87.20)
Positive	Pseudo nAb ID50	Not reported and unknown	D57 vs. D29	27.94	(24.10, 32.40)
Positive	Live Virus nAb ID50	Not reported and unknown	D57 vs. D29	21.67	(20.39, 23.02)
Positive	Pseudo nAb ID80	Not reported and unknown	D57 vs. D29	29.33	(20.80, 41.37)
Positive	Live Virus nAb ID80	Not reported and unknown	D57 vs. D29	22.26	(18.96, 26.13)
Positive	Anti-Spike IgG	Other	D57 vs. Baseline	2233289.66	(1496368.55, 3333124.52)
Positive	Anti-RBD IgG	Other	D57 vs. Baseline	974096.13	(780949.27, 1215012.69)
Positive	Pseudo nAb ID50	Other	D57 vs. Baseline	2407.37	(1387.66, 4176.41)
Positive	Live Virus nAb ID50	Other	D57 vs. Baseline	1396.73	(892.33, 2186.24)
Positive	Pseudo nAb ID80	Other	D57 vs. Baseline	291.45	(127.16, 668.00)
Positive	Live Virus nAb ID80	Other	D57 vs. Baseline	431.93	(224.79, 829.92)
Positive	Anti-Spike IgG	Other	D29 vs. Baseline	44715.20	(35591.33, 56177.99)
Positive	Anti-RBD IgG	Other	D29 vs. Baseline	12342.73	(10044.31, 15167.09)
Positive	Pseudo nAb ID50	Other	D29 vs. Baseline	97.33	(67.86, 139.60)
Positive	Live Virus nAb ID50	Other	D29 vs. Baseline	172.84	(151.56, 197.12)



Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Other	D29 vs. Baseline	31.06	(17.30, 55.74)
Positive	Live Virus nAb ID80	Other	D29 vs. Baseline	129.91	(123.71, 136.42)
Positive	Anti-Spike IgG	Other	D57 vs. D29	49.94	(41.96, 59.45)
Positive	Anti-RBD IgG	Other	D57 vs. D29	78.92	(69.51, 89.61)
Positive	Pseudo nAb ID50	Other	D57 vs. D29	24.73	(13.57, 45.08)
Positive	Live Virus nAb ID50	Other	D57 vs. D29	8.08	(4.99, 13.09)
Positive	Pseudo nAb ID80	Other	D57 vs. D29	9.38	(5.14, 17.15)
Positive	Live Virus nAb ID80	Other	D57 vs. D29	3.32	(1.75, 6.33)
Positive	Anti-Spike IgG	White	D57 vs. Baseline	1982338.44	(965814.13, 4068759.80)
Positive	Anti-RBD IgG	White	D57 vs. Baseline	973345.83	(218039.66, 4345090.85)
Positive	Pseudo nAb ID50	White	D57 vs. Baseline	6951.37	(4576.07, 10559.63)
Positive	Live Virus nAb ID50	White	D57 vs. Baseline	3322.21	(1835.58, 6012.85)
Positive	Pseudo nAb ID80	White	D57 vs. Baseline	1565.33	(545.10, 4495.07)
Positive	Live Virus nAb ID80	White	D57 vs. Baseline	1328.07	(478.20, 3688.38)
Positive	Anti-Spike IgG	White	D29 vs. Baseline	39648.38	(26077.11, 60282.54)
Positive	Anti-RBD IgG	White	D29 vs. Baseline	16825.64	(4484.72, 63125.95)
Positive	Pseudo nAb ID50	White	D29 vs. Baseline	279.40	(149.50, 522.16)
Positive	Live Virus nAb ID50	White	D29 vs. Baseline	211.30	(127.62, 349.83)
Positive	Pseudo nAb ID80	White	D29 vs. Baseline	128.69	(76.74, 215.79)
Positive	Live Virus nAb ID80	White	D29 vs. Baseline	108.82	(60.67, 195.18)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	White	D57 vs. D29	50.00	(32.35, 77.28)
Positive	Anti-RBD IgG	White	D57 vs. D29	57.85	(48.56, 68.92)
Positive	Pseudo nAb ID50	White	D57 vs. D29	24.88	(14.41, 42.94)
Positive	Live Virus nAb ID50	White	D57 vs. D29	15.72	(12.16, 20.32)
Positive	Pseudo nAb ID80	White	D57 vs. D29	12.16	(7.00, 21.14)
Positive	Live Virus nAb ID80	White	D57 vs. D29	12.20	(6.15, 24.22)
Positive	Anti-Spike IgG	White Non-Hispanic	D57 vs. Baseline	2590873.29	(1459247.63, 4600058.46)
Positive	Anti-RBD IgG	White Non-Hispanic	D57 vs. Baseline	1168852.32	(672677.59, 2031011.27)
Positive	Pseudo nAb ID50	White Non-Hispanic	D57 vs. Baseline	4622.33	(2507.27, 8521.59)
Positive	Live Virus nAb ID50	White Non-Hispanic	D57 vs. Baseline	3618.02	(2541.93, 5149.65)
Positive	Pseudo nAb ID80	White Non-Hispanic	D57 vs. Baseline	2010.66	(1161.26, 3481.35)
Positive	Live Virus nAb ID80	White Non-Hispanic	D57 vs. Baseline	2126.22	(1411.09, 3203.78)
Positive	Anti-Spike IgG	White Non-Hispanic	D29 vs. Baseline	37887.22	(21712.13, 66112.40)
Positive	Anti-RBD IgG	White Non-Hispanic	D29 vs. Baseline	20870.00	(12518.76, 34792.35)
Positive	Pseudo nAb ID50	White Non-Hispanic	D29 vs. Baseline	263.15	(154.92, 446.97)
Positive	Live Virus nAb ID50	White Non-Hispanic	D29 vs. Baseline	204.53	(135.68, 308.30)
Positive	Pseudo nAb ID80	White Non-Hispanic	D29 vs. Baseline	107.85	(64.36, 180.73)
Positive	Live Virus nAb ID80	White Non-Hispanic	D29 vs. Baseline	103.06	(66.81, 158.99)
Positive	Anti-Spike IgG	White Non-Hispanic	D57 vs. D29	68.38	(63.69, 73.43)
Positive	Anti-RBD IgG	White Non-Hispanic	D57 vs. D29	56.01	(50.63, 61.96)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	White Non-Hispanic	D57 vs. D29	17.57	(15.65, 19.71)
Positive	Live Virus nAb ID50	White Non-Hispanic	D57 vs. D29	17.69	(16.50, 18.97)
Positive	Pseudo nAb ID80	White Non-Hispanic	D57 vs. D29	18.64	(15.61, 22.27)
Positive	Live Virus nAb ID80	White Non-Hispanic	D57 vs. D29	20.63	(16.42, 25.93)
Positive	Anti-Spike IgG	White Non-Hispanic	D57 vs. Baseline	2590873.29	(1459247.63, 4600058.46)
Positive	Anti-RBD IgG	White Non-Hispanic	D57 vs. Baseline	1168852.32	(672677.59, 2031011.27)
Positive	Pseudo nAb ID50	White Non-Hispanic	D57 vs. Baseline	4622.33	(2507.27, 8521.59)
Positive	Live Virus nAb ID50	White Non-Hispanic	D57 vs. Baseline	3618.02	(2541.93, 5149.65)
Positive	Pseudo nAb ID80	White Non-Hispanic	D57 vs. Baseline	2010.66	(1161.26, 3481.35)
Positive	Live Virus nAb ID80	White Non-Hispanic	D57 vs. Baseline	2126.22	(1411.09, 3203.78)
Positive	Anti-Spike IgG	White Non-Hispanic	D29 vs. Baseline	37887.22	(21712.13, 66112.40)
Positive	Anti-RBD IgG	White Non-Hispanic	D29 vs. Baseline	20870.00	(12518.76, 34792.35)
Positive	Pseudo nAb ID50	White Non-Hispanic	D29 vs. Baseline	263.15	(154.92, 446.97)
Positive	Live Virus nAb ID50	White Non-Hispanic	D29 vs. Baseline	204.53	(135.68, 308.30)
Positive	Pseudo nAb ID80	White Non-Hispanic	D29 vs. Baseline	107.85	(64.36, 180.73)
Positive	Live Virus nAb ID80	White Non-Hispanic	D29 vs. Baseline	103.06	(66.81, 158.99)
Positive	Anti-Spike IgG	White Non-Hispanic	D57 vs. D29	68.38	(63.69, 73.43)
Positive	Anti-RBD IgG	White Non-Hispanic	D57 vs. D29	56.01	(50.63, 61.96)
Positive	Pseudo nAb ID50	White Non-Hispanic	D57 vs. D29	17.57	(15.65, 19.71)
Positive	Live Virus nAb ID50	White Non-Hispanic	D57 vs. D29	17.69	(16.50, 18.97)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	White Non-Hispanic	D57 vs. D29	18.64	(15.61, 22.27)
Positive	Live Virus nAb ID80	White Non-Hispanic	D57 vs. D29	20.63	(16.42, 25.93)
Positive	Anti-Spike IgG	Communities of Color	D57 vs. Baseline	2477475.00	(1424883.81, 4307637.12)
Positive	Anti-RBD IgG	Communities of Color	D57 vs. Baseline	1400471.60	(894518.32, 2192599.82)
Positive	Pseudo nAb ID50	Communities of Color	D57 vs. Baseline	3834.23	(2505.01, 5868.75)
Positive	Live Virus nAb ID50	Communities of Color	D57 vs. Baseline	3530.68	(2403.67, 5186.10)
Positive	Pseudo nAb ID80	Communities of Color	D57 vs. Baseline	1294.90	(767.49, 2184.76)
Positive	Live Virus nAb ID80	Communities of Color	D57 vs. Baseline	1683.46	(1253.02, 2261.77)
Positive	Anti-Spike IgG	Communities of Color	D29 vs. Baseline	41726.89	(26332.53, 66120.99)
Positive	Anti-RBD IgG	Communities of Color	D29 vs. Baseline	19643.48	(12050.36, 32021.13)
Positive	Pseudo nAb ID50	Communities of Color	D29 vs. Baseline	178.18	(101.10, 314.05)
Positive	Live Virus nAb ID50	Communities of Color	D29 vs. Baseline	228.95	(175.65, 298.42)
Positive	Pseudo nAb ID80	Communities of Color	D29 vs. Baseline	75.14	(41.96, 134.57)
Positive	Live Virus nAb ID80	Communities of Color	D29 vs. Baseline	117.10	(93.18, 147.17)
Positive	Anti-Spike IgG	Communities of Color	D57 vs. D29	59.37	(54.08, 65.18)
Positive	Anti-RBD IgG	Communities of Color	D57 vs. D29	71.29	(64.42, 78.90)
Positive	Pseudo nAb ID50	Communities of Color	D57 vs. D29	21.52	(14.96, 30.95)
Positive	Live Virus nAb ID50	Communities of Color	D57 vs. D29	15.42	(13.63, 17.44)
Positive	Pseudo nAb ID80	Communities of Color	D57 vs. D29	17.23	(13.58, 21.87)
Positive	Live Virus nAb ID80	Communities of Color	D57 vs. D29	14.38	(13.41, 15.41)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age < 65 Communities of Color	D57 vs. Baseline	2004934.86	(1787829.40, 2248404.58)
Positive	Anti-RBD IgG	Age < 65 Communities of Color	D57 vs. Baseline	1178669.92	(1050887.93, 1321989.47)
Positive	Pseudo nAb ID50	Age < 65 Communities of Color	D57 vs. Baseline	3260.25	(2556.15, 4158.31)
Positive	Live Virus nAb ID50	Age < 65 Communities of Color	D57 vs. Baseline	3062.19	(3022.65, 3102.26)
Positive	Pseudo nAb ID80	Age < 65 Communities of Color	D57 vs. Baseline	1060.76	(964.15, 1167.04)
Positive	Live Virus nAb ID80	Age < 65 Communities of Color	D57 vs. Baseline	1509.52	(1498.85, 1520.26)
Positive	Anti-Spike IgG	Age < 65 Communities of Color	D29 vs. Baseline	35007.62	(32158.82, 38108.79)
Positive	Anti-RBD IgG	Age < 65 Communities of Color	D29 vs. Baseline	16403.46	(16248.37, 16560.03)
Positive	Pseudo nAb ID50	Age < 65 Communities of Color	D29 vs. Baseline	147.33	(128.82, 168.50)
Positive	Live Virus nAb ID50	Age < 65 Communities of Color	D29 vs. Baseline	207.07	(199.22, 215.23)
Positive	Pseudo nAb ID80	Age < 65 Communities of Color	D29 vs. Baseline	62.30	(51.78, 74.96)
Positive	Live Virus nAb ID80	Age < 65 Communities of Color	D29 vs. Baseline	107.45	(104.82, 110.14)
Positive	Anti-Spike IgG	Age < 65 Communities of Color	D57 vs. D29	57.27	(55.59, 59.00)
Positive	Anti-RBD IgG	Age < 65 Communities of Color	D57 vs. D29	71.85	(64.68, 79.83)
Positive	Pseudo nAb ID50	Age < 65 Communities of Color	D57 vs. D29	22.13	(15.17, 32.28)
Positive	Live Virus nAb ID50	Age < 65 Communities of Color	D57 vs. D29	14.79	(14.41, 15.17)
Positive	Pseudo nAb ID80	Age < 65 Communities of Color	D57 vs. D29	17.03	(12.86, 22.54)
Positive	Live Virus nAb ID80	Age < 65 Communities of Color	D57 vs. D29	14.05	(13.80, 14.30)
Positive	Anti-Spike IgG	Age < 65 White Non-Hispanic	D57 vs. Baseline	2067749.38	(1711151.50, 2498661.00)
Positive	Anti-RBD IgG	Age < 65 White Non-Hispanic	D57 vs. Baseline	943980.04	(857658.53, 1038989.62)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D57 vs. Baseline	3786.13	(2088.45, 6863.84)
Positive	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D57 vs. Baseline	3150.30	(2835.72, 3499.76)
Positive	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D57 vs. Baseline	1624.89	(1182.64, 2232.53)
Positive	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D57 vs. Baseline	1829.86	(1323.97, 2529.05)
Positive	Anti-Spike IgG	Age < 65 White Non-Hispanic	D29 vs. Baseline	30537.78	(27564.21, 33832.15)
Positive	Anti-RBD IgG	Age < 65 White Non-Hispanic	D29 vs. Baseline	17068.62	(14057.67, 20724.48)
Positive	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D29 vs. Baseline	218.13	(138.47, 343.62)
Positive	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D29 vs. Baseline	174.04	(146.48, 206.78)
Positive	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D29 vs. Baseline	90.20	(56.80, 143.24)
Positive	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D29 vs. Baseline	87.12	(80.22, 94.62)
Positive	Anti-Spike IgG	Age < 65 White Non-Hispanic	D57 vs. D29	67.71	(62.08, 73.85)
Positive	Anti-RBD IgG	Age < 65 White Non-Hispanic	D57 vs. D29	55.30	(50.13, 61.01)
Positive	Pseudo nAb ID50	Age < 65 White Non-Hispanic	D57 vs. D29	17.36	(15.08, 19.98)
Positive	Live Virus nAb ID50	Age < 65 White Non-Hispanic	D57 vs. D29	18.10	(16.93, 19.36)
Positive	Pseudo nAb ID80	Age < 65 White Non-Hispanic	D57 vs. D29	18.01	(15.59, 20.82)
Positive	Live Virus nAb ID80	Age < 65 White Non-Hispanic	D57 vs. D29	21.00	(16.50, 26.73)
Positive	Anti-Spike IgG	Age >= 65 Communities of Color	D57 vs. Baseline	11571484.34	(11571484.34, 11571484.34)
Positive	Anti-RBD IgG	Age >= 65 Communities of Color	D57 vs. Baseline	4916385.58	(4916385.58, 4916385.58)
Positive	Pseudo nAb ID50	Age >= 65 Communities of Color	D57 vs. Baseline	12491.01	(12491.01, 12491.01)
Positive	Live Virus nAb ID50	Age >= 65 Communities of Color	D57 vs. Baseline	9957.17	(9957.17, 9957.17)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	5534.85	(5534.85, 5534.85)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. Baseline	3725.27	(3725.27, 3725.27)
Positive	Anti-Spike IgG	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	149890.68	(149890.68, 149890.68)
Positive	Anti-RBD IgG	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	73005.96	(73005.96, 73005.96)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	711.73	(711.73, 711.73)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	475.89	(475.89, 475.89)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	293.96	(293.96, 293.96)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D29 vs. Baseline	219.14	(219.14, 219.14)
Positive	Anti-Spike IgG	Age $\geq$ 65 Communities of Color	D57 vs. D29	77.20	(77.20, 77.20)
Positive	Anti-RBD IgG	Age $\geq$ 65 Communities of Color	D57 vs. D29	67.34	(67.34, 67.34)
Positive	Pseudo nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. D29	17.55	(17.55, 17.55)
Positive	Live Virus nAb ID50	Age $\geq$ 65 Communities of Color	D57 vs. D29	20.92	(20.92, 20.92)
Positive	Pseudo nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. D29	18.83	(18.83, 18.83)
Positive	Live Virus nAb ID80	Age $\geq$ 65 Communities of Color	D57 vs. D29	17.00	(17.00, 17.00)
Positive	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	10926361.44	(10926361.44, 10926361.44)
Positive	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	4570003.81	(4570003.81, 4570003.81)
Positive	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	16515.39	(16515.39, 16515.39)
Positive	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	8751.96	(8751.96, 8751.96)
Positive	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	7828.63	(7828.63, 7828.63)
Positive	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. Baseline	5541.16	(5541.16, 5541.16)

Table 3: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Baseline	Endpoint	Group	Visits	GMTR/GMCR	95% CI
Positive	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	150012.34	(150012.34, 150012.34)
Positive	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	75293.22	(75293.22, 75293.22)
Positive	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	871.29	(871.29, 871.29)
Positive	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	572.93	(572.93, 572.93)
Positive	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	337.33	(337.33, 337.33)
Positive	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D29 vs. Baseline	301.20	(301.20, 301.20)
Positive	Anti-Spike IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	72.84	(72.84, 72.84)
Positive	Anti-RBD IgG	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	60.70	(60.70, 60.70)
Positive	Pseudo nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	18.96	(18.96, 18.96)
Positive	Live Virus nAb ID50	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	15.28	(15.28, 15.28)
Positive	Pseudo nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	23.21	(23.21, 23.21)
Positive	Live Virus nAb ID80	Age $\geq$ 65 White Non-Hispanic	D57 vs. D29	18.40	(18.40, 18.40)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo



Table 4: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 4: Ratios of GMTs/GMCs between the vaccine arm vs.  
placebo arm, by baseline status

subgroup	Baseline	Endpoint	Visit	Ratios of GMT/GMC	95% CI
Total	Negative	Anti-RBD IgG	D1	1.00	(1.00, 1.00)
Total	Negative	Anti-Spike IgG	D1	1.00	(1.00, 1.00)
Total	Negative	Live Virus nAb ID50	D1	1.00	(1.00, 1.00)
Total	Negative	Live Virus nAb ID80	D1	1.00	(1.00, 1.00)
Total	Negative	Pseudo nAb ID50	D1	1.00	(1.00, 1.00)
Total	Negative	Pseudo nAb ID80	D1	1.00	(1.00, 1.00)
Total	Negative	Anti-RBD IgG	D29	1421.62	(1247.48, 1620.07)
Total	Negative	Anti-Spike IgG	D29	2563.24	(2287.33, 2872.43)
Total	Negative	Live Virus nAb ID50	D29	9.58	(8.30, 11.04)
Total	Negative	Live Virus nAb ID80	D29	5.92	(5.18, 6.77)
Total	Negative	Pseudo nAb ID50	D29	9.85	(8.53, 11.37)
Total	Negative	Pseudo nAb ID80	D29	5.27	(4.61, 6.01)
Total	Negative	Anti-RBD IgG	D57	66646.13	(57467.55, 77290.68)
Total	Negative	Anti-Spike IgG	D57	137501.59	(121548.53, 155548.46)
Total	Negative	Live Virus nAb ID50	D57	123.45	(102.80, 148.25)
Total	Negative	Live Virus nAb ID80	D57	79.16	(65.15, 96.19)
Total	Negative	Pseudo nAb ID50	D57	155.52	(129.05, 187.44)
Total	Negative	Pseudo nAb ID80	D57	90.39	(74.10, 110.25)
Total	Positive	Anti-RBD IgG	D1	1.00	(1.00, 1.00)
Total	Positive	Anti-Spike IgG	D1	1.00	(1.00, 1.00)
Total	Positive	Live Virus nAb ID50	D1	1.00	(1.00, 1.00)
Total	Positive	Live Virus nAb ID80	D1	1.00	(1.00, 1.00)
Total	Positive	Pseudo nAb ID50	D1	1.00	(1.00, 1.00)
Total	Positive	Pseudo nAb ID80	D1	1.00	(1.00, 1.00)
Total	Positive	Anti-RBD IgG	D29	2.43	(1.85, 3.20)
Total	Positive	Anti-Spike IgG	D29	3.56	(2.79, 4.56)

Table 4: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 4: Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status (*continued*)

subgroup	Baseline	Endpoint	Visit	Ratios of GMT/GMC	95% CI
Total	Positive	Live Virus nAb ID50	D29	2.82	(2.11, 3.77)
Total	Positive	Live Virus nAb ID80	D29	2.98	(2.26, 3.93)
Total	Positive	Pseudo nAb ID50	D29	2.34	(1.74, 3.15)
Total	Positive	Pseudo nAb ID80	D29	2.03	(1.54, 2.67)
Total	Positive	Anti-RBD IgG	D57	5.40	(4.03, 7.24)
Total	Positive	Anti-Spike IgG	D57	6.60	(5.09, 8.55)
Total	Positive	Live Virus nAb ID50	D57	4.10	(2.82, 5.97)
Total	Positive	Live Virus nAb ID80	D57	6.88	(4.77, 9.92)
Total	Positive	Pseudo nAb ID50	D57	6.93	(4.72, 10.18)
Total	Positive	Pseudo nAb ID80	D57	7.80	(5.31, 11.47)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 5: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 5: Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the recipients

subgroup	Endpoint	Visit	Ratios of GMT/GMC	95% CI
Total	Anti-RBD IgG	D1	1.00	(1.00, 1.00)
Total	Anti-Spike IgG	D1	1.00	(1.00, 1.00)
Total	Live Virus nAb ID50	D1	1.00	(1.00, 1.00)
Total	Live Virus nAb ID80	D1	1.00	(1.00, 1.00)
Total	Pseudo nAb ID50	D1	1.00	(1.00, 1.00)
Total	Pseudo nAb ID80	D1	1.00	(1.00, 1.00)
Total	Anti-RBD IgG	D29	1.29	(0.96, 1.74)
Total	Anti-Spike IgG	D29	1.63	(1.26, 2.11)
Total	Live Virus nAb ID50	D29	1.67	(1.21, 2.31)
Total	Live Virus nAb ID80	D29	1.88	(1.38, 2.54)
Total	Pseudo nAb ID50	D29	1.54	(1.11, 2.13)
Total	Pseudo nAb ID80	D29	1.38	(1.02, 1.86)
Total	Anti-RBD IgG	D57	2.37	(1.70, 3.30)
Total	Anti-Spike IgG	D57	2.20	(1.67, 2.90)
Total	Live Virus nAb ID50	D57	2.30	(1.52, 3.49)
Total	Live Virus nAb ID80	D57	2.89	(1.87, 4.48)
Total	Pseudo nAb ID50	D57	2.87	(1.88, 4.37)
Total	Pseudo nAb ID80	D57	2.29	(1.46, 3.59)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Negative	Anti-RBD IgG	D1	Age	1.00	(1.00, 1.00)
Negative	Anti-Spike IgG	D1	Age	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID50	D1	Age	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID80	D1	Age	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID50	D1	Age	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID80	D1	Age	1.00	(1.00, 1.00)
Negative	Anti-RBD IgG	D29	Age	3.83	(2.95, 4.96)
Negative	Anti-Spike IgG	D29	Age	3.71	(2.97, 4.63)
Negative	Live Virus nAb ID50	D29	Age	2.13	(1.58, 2.85)
Negative	Live Virus nAb ID80	D29	Age	2.22	(1.69, 2.92)
Negative	Pseudo nAb ID50	D29	Age	3.17	(2.37, 4.24)
Negative	Pseudo nAb ID80	D29	Age	2.83	(2.16, 3.70)
Negative	Anti-RBD IgG	D57	Age	3.29	(2.44, 4.45)
Negative	Anti-Spike IgG	D57	Age	2.82	(2.20, 3.61)
Negative	Live Virus nAb ID50	D57	Age	2.53	(1.73, 3.69)
Negative	Live Virus nAb ID80	D57	Age	2.61	(1.74, 3.90)
Negative	Pseudo nAb ID50	D57	Age	3.45	(2.36, 5.06)
Negative	Pseudo nAb ID80	D57	Age	3.40	(2.26, 5.11)
Positive	Anti-RBD IgG	D1	Age	1.00	(1.00, 1.00)
Positive	Anti-Spike IgG	D1	Age	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID50	D1	Age	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID80	D1	Age	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID50	D1	Age	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID80	D1	Age	1.00	(1.00, 1.00)
Positive	Anti-RBD IgG	D29	Age	5.53	(3.28, 9.31)
Positive	Anti-Spike IgG	D29	Age	5.17	(3.20, 8.35)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Positive	Live Virus nAb ID50	D29	Age	2.29	(1.26, 4.17)
Positive	Live Virus nAb ID80	D29	Age	1.95	(1.04, 3.66)
Positive	Pseudo nAb ID50	D29	Age	4.47	(2.47, 8.10)
Positive	Pseudo nAb ID80	D29	Age	4.52	(2.53, 8.07)
Positive	Anti-RBD IgG	D57	Age	2.90	(1.64, 5.13)
Positive	Anti-Spike IgG	D57	Age	2.85	(1.77, 4.58)
Positive	Live Virus nAb ID50	D57	Age	4.16	(1.88, 9.24)
Positive	Live Virus nAb ID80	D57	Age	2.30	(1.07, 4.96)
Positive	Pseudo nAb ID50	D57	Age	3.80	(1.72, 8.39)
Positive	Pseudo nAb ID80	D57	Age	5.75	(2.53, 13.07)
Negative	Anti-RBD IgG	D1	High Risk	1.00	(1.00, 1.00)
Negative	Anti-Spike IgG	D1	High Risk	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID50	D1	High Risk	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID80	D1	High Risk	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID50	D1	High Risk	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID80	D1	High Risk	1.00	(1.00, 1.00)
Negative	Anti-RBD IgG	D29	High Risk	0.85	(0.68, 1.07)
Negative	Anti-Spike IgG	D29	High Risk	0.77	(0.63, 0.93)
Negative	Live Virus nAb ID50	D29	High Risk	0.98	(0.76, 1.26)
Negative	Live Virus nAb ID80	D29	High Risk	0.85	(0.67, 1.07)
Negative	Pseudo nAb ID50	D29	High Risk	0.78	(0.61, 1.00)
Negative	Pseudo nAb ID80	D29	High Risk	0.76	(0.61, 0.96)
Negative	Anti-RBD IgG	D57	High Risk	0.90	(0.70, 1.17)
Negative	Anti-Spike IgG	D57	High Risk	0.99	(0.80, 1.23)
Negative	Live Virus nAb ID50	D57	High Risk	0.83	(0.60, 1.14)
Negative	Live Virus nAb ID80	D57	High Risk	0.71	(0.50, 0.99)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Negative	Pseudo nAb ID50	D57	High Risk	0.93	(0.67, 1.28)
Negative	Pseudo nAb ID80	D57	High Risk	0.84	(0.59, 1.18)
Positive	Anti-RBD IgG	D1	High Risk	1.00	(1.00, 1.00)
Positive	Anti-Spike IgG	D1	High Risk	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID50	D1	High Risk	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID80	D1	High Risk	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID50	D1	High Risk	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID80	D1	High Risk	1.00	(1.00, 1.00)
Positive	Anti-RBD IgG	D29	High Risk	0.77	(0.49, 1.21)
Positive	Anti-Spike IgG	D29	High Risk	1.10	(0.72, 1.67)
Positive	Live Virus nAb ID50	D29	High Risk	1.11	(0.68, 1.80)
Positive	Live Virus nAb ID80	D29	High Risk	1.24	(0.75, 2.07)
Positive	Pseudo nAb ID50	D29	High Risk	0.79	(0.48, 1.30)
Positive	Pseudo nAb ID80	D29	High Risk	0.75	(0.46, 1.23)
Positive	Anti-RBD IgG	D57	High Risk	0.86	(0.54, 1.38)
Positive	Anti-Spike IgG	D57	High Risk	1.05	(0.71, 1.57)
Positive	Live Virus nAb ID50	D57	High Risk	0.95	(0.49, 1.82)
Positive	Live Virus nAb ID80	D57	High Risk	1.21	(0.65, 2.25)
Positive	Pseudo nAb ID50	D57	High Risk	1.59	(0.83, 3.03)
Positive	Pseudo nAb ID80	D57	High Risk	0.81	(0.41, 1.60)
Negative	Anti-RBD IgG	D1	Sex	1.00	(1.00, 1.00)
Negative	Anti-Spike IgG	D1	Sex	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID50	D1	Sex	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID80	D1	Sex	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID50	D1	Sex	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID80	D1	Sex	1.00	(1.00, 1.00)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Negative	Anti-RBD IgG	D29	Sex	1.08	(0.89, 1.32)
Negative	Anti-Spike IgG	D29	Sex	1.08	(0.91, 1.29)
Negative	Live Virus nAb ID50	D29	Sex	1.06	(0.85, 1.32)
Negative	Live Virus nAb ID80	D29	Sex	1.11	(0.91, 1.36)
Negative	Pseudo nAb ID50	D29	Sex	0.87	(0.70, 1.08)
Negative	Pseudo nAb ID80	D29	Sex	0.98	(0.80, 1.20)
Negative	Anti-RBD IgG	D57	Sex	1.14	(0.91, 1.42)
Negative	Anti-Spike IgG	D57	Sex	1.01	(0.84, 1.22)
Negative	Live Virus nAb ID50	D57	Sex	1.15	(0.87, 1.52)
Negative	Live Virus nAb ID80	D57	Sex	1.10	(0.82, 1.48)
Negative	Pseudo nAb ID50	D57	Sex	1.02	(0.77, 1.36)
Negative	Pseudo nAb ID80	D57	Sex	1.11	(0.82, 1.50)
Positive	Anti-RBD IgG	D1	Sex	1.00	(1.00, 1.00)
Positive	Anti-Spike IgG	D1	Sex	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID50	D1	Sex	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID80	D1	Sex	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID50	D1	Sex	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID80	D1	Sex	1.00	(1.00, 1.00)
Positive	Anti-RBD IgG	D29	Sex	1.21	(0.83, 1.76)
Positive	Anti-Spike IgG	D29	Sex	1.05	(0.74, 1.49)
Positive	Live Virus nAb ID50	D29	Sex	1.15	(0.77, 1.73)
Positive	Live Virus nAb ID80	D29	Sex	1.16	(0.76, 1.78)
Positive	Pseudo nAb ID50	D29	Sex	1.17	(0.77, 1.78)
Positive	Pseudo nAb ID80	D29	Sex	1.45	(0.96, 2.17)
Positive	Anti-RBD IgG	D57	Sex	0.91	(0.61, 1.35)
Positive	Anti-Spike IgG	D57	Sex	1.43	(1.03, 1.98)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Positive	Live Virus nAb ID50	D57	Sex	0.91	(0.52, 1.57)
Positive	Live Virus nAb ID80	D57	Sex	0.86	(0.51, 1.45)
Positive	Pseudo nAb ID50	D57	Sex	0.92	(0.53, 1.58)
Positive	Pseudo nAb ID80	D57	Sex	0.62	(0.35, 1.09)
Negative	Anti-RBD IgG	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Anti-Spike IgG	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID50	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID80	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID50	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID80	D1	Ethnicity	1.00	(1.00, 1.00)
Negative	Anti-RBD IgG	D29	Ethnicity	0.80	(0.57, 1.11)
Negative	Anti-Spike IgG	D29	Ethnicity	0.96	(0.71, 1.28)
Negative	Live Virus nAb ID50	D29	Ethnicity	0.62	(0.43, 0.89)
Negative	Live Virus nAb ID80	D29	Ethnicity	0.52	(0.37, 0.73)
Negative	Pseudo nAb ID50	D29	Ethnicity	0.76	(0.53, 1.10)
Negative	Pseudo nAb ID80	D29	Ethnicity	0.82	(0.59, 1.15)
Negative	Anti-RBD IgG	D57	Ethnicity	0.68	(0.47, 0.99)
Negative	Anti-Spike IgG	D57	Ethnicity	0.69	(0.51, 0.95)
Negative	Live Virus nAb ID50	D57	Ethnicity	0.73	(0.46, 1.16)
Negative	Live Virus nAb ID80	D57	Ethnicity	0.80	(0.49, 1.32)
Negative	Pseudo nAb ID50	D57	Ethnicity	0.56	(0.34, 0.90)
Negative	Pseudo nAb ID80	D57	Ethnicity	0.76	(0.46, 1.26)
Positive	Anti-RBD IgG	D1	Ethnicity	1.00	(1.00, 1.00)
Positive	Anti-Spike IgG	D1	Ethnicity	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID50	D1	Ethnicity	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID80	D1	Ethnicity	1.00	(1.00, 1.00)



Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Positive	Pseudo nAb ID50	D1	Ethnicity	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID80	D1	Ethnicity	1.00	(1.00, 1.00)
Positive	Anti-RBD IgG	D29	Ethnicity	1.35	(0.75, 2.42)
Positive	Anti-Spike IgG	D29	Ethnicity	0.74	(0.43, 1.28)
Positive	Live Virus nAb ID50	D29	Ethnicity	0.85	(0.46, 1.60)
Positive	Live Virus nAb ID80	D29	Ethnicity	0.83	(0.43, 1.60)
Positive	Pseudo nAb ID50	D29	Ethnicity	1.06	(0.55, 2.03)
Positive	Pseudo nAb ID80	D29	Ethnicity	1.20	(0.64, 2.27)
Positive	Anti-RBD IgG	D57	Ethnicity	0.65	(0.35, 1.21)
Positive	Anti-Spike IgG	D57	Ethnicity	0.93	(0.55, 1.55)
Positive	Live Virus nAb ID50	D57	Ethnicity	1.06	(0.45, 2.49)
Positive	Live Virus nAb ID80	D57	Ethnicity	0.73	(0.32, 1.63)
Positive	Pseudo nAb ID50	D57	Ethnicity	0.39	(0.17, 0.91)
Positive	Pseudo nAb ID80	D57	Ethnicity	1.12	(0.46, 2.71)
Negative	Anti-RBD IgG	D1	Minority	1.00	(1.00, 1.00)
Negative	Anti-Spike IgG	D1	Minority	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID50	D1	Minority	1.00	(1.00, 1.00)
Negative	Live Virus nAb ID80	D1	Minority	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID50	D1	Minority	1.00	(1.00, 1.00)
Negative	Pseudo nAb ID80	D1	Minority	1.00	(1.00, 1.00)
Negative	Anti-RBD IgG	D29	Minority	1.02	(0.82, 1.25)
Negative	Anti-Spike IgG	D29	Minority	0.92	(0.77, 1.11)
Negative	Live Virus nAb ID50	D29	Minority	1.19	(0.95, 1.50)
Negative	Live Virus nAb ID80	D29	Minority	1.26	(1.02, 1.56)
Negative	Pseudo nAb ID50	D29	Minority	0.96	(0.76, 1.20)
Negative	Pseudo nAb ID80	D29	Minority	1.06	(0.86, 1.31)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
Negative	Anti-RBD IgG	D57	Minority	1.24	(0.98, 1.57)
Negative	Anti-Spike IgG	D57	Minority	1.13	(0.93, 1.38)
Negative	Live Virus nAb ID50	D57	Minority	0.99	(0.74, 1.32)
Negative	Live Virus nAb ID80	D57	Minority	1.10	(0.80, 1.49)
Negative	Pseudo nAb ID50	D57	Minority	1.22	(0.91, 1.65)
Negative	Pseudo nAb ID80	D57	Minority	1.16	(0.84, 1.59)
Positive	Anti-RBD IgG	D1	Minority	1.00	(1.00, 1.00)
Positive	Anti-Spike IgG	D1	Minority	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID50	D1	Minority	1.00	(1.00, 1.00)
Positive	Live Virus nAb ID80	D1	Minority	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID50	D1	Minority	1.00	(1.00, 1.00)
Positive	Pseudo nAb ID80	D1	Minority	1.00	(1.00, 1.00)
Positive	Anti-RBD IgG	D29	Minority	1.03	(0.69, 1.54)
Positive	Anti-Spike IgG	D29	Minority	1.13	(0.78, 1.63)
Positive	Live Virus nAb ID50	D29	Minority	1.61	(1.06, 2.45)
Positive	Live Virus nAb ID80	D29	Minority	1.21	(0.77, 1.90)
Positive	Pseudo nAb ID50	D29	Minority	0.85	(0.54, 1.32)
Positive	Pseudo nAb ID80	D29	Minority	0.87	(0.57, 1.35)
Positive	Anti-RBD IgG	D57	Minority	1.87	(1.24, 2.81)
Positive	Anti-Spike IgG	D57	Minority	1.25	(0.88, 1.76)
Positive	Live Virus nAb ID50	D57	Minority	1.34	(0.75, 2.40)
Positive	Live Virus nAb ID80	D57	Minority	0.99	(0.57, 1.72)
Positive	Pseudo nAb ID50	D57	Minority	1.42	(0.80, 2.52)
Positive	Pseudo nAb ID80	D57	Minority	1.42	(0.78, 2.58)

Table 6: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 6: Ratios of GMTs/GMCs between demographic subgroups  
among the vaccine recipients (*continued*)

Baseline	Endpoint	Visit	comp_i	Ratios of GMT/GMC	95% CI
----------	----------	-------	--------	-------------------	--------

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm  
and the placebo arm

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-RBD IgG	Total	Total	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Total	Total	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Total	Total	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Total	Total	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Total	Total	D29	81.4%	65.8%	81.4%
Negative	Live Virus nAb ID50	Total	Total	D29	(78.1%, 84.7%)	(61.7%, 69.8%)	(78.1%, 84.7%)
Negative	Live Virus nAb ID80	Total	Total	D29	69.9%	55.9%	69.9%
Negative	Live Virus nAb ID80	Total	Total	D29	(66.0%, 73.8%)	(51.6%, 60.1%)	(66.0%, 73.8%)
Negative	Pseudo nAb ID50	Total	Total	D29	80.9%	68.8%	80.9%
Negative	Pseudo nAb ID50	Total	Total	D29	(77.6%, 84.3%)	(64.9%, 72.8%)	(77.6%, 84.3%)
Negative	Pseudo nAb ID80	Total	Total	D29	67.6%	54.2%	67.6%
Negative	Pseudo nAb ID80	Total	Total	D29	(63.6%, 71.6%)	(49.9%, 58.4%)	(63.6%, 71.6%)
Negative	Anti-RBD IgG	Total	Total	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Total	Total	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Total	Total	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Total	Total	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Total	Total	D57	97.4%	94.8%	97.4%
Negative	Live Virus nAb ID50	Total	Total	D57	(96.1%, 98.8%)	(92.9%, 96.7%)	(96.1%, 98.8%)
Negative	Live Virus nAb ID80	Total	Total	D57	94.7%	89.6%	94.7%
Negative	Live Virus nAb ID80	Total	Total	D57	(92.8%, 96.6%)	(87.0%, 92.2%)	(92.8%, 96.6%)
Negative	Pseudo nAb ID50	Total	Total	D57	97.7%	95.6%	97.7%
Negative	Pseudo nAb ID50	Total	Total	D57	(96.5%, 99.0%)	(93.9%, 97.4%)	(96.5%, 99.0%)
Negative	Pseudo nAb ID80	Total	Total	D57	94.6%	89.8%	94.6%
Negative	Pseudo nAb ID80	Total	Total	D57	(92.7%, 96.5%)	(87.2%, 92.4%)	(92.7%, 96.5%)
Positive	Anti-RBD IgG	Total	Total	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Total	Total	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Total	Total	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Total	Total	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID50	Total	Total	D29	26.3%	26.1%	26.3%
Positive	Live Virus nAb ID50	Total	Total	D29	(19.4%, 33.2%)	(18.2%, 33.9%)	(19.4%, 33.2%)
Positive	Live Virus nAb ID80	Total	Total	D29	22.4%	33.8%	22.4%
Positive	Live Virus nAb ID80	Total	Total	D29	(14.7%, 30.0%)	(25.8%, 41.9%)	(14.7%, 30.0%)
Positive	Pseudo nAb ID50	Total	Total	D29	19.5%	25.0%	19.5%
Positive	Pseudo nAb ID50	Total	Total	D29	(12.7%, 26.4%)	(17.2%, 32.7%)	(12.7%, 26.4%)
Positive	Pseudo nAb ID80	Total	Total	D29	19.1%	19.7%	19.1%
Positive	Pseudo nAb ID80	Total	Total	D29	(11.0%, 27.1%)	(11.2%, 28.1%)	(11.0%, 27.1%)
Positive	Anti-RBD IgG	Total	Total	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Total	Total	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Total	Total	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Total	Total	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Total	Total	D57	2.5%	6.2%	2.5%
Positive	Live Virus nAb ID50	Total	Total	D57	(-0.6%, 5.6%)	(2.0%, 10.3%)	(-0.6%, 5.6%)
Positive	Live Virus nAb ID80	Total	Total	D57	7.9%	14.0%	7.9%
Positive	Live Virus nAb ID80	Total	Total	D57	(4.5%, 11.3%)	(9.6%, 18.4%)	(4.5%, 11.3%)
Positive	Pseudo nAb ID50	Total	Total	D57	4.9%	7.1%	4.9%
Positive	Pseudo nAb ID50	Total	Total	D57	(1.3%, 8.4%)	(3.1%, 11.2%)	(1.3%, 8.4%)
Positive	Pseudo nAb ID80	Total	Total	D57	11.3%	16.3%	11.3%
Positive	Pseudo nAb ID80	Total	Total	D57	(6.9%, 15.8%)	(10.7%, 21.9%)	(6.9%, 15.8%)
Negative	Anti-RBD IgG	Age	Age < 65	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age	Age < 65	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age	Age < 65	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age	Age < 65	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age	Age < 65	D29	79.7%	62.9%	79.7%
Negative	Live Virus nAb ID50	Age	Age < 65	D29	(74.7%, 84.8%)	(56.9%, 68.9%)	(74.7%, 84.8%)
Negative	Live Virus nAb ID80	Age	Age < 65	D29	67.6%	52.8%	67.6%
Negative	Live Virus nAb ID80	Age	Age < 65	D29	(61.8%, 73.5%)	(46.6%, 59.1%)	(61.8%, 73.5%)
Negative	Pseudo nAb ID50	Age	Age < 65	D29	78.8%	65.5%	78.8%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Age	Age < 65	D29	(73.7%, 83.9%)	(59.6%, 71.4%)	(73.7%, 83.9%)
Negative	Pseudo nAb ID80	Age	Age < 65	D29	64.5%	50.7%	64.5%
Negative	Pseudo nAb ID80	Age	Age < 65	D29	(58.5%, 70.4%)	(44.4%, 56.9%)	(58.5%, 70.4%)
Negative	Anti-RBD IgG	Age	Age < 65	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age	Age < 65	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age	Age < 65	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age	Age < 65	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age	Age < 65	D57	97.3%	94.4%	97.3%
Negative	Live Virus nAb ID50	Age	Age < 65	D57	(95.3%, 99.3%)	(91.6%, 97.3%)	(95.3%, 99.3%)
Negative	Live Virus nAb ID80	Age	Age < 65	D57	94.3%	88.8%	94.3%
Negative	Live Virus nAb ID80	Age	Age < 65	D57	(91.4%, 97.2%)	(84.9%, 92.8%)	(91.4%, 97.2%)
Negative	Pseudo nAb ID50	Age	Age < 65	D57	97.6%	95.4%	97.6%
Negative	Pseudo nAb ID50	Age	Age < 65	D57	(95.7%, 99.5%)	(92.7%, 98.0%)	(95.7%, 99.5%)
Negative	Pseudo nAb ID80	Age	Age < 65	D57	94.1%	88.9%	94.1%
Negative	Pseudo nAb ID80	Age	Age < 65	D57	(91.2%, 97.1%)	(85.0%, 92.8%)	(91.2%, 97.1%)
Positive	Anti-RBD IgG	Age	Age < 65	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age	Age < 65	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age	Age < 65	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age	Age < 65	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age	Age < 65	D29	29.8%	27.7%	29.8%
Positive	Live Virus nAb ID50	Age	Age < 65	D29	(20.4%, 39.1%)	(17.1%, 38.2%)	(20.4%, 39.1%)
Positive	Live Virus nAb ID80	Age	Age < 65	D29	24.1%	36.2%	24.1%
Positive	Live Virus nAb ID80	Age	Age < 65	D29	(13.8%, 34.4%)	(25.5%, 46.9%)	(13.8%, 34.4%)
Positive	Pseudo nAb ID50	Age	Age < 65	D29	21.8%	27.4%	21.8%
Positive	Pseudo nAb ID50	Age	Age < 65	D29	(12.4%, 31.2%)	(16.9%, 37.9%)	(12.4%, 31.2%)
Positive	Pseudo nAb ID80	Age	Age < 65	D29	19.9%	19.1%	19.9%
Positive	Pseudo nAb ID80	Age	Age < 65	D29	(9.0%, 30.8%)	(7.9%, 30.3%)	(9.0%, 30.8%)
Positive	Anti-RBD IgG	Age	Age < 65	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age	Age < 65	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	Age	Age < 65	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age	Age < 65	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age	Age < 65	D57	2.6%	6.6%	2.6%
Positive	Live Virus nAb ID50	Age	Age < 65	D57	(-1.8%, 6.9%)	(0.8%, 12.5%)	(-1.8%, 6.9%)
Positive	Live Virus nAb ID80	Age	Age < 65	D57	8.7%	15.4%	8.7%
Positive	Live Virus nAb ID80	Age	Age < 65	D57	(4.1%, 13.4%)	(9.4%, 21.4%)	(4.1%, 13.4%)
Positive	Pseudo nAb ID50	Age	Age < 65	D57	5.5%	7.6%	5.5%
Positive	Pseudo nAb ID50	Age	Age < 65	D57	(0.5%, 10.5%)	(1.9%, 13.3%)	(0.5%, 10.5%)
Positive	Pseudo nAb ID80	Age	Age < 65	D57	12.5%	17.5%	12.5%
Positive	Pseudo nAb ID80	Age	Age < 65	D57	(6.2%, 18.7%)	(9.8%, 25.2%)	(6.2%, 18.7%)
Negative	Anti-RBD IgG	Age	Age >= 65	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age	Age >= 65	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age	Age >= 65	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age	Age >= 65	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age	Age >= 65	D29	90.6%	81.5%	90.6%
Negative	Live Virus nAb ID50	Age	Age >= 65	D29	(87.3%, 94.0%)	(77.1%, 86.0%)	(87.3%, 94.0%)
Negative	Live Virus nAb ID80	Age	Age >= 65	D29	82.5%	72.4%	82.5%
Negative	Live Virus nAb ID80	Age	Age >= 65	D29	(78.2%, 86.9%)	(67.3%, 77.5%)	(78.2%, 86.9%)
Negative	Pseudo nAb ID50	Age	Age >= 65	D29	92.5%	86.9%	92.5%
Negative	Pseudo nAb ID50	Age	Age >= 65	D29	(89.5%, 95.5%)	(83.1%, 90.8%)	(89.5%, 95.5%)
Negative	Pseudo nAb ID80	Age	Age >= 65	D29	84.6%	73.2%	84.6%
Negative	Pseudo nAb ID80	Age	Age >= 65	D29	(80.5%, 88.7%)	(68.1%, 78.2%)	(80.5%, 88.7%)
Negative	Anti-RBD IgG	Age	Age >= 65	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age	Age >= 65	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age	Age >= 65	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age	Age >= 65	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age	Age >= 65	D57	98.1%	96.6%	98.1%
Negative	Live Virus nAb ID50	Age	Age >= 65	D57	(96.5%, 99.6%)	(94.5%, 98.6%)	(96.5%, 99.6%)
Negative	Live Virus nAb ID80	Age	Age >= 65	D57	96.8%	93.6%	96.8%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID80	Age	Age $\geq$ 65	D57	(94.8%, 98.8%)	(90.8%, 96.4%)	(94.8%, 98.8%)
Negative	Pseudo nAb ID50	Age	Age $\geq$ 65	D57	98.5%	97.2%	98.5%
Negative	Pseudo nAb ID50	Age	Age $\geq$ 65	D57	(97.2%, 99.9%)	(95.4%, 99.1%)	(97.2%, 99.9%)
Negative	Pseudo nAb ID80	Age	Age $\geq$ 65	D57	97.2%	94.7%	97.2%
Negative	Pseudo nAb ID80	Age	Age $\geq$ 65	D57	(95.4%, 99.1%)	(92.2%, 97.3%)	(95.4%, 99.1%)
Positive	Anti-RBD IgG	Age	Age $\geq$ 65	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age	Age $\geq$ 65	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age	Age $\geq$ 65	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age	Age $\geq$ 65	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age	Age $\geq$ 65	D29	4.4%	16.2%	4.4%
Positive	Live Virus nAb ID50	Age	Age $\geq$ 65	D29	(-3.4%, 12.2%)	(6.1%, 26.2%)	(-3.4%, 12.2%)
Positive	Live Virus nAb ID80	Age	Age $\geq$ 65	D29	11.7%	19.1%	11.7%
Positive	Live Virus nAb ID80	Age	Age $\geq$ 65	D29	(2.0%, 21.4%)	(7.6%, 30.6%)	(2.0%, 21.4%)
Positive	Pseudo nAb ID50	Age	Age $\geq$ 65	D29	5.5%	10.1%	5.5%
Positive	Pseudo nAb ID50	Age	Age $\geq$ 65	D29	(-1.0%, 12.0%)	(1.6%, 18.6%)	(-1.0%, 12.0%)
Positive	Pseudo nAb ID80	Age	Age $\geq$ 65	D29	14.9%	24.2%	14.9%
Positive	Pseudo nAb ID80	Age	Age $\geq$ 65	D29	(5.7%, 24.1%)	(12.6%, 35.8%)	(5.7%, 24.1%)
Positive	Anti-RBD IgG	Age	Age $\geq$ 65	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age	Age $\geq$ 65	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age	Age $\geq$ 65	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age	Age $\geq$ 65	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age	Age $\geq$ 65	D57	2.4%	3.3%	2.4%
Positive	Live Virus nAb ID50	Age	Age $\geq$ 65	D57	(-0.4%, 5.2%)	(-0.0%, 6.5%)	(-0.4%, 5.2%)
Positive	Live Virus nAb ID80	Age	Age $\geq$ 65	D57	2.7%	5.1%	2.7%
Positive	Live Virus nAb ID80	Age	Age $\geq$ 65	D57	(-1.1%, 6.5%)	(-0.6%, 10.9%)	(-1.1%, 6.5%)
Positive	Pseudo nAb ID50	Age	Age $\geq$ 65	D57	0.9%	4.2%	0.9%
Positive	Pseudo nAb ID50	Age	Age $\geq$ 65	D57	(-0.8%, 2.6%)	(0.5%, 7.8%)	(-0.8%, 2.6%)
Positive	Pseudo nAb ID80	Age	Age $\geq$ 65	D57	4.2%	8.6%	4.2%



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID80	Age	Age $\geq 65$	D57	(0.5%, 7.8%)	(3.5%, 13.8%)	(0.5%, 7.8%)
Negative	Anti-RBD IgG	High Risk	At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	High Risk	At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	High Risk	At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	High Risk	At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	High Risk	At-risk	D29	79.1%	66.1%	79.1%
Negative	Live Virus nAb ID50	High Risk	At-risk	D29	(74.4%, 83.9%)	(60.5%, 71.6%)	(74.4%, 83.9%)
Negative	Live Virus nAb ID80	High Risk	At-risk	D29	72.3%	58.4%	72.3%
Negative	Live Virus nAb ID80	High Risk	At-risk	D29	(67.1%, 77.6%)	(52.6%, 64.2%)	(67.1%, 77.6%)
Negative	Pseudo nAb ID50	High Risk	At-risk	D29	81.6%	70.6%	81.6%
Negative	Pseudo nAb ID50	High Risk	At-risk	D29	(77.1%, 86.1%)	(65.2%, 75.9%)	(77.1%, 86.1%)
Negative	Pseudo nAb ID80	High Risk	At-risk	D29	71.3%	57.5%	71.3%
Negative	Pseudo nAb ID80	High Risk	At-risk	D29	(66.0%, 76.6%)	(51.7%, 63.3%)	(66.0%, 76.6%)
Negative	Anti-RBD IgG	High Risk	At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	High Risk	At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	High Risk	At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	High Risk	At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	High Risk	At-risk	D57	97.5%	92.1%	97.5%
Negative	Live Virus nAb ID50	High Risk	At-risk	D57	(95.7%, 99.3%)	(88.9%, 95.2%)	(95.7%, 99.3%)
Negative	Live Virus nAb ID80	High Risk	At-risk	D57	94.3%	91.2%	94.3%
Negative	Live Virus nAb ID80	High Risk	At-risk	D57	(91.6%, 97.0%)	(87.9%, 94.5%)	(91.6%, 97.0%)
Negative	Pseudo nAb ID50	High Risk	At-risk	D57	96.1%	94.1%	96.1%
Negative	Pseudo nAb ID50	High Risk	At-risk	D57	(93.9%, 98.4%)	(91.3%, 96.9%)	(93.9%, 98.4%)
Negative	Pseudo nAb ID80	High Risk	At-risk	D57	95.2%	90.4%	95.2%
Negative	Pseudo nAb ID80	High Risk	At-risk	D57	(92.7%, 97.7%)	(87.0%, 93.9%)	(92.7%, 97.7%)
Positive	Anti-RBD IgG	High Risk	At-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	High Risk	At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	High Risk	At-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	High Risk	At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID50	High Risk	At-risk	D29	30.5%	34.3%	30.5%
Positive	Live Virus nAb ID50	High Risk	At-risk	D29	(20.1%, 40.8%)	(22.3%, 46.3%)	(20.1%, 40.8%)
Positive	Live Virus nAb ID80	High Risk	At-risk	D29	23.7%	28.7%	23.7%
Positive	Live Virus nAb ID80	High Risk	At-risk	D29	(11.8%, 35.5%)	(16.0%, 41.3%)	(11.8%, 35.5%)
Positive	Pseudo nAb ID50	High Risk	At-risk	D29	27.7%	23.2%	27.7%
Positive	Pseudo nAb ID50	High Risk	At-risk	D29	(17.5%, 38.0%)	(11.3%, 35.0%)	(17.5%, 38.0%)
Positive	Pseudo nAb ID80	High Risk	At-risk	D29	23.0%	29.1%	23.0%
Positive	Pseudo nAb ID80	High Risk	At-risk	D29	(10.8%, 35.2%)	(16.4%, 41.7%)	(10.8%, 35.2%)
Positive	Anti-RBD IgG	High Risk	At-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	High Risk	At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	High Risk	At-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	High Risk	At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	High Risk	At-risk	D57	2.8%	11.2%	2.8%
Positive	Live Virus nAb ID50	High Risk	At-risk	D57	(-1.3%, 6.9%)	(4.4%, 18.1%)	(-1.3%, 6.9%)
Positive	Live Virus nAb ID80	High Risk	At-risk	D57	14.6%	20.2%	14.6%
Positive	Live Virus nAb ID80	High Risk	At-risk	D57	(7.6%, 21.5%)	(11.9%, 28.6%)	(7.6%, 21.5%)
Positive	Pseudo nAb ID50	High Risk	At-risk	D57	5.6%	6.3%	5.6%
Positive	Pseudo nAb ID50	High Risk	At-risk	D57	(0.6%, 10.7%)	(-0.1%, 12.6%)	(0.6%, 10.7%)
Positive	Pseudo nAb ID80	High Risk	At-risk	D57	12.9%	21.9%	12.9%
Positive	Pseudo nAb ID80	High Risk	At-risk	D57	(6.2%, 19.6%)	(13.0%, 30.9%)	(6.2%, 19.6%)
Negative	Anti-RBD IgG	High Risk	Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	High Risk	Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	High Risk	Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	High Risk	Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	High Risk	Not at-risk	D29	82.2%	65.7%	82.2%
Negative	Live Virus nAb ID50	High Risk	Not at-risk	D29	(77.5%, 86.9%)	(59.8%, 71.6%)	(77.5%, 86.9%)
Negative	Live Virus nAb ID80	High Risk	Not at-risk	D29	69.1%	55.0%	69.1%
Negative	Live Virus nAb ID80	High Risk	Not at-risk	D29	(63.4%, 74.9%)	(48.9%, 61.2%)	(63.4%, 74.9%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	High Risk	Not at-risk	D29	80.7%	68.2%	80.7%
Negative	Pseudo nAb ID50	High Risk	Not at-risk	D29	(75.8%, 85.6%)	(62.5%, 74.0%)	(75.8%, 85.6%)
Negative	Pseudo nAb ID80	High Risk	Not at-risk	D29	66.3%	53.1%	66.3%
Negative	Pseudo nAb ID80	High Risk	Not at-risk	D29	(60.5%, 72.2%)	(46.9%, 59.2%)	(60.5%, 72.2%)
Negative	Anti-RBD IgG	High Risk	Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	High Risk	Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	High Risk	Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	High Risk	Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	High Risk	Not at-risk	D57	97.4%	95.7%	97.4%
Negative	Live Virus nAb ID50	High Risk	Not at-risk	D57	(95.4%, 99.4%)	(93.1%, 98.2%)	(95.4%, 99.4%)
Negative	Live Virus nAb ID80	High Risk	Not at-risk	D57	94.9%	89.0%	94.9%
Negative	Live Virus nAb ID80	High Risk	Not at-risk	D57	(92.1%, 97.6%)	(85.2%, 92.9%)	(92.1%, 97.6%)
Negative	Pseudo nAb ID50	High Risk	Not at-risk	D57	98.3%	96.2%	98.3%
Negative	Pseudo nAb ID50	High Risk	Not at-risk	D57	(96.7%, 99.9%)	(93.8%, 98.5%)	(96.7%, 99.9%)
Negative	Pseudo nAb ID80	High Risk	Not at-risk	D57	94.4%	89.6%	94.4%
Negative	Pseudo nAb ID80	High Risk	Not at-risk	D57	(91.6%, 97.3%)	(85.8%, 93.4%)	(91.6%, 97.3%)
Positive	Anti-RBD IgG	High Risk	Not at-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	High Risk	Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	High Risk	Not at-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	High Risk	Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	High Risk	Not at-risk	D29	25.1%	23.6%	25.1%
Positive	Live Virus nAb ID50	High Risk	Not at-risk	D29	(16.0%, 34.3%)	(13.3%, 34.0%)	(16.0%, 34.3%)
Positive	Live Virus nAb ID80	High Risk	Not at-risk	D29	22.0%	35.3%	22.0%
Positive	Live Virus nAb ID80	High Risk	Not at-risk	D29	(12.0%, 32.0%)	(24.8%, 45.9%)	(12.0%, 32.0%)
Positive	Pseudo nAb ID50	High Risk	Not at-risk	D29	17.2%	25.5%	17.2%
Positive	Pseudo nAb ID50	High Risk	Not at-risk	D29	(8.1%, 26.2%)	(15.2%, 35.7%)	(8.1%, 26.2%)
Positive	Pseudo nAb ID80	High Risk	Not at-risk	D29	17.9%	16.9%	17.9%
Positive	Pseudo nAb ID80	High Risk	Not at-risk	D29	(7.3%, 28.6%)	(5.7%, 28.1%)	(7.3%, 28.6%)
Positive	Anti-RBD IgG	High Risk	Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	High Risk	Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	High Risk	Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	High Risk	Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	High Risk	Not at-risk	D57	2.4%	4.7%	2.4%
Positive	Live Virus nAb ID50	High Risk	Not at-risk	D57	(-1.8%, 6.7%)	(-0.7%, 10.0%)	(-1.8%, 6.7%)
Positive	Live Virus nAb ID80	High Risk	Not at-risk	D57	6.0%	12.2%	6.0%
Positive	Live Virus nAb ID80	High Risk	Not at-risk	D57	(2.1%, 9.8%)	(6.9%, 17.5%)	(2.1%, 9.8%)
Positive	Pseudo nAb ID50	High Risk	Not at-risk	D57	4.6%	7.4%	4.6%
Positive	Pseudo nAb ID50	High Risk	Not at-risk	D57	(-0.1%, 9.4%)	(2.0%, 12.7%)	(-0.1%, 9.4%)
Positive	Pseudo nAb ID80	High Risk	Not at-risk	D57	10.9%	14.7%	10.9%
Positive	Pseudo nAb ID80	High Risk	Not at-risk	D57	(4.9%, 16.8%)	(7.5%, 21.9%)	(4.9%, 16.8%)
Negative	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D29	75.4%	60.3%	75.4%
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D29	(67.9%, 82.8%)	(51.8%, 68.8%)	(67.9%, 82.8%)
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D29	69.0%	53.0%	69.0%
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D29	(61.0%, 77.0%)	(44.3%, 61.6%)	(61.0%, 77.0%)
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D29	78.1%	63.9%	78.1%
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D29	(70.9%, 85.3%)	(55.6%, 72.3%)	(70.9%, 85.3%)
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D29	66.2%	51.6%	66.2%
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D29	(58.0%, 74.4%)	(42.9%, 60.2%)	(58.0%, 74.4%)
Negative	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D57	97.7%	90.8%	97.7%
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D57	(95.1%, 100.3%)	(85.8%, 95.8%)	(95.1%, 100.3%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D57	94.1%	90.9%	94.1%
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D57	(90.0%, 98.2%)	(85.9%, 95.9%)	(90.0%, 98.2%)
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D57	95.4%	93.6%	95.4%
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D57	(91.8%, 99.0%)	(89.4%, 97.8%)	(91.8%, 99.0%)
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D57	95.0%	89.5%	95.0%
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D57	(91.2%, 98.8%)	(84.1%, 94.8%)	(91.2%, 98.8%)
Positive	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D29	35.1%	37.2%	35.1%
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D29	(21.9%, 48.3%)	(22.2%, 52.1%)	(21.9%, 48.3%)
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D29	24.6%	29.3%	24.6%
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D29	(9.6%, 39.5%)	(13.8%, 44.9%)	(9.6%, 39.5%)
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D29	32.3%	25.9%	32.3%
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D29	(19.2%, 45.4%)	(11.0%, 40.9%)	(19.2%, 45.4%)
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D29	26.1%	30.8%	26.1%
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D29	(10.8%, 41.4%)	(15.4%, 46.2%)	(10.8%, 41.4%)
Positive	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age < 65 At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Risk	Age < 65 At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D57	2.8%	12.6%	2.8%
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 At-risk	D57	(-2.4%, 8.1%)	(3.6%, 21.6%)	(-2.4%, 8.1%)
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D57	16.7%	23.7%	16.7%
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 At-risk	D57	(7.6%, 25.9%)	(13.0%, 34.4%)	(7.6%, 25.9%)
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D57	7.0%	7.1%	7.0%
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 At-risk	D57	(0.2%, 13.8%)	(-1.4%, 15.6%)	(0.2%, 13.8%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D57	15.3%	25.2%	15.3%
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 At-risk	D57	(6.5%, 24.2%)	(13.5%, 36.9%)	(6.5%, 24.2%)
Negative	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	80.8%	63.6%	80.8%
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	(73.8%, 87.9%)	(54.9%, 72.2%)	(73.8%, 87.9%)
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	67.3%	52.8%	67.3%
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	(58.9%, 75.7%)	(43.9%, 61.7%)	(58.9%, 75.7%)
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	79.0%	65.9%	79.0%
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	(71.7%, 86.3%)	(57.4%, 74.4%)	(71.7%, 86.3%)
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	64.0%	50.5%	64.0%
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	(55.4%, 72.6%)	(41.5%, 59.4%)	(55.4%, 72.6%)
Negative	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	97.2%	95.3%	97.2%
Negative	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	(94.2%, 100.1%)	(91.6%, 99.1%)	(94.2%, 100.1%)
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	94.4%	88.3%	94.4%
Negative	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	(90.3%, 98.5%)	(82.6%, 94.1%)	(90.3%, 98.5%)
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	98.1%	95.8%	98.1%
Negative	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	(95.7%, 100.6%)	(92.2%, 99.4%)	(95.7%, 100.6%)
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	93.9%	88.8%	93.9%
Negative	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	(89.7%, 98.2%)	(83.1%, 94.4%)	(89.7%, 98.2%)
Positive	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D29	-0.0%	-0.0%	-0.0%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	28.4%	25.1%	28.4%
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	(15.1%, 41.6%)	(10.3%, 40.0%)	(15.1%, 41.6%)
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	24.0%	38.0%	24.0%
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	(9.5%, 38.5%)	(23.1%, 53.0%)	(9.5%, 38.5%)
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	19.0%	27.8%	19.0%
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D29	(5.7%, 32.3%)	(12.9%, 42.7%)	(5.7%, 32.3%)
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	18.2%	16.0%	18.2%
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D29	(2.7%, 33.7%)	(0.0%, 32.0%)	(2.7%, 33.7%)
Positive	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age < 65 Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Risk	Age < 65 Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	2.5%	5.0%	2.5%
Positive	Live Virus nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	(-3.8%, 8.8%)	(-3.0%, 13.1%)	(-3.8%, 8.8%)
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	6.6%	13.2%	6.6%
Positive	Live Virus nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	(1.0%, 12.2%)	(5.5%, 20.8%)	(1.0%, 12.2%)
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	5.1%	7.7%	5.1%
Positive	Pseudo nAb ID50	Age, Risk	Age < 65 Not at-risk	D57	(-2.1%, 12.3%)	(-0.2%, 15.7%)	(-2.1%, 12.3%)
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	11.7%	15.5%	11.7%
Positive	Pseudo nAb ID80	Age, Risk	Age < 65 Not at-risk	D57	(2.9%, 20.5%)	(4.8%, 26.1%)	(2.9%, 20.5%)
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D29	87.0%	78.1%	87.0%
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D29	(81.6%, 92.4%)	(71.4%, 84.7%)	(81.6%, 92.4%)
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D29	79.3%	69.6%	79.3%
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D29	(72.7%, 85.8%)	(62.2%, 77.0%)	(72.7%, 85.8%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D29	88.9%	84.3%	88.9%
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D29	(83.8%, 94.0%)	(78.5%, 90.2%)	(83.8%, 94.0%)
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D29	81.8%	69.7%	81.8%
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D29	(75.6%, 88.1%)	(62.3%, 77.1%)	(75.6%, 88.1%)
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D57	97.1%	94.6%	97.1%
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D57	(94.4%, 99.8%)	(91.0%, 98.3%)	(94.4%, 99.8%)
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D57	94.7%	91.9%	94.7%
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D57	(91.1%, 98.3%)	(87.5%, 96.3%)	(91.1%, 98.3%)
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D57	97.6%	95.1%	97.6%
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D57	(95.2%, 100.1%)	(91.7%, 98.6%)	(95.2%, 100.1%)
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D57	95.6%	92.5%	95.6%
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D57	(92.4%, 98.9%)	(88.2%, 96.7%)	(92.4%, 98.9%)
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D29	11.3%	22.6%	11.3%
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D29	(-1.0%, 23.6%)	(6.5%, 38.7%)	(-1.0%, 23.6%)
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D29	20.0%	26.0%	20.0%
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D29	(3.2%, 36.9%)	(6.8%, 45.1%)	(3.2%, 36.9%)
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D29	8.5%	11.7%	8.5%
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D29	(-2.8%, 19.9%)	(-3.8%, 27.1%)	(-2.8%, 19.9%)
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D29	10.0%	21.9%	10.0%
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D29	(-5.9%, 25.9%)	(1.4%, 42.4%)	(-5.9%, 25.9%)
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D57	0.0%	0.0%	0.0%



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 At-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D57	2.8%	5.6%	2.8%
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 At-risk	D57	(-2.5%, 8.1%)	(-1.8%, 12.9%)	(-2.5%, 8.1%)
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D57	5.6%	5.7%	5.6%
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 At-risk	D57	(-1.8%, 12.9%)	(-4.5%, 16.0%)	(-1.8%, 12.9%)
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D57	0.0%	2.8%	0.0%
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 At-risk	D57	(-0.0%, 0.0%)	(-2.5%, 8.1%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D57	2.8%	8.3%	2.8%
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 At-risk	D57	(-2.5%, 8.1%)	(-0.5%, 17.2%)	(-2.5%, 8.1%)
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	94.7%	85.4%	94.7%
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	(91.0%, 98.4%)	(79.6%, 91.2%)	(91.0%, 98.4%)
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	86.2%	75.6%	86.2%
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	(80.6%, 91.8%)	(68.6%, 82.6%)	(80.6%, 91.8%)
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	96.5%	89.8%	96.5%
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	(93.4%, 99.5%)	(84.9%, 94.8%)	(93.4%, 99.5%)
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	87.6%	77.0%	87.6%
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	(82.2%, 93.0%)	(70.1%, 83.9%)	(82.2%, 93.0%)
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	99.1%	98.7%	99.1%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	(97.6%, 100.6%)	(96.8%, 100.5%)	(97.6%, 100.6%)
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	99.1%	95.6%	99.1%
Negative	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	(97.6%, 100.6%)	(92.2%, 98.9%)	(97.6%, 100.6%)
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	99.6%	99.6%	99.6%
Negative	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	(98.5%, 100.6%)	(98.5%, 100.6%)	(98.5%, 100.6%)
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	99.0%	97.2%	99.0%
Negative	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	(97.4%, 100.6%)	(94.6%, 99.9%)	(97.4%, 100.6%)
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	1.0%	12.9%	1.0%
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	(-9.0%, 10.9%)	(0.1%, 25.7%)	(-9.0%, 10.9%)
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	7.6%	15.7%	7.6%
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	(-4.3%, 19.5%)	(1.3%, 30.1%)	(-4.3%, 19.5%)
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	4.0%	9.3%	4.0%
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D29	(-4.0%, 12.0%)	(-1.0%, 19.6%)	(-4.0%, 12.0%)
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	17.3%	25.3%	17.3%
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D29	(5.9%, 28.6%)	(11.2%, 39.5%)	(5.9%, 28.6%)
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Risk	Age >= 65 Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Risk	Age >= 65 Not at-risk	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	2.2%	2.2%	2.2%
Positive	Live Virus nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	(-1.1%, 5.4%)	(-1.1%, 5.4%)	(-1.1%, 5.4%)
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	1.3%	4.8%	1.3%
Positive	Live Virus nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	(-3.1%, 5.8%)	(-2.1%, 11.8%)	(-3.1%, 5.8%)
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	1.3%	4.8%	1.3%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID50	Age, Risk	Age >= 65 Not at-risk	D57	(-1.3%, 3.9%)	(-0.0%, 9.6%)	(-1.3%, 3.9%)
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	4.8%	8.8%	4.8%
Positive	Pseudo nAb ID80	Age, Risk	Age >= 65 Not at-risk	D57	(-0.0%, 9.6%)	(2.4%, 15.2%)	(-0.0%, 9.6%)
Negative	Anti-RBD IgG	Sex	Female	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Sex	Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Sex	Female	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Sex	Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Sex	Female	D29	79.8%	63.2%	79.8%
Negative	Live Virus nAb ID50	Sex	Female	D29	(75.1%, 84.5%)	(57.6%, 68.9%)	(75.1%, 84.5%)
Negative	Live Virus nAb ID80	Sex	Female	D29	68.1%	54.5%	68.1%
Negative	Live Virus nAb ID80	Sex	Female	D29	(62.7%, 73.5%)	(48.7%, 60.3%)	(62.7%, 73.5%)
Negative	Pseudo nAb ID50	Sex	Female	D29	82.0%	69.9%	82.0%
Negative	Pseudo nAb ID50	Sex	Female	D29	(77.5%, 86.4%)	(64.5%, 75.2%)	(77.5%, 86.4%)
Negative	Pseudo nAb ID80	Sex	Female	D29	68.5%	53.9%	68.5%
Negative	Pseudo nAb ID80	Sex	Female	D29	(63.1%, 73.9%)	(48.1%, 59.7%)	(63.1%, 73.9%)
Negative	Anti-RBD IgG	Sex	Female	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Sex	Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Sex	Female	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Sex	Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Sex	Female	D57	96.4%	94.2%	96.4%
Negative	Live Virus nAb ID50	Sex	Female	D57	(94.2%, 98.5%)	(91.5%, 97.0%)	(94.2%, 98.5%)
Negative	Live Virus nAb ID80	Sex	Female	D57	94.0%	87.6%	94.0%
Negative	Live Virus nAb ID80	Sex	Female	D57	(91.2%, 96.7%)	(83.8%, 91.5%)	(91.2%, 96.7%)
Negative	Pseudo nAb ID50	Sex	Female	D57	98.0%	96.4%	98.0%
Negative	Pseudo nAb ID50	Sex	Female	D57	(96.4%, 99.6%)	(94.2%, 98.6%)	(96.4%, 99.6%)
Negative	Pseudo nAb ID80	Sex	Female	D57	93.0%	88.6%	93.0%
Negative	Pseudo nAb ID80	Sex	Female	D57	(90.0%, 96.0%)	(84.9%, 92.3%)	(90.0%, 96.0%)
Positive	Anti-RBD IgG	Sex	Female	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Sex	Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	Sex	Female	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Sex	Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Sex	Female	D29	25.3%	21.4%	25.3%
Positive	Live Virus nAb ID50	Sex	Female	D29	(16.4%, 34.3%)	(10.6%, 32.1%)	(16.4%, 34.3%)
Positive	Live Virus nAb ID80	Sex	Female	D29	18.3%	29.0%	18.3%
Positive	Live Virus nAb ID80	Sex	Female	D29	(8.1%, 28.5%)	(18.1%, 40.0%)	(8.1%, 28.5%)
Positive	Pseudo nAb ID50	Sex	Female	D29	16.6%	27.0%	16.6%
Positive	Pseudo nAb ID50	Sex	Female	D29	(7.3%, 26.0%)	(16.4%, 37.6%)	(7.3%, 26.0%)
Positive	Pseudo nAb ID80	Sex	Female	D29	19.6%	23.7%	19.6%
Positive	Pseudo nAb ID80	Sex	Female	D29	(8.6%, 30.6%)	(12.6%, 34.9%)	(8.6%, 30.6%)
Positive	Anti-RBD IgG	Sex	Female	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Sex	Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Sex	Female	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Sex	Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Sex	Female	D57	-0.5%	4.9%	-0.5%
Positive	Live Virus nAb ID50	Sex	Female	D57	(-3.3%, 2.3%)	(0.1%, 9.8%)	(-3.3%, 2.3%)
Positive	Live Virus nAb ID80	Sex	Female	D57	9.1%	12.9%	9.1%
Positive	Live Virus nAb ID80	Sex	Female	D57	(4.3%, 13.8%)	(7.0%, 18.7%)	(4.3%, 13.8%)
Positive	Pseudo nAb ID50	Sex	Female	D57	1.8%	5.1%	1.8%
Positive	Pseudo nAb ID50	Sex	Female	D57	(-1.9%, 5.5%)	(-0.0%, 10.2%)	(-1.9%, 5.5%)
Positive	Pseudo nAb ID80	Sex	Female	D57	9.2%	13.9%	9.2%
Positive	Pseudo nAb ID80	Sex	Female	D57	(3.4%, 14.9%)	(7.0%, 20.9%)	(3.4%, 14.9%)
Negative	Anti-RBD IgG	Sex	Male	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Sex	Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Sex	Male	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Sex	Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Sex	Male	D29	83.4%	68.9%	83.4%
Negative	Live Virus nAb ID50	Sex	Male	D29	(78.8%, 88.1%)	(63.1%, 74.7%)	(78.8%, 88.1%)
Negative	Live Virus nAb ID80	Sex	Male	D29	72.2%	57.5%	72.2%
Negative	Live Virus nAb ID80	Sex	Male	D29	(66.6%, 77.8%)	(51.3%, 63.7%)	(66.6%, 77.8%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Sex	Male	D29	79.7%	67.5%	79.7%
Negative	Pseudo nAb ID50	Sex	Male	D29	(74.6%, 84.7%)	(61.7%, 73.4%)	(74.6%, 84.7%)
Negative	Pseudo nAb ID80	Sex	Male	D29	66.4%	54.5%	66.4%
Negative	Pseudo nAb ID80	Sex	Male	D29	(60.5%, 72.4%)	(48.2%, 60.7%)	(60.5%, 72.4%)
Negative	Anti-RBD IgG	Sex	Male	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Sex	Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Sex	Male	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Sex	Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Sex	Male	D57	98.7%	95.4%	98.7%
Negative	Live Virus nAb ID50	Sex	Male	D57	(97.3%, 100.1%)	(92.7%, 98.0%)	(97.3%, 100.1%)
Negative	Live Virus nAb ID80	Sex	Male	D57	95.6%	91.9%	95.6%
Negative	Live Virus nAb ID80	Sex	Male	D57	(93.0%, 98.2%)	(88.5%, 95.3%)	(93.0%, 98.2%)
Negative	Pseudo nAb ID50	Sex	Male	D57	97.4%	94.8%	97.4%
Negative	Pseudo nAb ID50	Sex	Male	D57	(95.4%, 99.4%)	(92.0%, 97.5%)	(95.4%, 99.4%)
Negative	Pseudo nAb ID80	Sex	Male	D57	96.6%	91.3%	96.6%
Negative	Pseudo nAb ID80	Sex	Male	D57	(94.3%, 98.9%)	(87.8%, 94.9%)	(94.3%, 98.9%)
Positive	Anti-RBD IgG	Sex	Male	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Sex	Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Sex	Male	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Sex	Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Sex	Male	D29	28.6%	31.8%	28.6%
Positive	Live Virus nAb ID50	Sex	Male	D29	(17.8%, 39.4%)	(20.3%, 43.2%)	(17.8%, 39.4%)
Positive	Live Virus nAb ID80	Sex	Male	D29	28.4%	40.1%	28.4%
Positive	Live Virus nAb ID80	Sex	Male	D29	(16.9%, 40.0%)	(28.3%, 52.0%)	(16.9%, 40.0%)
Positive	Pseudo nAb ID50	Sex	Male	D29	23.2%	21.2%	23.2%
Positive	Pseudo nAb ID50	Sex	Male	D29	(13.2%, 33.2%)	(9.8%, 32.6%)	(13.2%, 33.2%)
Positive	Pseudo nAb ID80	Sex	Male	D29	16.9%	13.3%	16.9%
Positive	Pseudo nAb ID80	Sex	Male	D29	(5.2%, 28.7%)	(0.3%, 26.2%)	(5.2%, 28.7%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Sex	Male	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Sex	Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Sex	Male	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Sex	Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Sex	Male	D57	7.3%	8.4%	7.3%
Positive	Live Virus nAb ID50	Sex	Male	D57	(1.2%, 13.3%)	(1.3%, 15.6%)	(1.2%, 13.3%)
Positive	Live Virus nAb ID80	Sex	Male	D57	6.3%	15.7%	6.3%
Positive	Live Virus nAb ID80	Sex	Male	D57	(1.5%, 11.1%)	(9.0%, 22.5%)	(1.5%, 11.1%)
Positive	Pseudo nAb ID50	Sex	Male	D57	9.7%	10.2%	9.7%
Positive	Pseudo nAb ID50	Sex	Male	D57	(3.2%, 16.2%)	(3.6%, 16.8%)	(3.2%, 16.2%)
Positive	Pseudo nAb ID80	Sex	Male	D57	14.6%	20.4%	14.6%
Positive	Pseudo nAb ID80	Sex	Male	D57	(7.5%, 21.6%)	(11.3%, 29.4%)	(7.5%, 21.6%)
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Female	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Female	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D29	77.6%	60.0%	77.6%
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D29	(70.5%, 84.8%)	(51.6%, 68.3%)	(70.5%, 84.8%)
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D29	65.3%	51.0%	65.3%
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D29	(57.2%, 73.5%)	(42.5%, 59.6%)	(57.2%, 73.5%)
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D29	80.3%	67.0%	80.3%
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D29	(73.5%, 87.1%)	(59.0%, 75.1%)	(73.5%, 87.1%)
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D29	65.8%	51.0%	65.8%
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D29	(57.7%, 73.9%)	(42.4%, 59.6%)	(57.7%, 73.9%)
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Female	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Female	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D57	96.3%	94.1%	96.3%
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D57	(93.0%, 99.5%)	(90.1%, 98.1%)	(93.0%, 99.5%)
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D57	93.4%	86.7%	93.4%
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D57	(89.2%, 97.7%)	(80.9%, 92.5%)	(89.2%, 97.7%)
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D57	98.0%	96.3%	98.0%
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D57	(95.6%, 100.4%)	(93.1%, 99.5%)	(95.6%, 100.4%)
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D57	92.2%	87.7%	92.2%
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D57	(87.7%, 96.8%)	(82.1%, 93.3%)	(87.7%, 96.8%)
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Female	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Female	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D29	27.1%	21.6%	27.1%
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D29	(15.4%, 38.9%)	(7.5%, 35.6%)	(15.4%, 38.9%)
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D29	18.3%	28.9%	18.3%
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D29	(5.0%, 31.6%)	(14.7%, 43.1%)	(5.0%, 31.6%)
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D29	18.0%	28.5%	18.0%
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D29	(5.6%, 30.5%)	(14.6%, 42.4%)	(5.6%, 30.5%)
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D29	20.0%	23.0%	20.0%
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D29	(5.6%, 34.4%)	(8.7%, 37.3%)	(5.6%, 34.4%)
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Female	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Female	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D57	-0.7%	5.5%	-0.7%
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Female	D57	(-4.5%, 3.2%)	(-1.2%, 12.1%)	(-4.5%, 3.2%)
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D57	9.7%	14.4%	9.7%
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Female	D57	(3.4%, 16.1%)	(6.6%, 22.2%)	(3.4%, 16.1%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D57	2.0%	5.2%	2.0%
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Female	D57	(-3.2%, 7.1%)	(-1.7%, 12.1%)	(-3.2%, 7.1%)
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D57	9.5%	14.6%	9.5%
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Female	D57	(1.8%, 17.3%)	(5.3%, 23.9%)	(1.8%, 17.3%)
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Male	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Male	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D29	82.3%	66.5%	82.3%
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D29	(75.3%, 89.4%)	(57.9%, 75.2%)	(75.3%, 89.4%)
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D29	70.5%	55.1%	70.5%
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D29	(62.1%, 78.9%)	(45.9%, 64.2%)	(62.1%, 78.9%)
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D29	76.9%	63.6%	76.9%
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D29	(69.2%, 84.7%)	(54.8%, 72.5%)	(69.2%, 84.7%)
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D29	62.8%	50.3%	62.8%
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D29	(53.9%, 71.7%)	(41.1%, 59.5%)	(53.9%, 71.7%)
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Male	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age < 65 Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Male	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age < 65 Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D57	98.6%	94.8%	98.6%
Negative	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D57	(96.4%, 100.7%)	(90.7%, 98.9%)	(96.4%, 100.7%)
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D57	95.4%	91.5%	95.4%
Negative	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D57	(91.6%, 99.3%)	(86.3%, 96.6%)	(91.6%, 99.3%)
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D57	97.1%	94.2%	97.1%
Negative	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D57	(94.0%, 100.2%)	(89.9%, 98.5%)	(94.0%, 100.2%)
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D57	96.5%	90.4%	96.5%
Negative	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D57	(93.1%, 99.9%)	(85.0%, 95.8%)	(93.1%, 99.9%)
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Male	D29	-0.0%	-0.0%	-0.0%



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Male	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D29	35.3%	35.6%	35.3%
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D29	(20.0%, 50.7%)	(19.5%, 51.8%)	(20.0%, 50.7%)
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D29	33.6%	46.4%	33.6%
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D29	(17.2%, 49.9%)	(30.2%, 62.7%)	(17.2%, 49.9%)
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D29	27.0%	24.6%	27.0%
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D29	(12.5%, 41.4%)	(8.2%, 40.9%)	(12.5%, 41.4%)
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D29	17.9%	12.8%	17.9%
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D29	(1.0%, 34.8%)	(-5.5%, 31.0%)	(1.0%, 34.8%)
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Male	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Sex	Age < 65 Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Male	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Sex	Age < 65 Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D57	8.0%	9.2%	8.0%
Positive	Live Virus nAb ID50	Age, Sex	Age < 65 Male	D57	(-0.9%, 16.9%)	(-1.3%, 19.7%)	(-0.9%, 16.9%)
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D57	7.2%	17.0%	7.2%
Positive	Live Virus nAb ID80	Age, Sex	Age < 65 Male	D57	(0.4%, 14.0%)	(7.5%, 26.4%)	(0.4%, 14.0%)
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D57	11.5%	11.5%	11.5%
Positive	Pseudo nAb ID50	Age, Sex	Age < 65 Male	D57	(1.8%, 21.2%)	(1.8%, 21.2%)	(1.8%, 21.2%)
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D57	17.2%	23.0%	17.2%
Positive	Pseudo nAb ID80	Age, Sex	Age < 65 Male	D57	(6.7%, 27.6%)	(9.9%, 36.2%)	(6.7%, 27.6%)
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D29	92.3%	82.2%	92.3%
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D29	(88.3%, 96.3%)	(76.5%, 88.0%)	(88.3%, 96.3%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D29	84.1%	74.7%	84.1%
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D29	(78.6%, 89.6%)	(68.2%, 81.3%)	(78.6%, 89.6%)
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D29	91.4%	86.5%	91.4%
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D29	(87.2%, 95.6%)	(81.3%, 91.6%)	(87.2%, 95.6%)
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D29	84.1%	70.7%	84.1%
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D29	(78.6%, 89.6%)	(63.9%, 77.6%)	(78.6%, 89.6%)
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D57	96.8%	95.1%	96.8%
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D57	(94.1%, 99.4%)	(91.8%, 98.3%)	(94.1%, 99.4%)
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D57	97.1%	93.1%	97.1%
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D57	(94.6%, 99.6%)	(89.3%, 96.9%)	(94.6%, 99.6%)
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D57	98.0%	96.8%	98.0%
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D57	(95.9%, 100.1%)	(94.1%, 99.4%)	(95.9%, 100.1%)
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D57	97.2%	93.6%	97.2%
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D57	(94.7%, 99.7%)	(89.9%, 97.3%)	(94.7%, 99.7%)
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D29	10.5%	16.8%	10.5%
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D29	(-1.7%, 22.6%)	(2.3%, 31.3%)	(-1.7%, 22.6%)
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D29	16.8%	26.5%	16.8%
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D29	(2.3%, 31.3%)	(10.7%, 42.4%)	(2.3%, 31.3%)
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D29	3.4%	11.3%	3.4%
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D29	(-6.2%, 13.0%)	(-1.4%, 24.0%)	(-6.2%, 13.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D29	12.4%	25.2%	12.4%
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D29	(-1.4%, 26.1%)	(8.4%, 42.0%)	(-1.4%, 26.1%)
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D57	-0.0%	-0.0%	-0.0%
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Female	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D57	3.7%	0.5%	3.7%
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Female	D57	(-1.0%, 8.4%)	(-6.2%, 7.2%)	(-1.0%, 8.4%)
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D57	-0.0%	3.7%	-0.0%
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Female	D57	(-0.0%, 0.0%)	(-1.0%, 8.4%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D57	5.6%	7.4%	5.6%
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Female	D57	(-0.2%, 11.3%)	(0.8%, 14.0%)	(-0.2%, 11.3%)
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D29	88.9%	80.8%	88.9%
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D29	(83.3%, 94.5%)	(73.8%, 87.8%)	(83.3%, 94.5%)
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D29	80.9%	69.9%	80.9%
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D29	(73.9%, 87.9%)	(61.8%, 78.1%)	(73.9%, 87.9%)
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D29	93.7%	87.4%	93.7%
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D29	(89.3%, 98.0%)	(81.5%, 93.3%)	(89.3%, 98.0%)
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D29	85.1%	75.9%	85.1%
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D29	(78.8%, 91.5%)	(68.2%, 83.5%)	(78.8%, 91.5%)
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D57	99.5%	98.1%	99.5%
Negative	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D57	(98.1%, 100.8%)	(95.7%, 100.5%)	(98.1%, 100.8%)
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D57	96.5%	94.2%	96.5%
Negative	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D57	(93.2%, 99.8%)	(90.1%, 98.4%)	(93.2%, 99.8%)
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D57	99.1%	97.7%	99.1%
Negative	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D57	(97.5%, 100.8%)	(95.0%, 100.4%)	(97.5%, 100.8%)
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D57	97.3%	96.0%	97.3%
Negative	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D57	(94.4%, 100.2%)	(92.5%, 99.5%)	(94.4%, 100.2%)
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D29	-1.2%	16.0%	-1.2%
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D29	(-10.8%, 8.3%)	(1.9%, 30.0%)	(-10.8%, 8.3%)
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D29	7.3%	11.4%	7.3%
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D29	(-5.4%, 20.0%)	(-5.4%, 28.3%)	(-5.4%, 20.0%)
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D29	7.9%	9.3%	7.9%
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D29	(-1.0%, 16.7%)	(-2.1%, 20.8%)	(-1.0%, 16.7%)
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D29	18.1%	24.3%	18.1%
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D29	(5.8%, 30.5%)	(8.5%, 40.2%)	(5.8%, 30.5%)
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Sex	Age >= 65 Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Sex	Age >= 65 Male	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D57	4.6%	6.3%	4.6%
Positive	Live Virus nAb ID50	Age, Sex	Age >= 65 Male	D57	(-1.1%, 10.3%)	(-0.3%, 12.9%)	(-1.1%, 10.3%)
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D57	1.6%	9.6%	1.6%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID80	Age, Sex	Age >= 65 Male	D57	(-4.5%, 7.7%)	(0.2%, 19.0%)	(-4.5%, 7.7%)
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D57	1.7%	4.6%	1.7%
Positive	Pseudo nAb ID50	Age, Sex	Age >= 65 Male	D57	(-1.8%, 5.3%)	(-1.1%, 10.3%)	(-1.8%, 5.3%)
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D57	2.8%	9.8%	2.8%
Positive	Pseudo nAb ID80	Age, Sex	Age >= 65 Male	D57	(-1.7%, 7.4%)	(1.7%, 17.9%)	(-1.7%, 7.4%)
Negative	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D29	89.7%	71.9%	89.7%
Negative	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D29	(82.5%, 96.8%)	(61.4%, 82.4%)	(82.5%, 96.8%)
Negative	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D29	80.4%	70.3%	80.4%
Negative	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D29	(71.1%, 89.7%)	(59.6%, 81.0%)	(71.1%, 89.7%)
Negative	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D29	82.4%	78.9%	82.4%
Negative	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D29	(73.5%, 91.3%)	(69.3%, 88.4%)	(73.5%, 91.3%)
Negative	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D29	78.2%	59.9%	78.2%
Negative	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D29	(68.5%, 87.8%)	(48.5%, 71.4%)	(68.5%, 87.8%)
Negative	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D57	98.7%	97.1%	98.7%
Negative	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D57	(96.0%, 101.3%)	(93.1%, 101.0%)	(96.0%, 101.3%)
Negative	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D57	93.7%	89.0%	93.7%
Negative	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D57	(88.0%, 99.4%)	(81.7%, 96.3%)	(88.0%, 99.4%)
Negative	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D57	96.4%	96.4%	96.4%
Negative	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D57	(92.1%, 100.8%)	(92.1%, 100.8%)	(92.1%, 100.8%)
Negative	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D57	96.0%	92.6%	96.0%
Negative	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D57	(91.4%, 100.6%)	(86.5%, 98.7%)	(91.4%, 100.6%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D29	13.5%	7.9%	13.5%
Positive	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D29	(0.3%, 26.7%)	(-11.3%, 27.1%)	(0.3%, 26.7%)
Positive	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D29	12.1%	26.6%	12.1%
Positive	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D29	(-7.4%, 31.6%)	(2.9%, 50.3%)	(-7.4%, 31.6%)
Positive	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D29	18.4%	19.2%	18.4%
Positive	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D29	(-0.8%, 37.6%)	(-3.6%, 41.9%)	(-0.8%, 37.6%)
Positive	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D29	20.1%	1.0%	20.1%
Positive	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D29	(-2.1%, 42.4%)	(-24.7%, 26.8%)	(-2.1%, 42.4%)
Positive	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Ethnicity	Hispanic or Latino	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Ethnicity	Hispanic or Latino	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D57	1.6%	1.8%	1.6%
Positive	Live Virus nAb ID50	Ethnicity	Hispanic or Latino	D57	(-2.9%, 6.2%)	(-6.8%, 10.4%)	(-2.9%, 6.2%)
Positive	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D57	4.2%	14.4%	4.2%
Positive	Live Virus nAb ID80	Ethnicity	Hispanic or Latino	D57	(-3.0%, 11.4%)	(1.7%, 27.1%)	(-3.0%, 11.4%)
Positive	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D57	7.5%	8.1%	7.5%
Positive	Pseudo nAb ID50	Ethnicity	Hispanic or Latino	D57	(-2.0%, 17.0%)	(-1.7%, 18.0%)	(-2.0%, 17.0%)
Positive	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D57	2.7%	5.9%	2.7%
Positive	Pseudo nAb ID80	Ethnicity	Hispanic or Latino	D57	(-3.2%, 8.6%)	(-2.6%, 14.3%)	(-3.2%, 8.6%)
Negative	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D29	80.8%	64.9%	80.8%
Negative	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D29	(76.9%, 84.7%)	(60.1%, 69.6%)	(76.9%, 84.7%)
Negative	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D29	67.8%	53.6%	67.8%
Negative	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D29	(63.2%, 72.5%)	(48.7%, 58.6%)	(63.2%, 72.5%)
Negative	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D29	81.7%	67.6%	81.7%
Negative	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D29	(77.8%, 85.5%)	(62.9%, 72.3%)	(77.8%, 85.5%)
Negative	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D29	67.6%	54.5%	67.6%
Negative	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D29	(63.0%, 72.3%)	(49.6%, 59.5%)	(63.0%, 72.3%)
Negative	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D57	97.3%	94.7%	97.3%
Negative	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D57	(95.7%, 98.9%)	(92.5%, 96.9%)	(95.7%, 98.9%)
Negative	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D57	95.1%	89.7%	95.1%
Negative	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D57	(93.0%, 97.3%)	(86.7%, 92.8%)	(93.0%, 97.3%)
Negative	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D57	97.7%	95.5%	97.7%
Negative	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D57	(96.3%, 99.2%)	(93.4%, 97.6%)	(96.3%, 99.2%)
Negative	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D57	94.6%	89.8%	94.6%
Negative	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D57	(92.3%, 96.8%)	(86.8%, 92.8%)	(92.3%, 96.8%)
Positive	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D29	29.4%	29.5%	29.4%
Positive	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D29	(21.6%, 37.2%)	(20.7%, 38.3%)	(21.6%, 37.2%)
Positive	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D29	24.9%	36.9%	24.9%
Positive	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D29	(16.2%, 33.6%)	(27.9%, 45.8%)	(16.2%, 33.6%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D29	19.6%	27.0%	19.6%
Positive	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D29	(11.8%, 27.3%)	(18.3%, 35.8%)	(11.8%, 27.3%)
Positive	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D29	18.2%	21.9%	18.2%
Positive	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D29	(9.1%, 27.3%)	(12.5%, 31.3%)	(9.1%, 27.3%)
Positive	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Ethnicity	Not Hispanic or Latino	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Ethnicity	Not Hispanic or Latino	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D57	1.9%	6.6%	1.9%
Positive	Live Virus nAb ID50	Ethnicity	Not Hispanic or Latino	D57	(-1.6%, 5.5%)	(1.7%, 11.4%)	(-1.6%, 5.5%)
Positive	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D57	6.8%	11.9%	6.8%
Positive	Live Virus nAb ID80	Ethnicity	Not Hispanic or Latino	D57	(3.2%, 10.4%)	(7.2%, 16.5%)	(3.2%, 10.4%)
Positive	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D57	3.7%	6.5%	3.7%
Positive	Pseudo nAb ID50	Ethnicity	Not Hispanic or Latino	D57	(-0.2%, 7.6%)	(1.8%, 11.1%)	(-0.2%, 7.6%)
Positive	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D57	10.8%	16.4%	10.8%
Positive	Pseudo nAb ID80	Ethnicity	Not Hispanic or Latino	D57	(5.7%, 15.8%)	(10.0%, 22.9%)	(5.7%, 15.8%)
Negative	Anti-RBD IgG	Race	American Indian or Alaska Native	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	American Indian or Alaska Native	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	American Indian or Alaska Native	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	American Indian or Alaska Native	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	American Indian or Alaska Native	D29	93.4%	67.5%	93.4%
Negative	Live Virus nAb ID50	Race	American Indian or Alaska Native	D29	(79.2%, 107.7%)	(40.5%, 94.4%)	(79.2%, 107.7%)
Negative	Live Virus nAb ID80	Race	American Indian or Alaska Native	D29	78.5%	78.5%	78.5%
Negative	Live Virus nAb ID80	Race	American Indian or Alaska Native	D29	(54.9%, 102.2%)	(54.9%, 102.2%)	(54.9%, 102.2%)
Negative	Pseudo nAb ID50	Race	American Indian or Alaska Native	D29	72.9%	59.1%	72.9%
Negative	Pseudo nAb ID50	Race	American Indian or Alaska Native	D29	(47.3%, 98.5%)	(30.8%, 87.4%)	(47.3%, 98.5%)
Negative	Pseudo nAb ID80	Race	American Indian or Alaska Native	D29	56.4%	55.0%	56.4%
Negative	Pseudo nAb ID80	Race	American Indian or Alaska Native	D29	(27.8%, 84.9%)	(26.3%, 83.6%)	(27.8%, 84.9%)



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-RBD IgG	Race	American Indian or Alaska Native	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	American Indian or Alaska Native	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	American Indian or Alaska Native	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	American Indian or Alaska Native	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	American Indian or Alaska Native	D57	97.3%	93.4%	97.3%
Negative	Live Virus nAb ID50	Race	American Indian or Alaska Native	D57	(87.9%, 106.6%)	(79.2%, 107.7%)	(87.9%, 106.6%)
Negative	Live Virus nAb ID80	Race	American Indian or Alaska Native	D57	100.0%	88.9%	100.0%
Negative	Live Virus nAb ID80	Race	American Indian or Alaska Native	D57	(100.0%, 100.0%)	(70.8%, 107.0%)	(100.0%, 100.0%)
Negative	Pseudo nAb ID50	Race	American Indian or Alaska Native	D57	94.6%	93.4%	94.6%
Negative	Pseudo nAb ID50	Race	American Indian or Alaska Native	D57	(81.5%, 107.6%)	(79.2%, 107.7%)	(81.5%, 107.6%)
Negative	Pseudo nAb ID80	Race	American Indian or Alaska Native	D57	87.8%	86.7%	87.8%
Negative	Pseudo nAb ID80	Race	American Indian or Alaska Native	D57	(68.9%, 106.7%)	(67.1%, 106.2%)	(68.9%, 106.7%)
Positive	Anti-RBD IgG	Race	American Indian or Alaska Native	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	American Indian or Alaska Native	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	American Indian or Alaska Native	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	American Indian or Alaska Native	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	American Indian or Alaska Native	D29	0.0%	0.0%	0.0%
Positive	Live Virus nAb ID50	Race	American Indian or Alaska Native	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Race	American Indian or Alaska Native	D29	0.0%	-6.6%	0.0%
Positive	Live Virus nAb ID80	Race	American Indian or Alaska Native	D29	(-0.0%, 0.0%)	(-83.2%, 70.0%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID50	Race	American Indian or Alaska Native	D29	-30.7%	-61.5%	-30.7%
Positive	Pseudo nAb ID50	Race	American Indian or Alaska Native	D29	(-85.0%, 23.6%)	(-118.7%, -4.2%)	(-85.0%, 23.6%)
Positive	Pseudo nAb ID80	Race	American Indian or Alaska Native	D29	-61.5%	-61.5%	-61.5%
Positive	Pseudo nAb ID80	Race	American Indian or Alaska Native	D29	(-118.7%, -4.2%)	(-118.7%, -4.2%)	(-118.7%, -4.2%)
Positive	Anti-RBD IgG	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID50	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%
Positive	Live Virus nAb ID80	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID50	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%
Positive	Pseudo nAb ID50	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Race	American Indian or Alaska Native	D57	0.0%	0.0%	0.0%
Positive	Pseudo nAb ID80	Race	American Indian or Alaska Native	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Negative	Anti-RBD IgG	Race	Asian	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Asian	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Asian	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Asian	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Asian	D29	71.2%	62.2%	71.2%
Negative	Live Virus nAb ID50	Race	Asian	D29	(57.1%, 85.3%)	(47.1%, 77.2%)	(57.1%, 85.3%)
Negative	Live Virus nAb ID80	Race	Asian	D29	69.9%	55.9%	69.9%
Negative	Live Virus nAb ID80	Race	Asian	D29	(55.7%, 84.2%)	(40.4%, 71.3%)	(55.7%, 84.2%)
Negative	Pseudo nAb ID50	Race	Asian	D29	76.2%	48.6%	76.2%
Negative	Pseudo nAb ID50	Race	Asian	D29	(63.0%, 89.4%)	(33.0%, 64.1%)	(63.0%, 89.4%)
Negative	Pseudo nAb ID80	Race	Asian	D29	46.7%	35.8%	46.7%
Negative	Pseudo nAb ID80	Race	Asian	D29	(31.2%, 62.3%)	(20.9%, 50.7%)	(31.2%, 62.3%)
Negative	Anti-RBD IgG	Race	Asian	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Asian	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Asian	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Asian	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Asian	D57	89.0%	80.8%	89.0%
Negative	Live Virus nAb ID50	Race	Asian	D57	(79.3%, 98.8%)	(68.5%, 93.0%)	(79.3%, 98.8%)
Negative	Live Virus nAb ID80	Race	Asian	D57	91.2%	86.0%	91.2%
Negative	Live Virus nAb ID80	Race	Asian	D57	(82.4%, 100.0%)	(75.2%, 96.8%)	(82.4%, 100.0%)
Negative	Pseudo nAb ID50	Race	Asian	D57	99.5%	91.2%	99.5%
Negative	Pseudo nAb ID50	Race	Asian	D57	(97.2%, 101.7%)	(82.4%, 100.0%)	(97.2%, 101.7%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID80	Race	Asian	D57	93.0%	87.2%	93.0%
Negative	Pseudo nAb ID80	Race	Asian	D57	(85.0%, 100.9%)	(76.9%, 97.6%)	(85.0%, 100.9%)
Positive	Anti-RBD IgG	Race	Asian	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	Asian	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Asian	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	Asian	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Asian	D29	53.0%	59.5%	53.0%
Positive	Live Virus nAb ID50	Race	Asian	D29	(28.4%, 77.6%)	(32.8%, 86.3%)	(28.4%, 77.6%)
Positive	Live Virus nAb ID80	Race	Asian	D29	26.9%	64.1%	26.9%
Positive	Live Virus nAb ID80	Race	Asian	D29	(-2.1%, 55.8%)	(37.1%, 91.1%)	(-2.1%, 55.8%)
Positive	Pseudo nAb ID50	Race	Asian	D29	43.1%	71.8%	43.1%
Positive	Pseudo nAb ID50	Race	Asian	D29	(18.7%, 67.5%)	(48.6%, 95.1%)	(18.7%, 67.5%)
Positive	Pseudo nAb ID80	Race	Asian	D29	60.1%	31.3%	60.1%
Positive	Pseudo nAb ID80	Race	Asian	D29	(32.1%, 88.0%)	(-0.3%, 62.8%)	(32.1%, 88.0%)
Positive	Anti-RBD IgG	Race	Asian	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	Asian	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Asian	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	Asian	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Asian	D57	0.0%	4.0%	0.0%
Positive	Live Virus nAb ID50	Race	Asian	D57	(-0.0%, 0.0%)	(-5.7%, 13.8%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Race	Asian	D57	14.4%	14.4%	14.4%
Positive	Live Virus nAb ID80	Race	Asian	D57	(-2.9%, 31.7%)	(-2.9%, 31.7%)	(-2.9%, 31.7%)
Positive	Pseudo nAb ID50	Race	Asian	D57	0.0%	14.4%	0.0%
Positive	Pseudo nAb ID50	Race	Asian	D57	(-0.0%, 0.0%)	(-2.9%, 31.7%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Race	Asian	D57	30.7%	26.8%	30.7%
Positive	Pseudo nAb ID80	Race	Asian	D57	(8.0%, 53.4%)	(2.0%, 51.5%)	(8.0%, 53.4%)
Negative	Anti-RBD IgG	Race	Black or African American	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Black or African American	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-Spike IgG	Race	Black or African American	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Black or African American	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Black or African American	D29	82.8%	60.6%	82.8%
Negative	Live Virus nAb ID50	Race	Black or African American	D29	(75.1%, 90.4%)	(50.7%, 70.5%)	(75.1%, 90.4%)
Negative	Live Virus nAb ID80	Race	Black or African American	D29	68.7%	55.3%	68.7%
Negative	Live Virus nAb ID80	Race	Black or African American	D29	(59.3%, 78.1%)	(45.2%, 65.4%)	(59.3%, 78.1%)
Negative	Pseudo nAb ID50	Race	Black or African American	D29	78.5%	67.0%	78.5%
Negative	Pseudo nAb ID50	Race	Black or African American	D29	(70.2%, 86.8%)	(57.4%, 76.5%)	(70.2%, 86.8%)
Negative	Pseudo nAb ID80	Race	Black or African American	D29	67.1%	48.9%	67.1%
Negative	Pseudo nAb ID80	Race	Black or African American	D29	(57.6%, 76.6%)	(38.8%, 59.0%)	(57.6%, 76.6%)
Negative	Anti-RBD IgG	Race	Black or African American	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Black or African American	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Black or African American	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Black or African American	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Black or African American	D57	99.9%	94.2%	99.9%
Negative	Live Virus nAb ID50	Race	Black or African American	D57	(99.1%, 100.6%)	(89.4%, 98.9%)	(99.1%, 100.6%)
Negative	Live Virus nAb ID80	Race	Black or African American	D57	93.2%	88.1%	93.2%
Negative	Live Virus nAb ID80	Race	Black or African American	D57	(88.1%, 98.3%)	(81.5%, 94.7%)	(88.1%, 98.3%)
Negative	Pseudo nAb ID50	Race	Black or African American	D57	97.2%	94.2%	97.2%
Negative	Pseudo nAb ID50	Race	Black or African American	D57	(93.9%, 100.6%)	(89.4%, 98.9%)	(93.9%, 100.6%)
Negative	Pseudo nAb ID80	Race	Black or African American	D57	95.3%	89.3%	95.3%
Negative	Pseudo nAb ID80	Race	Black or African American	D57	(91.0%, 99.6%)	(83.0%, 95.6%)	(91.0%, 99.6%)
Positive	Anti-RBD IgG	Race	Black or African American	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Black or African American	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Black or African American	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Black or African American	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Black or African American	D29	29.2%	27.8%	29.2%
Positive	Live Virus nAb ID50	Race	Black or African American	D29	(13.3%, 45.0%)	(10.0%, 45.6%)	(13.3%, 45.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID80	Race	Black or African American	D29	29.9%	37.4%	29.9%
Positive	Live Virus nAb ID80	Race	Black or African American	D29	(12.2%, 47.6%)	(19.6%, 55.2%)	(12.2%, 47.6%)
Positive	Pseudo nAb ID50	Race	Black or African American	D29	29.1%	34.3%	29.1%
Positive	Pseudo nAb ID50	Race	Black or African American	D29	(11.9%, 46.4%)	(16.9%, 51.7%)	(11.9%, 46.4%)
Positive	Pseudo nAb ID80	Race	Black or African American	D29	22.5%	30.0%	22.5%
Positive	Pseudo nAb ID80	Race	Black or African American	D29	(3.7%, 41.3%)	(11.2%, 48.8%)	(3.7%, 41.3%)
Positive	Anti-RBD IgG	Race	Black or African American	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Black or African American	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Black or African American	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Black or African American	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Black or African American	D57	3.1%	8.8%	3.1%
Positive	Live Virus nAb ID50	Race	Black or African American	D57	(-3.6%, 9.9%)	(-1.3%, 19.0%)	(-3.6%, 9.9%)
Positive	Live Virus nAb ID80	Race	Black or African American	D57	5.1%	14.7%	5.1%
Positive	Live Virus nAb ID80	Race	Black or African American	D57	(-3.2%, 13.3%)	(3.5%, 26.0%)	(-3.2%, 13.3%)
Positive	Pseudo nAb ID50	Race	Black or African American	D57	11.6%	17.4%	11.6%
Positive	Pseudo nAb ID50	Race	Black or African American	D57	(2.5%, 20.7%)	(6.7%, 28.2%)	(2.5%, 20.7%)
Positive	Pseudo nAb ID80	Race	Black or African American	D57	18.1%	32.7%	18.1%
Positive	Pseudo nAb ID80	Race	Black or African American	D57	(7.1%, 29.0%)	(18.9%, 46.6%)	(7.1%, 29.0%)
Negative	Anti-RBD IgG	Race	Multiracial	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Multiracial	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Multiracial	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Multiracial	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Multiracial	D29	92.6%	78.6%	92.6%
Negative	Live Virus nAb ID50	Race	Multiracial	D29	(84.3%, 100.9%)	(65.7%, 91.6%)	(84.3%, 100.9%)
Negative	Live Virus nAb ID80	Race	Multiracial	D29	83.6%	59.7%	83.6%
Negative	Live Virus nAb ID80	Race	Multiracial	D29	(72.0%, 95.3%)	(44.3%, 75.2%)	(72.0%, 95.3%)
Negative	Pseudo nAb ID50	Race	Multiracial	D29	75.8%	74.2%	75.8%
Negative	Pseudo nAb ID50	Race	Multiracial	D29	(62.3%, 89.3%)	(60.3%, 88.0%)	(62.3%, 89.3%)
Negative	Pseudo nAb ID80	Race	Multiracial	D29	78.9%	67.6%	78.9%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID80	Race	Multiracial	D29	(66.0%, 91.8%)	(52.8%, 82.3%)	(66.0%, 91.8%)
Negative	Anti-RBD IgG	Race	Multiracial	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Multiracial	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Multiracial	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Multiracial	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Multiracial	D57	93.8%	93.8%	93.8%
Negative	Live Virus nAb ID50	Race	Multiracial	D57	(86.2%, 101.4%)	(86.2%, 101.4%)	(86.2%, 101.4%)
Negative	Live Virus nAb ID80	Race	Multiracial	D57	96.9%	95.2%	96.9%
Negative	Live Virus nAb ID80	Race	Multiracial	D57	(91.5%, 102.4%)	(88.5%, 102.0%)	(91.5%, 102.4%)
Negative	Pseudo nAb ID50	Race	Multiracial	D57	97.6%	95.9%	97.6%
Negative	Pseudo nAb ID50	Race	Multiracial	D57	(92.8%, 102.4%)	(89.7%, 102.2%)	(92.8%, 102.4%)
Negative	Pseudo nAb ID80	Race	Multiracial	D57	97.6%	92.9%	97.6%
Negative	Pseudo nAb ID80	Race	Multiracial	D57	(92.8%, 102.4%)	(84.7%, 101.0%)	(92.8%, 102.4%)
Positive	Anti-RBD IgG	Race	Multiracial	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Multiracial	D29	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Anti-Spike IgG	Race	Multiracial	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Multiracial	D29	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Live Virus nAb ID50	Race	Multiracial	D29	16.1%	22.6%	16.1%
Positive	Live Virus nAb ID50	Race	Multiracial	D29	(-6.8%, 39.0%)	(-2.2%, 47.5%)	(-6.8%, 39.0%)
Positive	Live Virus nAb ID80	Race	Multiracial	D29	-10.3%	7.6%	-10.3%
Positive	Live Virus nAb ID80	Race	Multiracial	D29	(-36.8%, 16.3%)	(-25.4%, 40.7%)	(-36.8%, 16.3%)
Positive	Pseudo nAb ID50	Race	Multiracial	D29	9.8%	14.2%	9.8%
Positive	Pseudo nAb ID50	Race	Multiracial	D29	(-21.1%, 40.7%)	(-17.4%, 45.8%)	(-21.1%, 40.7%)
Positive	Pseudo nAb ID80	Race	Multiracial	D29	18.6%	25.0%	18.6%
Positive	Pseudo nAb ID80	Race	Multiracial	D29	(-13.5%, 50.7%)	(-7.6%, 57.6%)	(-13.5%, 50.7%)
Positive	Anti-RBD IgG	Race	Multiracial	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Multiracial	D57	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Anti-Spike IgG	Race	Multiracial	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Multiracial	D57	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID50	Race	Multiracial	D57	-0.0%	4.4%	-0.0%
Positive	Live Virus nAb ID50	Race	Multiracial	D57	(-0.0%, -0.0%)	(-6.1%, 14.9%)	(-0.0%, -0.0%)
Positive	Live Virus nAb ID80	Race	Multiracial	D57	-0.0%	4.4%	-0.0%
Positive	Live Virus nAb ID80	Race	Multiracial	D57	(-0.0%, -0.0%)	(-6.1%, 14.9%)	(-0.0%, -0.0%)
Positive	Pseudo nAb ID50	Race	Multiracial	D57	-0.0%	2.1%	-0.0%
Positive	Pseudo nAb ID50	Race	Multiracial	D57	(-0.0%, -0.0%)	(-5.3%, 9.5%)	(-0.0%, -0.0%)
Positive	Pseudo nAb ID80	Race	Multiracial	D57	15.7%	15.7%	15.7%
Positive	Pseudo nAb ID80	Race	Multiracial	D57	(-2.9%, 34.3%)	(-2.9%, 34.3%)	(-2.9%, 34.3%)
Negative	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	78.2%	73.7%	78.2%
Negative	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	(45.7%, 110.8%)	(38.9%, 108.4%)	(45.7%, 110.8%)
Negative	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	84.5%	80.0%	84.5%
Negative	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	(56.0%, 113.1%)	(48.4%, 111.6%)	(56.0%, 113.1%)
Negative	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	100.0%	100.0%	100.0%
Negative	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	100.0%	89.1%	100.0%
Negative	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	(100.0%, 100.0%)	(64.5%, 113.7%)	(100.0%, 100.0%)
Negative	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	100.0%	100.0%	100.0%
Negative	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Positive	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	-75.1%	-92.1%	-75.1%
Positive	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	(-131.0%, -19.1%)	(-127.0%, -57.3%)	(-131.0%, -19.1%)
Positive	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	-67.2%	6.2%	-67.2%
Positive	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	(-127.9%, -6.4%)	(-52.5%, 65.0%)	(-127.9%, -6.4%)
Positive	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	0.0%	-67.2%	0.0%
Positive	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D29	(-0.0%, 0.0%)	(-127.9%, -6.4%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	-67.2%	-55.2%	-67.2%
Positive	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D29	(-127.9%, -6.4%)	(-128.6%, 18.2%)	(-127.9%, -6.4%)
Positive	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	Native Hawaiian or Other Pacific Islander	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	Native Hawaiian or Other Pacific Islander	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	0.0%	0.0%	0.0%
Positive	Live Virus nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	0.0%	0.0%	0.0%
Positive	Live Virus nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	-67.2%	-67.2%	-67.2%
Positive	Pseudo nAb ID50	Race	Native Hawaiian or Other Pacific Islander	D57	(-127.9%, -6.4%)	(-127.9%, -6.4%)	(-127.9%, -6.4%)
Positive	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	0.0%	0.0%	0.0%
Positive	Pseudo nAb ID80	Race	Native Hawaiian or Other Pacific Islander	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-RBD IgG	Race	Not reported and unknown	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Not reported and unknown	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Not reported and unknown	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Not reported and unknown	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Not reported and unknown	D29	76.8%	70.0%	76.8%
Negative	Live Virus nAb ID50	Race	Not reported and unknown	D29	(66.4%, 87.1%)	(58.8%, 81.3%)	(66.4%, 87.1%)
Negative	Live Virus nAb ID80	Race	Not reported and unknown	D29	79.1%	65.8%	79.1%
Negative	Live Virus nAb ID80	Race	Not reported and unknown	D29	(69.1%, 89.1%)	(54.1%, 77.5%)	(69.1%, 89.1%)
Negative	Pseudo nAb ID50	Race	Not reported and unknown	D29	87.8%	71.4%	87.8%
Negative	Pseudo nAb ID50	Race	Not reported and unknown	D29	(79.8%, 95.9%)	(60.3%, 82.5%)	(79.8%, 95.9%)
Negative	Pseudo nAb ID80	Race	Not reported and unknown	D29	81.3%	66.6%	81.3%
Negative	Pseudo nAb ID80	Race	Not reported and unknown	D29	(71.7%, 90.9%)	(55.0%, 78.2%)	(71.7%, 90.9%)
Negative	Anti-RBD IgG	Race	Not reported and unknown	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Not reported and unknown	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Not reported and unknown	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Not reported and unknown	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Not reported and unknown	D57	99.7%	98.2%	99.7%
Negative	Live Virus nAb ID50	Race	Not reported and unknown	D57	(98.3%, 101.1%)	(94.9%, 101.5%)	(98.3%, 101.1%)
Negative	Live Virus nAb ID80	Race	Not reported and unknown	D57	99.3%	89.2%	99.3%
Negative	Live Virus nAb ID80	Race	Not reported and unknown	D57	(97.1%, 101.4%)	(81.5%, 96.8%)	(97.1%, 101.4%)
Negative	Pseudo nAb ID50	Race	Not reported and unknown	D57	97.0%	96.6%	97.0%
Negative	Pseudo nAb ID50	Race	Not reported and unknown	D57	(92.7%, 101.2%)	(92.2%, 101.1%)	(92.7%, 101.2%)
Negative	Pseudo nAb ID80	Race	Not reported and unknown	D57	99.9%	90.7%	99.9%
Negative	Pseudo nAb ID80	Race	Not reported and unknown	D57	(99.2%, 100.6%)	(83.5%, 97.8%)	(99.2%, 100.6%)
Positive	Anti-RBD IgG	Race	Not reported and unknown	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Not reported and unknown	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Not reported and unknown	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Not reported and unknown	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID50	Race	Not reported and unknown	D29	49.2%	55.4%	49.2%
Positive	Live Virus nAb ID50	Race	Not reported and unknown	D29	(30.4%, 68.0%)	(34.6%, 76.2%)	(30.4%, 68.0%)
Positive	Live Virus nAb ID80	Race	Not reported and unknown	D29	38.4%	45.2%	38.4%
Positive	Live Virus nAb ID80	Race	Not reported and unknown	D29	(15.0%, 61.9%)	(21.9%, 68.6%)	(15.0%, 61.9%)
Positive	Pseudo nAb ID50	Race	Not reported and unknown	D29	18.0%	39.4%	18.0%
Positive	Pseudo nAb ID50	Race	Not reported and unknown	D29	(-1.7%, 37.6%)	(17.5%, 61.3%)	(-1.7%, 37.6%)
Positive	Pseudo nAb ID80	Race	Not reported and unknown	D29	32.5%	21.1%	32.5%
Positive	Pseudo nAb ID80	Race	Not reported and unknown	D29	(8.6%, 56.4%)	(-4.5%, 46.8%)	(8.6%, 56.4%)
Positive	Anti-RBD IgG	Race	Not reported and unknown	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Not reported and unknown	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Not reported and unknown	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Not reported and unknown	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Not reported and unknown	D57	2.5%	-5.9%	2.5%
Positive	Live Virus nAb ID50	Race	Not reported and unknown	D57	(-3.1%, 8.0%)	(-18.1%, 6.2%)	(-3.1%, 8.0%)
Positive	Live Virus nAb ID80	Race	Not reported and unknown	D57	11.2%	13.7%	11.2%
Positive	Live Virus nAb ID80	Race	Not reported and unknown	D57	(-0.1%, 22.6%)	(1.3%, 26.1%)	(-0.1%, 22.6%)
Positive	Pseudo nAb ID50	Race	Not reported and unknown	D57	11.2%	12.4%	11.2%
Positive	Pseudo nAb ID50	Race	Not reported and unknown	D57	(-0.1%, 22.6%)	(0.5%, 24.3%)	(-0.1%, 22.6%)
Positive	Pseudo nAb ID80	Race	Not reported and unknown	D57	2.8%	6.5%	2.8%
Positive	Pseudo nAb ID80	Race	Not reported and unknown	D57	(-12.8%, 18.5%)	(-10.3%, 23.2%)	(-12.8%, 18.5%)
Negative	Anti-RBD IgG	Race	Other	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Other	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Other	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Other	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Other	D29	84.8%	84.8%	84.8%
Negative	Live Virus nAb ID50	Race	Other	D29	(32.3%, 137.4%)	(32.3%, 137.4%)	(32.3%, 137.4%)
Negative	Live Virus nAb ID80	Race	Other	D29	83.6%	78.1%	83.6%
Negative	Live Virus nAb ID80	Race	Other	D29	(29.3%, 137.9%)	(17.5%, 138.7%)	(29.3%, 137.9%)
Negative	Pseudo nAb ID50	Race	Other	D29	87.8%	84.8%	87.8%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Race	Other	D29	(39.9%, 135.8%)	(32.3%, 137.4%)	(39.9%, 135.8%)
Negative	Pseudo nAb ID80	Race	Other	D29	82.3%	67.2%	82.3%
Negative	Pseudo nAb ID80	Race	Other	D29	(26.4%, 138.3%)	(-1.7%, 136.0%)	(26.4%, 138.3%)
Negative	Anti-RBD IgG	Race	Other	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	Other	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	Other	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	Other	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	Other	D57	100.0%	100.0%	100.0%
Negative	Live Virus nAb ID50	Race	Other	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID80	Race	Other	D57	84.8%	84.8%	84.8%
Negative	Live Virus nAb ID80	Race	Other	D57	(32.3%, 137.4%)	(32.3%, 137.4%)	(32.3%, 137.4%)
Negative	Pseudo nAb ID50	Race	Other	D57	87.8%	87.8%	87.8%
Negative	Pseudo nAb ID50	Race	Other	D57	(39.9%, 135.8%)	(39.9%, 135.8%)	(39.9%, 135.8%)
Negative	Pseudo nAb ID80	Race	Other	D57	86.6%	85.3%	86.6%
Negative	Pseudo nAb ID80	Race	Other	D57	(36.6%, 136.6%)	(33.4%, 137.2%)	(36.6%, 136.6%)
Positive	Anti-RBD IgG	Race	Other	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Other	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	Other	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Other	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Other	D29	42.1%	45.5%	42.1%
Positive	Live Virus nAb ID50	Race	Other	D29	(4.3%, 79.8%)	(7.4%, 83.6%)	(4.3%, 79.8%)
Positive	Live Virus nAb ID80	Race	Other	D29	34.9%	40.2%	34.9%
Positive	Live Virus nAb ID80	Race	Other	D29	(-1.6%, 71.3%)	(-11.0%, 91.5%)	(-1.6%, 71.3%)
Positive	Pseudo nAb ID50	Race	Other	D29	34.9%	36.8%	34.9%
Positive	Pseudo nAb ID50	Race	Other	D29	(-1.6%, 71.3%)	(-14.9%, 88.5%)	(-1.6%, 71.3%)
Positive	Pseudo nAb ID80	Race	Other	D29	6.0%	0.2%	6.0%
Positive	Pseudo nAb ID80	Race	Other	D29	(-50.7%, 62.7%)	(-51.4%, 51.8%)	(-50.7%, 62.7%)
Positive	Anti-RBD IgG	Race	Other	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Race	Other	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	Race	Other	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Race	Other	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	Other	D57	2.2%	27.7%	2.2%
Positive	Live Virus nAb ID50	Race	Other	D57	(-9.0%, 13.3%)	(-6.5%, 61.9%)	(-9.0%, 13.3%)
Positive	Live Virus nAb ID80	Race	Other	D57	32.7%	60.4%	32.7%
Positive	Live Virus nAb ID80	Race	Other	D57	(-3.2%, 68.6%)	(23.0%, 97.8%)	(-3.2%, 68.6%)
Positive	Pseudo nAb ID50	Race	Other	D57	-0.0%	2.2%	-0.0%
Positive	Pseudo nAb ID50	Race	Other	D57	(-0.0%, 0.0%)	(-9.0%, 13.3%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Race	Other	D57	42.1%	42.1%	42.1%
Positive	Pseudo nAb ID80	Race	Other	D57	(4.3%, 79.8%)	(4.3%, 79.8%)	(4.3%, 79.8%)
Negative	Anti-RBD IgG	Race	White	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	White	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	White	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	White	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	White	D29	76.8%	66.4%	76.8%
Negative	Live Virus nAb ID50	Race	White	D29	(60.4%, 93.1%)	(48.2%, 84.7%)	(60.4%, 93.1%)
Negative	Live Virus nAb ID80	Race	White	D29	79.8%	65.1%	79.8%
Negative	Live Virus nAb ID80	Race	White	D29	(64.2%, 95.3%)	(46.6%, 83.5%)	(64.2%, 95.3%)
Negative	Pseudo nAb ID50	Race	White	D29	78.1%	75.2%	78.1%
Negative	Pseudo nAb ID50	Race	White	D29	(62.1%, 94.1%)	(58.4%, 91.9%)	(62.1%, 94.1%)
Negative	Pseudo nAb ID80	Race	White	D29	57.1%	41.5%	57.1%
Negative	Pseudo nAb ID80	Race	White	D29	(38.0%, 76.3%)	(22.4%, 60.6%)	(38.0%, 76.3%)
Negative	Anti-RBD IgG	Race	White	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	White	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	White	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	White	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	White	D57	93.5%	92.8%	93.5%
Negative	Live Virus nAb ID50	Race	White	D57	(83.9%, 103.0%)	(82.8%, 102.8%)	(83.9%, 103.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID80	Race	White	D57	91.4%	90.8%	91.4%
Negative	Live Virus nAb ID80	Race	White	D57	(80.6%, 102.3%)	(79.6%, 102.0%)	(80.6%, 102.3%)
Negative	Pseudo nAb ID50	Race	White	D57	99.3%	99.3%	99.3%
Negative	Pseudo nAb ID50	Race	White	D57	(96.2%, 102.5%)	(96.2%, 102.5%)	(96.2%, 102.5%)
Negative	Pseudo nAb ID80	Race	White	D57	92.8%	85.6%	92.8%
Negative	Pseudo nAb ID80	Race	White	D57	(82.8%, 102.8%)	(72.0%, 99.2%)	(82.8%, 102.8%)
Positive	Anti-RBD IgG	Race	White	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	White	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	White	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	White	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	White	D29	-14.7%	-4.6%	-14.7%
Positive	Live Virus nAb ID50	Race	White	D29	(-47.4%, 18.0%)	(-40.2%, 31.0%)	(-47.4%, 18.0%)
Positive	Live Virus nAb ID80	Race	White	D29	1.9%	-6.6%	1.9%
Positive	Live Virus nAb ID80	Race	White	D29	(-27.7%, 31.5%)	(-45.2%, 32.0%)	(-27.7%, 31.5%)
Positive	Pseudo nAb ID50	Race	White	D29	11.8%	11.8%	11.8%
Positive	Pseudo nAb ID50	Race	White	D29	(-14.8%, 38.4%)	(-14.8%, 38.4%)	(-14.8%, 38.4%)
Positive	Pseudo nAb ID80	Race	White	D29	26.2%	5.3%	26.2%
Positive	Pseudo nAb ID80	Race	White	D29	(-5.9%, 58.3%)	(-33.5%, 44.1%)	(-5.9%, 58.3%)
Positive	Anti-RBD IgG	Race	White	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	White	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	White	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	White	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	White	D57	0.0%	0.0%	0.0%
Positive	Live Virus nAb ID50	Race	White	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID80	Race	White	D57	14.4%	28.9%	14.4%
Positive	Live Virus nAb ID80	Race	White	D57	(-7.1%, 35.9%)	(1.2%, 56.6%)	(-7.1%, 35.9%)
Positive	Pseudo nAb ID50	Race	White	D57	0.0%	0.0%	0.0%
Positive	Pseudo nAb ID50	Race	White	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID80	Race	White	D57	14.4%	14.4%	14.4%
Positive	Pseudo nAb ID80	Race	White	D57	(-7.1%, 35.9%)	(-7.1%, 35.9%)	(-7.1%, 35.9%)
Negative	Anti-RBD IgG	Race	White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	White Non-Hispanic	D29	80.9%	65.3%	80.9%
Negative	Live Virus nAb ID50	Race	White Non-Hispanic	D29	(75.6%, 86.3%)	(58.9%, 71.8%)	(75.6%, 86.3%)
Negative	Live Virus nAb ID80	Race	White Non-Hispanic	D29	63.7%	49.0%	63.7%
Negative	Live Virus nAb ID80	Race	White Non-Hispanic	D29	(57.2%, 70.2%)	(42.2%, 55.8%)	(57.2%, 70.2%)
Negative	Pseudo nAb ID50	Race	White Non-Hispanic	D29	82.2%	69.8%	82.2%
Negative	Pseudo nAb ID50	Race	White Non-Hispanic	D29	(77.0%, 87.4%)	(63.6%, 76.1%)	(77.0%, 87.4%)
Negative	Pseudo nAb ID80	Race	White Non-Hispanic	D29	66.5%	55.5%	66.5%
Negative	Pseudo nAb ID80	Race	White Non-Hispanic	D29	(60.1%, 72.9%)	(48.7%, 62.2%)	(60.1%, 72.9%)
Negative	Anti-RBD IgG	Race	White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Race	White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Race	White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Race	White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Race	White Non-Hispanic	D57	97.2%	96.0%	97.2%
Negative	Live Virus nAb ID50	Race	White Non-Hispanic	D57	(95.0%, 99.5%)	(93.3%, 98.6%)	(95.0%, 99.5%)
Negative	Live Virus nAb ID80	Race	White Non-Hispanic	D57	95.0%	90.0%	95.0%
Negative	Live Virus nAb ID80	Race	White Non-Hispanic	D57	(92.0%, 97.9%)	(85.9%, 94.1%)	(92.0%, 97.9%)
Negative	Pseudo nAb ID50	Race	White Non-Hispanic	D57	98.5%	96.7%	98.5%
Negative	Pseudo nAb ID50	Race	White Non-Hispanic	D57	(96.8%, 100.1%)	(94.3%, 99.1%)	(96.8%, 100.1%)
Negative	Pseudo nAb ID80	Race	White Non-Hispanic	D57	93.7%	90.5%	93.7%
Negative	Pseudo nAb ID80	Race	White Non-Hispanic	D57	(90.4%, 97.0%)	(86.5%, 94.5%)	(90.4%, 97.0%)
Positive	Anti-RBD IgG	Race	White Non-Hispanic	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	White Non-Hispanic	D29	0.0%	0.0%	0.0%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-Spike IgG	Race	White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	White Non-Hispanic	D29	24.9%	23.1%	24.9%
Positive	Live Virus nAb ID50	Race	White Non-Hispanic	D29	(14.0%, 35.7%)	(10.8%, 35.4%)	(14.0%, 35.7%)
Positive	Live Virus nAb ID80	Race	White Non-Hispanic	D29	23.7%	34.6%	23.7%
Positive	Live Virus nAb ID80	Race	White Non-Hispanic	D29	(11.8%, 35.6%)	(22.5%, 46.8%)	(11.8%, 35.6%)
Positive	Pseudo nAb ID50	Race	White Non-Hispanic	D29	16.4%	22.3%	16.4%
Positive	Pseudo nAb ID50	Race	White Non-Hispanic	D29	(6.1%, 26.7%)	(10.3%, 34.3%)	(6.1%, 26.7%)
Positive	Pseudo nAb ID80	Race	White Non-Hispanic	D29	16.5%	24.5%	16.5%
Positive	Pseudo nAb ID80	Race	White Non-Hispanic	D29	(4.4%, 28.6%)	(11.9%, 37.1%)	(4.4%, 28.6%)
Positive	Anti-RBD IgG	Race	White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Race	White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Race	White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Race	White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Race	White Non-Hispanic	D57	3.4%	8.2%	3.4%
Positive	Live Virus nAb ID50	Race	White Non-Hispanic	D57	(-2.7%, 9.6%)	(1.1%, 15.2%)	(-2.7%, 9.6%)
Positive	Live Virus nAb ID80	Race	White Non-Hispanic	D57	5.8%	10.1%	5.8%
Positive	Live Virus nAb ID80	Race	White Non-Hispanic	D57	(1.6%, 10.0%)	(4.1%, 16.0%)	(1.6%, 10.0%)
Positive	Pseudo nAb ID50	Race	White Non-Hispanic	D57	5.6%	5.4%	5.6%
Positive	Pseudo nAb ID50	Race	White Non-Hispanic	D57	(-0.2%, 11.4%)	(-0.9%, 11.7%)	(-0.2%, 11.4%)
Positive	Pseudo nAb ID80	Race	White Non-Hispanic	D57	5.6%	9.3%	5.6%
Positive	Pseudo nAb ID80	Race	White Non-Hispanic	D57	(-0.2%, 11.4%)	(1.0%, 17.7%)	(-0.2%, 11.4%)
Negative	Anti-RBD IgG	Minority	White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Minority	White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Minority	White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Minority	White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Minority	White Non-Hispanic	D29	80.9%	65.3%	80.9%
Negative	Live Virus nAb ID50	Minority	White Non-Hispanic	D29	(75.6%, 86.3%)	(58.9%, 71.8%)	(75.6%, 86.3%)
Negative	Live Virus nAb ID80	Minority	White Non-Hispanic	D29	63.7%	49.0%	63.7%
Negative	Live Virus nAb ID80	Minority	White Non-Hispanic	D29	(57.2%, 70.2%)	(42.2%, 55.8%)	(57.2%, 70.2%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Pseudo nAb ID50	Minority	White Non-Hispanic	D29	82.2%	69.8%	82.2%
Negative	Pseudo nAb ID50	Minority	White Non-Hispanic	D29	(77.0%, 87.4%)	(63.6%, 76.1%)	(77.0%, 87.4%)
Negative	Pseudo nAb ID80	Minority	White Non-Hispanic	D29	66.5%	55.5%	66.5%
Negative	Pseudo nAb ID80	Minority	White Non-Hispanic	D29	(60.1%, 72.9%)	(48.7%, 62.2%)	(60.1%, 72.9%)
Negative	Anti-RBD IgG	Minority	White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Minority	White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Minority	White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Minority	White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Minority	White Non-Hispanic	D57	97.2%	96.0%	97.2%
Negative	Live Virus nAb ID50	Minority	White Non-Hispanic	D57	(95.0%, 99.5%)	(93.3%, 98.6%)	(95.0%, 99.5%)
Negative	Live Virus nAb ID80	Minority	White Non-Hispanic	D57	95.0%	90.0%	95.0%
Negative	Live Virus nAb ID80	Minority	White Non-Hispanic	D57	(92.0%, 97.9%)	(85.9%, 94.1%)	(92.0%, 97.9%)
Negative	Pseudo nAb ID50	Minority	White Non-Hispanic	D57	98.5%	96.7%	98.5%
Negative	Pseudo nAb ID50	Minority	White Non-Hispanic	D57	(96.8%, 100.1%)	(94.3%, 99.1%)	(96.8%, 100.1%)
Negative	Pseudo nAb ID80	Minority	White Non-Hispanic	D57	93.7%	90.5%	93.7%
Negative	Pseudo nAb ID80	Minority	White Non-Hispanic	D57	(90.4%, 97.0%)	(86.5%, 94.5%)	(90.4%, 97.0%)
Positive	Anti-RBD IgG	Minority	White Non-Hispanic	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Minority	White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Minority	White Non-Hispanic	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Minority	White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Minority	White Non-Hispanic	D29	24.9%	23.1%	24.9%
Positive	Live Virus nAb ID50	Minority	White Non-Hispanic	D29	(14.0%, 35.7%)	(10.8%, 35.4%)	(14.0%, 35.7%)
Positive	Live Virus nAb ID80	Minority	White Non-Hispanic	D29	23.7%	34.6%	23.7%
Positive	Live Virus nAb ID80	Minority	White Non-Hispanic	D29	(11.8%, 35.6%)	(22.5%, 46.8%)	(11.8%, 35.6%)
Positive	Pseudo nAb ID50	Minority	White Non-Hispanic	D29	16.4%	22.3%	16.4%
Positive	Pseudo nAb ID50	Minority	White Non-Hispanic	D29	(6.1%, 26.7%)	(10.3%, 34.3%)	(6.1%, 26.7%)
Positive	Pseudo nAb ID80	Minority	White Non-Hispanic	D29	16.5%	24.5%	16.5%
Positive	Pseudo nAb ID80	Minority	White Non-Hispanic	D29	(4.4%, 28.6%)	(11.9%, 37.1%)	(4.4%, 28.6%)



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Minority	White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Minority	White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Minority	White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Minority	White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Minority	White Non-Hispanic	D57	3.4%	8.2%	3.4%
Positive	Live Virus nAb ID50	Minority	White Non-Hispanic	D57	(-2.7%, 9.6%)	(1.1%, 15.2%)	(-2.7%, 9.6%)
Positive	Live Virus nAb ID80	Minority	White Non-Hispanic	D57	5.8%	10.1%	5.8%
Positive	Live Virus nAb ID80	Minority	White Non-Hispanic	D57	(1.6%, 10.0%)	(4.1%, 16.0%)	(1.6%, 10.0%)
Positive	Pseudo nAb ID50	Minority	White Non-Hispanic	D57	5.6%	5.4%	5.6%
Positive	Pseudo nAb ID50	Minority	White Non-Hispanic	D57	(-0.2%, 11.4%)	(-0.9%, 11.7%)	(-0.2%, 11.4%)
Positive	Pseudo nAb ID80	Minority	White Non-Hispanic	D57	5.6%	9.3%	5.6%
Positive	Pseudo nAb ID80	Minority	White Non-Hispanic	D57	(-0.2%, 11.4%)	(1.0%, 17.7%)	(-0.2%, 11.4%)
Negative	Anti-RBD IgG	Minority	Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Minority	Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Minority	Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Minority	Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Minority	Communities of Color	D29	81.7%	66.1%	81.7%
Negative	Live Virus nAb ID50	Minority	Communities of Color	D29	(77.1%, 86.3%)	(60.5%, 71.8%)	(77.1%, 86.3%)
Negative	Live Virus nAb ID80	Minority	Communities of Color	D29	73.9%	60.7%	73.9%
Negative	Live Virus nAb ID80	Minority	Communities of Color	D29	(68.6%, 79.1%)	(54.9%, 66.6%)	(68.6%, 79.1%)
Negative	Pseudo nAb ID50	Minority	Communities of Color	D29	80.4%	67.3%	80.4%
Negative	Pseudo nAb ID50	Minority	Communities of Color	D29	(75.6%, 85.1%)	(61.6%, 72.9%)	(75.6%, 85.1%)
Negative	Pseudo nAb ID80	Minority	Communities of Color	D29	69.3%	54.5%	69.3%
Negative	Pseudo nAb ID80	Minority	Communities of Color	D29	(63.8%, 74.8%)	(48.5%, 60.4%)	(63.8%, 74.8%)
Negative	Anti-RBD IgG	Minority	Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Minority	Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Minority	Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Minority	Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID50	Minority	Communities of Color	D57	97.9%	93.7%	97.9%
Negative	Live Virus nAb ID50	Minority	Communities of Color	D57	(96.1%, 99.6%)	(90.8%, 96.6%)	(96.1%, 99.6%)
Negative	Live Virus nAb ID80	Minority	Communities of Color	D57	94.6%	88.8%	94.6%
Negative	Live Virus nAb ID80	Minority	Communities of Color	D57	(91.9%, 97.3%)	(85.0%, 92.5%)	(91.9%, 97.3%)
Negative	Pseudo nAb ID50	Minority	Communities of Color	D57	96.9%	94.2%	96.9%
Negative	Pseudo nAb ID50	Minority	Communities of Color	D57	(94.8%, 99.0%)	(91.4%, 97.0%)	(94.8%, 99.0%)
Negative	Pseudo nAb ID80	Minority	Communities of Color	D57	95.4%	89.4%	95.4%
Negative	Pseudo nAb ID80	Minority	Communities of Color	D57	(92.9%, 97.9%)	(85.8%, 93.1%)	(92.9%, 97.9%)
Positive	Anti-RBD IgG	Minority	Communities of Color	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Minority	Communities of Color	D29	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Anti-Spike IgG	Minority	Communities of Color	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Minority	Communities of Color	D29	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Live Virus nAb ID50	Minority	Communities of Color	D29	31.5%	33.8%	31.5%
Positive	Live Virus nAb ID50	Minority	Communities of Color	D29	(22.0%, 40.9%)	(23.2%, 44.4%)	(22.0%, 40.9%)
Positive	Live Virus nAb ID80	Minority	Communities of Color	D29	23.0%	35.4%	23.0%
Positive	Live Virus nAb ID80	Minority	Communities of Color	D29	(12.2%, 33.8%)	(24.0%, 46.9%)	(12.2%, 33.8%)
Positive	Pseudo nAb ID50	Minority	Communities of Color	D29	22.9%	29.5%	22.9%
Positive	Pseudo nAb ID50	Minority	Communities of Color	D29	(12.9%, 33.0%)	(18.3%, 40.6%)	(12.9%, 33.0%)
Positive	Pseudo nAb ID80	Minority	Communities of Color	D29	20.2%	17.1%	20.2%
Positive	Pseudo nAb ID80	Minority	Communities of Color	D29	(8.4%, 32.1%)	(4.8%, 29.3%)	(8.4%, 32.1%)
Positive	Anti-RBD IgG	Minority	Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Minority	Communities of Color	D57	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Anti-Spike IgG	Minority	Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Minority	Communities of Color	D57	(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
Positive	Live Virus nAb ID50	Minority	Communities of Color	D57	2.0%	5.2%	2.0%
Positive	Live Virus nAb ID50	Minority	Communities of Color	D57	(-1.0%, 5.0%)	(-0.4%, 10.8%)	(-1.0%, 5.0%)
Positive	Live Virus nAb ID80	Minority	Communities of Color	D57	8.6%	15.4%	8.6%
Positive	Live Virus nAb ID80	Minority	Communities of Color	D57	(3.3%, 13.8%)	(8.8%, 22.0%)	(3.3%, 13.8%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID50	Minority	Communities of Color	D57	5.0%	9.8%	5.0%
Positive	Pseudo nAb ID50	Minority	Communities of Color	D57	(-0.0%, 10.1%)	(3.7%, 15.9%)	(-0.0%, 10.1%)
Positive	Pseudo nAb ID80	Minority	Communities of Color	D57	16.2%	22.4%	16.2%
Positive	Pseudo nAb ID80	Minority	Communities of Color	D57	(9.1%, 23.4%)	(14.3%, 30.5%)	(9.1%, 23.4%)
Negative	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	79.8%	62.8%	79.8%
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	(72.7%, 86.9%)	(54.3%, 71.4%)	(72.7%, 86.9%)
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	72.4%	58.9%	72.4%
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	(64.5%, 80.3%)	(50.2%, 67.7%)	(64.5%, 80.3%)
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	78.3%	63.5%	78.3%
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	(71.0%, 85.6%)	(55.0%, 72.1%)	(71.0%, 85.6%)
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	66.3%	50.8%	66.3%
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	(57.9%, 74.7%)	(42.0%, 59.7%)	(57.9%, 74.7%)
Negative	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	98.0%	93.2%	98.0%
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	(95.5%, 100.5%)	(88.7%, 97.7%)	(95.5%, 100.5%)
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	94.1%	87.7%	94.1%
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	(89.9%, 98.3%)	(81.8%, 93.5%)	(89.9%, 98.3%)
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	96.5%	93.6%	96.5%
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	(93.3%, 99.8%)	(89.2%, 97.9%)	(93.3%, 99.8%)
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	95.0%	88.6%	95.0%
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	(91.2%, 98.9%)	(82.9%, 94.2%)	(91.2%, 98.9%)
Positive	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D29	-0.0%	-0.0%	-0.0%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	36.2%	36.7%	36.2%
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	(23.9%, 48.6%)	(22.9%, 50.5%)	(23.9%, 48.6%)
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	25.2%	37.5%	25.2%
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	(11.0%, 39.4%)	(22.6%, 52.3%)	(11.0%, 39.4%)
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	27.0%	32.8%	27.0%
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D29	(13.6%, 40.4%)	(18.2%, 47.4%)	(13.6%, 40.4%)
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	22.4%	16.8%	22.4%
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D29	(6.8%, 37.9%)	(0.8%, 32.8%)	(6.8%, 37.9%)
Positive	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Minority	Age < 65 Communities of Color	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age < 65 Communities of Color	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	2.1%	5.8%	2.1%
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	(-1.9%, 6.1%)	(-2.0%, 13.5%)	(-1.9%, 6.1%)
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	10.0%	17.4%	10.0%
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	(2.8%, 17.2%)	(8.5%, 26.3%)	(2.8%, 17.2%)
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	5.7%	10.5%	5.7%
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 Communities of Color	D57	(-1.3%, 12.8%)	(2.2%, 18.7%)	(-1.3%, 12.8%)
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	17.8%	24.3%	17.8%
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 Communities of Color	D57	(8.1%, 27.5%)	(13.4%, 35.3%)	(8.1%, 27.5%)
Negative	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	79.6%	63.2%	79.6%
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	(71.8%, 87.5%)	(53.8%, 72.6%)	(71.8%, 87.5%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	60.1%	44.5%	60.1%
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	(50.5%, 69.6%)	(34.8%, 54.2%)	(50.5%, 69.6%)
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	80.3%	67.1%	80.3%
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	(72.5%, 88.0%)	(57.9%, 76.2%)	(72.5%, 88.0%)
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	63.8%	52.7%	63.8%
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	(54.4%, 73.1%)	(43.0%, 62.4%)	(54.4%, 73.1%)
Negative	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	97.0%	95.9%	97.0%
Negative	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	(93.6%, 100.3%)	(92.0%, 99.7%)	(93.6%, 100.3%)
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	94.6%	89.4%	94.6%
Negative	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	(90.2%, 99.0%)	(83.4%, 95.4%)	(90.2%, 99.0%)
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	98.5%	96.7%	98.5%
Negative	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	(96.1%, 100.9%)	(93.3%, 100.2%)	(96.1%, 100.9%)
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	93.1%	89.6%	93.1%
Negative	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	(88.1%, 98.0%)	(83.6%, 95.5%)	(88.1%, 98.0%)
Positive	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	27.3%	24.2%	27.3%
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	(12.4%, 42.3%)	(7.4%, 40.9%)	(12.4%, 42.3%)
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	24.6%	38.1%	24.6%
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	(8.3%, 40.9%)	(21.9%, 54.2%)	(8.3%, 40.9%)
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	16.3%	23.4%	16.3%
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D29	(2.0%, 30.7%)	(7.0%, 39.9%)	(2.0%, 30.7%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	15.1%	23.5%	15.1%
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D29	(-1.5%, 31.7%)	(6.5%, 40.4%)	(-1.5%, 31.7%)
Positive	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age < 65 White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	3.6%	8.8%	3.6%
Positive	Live Virus nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	(-5.1%, 12.4%)	(-1.2%, 18.7%)	(-5.1%, 12.4%)
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	5.4%	9.9%	5.4%
Positive	Live Virus nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	(-0.0%, 10.9%)	(2.2%, 17.6%)	(-0.0%, 10.9%)
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	6.2%	5.6%	6.2%
Positive	Pseudo nAb ID50	Age, Minority	Age < 65 White Non-Hispanic	D57	(-2.1%, 14.4%)	(-3.3%, 14.5%)	(-2.1%, 14.4%)
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	5.8%	9.5%	5.8%
Positive	Pseudo nAb ID80	Age, Minority	Age < 65 White Non-Hispanic	D57	(-2.4%, 14.0%)	(-2.2%, 21.2%)	(-2.4%, 14.0%)
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	91.8%	83.8%	91.8%
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	(87.5%, 96.2%)	(78.0%, 89.6%)	(87.5%, 96.2%)
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	81.7%	70.3%	81.7%
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	(75.6%, 87.8%)	(63.1%, 77.5%)	(75.6%, 87.8%)
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	91.4%	87.0%	91.4%
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	(87.0%, 95.9%)	(81.7%, 92.3%)	(87.0%, 95.9%)
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	85.0%	73.9%	85.0%
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	(79.4%, 90.6%)	(67.0%, 80.9%)	(79.4%, 90.6%)
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	97.2%	96.3%	97.2%
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	(94.6%, 99.8%)	(93.3%, 99.3%)	(94.6%, 99.8%)
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	97.1%	94.7%	97.1%
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	(94.4%, 99.7%)	(91.1%, 98.2%)	(94.4%, 99.7%)
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	98.8%	97.6%	98.8%
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	(97.1%, 100.5%)	(95.2%, 100.0%)	(97.1%, 100.5%)
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	97.3%	94.1%	97.3%
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	(94.7%, 99.9%)	(90.3%, 97.8%)	(94.7%, 99.9%)
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D29	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	-2.5%	13.4%	-2.5%
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	(-14.4%, 9.4%)	(-2.1%, 28.8%)	(-14.4%, 9.4%)
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	7.4%	21.4%	7.4%
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	(-7.2%, 22.1%)	(4.0%, 38.8%)	(-7.2%, 22.1%)
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	-5.8%	6.1%	-5.8%
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D29	(-15.0%, 3.5%)	(-7.4%, 19.6%)	(-15.0%, 3.5%)
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	6.1%	20.2%	6.1%
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D29	(-8.1%, 20.4%)	(2.3%, 38.0%)	(-8.1%, 20.4%)
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 Communities of Color	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D57	-0.0%	-0.0%	-0.0%
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 Communities of Color	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	1.2%	1.2%	1.2%
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	(-1.8%, 4.3%)	(-1.8%, 4.3%)	(-1.8%, 4.3%)
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	-1.9%	1.3%	-1.9%

Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	(-5.7%, 1.9%)	(-4.9%, 7.5%)	(-5.7%, 1.9%)
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	-0.0%	5.2%	-0.0%
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 Communities of Color	D57	(-0.0%, 0.0%)	(-0.9%, 11.3%)	(-0.0%, 0.0%)
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	5.2%	9.1%	5.2%
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 Communities of Color	D57	(-0.9%, 11.3%)	(1.2%, 17.1%)	(-0.9%, 11.3%)
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	88.8%	78.7%	88.8%
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	(82.9%, 94.6%)	(71.1%, 86.4%)	(82.9%, 94.6%)
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	86.0%	76.7%	86.0%
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	(79.6%, 92.5%)	(68.8%, 84.5%)	(79.6%, 92.5%)
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	94.1%	86.7%	94.1%
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	(89.7%, 98.5%)	(80.4%, 93.0%)	(89.7%, 98.5%)
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	83.3%	72.3%	83.3%
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	(76.3%, 90.2%)	(64.0%, 80.6%)	(76.3%, 90.2%)
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	100.0%	100.0%	100.0%
Negative	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	98.8%	96.6%	98.8%
Negative	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	(96.7%, 100.8%)	(93.2%, 100.0%)	(96.7%, 100.8%)
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	97.3%	93.8%	97.3%
Negative	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	(94.2%, 100.3%)	(89.4%, 98.3%)	(94.2%, 100.3%)
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	98.4%	96.6%	98.4%
Negative	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	(96.0%, 100.7%)	(93.2%, 100.0%)	(96.0%, 100.7%)
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	97.7%	96.0%	97.7%
Negative	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	(94.9%, 100.5%)	(92.4%, 99.7%)	(94.9%, 100.5%)



Table 7: CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity

Mock Report

Data as of January 14, 2021

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Endpoint	subgroup	Group	Visit	2-Fold Rise	4-Fold Rise	Responder
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D29	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	9.0%	16.0%	9.0%
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	(-2.5%, 20.6%)	(1.0%, 31.0%)	(-2.5%, 20.6%)
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	17.6%	12.7%	17.6%
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	(3.7%, 31.5%)	(-4.0%, 29.4%)	(3.7%, 31.5%)
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	16.7%	15.3%	16.7%
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D29	(6.6%, 26.8%)	(2.5%, 28.1%)	(6.6%, 26.8%)
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	25.5%	30.8%	25.5%
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D29	(12.0%, 38.9%)	(14.3%, 47.3%)	(12.0%, 38.9%)
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-RBD IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	0.0%	0.0%	0.0%
Positive	Anti-Spike IgG	Age, Minority	Age >= 65 White Non-Hispanic	D57	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	2.1%	4.2%	2.1%
Positive	Live Virus nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	(-1.8%, 6.0%)	(-1.3%, 9.6%)	(-1.8%, 6.0%)
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	8.3%	10.9%	8.3%
Positive	Live Virus nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	(0.8%, 15.8%)	(-0.1%, 21.8%)	(0.8%, 15.8%)
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	2.1%	4.2%	2.1%
Positive	Pseudo nAb ID50	Age, Minority	Age >= 65 White Non-Hispanic	D57	(-1.8%, 6.0%)	(-1.3%, 9.6%)	(-1.8%, 6.0%)
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	4.2%	8.3%	4.2%
Positive	Pseudo nAb ID80	Age, Minority	Age >= 65 White Non-Hispanic	D57	(-1.3%, 9.6%)	(0.8%, 15.8%)	(-1.3%, 9.6%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo